



Effective Health Care Program

Technical Brief
Number 5

Maternal-Fetal Surgical Procedures



Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

This report is based on research conducted by the Vanderbilt Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10065). The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products or actions may not be stated or implied.

Technical Brief

Number 5

Maternal-Fetal Surgical Procedures

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2007-10065

Prepared by:

Vanderbilt Evidence-based Practice Center
Nashville, TN

Investigators:

William F. Walsh, M.D.
Nancy C. Chescheir, M.D.
Maria Gillam-Krakauer, M.D.
Melissa L. McPheeters, Ph.D., M.P.H.
J. Nikki McKoy, M.P.H.
Rebecca Jerome, M.L.I.S., M.P.H.
Jill A. Fisher, Ph.D.
Laura Meints, M.D.
Katherine E. Hartmann, M.D., Ph.D.

**AHRQ Publication No. 10(11)-EHC059-EF
April 2011**

This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation: Walsh WF, Chescheir NC, Gillam-Krakauer M, McPheeters ML, McKoy JN, Jerome R, Fisher JA, Meints L, Hartmann, KE. Maternal-Fetal Surgical Procedures. Technical Brief No. 5. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065.) AHRQ Publication No. 10(11)-EHC059-EF. Rockville, MD: Agency for Healthcare Research and Quality. April 2011.

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies and strategies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments.

This EPC evidence report is a Technical Brief. A Technical Brief is a rapid report, typically on an emerging medical technology, strategy or intervention. It provides an overview of key issues related to the intervention—for example, current indications, relevant patient populations and subgroups of interest, outcomes measured, and contextual factors that may affect decisions regarding the intervention. Although Technical Briefs generally focus on interventions for which there are limited published data and too few completed protocol-driven studies to support definitive conclusions, the decision to request a Technical Brief is not solely based on the availability of clinical studies. The goals of the Technical Brief are to provide an early objective description of the state of the science, a potential framework for assessing the applications and implications of the intervention, a summary of ongoing research, and information on future research needs. In particular, through the Technical Brief, AHRQ hopes to gain insight on the appropriate conceptual framework and critical issues that will inform future comparative effectiveness research.

AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality.

We welcome comments on this Technical Brief. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by e-mail to epc@ahrq.hhs.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director
Evidence-based Practice Program
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Beth A. Collins Sharp, R.N., Ph.D.
Task Order Officer
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Acknowledgments

We are indebted to the tireless, timely, and insightful assistance of colleagues who made this technical brief possible:

Ms. Allison Glasser provided research assistance on this report, including assisting with gray literature research on the Internet, carefully constructing many tables and efficiently coordinating key informant discussions.

Ms. Toye Spencer oversaw the completion and formatting of the summary tables, and other critical elements of the report as a whole.

Maternal-Fetal Surgical Procedures

Structured Abstract

Objectives. This report is intended to summarize the current state of practice and research in maternal-fetal surgical procedures, which is the surgical repair of abnormalities in fetuses in the womb.

Data Sources. We searched MEDLINE from 1980 forward for studies of fetal surgical procedures for the following seven conditions: congenital diaphragmatic hernia, cardiac malformations, myelomeningocele, obstructive uropathy, sacrococcygeal teratoma, twin-twin transfusion syndrome, and thoracic lesions. We also searched the Internet for sources of current practice, current insurance coverage of fetal surgery, and ongoing research (including the clinicaltrials.gov and NIH (National Institutes of Health) Reporter databases). We spoke with experts in the field regarding their knowledge of practice sites, ongoing training programs, research in the field, and considerations for the future of maternal-fetal surgical procedures.

Review Methods. We abstracted data on operational definitions of fetal diagnoses, type of procedure, maternal inclusion criteria, training of providers, study design, country, setting, comparators used, followup, outcomes measured, and adverse events. We summarized these data quantitatively. We attempted to identify all potential sources of care for maternal-fetal surgical procedures in the United States, and to summarize the state of the field.

Results. One hundred sixteen studies captured for this review were case series. There were 3 randomized controlled studies (RCTs) and the rest (47) were cohorts. Seventy-four studies were conducted in the United States; 68 were in Europe, and the rest in other parts of the world. One RCT was published as this report was in press; the study's findings add to the body of literature on maternal-fetal surgical procedures for myelomeningocele and are summarized in that section of the report. The most common outcomes measured across diagnoses were survival to birth, preterm birth, and neonatal death. Additional, longer term outcomes for infants were rare, but when reported included pulmonary and neurologic status as well as achievement of developmental milestones. Reports of maternal outcomes were exceedingly rare, and in particular, we note very few studies that addressed the issues of future reproductive function for the mother. There are few formal training programs and no system of accreditation or licensure.

Conclusions. While developing rapidly, research on fetal surgical procedures has not achieved the typical level of quality of studies and aggregate strength of the evidence used to reach definitive conclusions about care and policy. Overall momentum is toward more robust research and rigorous, more consistent documentation of outcomes over longer periods of time. Experts concurred in discussions as well as in the literature that they are eager to develop consensus measures as well as mechanisms to make implementation of common protocols and larger studies increasingly possible. Favorable signs include the substantive leadership of U.S. researchers across each of the topics considered. For each target condition, there are both fetal surgical centers and associated research enterprises engaged in the full spectrum of academic endeavor, from animal research and development of surgical interventions and refinements, to patient care, surgical training, bioethics forums, and reporting of results in the scientific literature.

Contents

Introduction.....	1
Background.....	1
Key Questions Addressed in This Report.....	1
Methods.....	3
Overview.....	3
Search Strategy.....	3
Eligibility Criteria.....	3
Expert Panel Discussions.....	4
Describing the State of the Science.....	4
Results.....	6
State of the Science.....	6
State of the Science: Cardiac Malformations.....	7
State of the Science: Congenital Diaphragmatic Hernia.....	12
State of the Science: Myelomeningocele/Spina Bifida.....	17
State of the Science: Obstructive Uropathy.....	22
State of the Science: Sacrococcygeal Teratoma.....	33
State of the Science: Thoracic Lesions.....	36
State of the Science: Twin-Twin Transfusion Syndrome.....	40
Discussion.....	47
State of the Science.....	47
Challenges and Opportunities.....	50
References and Included Studies.....	52
Acronyms/Abbreviations.....	61

Tables

Table 1. Inclusion/Exclusion Criteria.....	4
Table 2. Overview of Maternal-Fetal Surgical Procedures Literature.....	6
Table 3. Summary of Case Series of Maternal-Fetal Surgical Procedures for Cardiac Malformations.....	8
Table 4. Primary Outcomes of Maternal-Fetal Surgical Procedures for Cardiac Malformations ..	9
Table 5. Summary of Maternal-Fetal Surgical Procedures for Congenital Diaphragmatic Hernia.....	13
Table 6. Primary Outcomes of Maternal-Fetal Surgical Procedures for Congenital Diaphragmatic Hernia.....	15
Table 7. Summary of Studies of Maternal-Fetal Surgical Procedures for Myelomeningocele (MMC).....	18
Table 8. Primary Outcomes of Maternal-Fetal Surgical Procedures for MMC.....	20
Table 9. Summary of Studies of Maternal-Fetal Surgical Procedures for Obstructive Uropathy.....	24
Table 10. Primary Outcomes of Maternal-Fetal Surgical Procedures for Obstructive Uropathy..	27
Table 11. Summary of Studies of Maternal-Fetal Surgical Procedures for Sacrococcygeal Teratoma.....	33
Table 12. Primary Outcomes of Maternal-Fetal Surgical Procedures for Sacrococcygeal Teratoma.....	34

Table 13. Summary of Cohort and Case Series Studies of Maternal-Fetal Surgical Procedures for Thoracic Lesions	37
Table 14. Primary Outcomes of Maternal-Fetal Surgical Procedures for Thoracic Lesions	38
Table 15. Summary of Trials and Cohort Studies of Laser Ablation for Twin-Twin Transfusion Syndrome (TTTS)	42
Table 16. Primary Outcomes of Trials and Cohort Studies of Laser Ablation for TTTS	44
Table 17. Counts of Studies Reporting Outcomes of Maternal-Fetal Surgical Procedures	49

Appendixes

Appendix A. Exact Search Strings
Appendix B. Sample Data Abstraction Forms
Appendix C. Excluded Studies
Appendix D. Ongoing Research
Appendix E. Peer Reviewers
Appendix F. Maternal-Fetal Surgical Procedures: Background and Context

Introduction

Background

The purpose of this report is to describe the current state of research and practice of maternal-fetal surgical procedures; the report does not offer guidance on whether or when such procedures are appropriate.

Congenital abnormalities that can be repaired prenatally occur in a small percentage of full-term births, and because of advances in imaging techniques such as ultrasound, many more congenital abnormalities are being diagnosed in utero. As these abnormalities are increasingly frequently recognized prior to delivery, maternal-fetal surgical procedures have emerged as a potential option for treating some of these defects. Although postnatal intervention is best for most fetal abnormalities (particularly in light of risks associated with in utero surgeries), for a few conditions, the fetus' condition can deteriorate so rapidly in the womb as to make early intervention necessary either to avoid death or substantially higher morbidity after birth. Substantial questions remain about both the safety and efficacy of fetal surgical corrections. In some cases, the natural history of the conditions is poorly understood, making comparisons to no treatment or postnatal intervention difficult.

In addition, comparisons of fetal versus postnatal surgery must consider the safety of the mother, yet limited comparative data exist. The issue is particularly complicated because while congenital defects are relatively common in aggregate, individual congenital abnormalities occur infrequently, making effective study very difficult. Ongoing trials are evaluating some of the most common fetal surgeries (Appendix D).

The goal of this brief is to describe the current state of literature and practice of maternal-fetal surgical procedures for seven congenital abnormalities ranked of high importance by stakeholders:

- Sacrococcygeal teratoma
- Congenital diaphragmatic hernia
- Thoracic lesions: congenital cystic adenomatoid malformation and bronchopulmonary sequestration
- Obstructive uropathy
- Myelomeningocele
- Twin-twin transfusion syndrome
- Cardiac malformations

Key Questions Addressed in This Report

The key questions for this brief were as follows:

Key Question 1.

- a. What fetal diagnoses are currently treatable with a maternal-fetal surgical procedure? For each fetal diagnosis that is potentially treatable with a maternal-fetal surgical procedure, what is the annual number of fetuses that could potentially benefit from the procedure?

- b. What maternal-fetal surgical procedures are done in the United States? What is an estimate of the number of hospitals that perform each procedure and utilization of each procedure?
- c. For each fetal diagnosis, which procedures or techniques are used?
- d. For each maternal-fetal surgical procedure, what anesthesia is used? What are the potential harms to the fetus and mother from the anesthesia?
- e. For each fetal diagnosis, what are the alternatives? For each fetal diagnosis, what are the theoretical advantages and disadvantages (including potential safety issues and harms to both the mother and fetus) of maternal-fetal surgical procedures relative to the alternatives?
- f. What training programs exist for maternal-fetal surgical procedures? What special requirements are needed in hospitals that perform fetal surgical procedures?

Key Question 2.

Perform a systematic literature scan on studies on the use and safety of maternal-fetal surgical procedures for the selected conditions, with a synthesis of:

- a. Operational definition of fetal diagnoses
- b. Type of procedure
- c. Maternal inclusion criteria
- d. Training of providers of specialized expertise and equipment in the study hospital(s)
- e. Study design or size/country or setting
- f. Comparator used (if any)
- g. Length of followup
- h. Outcomes measured for both fetus and mother
- i. Adverse events /harms/safety issues reported for both fetus and mother

We systematically searched, reviewed, and summarized the scientific evidence for each key question and any subsidiary questions.

A context section describing centers offering in utero procedures, training for such procedures, and access to care, and ethical issues surrounding maternal-fetal medicine is available in Appendix F. The state of the science sections for each condition, presented here, provide an overview of research in each area, including discussion of study designs, reporting of inclusion criteria, composition of comparison groups, and presence or absence of consideration of specific outcomes deemed important by the report team and expert consultants.

Methods

Overview

This brief combined standard systematic review approaches with Internet searches and key informant discussions.

Search Strategy

Search of the literature. We began our scan of the literature with a broad, general search query including key Medical Subject Heading (MeSH) terms and keywords related to fetal surgical procedures. The variability in subject term indexing among the retrieved citations in PubMed led to the development of additional search strategies to increase the comprehensiveness of our search retrieval.

From the combined retrieval of each of these search sets, we excluded publications that lay beyond the scope of the technical brief (letters, comments, editorials, reviews, news, practice guidelines), focusing on retaining items comprising primary data (case reports, prospective and retrospective studies).

We searched the Internet extensively to identify locations in the United States offering maternal-fetal surgical procedures; we also searched for insurance policies related to fetal interventions for a selected set of insurers. Searches were conducted across a number of fetal medicine-related Web sites as well as commercial databases including LexisNexis and ProQuest. We searched databases including Clinicaltrials.gov to identify current research. Appendix A includes further information about our search strategies and results.

Eligibility Criteria

Our inclusion/exclusion criteria for the research literature are shown in Table 1. All titles and abstracts identified through searches against our inclusion/exclusion criteria were reviewed by at least two investigators. When differences between the reviewers arose, we erred on the side of inclusion. For studies without adequate information to make the determination, we retrieved the full-text articles and reviewed them against the inclusion/exclusion criteria.

Table 1. Inclusion/exclusion criteria

Category	Criteria
Study population	Women and their fetuses with documented abnormalities on ultrasound that would require surgical correction
Publication languages	English only
Admissible evidence (study design and other criteria)	<p><u>Admissible designs</u> Randomized controlled trials, cohorts with comparison, case-control and case series with $n \geq 2$</p> <p><u>Other criteria</u></p> <ul style="list-style-type: none"> • Original research studies that provide sufficient detail regarding methods and results to enable use and adjustment of the data and results • Studies must address one or more of the following for fetal procedures: <ul style="list-style-type: none"> - Treatment modality - Current medical practice of training - Short- and long-term outcomes, including maternal morbidity and mortality

We collected data from the studies to provide an overview of the status of research in the field by collecting the following information:

- Study design, country, and setting
- Research methods
- Type of procedure
- Fetal and maternal inclusion criteria
- Training of providers/specialized expertise and equipment in the study hospital
- Comparator used in comparative studies
- Length of followup
- Fetal and maternal outcomes measured
- Adverse events/harms/safety issues

Expert Panel Discussions

We consulted with experts selected because of their expertise in the following areas: expertise in each of the conditions of interest, those who could offer historical perspective on maternal-fetal surgical procedures, and individuals who had a particular subspecialty expertise, such as ethics. These three panels included a total of 17 experts with whom we held conversations via phone, lasting from 20 to 45 minutes. The conversations were unstructured and intended to elicit context and background related in particular to current practice of maternal-fetal surgery.

Describing the State of the Science

In text and tables through the report, we aimed to use counts to effectively describe the status of the available science on maternal-fetal surgical intervention. When possible, studies that include common participants from a single site are grouped together, and groupings are indicated. We recognize that duplications of individual mother-baby pairs nonetheless occur in the total counts. The total number of cases studied is certain to be lower than totals in tables

reflect. Our tables provide information that exceeds that in the text, and taken together within a section, they are the best source of a single view of the quality and strength of the evidence by topic.

Results

State of the Science

We present an overview of the state of the science for each of the seven conditions that are the focus of this report. As possible, we have attempted to either combine related publications in the citations or call the reader's attention to overlap. Total numbers of participants in text and tables overestimates the number of pregnancies because not all duplicate inclusions, especially those from registries and databases, can be deciphered from the information in the publications. Table 2 presents summary information for the studies included in this brief. Five studies were reported in the 1980s, 37 in the 1990s, and 121 since 2000.

Table 2. Overview of maternal-fetal surgical procedures literature

Study Characteristic	Cardiac malformations	Congenital diaphragmatic hernia	Myelomeningocele	Obstructive uropathy	Sacroccygeal teratoma	Thoracic lesions (CCAM and BPS)	Twin-twin transfusion syndrome	Total Literature
Study Populations	(n=9)	(n=21)	(n=11)	(n=25)	(n=5)	(n=11)	(n=84)	(n=166)
U.S.	6	12	11	14	4	6	21	74
European	2	9	0	4	1	3	49	68
Asian	0	0	0	2	0	1	5	8
Other	1	0	0	5	0	1	9	16
Study Type								
Case series	9	12	4	14	1	3	73	116
Retrospective cohort	0	5	6	8	4	7	6	36
Prospective cohort	0	3	1	3	0	1	3	11
Randomized clinical trial	0	1	0	0	0	0	2	3
Approaches Assessed*								
Hysterotomy	1	8	9	3	3	3	4	31
Laparoscopic	0	12	2	0	1	2	7	24
Percutaneous	9	7	0	24	5	9	49†	103
Last Infant Outcome Assessment								
Birth	6	3	1	9	2	4	22	47
≤ 6 months	1	9	2	2	0	2	19	35
> 6 to ≤ 12 months	0	1	4	1	0	1	1	8
> 12 months	2	8	4	11	3	4	19	51
Unknown	0	0	0	2	0	0	23	25
Total Pregnancies: ^	90	503	262	450	130	414	2532	4381

BPS=bronchopulmonary sequestration; CCAM=Congenital Cystic Adenomatoid Malformation

*Total is greater than number of studies, some publications report more than one approach. ^Minus duplication reported by authors. †Surgical approach is not clearly reported, therefore totals to less than 84 studies.

State of the Science: Cardiac Malformations

Background. In utero interventions are being performed for cardiac conditions including: Pulmonary atresia with intact ventricular septum (very narrow pulmonary valve without a connection between the right and left ventricles), critical aortic stenosis with impending hypoplastic left heart syndrome (HLHS) (very small, nonfunctional left ventricle, hypothesized by some investigators to be from underuse secondary to a severely narrow aortic valve), and

hypoplastic left heart syndrome with intact atrial septum (no connection between the left and right atrium). All of these conditions, if untreated either in utero or soon after birth, are lethal.

Critical pulmonary stenosis or atresia with intact ventricular septum. These anomalies portend a poor prognosis. A prospective prevalence study in Canada showed that overall survival was 77 percent at one month and 58 percent at 15 years.¹ Fetal intervention to relieve the stenosis and allow for ventricular growth could theoretically increase the number of patients who ultimately end up with a biventricular repair. There is some debate as to whether this is an adequate measure of success since the right ventricle in a two-ventricle repair still has abnormal diastolic dysfunction and may not lead to increased exercise capacity.² However, these studies were performed in patients who had not undergone in utero repair. It is possible that if the stenosis is relieved early enough in gestation that there may be adequate time before delivery for growth of the right ventricle. In fetuses with impending hydrops, in utero valvuloplasty could reverse the condition and prevent hydrops and death.

Included publications. We identified two published reports³⁻⁴ of in utero fetal pulmonary balloon valvuloplasty in fetuses with pulmonary atresia of intact ventricular septum meeting our inclusion criteria (Table 3). Tulzer's case series³ describes two patients who underwent in utero pulmonary balloon valvuloplasty at a specialty center in Europe. One fetus was diagnosed at 28 weeks and the other at 30 weeks gestation; both had imminent hydrops, which was not defined in the paper. Both fetuses showed successful valve perforations and immediate improvement in right ventricular function. Both fetuses sustained spontaneously resolving pericardial effusions.

No maternal selection criteria were noted. General maternal anesthesia was used in one case, and local maternal anesthesia was used in the second case. There was no additional fetal anesthesia used in the case with general maternal anesthesia. In the case with local maternal anesthesia, the fetus was given fentanyl, pancuronium, and atropine through the intrahepatic vein.

Table 3. Summary of case series of maternal-fetal surgical procedures for cardiac malformations

Author Year	With fetal procedure, N*	Fetal inclusion criteria provided?	Maternal inclusion criteria provided?	Comparison group	Outcomes beyond neonatal hospital stay?
Pulmonary atresia and intact ventricular septum					
Mizrahi-Arnaud et al. ⁴ 2007	8	No	No	None	No
Tulzer et al. ³ 2002	2	Yes	No	None	Yes
Aortic stenosis with developing hypoplastic left heart syndrome (HLHS)					
McElhinney et al. ⁵⁻⁶ 2009	70	Yes	No	Yes	Yes
Mizrahi-Arnaud et al. ⁴ 2007	50	No	No	No	Yes
Wilkins-Haug et al. ⁷ 2006	22	Yes	No	No	No
Marshall et al. ⁸ 2005	26	No	No	No	Yes
Tworetzky et al. ⁹ 2004	14	No	No	No	Yes (30 mos)
Kohl et al. ¹⁰ 2000*	12	No	No	No	Yes
Maxwell et al. ¹¹ 1991	2	No	No	No	Yes
Intact atrial septum studies					
Marshall et al. ¹² 2004 ¹³ 2008	19	Yes	No	No	No
Mizrahi-Arnaud et al. ⁴ 2007	20	Yes	No	No	No

*These totals represent an unknown number of duplicated cases; estimated total of unique cases is 93.

Both fetuses developed restenosis of the valve which prompted delivery, one at 38 weeks + 2 days and the other at 35 weeks + 3 days. Both required postnatal balloon pulmonary valvuloplasty and systemic-to-pulmonary shunt. They were both reported to have biventricular circulation at 18 and 12 months of life.

Mizrahi-Arnaud's publication^{4,8} regarding experience with fetal hemodynamic instability in 83 fetuses undergoing 3 different fetal cardiac surgeries included 8 patients with pulmonary atresia with evolving hypoplastic right heart syndrome (HRHS). Six of the eight fetuses experienced major fetal hemodynamic instability (defined as fetal heart rate $\leq 110 \text{ min}^{-1}$ for ≥ 30 min with ventricular dysfunction of the dominant ventricle requiring resuscitation). There was no information provided on fetal inclusion criteria or survival of procedure, to birth, or beyond.

Critical aortic stenosis. Severe aortic stenosis, a very narrow aortic valve that develops early during gestation, may result in HLHS. In utero aortic balloon valvuloplasty has been suggested as a way to relieve aortic stenosis, thus preserving left ventricular growth and halting progression to HLHS.

The first described attempt at in utero balloon aortic valvuloplasty was reported by Maxwell in London in 1991. The same group reported the first survivor in a case report in 1995.¹⁴ Since then, there have been scattered attempts at this procedure around the world, but the most

abundant work has been performed by the fetal surgery team at Children’s Hospital Boston, Massachusetts.

Included publications. For this technical brief, we identified eight publications.⁴⁻¹¹ The fetal surgery team at Children’s Hospital Boston has published several papers about its experience with a series of patients undergoing balloon dilation for severe aortic stenosis, some with additional participants and others with followup of the same participants. There is one publication from the United Kingdom¹¹ and one publication that pools data from six international centers,¹⁰ including the aforementioned site in the United Kingdom. Two centers in Germany, two in Brazil, and an additional one in the United States (Pennsylvania) perform the procedures.

All publications are prospective case series that took place between 1989 and 2010. An estimated total of 90 fetuses underwent in utero balloon aortic valvuloplasty (the literature includes reports of 154 with some level of duplication). Seventy patients are from Boston. Technical successes have improved over time and appear to be related to center and team experience. In 2000, Kohl¹⁰ reported on 12 cases in 6 different centers in Europe, Brazil, and the United States (the first 2 reported cases were also published separately by Maxwell in 1991). Technical success was achieved in 7 of 12 (58 percent), but 4 of 7 (57 percent) of those fetuses died within 24 hours of the procedure. By 2009, McElhinney⁵ was reporting technical success in 52 of 70 (74 percent) cases with 5 of 50 (10 percent) of the technical successes resulting in fetal loss or stillbirth. Of the technical successes, 15 of 45 with live birth (33 percent) were born with a biventricular circulation, and 28 of 4,514 (62 percent) were born with HLHS. Of the 18 (26 percent) who had technical failures, 14 survived to birth, and all were born with HLHS. When the numbers of fetal deaths are included (excluding terminations for any reason), the rate of loss was 9 of 68 (13 percent) in those who underwent a procedure, whether successful or not, and 3 of 14 participants who declined procedures had neonatal deaths (21 percent). It is difficult to determine whether the procedure changes long-term outcomes, since it appears to increase risk of fetal loss but potentially prevent neonatal deaths

Table 4. Primary outcomes of maternal-fetal surgical procedures for cardiac malformations

Author, Year, Country	Key outcomes
Pulmonary atresia with intact ventricular septum	
Mizrahi-Arnaud et al. ⁴ 2007* U.S.	<ul style="list-style-type: none"> • Focuses on fetal hemodynamic instability (FHI), defined as fetal heart rate $\leq 110 \text{ min}^{-1}$ for ≥ 30 min with ventricular dysfunction of dominant ventricle. Major FHI if required resuscitation. Minor FHI if no intervention required • 6 of 8 (75%) had major FHI. More likely in younger fetuses ($p=0.03$) and those with hemopericardium ($p=0.07$) • No fetal outcomes regarding procedure success, survival to birth or neonatal survival are available
Tulzer et al. ³ 2002 Austria	<ul style="list-style-type: none"> • 2 fetuses with imminent hydrops (undefined) had valvuloplasty • 35 weeks and 38 weeks at birth; follow up at 12 and 18 months

Table 4. Primary outcomes of maternal-fetal surgical procedures for cardiac malformations (continued)

Author, Year, Country	Key outcomes
Aortic stenosis with developing HLHS	
McElhinney et al. ⁵⁻⁶ 2009	<ul style="list-style-type: none"> • 59 of 70 (84%) with attempted procedures survived to viability at birth • 15 of 50 (30%) with successful procedures had biventricular circulation at birth • Of those without biventricular circulation at birth (n=30), 2 died without intervention, 1 had heart transplant and died, 3 died after neonatal procedures; 2 achieved biventricular circulation via surgeries in childhood. • Prenatal aortic valvuloplasty does not reverse abnormally low cerebrovascular impedance observed in studies of cerebral blood flow in fetuses with HLHS.
Mizrahi-Arnaud et al. ⁴ 2007* U.S.	<ul style="list-style-type: none"> • No differentiation in outcomes between pulmonary valvuloplasty and aortic valvuloplasty so many outcomes are overall for both • 45% had major FHI • More likely in younger fetuses (p=0.03) and those with hemopericardium (p=0.07) • No fetal outcomes regarding procedure success, survival to birth or neonatal survival available
Wilkins-Haug et al. ⁷ 2006* U.S.	<ul style="list-style-type: none"> • Only assessed factors affecting technical success • Descriptive series 22 fetuses
Marshall et al. ⁸ 2005* U.S.	<ul style="list-style-type: none"> • 14 of 26 (54%) performed percutaneously • 22 cases laparotomies • 20 of 26 technically successful. Neither gestational age nor annulus size associated with technical success
Tworetzky et al. ⁹ 2004* U.S.	<ul style="list-style-type: none"> • Technical success in 14 of 20 • 2 of 14 in utero demise • 3 of 14 (21%) born with 2 functioning ventricles, 2 required procedures in first week of life • 6 of 14 had HLHS; of the technical failures, 1 of 6 terminated, 3 of 6 HLHS, 2 of 6 fetal demise
Kohl et al. ¹⁰ 2000 Europe, Brazil, U.S.	<ul style="list-style-type: none"> • 12 fetuses in 6 different centers in Europe, Brazil, U.S. • 5 technical failures; 1 of 5 (20%) of these survived long-term • 1 of 7 (14%) who survived prenatal intervention survived long-term • Four fetuses died within 24 hours after procedure from bleeding, bradycardia and valvotomy following emergency delivery; two cesarean sections and one chorioamnionitis
Maxwell et al. ¹¹ 1991 U.K.	<ul style="list-style-type: none"> • 2 fetuses with critical aortic stenosis. One fetal demise within 24 hours of technically unsuccessful procedure • One neonatal death from heart failure after one technically unsuccessful attempt and one successful attempt
Hypoplastic left heart with intact atrial septum	
Marshall et al. ¹³ 2008* U.S.	<ul style="list-style-type: none"> • 19 of 21 successful atrial septoplasty (excluded hydropic fetuses) • Fetal bradycardia, pericardial effusion, or pleural effusion in 8 of 21 (38%) • 12 of 19 required urgent intervention at birth • 7 of 19 underwent routine stage I postnatal surgery • Overall survival including two fetal demises 11 of 21 (58%)
Mizrahi-Arnaud et al. ⁴ 2007* U.S.	<ul style="list-style-type: none"> • Focuses on fetal hemodynamic instability defined as fetal heart rate ≤ 110 min⁻¹ for ≥ 30 min with ventricular dysfunction of dominant ventricle • No major (requiring resuscitation) fetal hemodynamic instability from septoplasty; Minor FHI (no intervention required) occurred in 1 patient

FHI = fetal hemodynamic instability; HLHS=hypoplastic left heart syndrome

*Overlapping populations

Three successive papers were published by the same group, each focusing on different aspects related to the procedure: technical characteristics of successful balloon dilation,⁸ examination of factors affecting technical success, and fetal hemodynamic instability during intervention. In all, they performed at least 50 attempts at in utero aortic valvuloplasty. Because

each of these subsequent studies has an independent focus, some during a very narrow time period, it is impossible to tell the overall success rate, survival to birth, and cardiac function and need for surgery postnatally. None of these publications focus on long-term outcomes, so it is difficult to determine whether there is an increase in biventricular function, and even whether any biventricular function is clinically superior to a univentricular circulation. There is also no published data discussing long-term survival and neurologic outcomes of these patients.

It does appear clear that technical success improves over time within a dedicated team and center. The group in Boston improved their success rate from 25 percent to 90 percent⁸ over a period of several years. All procedures were performed percutaneously except for 12 laparotomies for failed percutaneous attempts (due to fetal positioning and maternal habitus). This is the only information available regarding maternal inclusion criteria, and there is limited information on maternal outcomes.

Hypoplastic left heart syndrome and intact atrial septum. The Centers for Disease Control and Prevention (CDC) estimates that each year about 975 babies in the United States are born with HLHS.¹⁵⁻¹⁶ In other words, each year about 2 out of every 10,000 babies born will be born with HLHS. Given the high mortality of infants with HLHS and intact atrial septum, considered to be due to the pulmonary vasculopathy that develops before birth, in utero atrial septostomy has been performed in an attempt to improve postnatal survival. The first report of a balloon atrial septoplasty was in 2004. There is also a single case report using a laser to perform atrial septoplasty.¹⁷ In two cases of balloon septoplasty, teams were unable to achieve technical success due to inability to reach the fetal left atrium.¹⁷

Included publications. We identified four publications reporting on the creation in utero of an atrial septal defect (ASD). Of these, three met criteria for inclusion.^{4, 12-13} The fourth paper is the only published report using a laser to perform atrial septoplasty on a fetus but was excluded from evaluation since it was a single case report.¹⁸ The first report of in utero creation of an ASD was published in 2004 by a large academic center that specializes in fetal cardiac surgery.¹² All publications included were case series from this group and represent one distinct population with additional participants in each subsequent publication for a total of 24 patients between 2001 and 2007.¹³ There are no reports of this procedure being performed outside the United States.

Patients were consecutive fetuses diagnosed via fetal echocardiogram with HLHS and either an intact atrial septum or a ≤ 1 mm ASD. Three patients had hydrops fetalis and were excluded from evaluation in the more recent publication. The fetuses were between 23 and 34 weeks gestation at time of intervention. The atrial septum was approached from the right in all but two of the cases.

Technical success was defined by documentation of passage and inflation of the balloon catheter across the atrial septum and echocardiographic flow across a new septal defect.¹³ There was technical success in at least 19 of 21 cases (90 percent).¹²⁻¹³ At least two of the three hydropic cases were a technical success. The two technical failures were because the introducer could not reach the fetal left atrium due to a combination of introducer length, maternal habitus, and fetal position.¹³

Fetal complications occurred in 8 of 21 cases (38 percent) and included bradycardia, pericardial effusion, or pleural effusion. Complications occurred in five of nine cases (56 percent) with a larger cannula compared to three of 11 cases (27 percent, $p=0.36$) with a smaller cannula. Two fetuses, both which developed hemopericardium, died within 24 hours of the

procedure.¹³ At least one was hydropic. Another hydropic fetus died after delivery at 34 weeks due to respiratory compromise. All 19 underwent a stage I procedure, and overall surgical survival was 11 of 19 (58 percent). Of the non-hydropic fetuses, 12 of 19 (63 percent) required an urgent left atrial decompression and surgical survival was 5 of 12 (42 percent) compared to 5 of 7 (86 percent) in patients who underwent a routine stage I procedure.

No maternal selection criteria were provided. The average length of hospitalization was 2.4 ± 1 days.¹²⁻¹³ One woman developed preintervention mirror syndrome (a form of severe preeclampsia) and postoperatively developed an oxygen requirement, which resolved with diuresis, and cellulitis. No maternal deaths or blood transfusion were reported. There is no report of long-term maternal outcomes.

HLHS with intact atrial septum has a poor prognosis, despite the availability of aggressive postnatal surgical options. The attempts to improve the outcomes by creating an adequate atrial septum in utero to allow for a routine stage I palliation have met with technical success. However, the mortality remains high, and there are no randomized controlled trials available to adequately compare the outcomes in patients treated prenatally with those treated postnatally, especially regarding need for definitive postnatal surgical repair. There is no data available on long-term neurologic outcomes.

Summary of fetal cardiac intervention literature. The procedures for severe fetal cardiac anomalies are in developmental stages. As is the history in most areas of new surgical interventions, preliminary work is based in a few highly specialized centers which are laying the groundwork for better understanding the feasibility and subsequent directions for outcomes research in this area. Key informants in our process identified as the most pressing challenge in this area the ability to identify the “right” patient whose care would be compromised by waiting to do a postnatal repair. They stressed the need for more work in developing tools for patient selection in this area. Future research should also include better controlled observational studies and investigate animal and other models to assist in the evaluation of fetal cardiac intervention.

State of the Science: Congenital Diaphragmatic Hernia

Congenital diaphragmatic hernia (CDH) results from abnormal development of the diaphragm which allows abdominal organs like the bowel, the stomach, and the liver to protrude into the chest cavity. CDH is an important, relatively common congenital malformation, with incidence in the United States of approximately one in every 2,500 births.¹⁹⁻²⁰ Fetuses diagnosed in utero as a result of maternal symptoms have mortality risk approaching 75 percent in some older reviews. One of the paradoxes of diaphragmatic hernia care is a trend toward improved outcome of fetuses not diagnosed before birth. This may reflect the fact that less severe lesions, without the findings of liver in the chest, stomach in the chest, or increased amniotic fluid volume are less likely to be detected by routine ultrasound.

Less invasive fetal procedures have more recently focused on methods to accomplish tracheal occlusion. Occluding the trachea of a fetus results in buildup of lung secretions in the pulmonary tree, gradually distending the lungs as well as triggering complex changes in maturation, including DNA synthesis, epithelial and endothelial proliferation, increased phospholipid metabolism, and surfactant synthesis. The growing lungs push the bowel and abdominal contents out of the chest cavity to an extent and promote improved lung growth.

Included publications. Our search for reports of fetal interventions for congenital diaphragmatic hernia identified 25 publications²¹⁻⁴⁵ with 21 unduplicated populations.

These 21 studies included data from 10 U.S. sites, 9 European, 3 multinational, and 5 from other countries. The Harrison group at the University of California, San Francisco is responsible for the largest number of papers that met criteria for this review, with seven of the publications reflecting their institution and approaches. Of the 21 reports summarized here, 1 is a randomized clinical trial with 3 publications;^{21,29,38} 3 are prospective cohort studies;^{25,31,45} 5 are retrospective cohorts;^{22,35,37,41,43} and the balance are case series (Table 5).

Table 5. Summary of maternal-fetal surgical procedures for congenital diaphragmatic hernia

Author Year	Tracheal occlusion cases N	Other infants N	Fetal inclusion criteria?	Maternal inclusion criteria?	Comparison group	Outcome beyond neonatal hospital stay?
Randomized clinical trials						
Cortes et al. ^{21, 29, 38} 2005	11	13	Yes	Yes	No fetal procedure	Yes (24 mos)
Total	11	13	1 of 1	1 of 1	1 of 1	1 of 1
Prospective cohorts						
Cannie et al. ⁴⁵	40	18	Yes	No	No fetal procedure	No
Harrison et al. ³¹ 1998	8	13 (open repair) 13 (no procedure)	Yes	Yes	Open repair; no fetal procedure	No (unclear)
Harrison et al. ²⁵ 1997	0	4 (open repair) 7 (no procedure)	Yes	No	Open repair; No fetal procedure	Yes (24 mos)
Total	48	17, 38	3 of 3	1 of 3	23 of 3	2 of 3
Retrospective cohorts						
Sinha et al. ⁴³	31	55 (no procedure)	Yes	No	No fetal procedure	No
Saura et al. ⁴¹ 2007	13	6	Yes	No	No fetal procedure	Yes (6 mos)
Jani et al. ³⁵ 2005	24	37	Yes	No	No fetal procedure	No
Deprest et al. ²² 2004	21	17	Yes	No	No fetal procedure	No
Keller et al. ³⁷ 2003	16	40	Yes	Yes	No fetal procedure	No
Total	105	155	5 of 5	1 of 5	5 of 5	1 of 5

Table 5. Summary of maternal-fetal surgical procedures for congenital diaphragmatic hernia (continued)

Author Year	Tracheal occlusion cases N	Other infants N	Fetal inclusion criteria?	Maternal inclusion criteria?	Comparison group	Outcome beyond neonatal hospital stay?
Prospective case series						
Jani et al. ³⁶ 2006	28	NA	Yes	No	NA	No
Kohl et al. ³⁹ 2006	8	NA	Yes	Yes	NA	No
Total	36	NA	2 of 2	1 of 2	NA	0 of 2
Retrospective case series						
Peiro et al. ⁴⁴ 2009	18	NA	Yes	No	NA	No
Peralta et al. ⁴⁰ 2008	30	NA	Yes	No	NA	No
Heerema et al. ³³ 2003	17	NA	No	No	NA	No
Harrison et al. ^{27, 32} 1996, 2003	19	NA	Yes	Yes	NA	Yes (40 mos)
Harrison et al. ²⁸ 2001	2	NA	Yes	No	NA	Yes (18 mos)
Flake et al. ^{23, 42} 2000, 2009	15	NA	Yes	Yes	NA	Yes (24-48 mos)
Gibbs et al. ²⁴ 1998	11	NA	Yes	No	NA	Yes (48 mos)
Hubbard et al. ³⁴ 1997	3	NA	No	No	NA	No
Harrison et al. ²⁶ 1993	14	NA	Yes	No	NA	No (discharge)
Harrison et al. ³⁰ 1990	6	NA	Yes	No	NA	No
Total	135	NA	8 of 10	3 of 10	NA	4 of 10

The 2003 randomized trial compared fetal tracheal occlusion to intervention at birth.²⁹ Entry criteria for the trial included a lung-to-head measurement ratio (LHR) of less than 1.4, which in historical cohorts had resulted in a survival rate of less than 40 percent. Participants were randomized into strata of severity as indicated by this ratio. The endoscopic procedure was successfully carried out in 11 fetuses, two with a tracheal clip procedure and nine with an intra tracheal balloon procedure. The study was stopped after 24 participants because the findings revealed similar survival rates to 90 days of life: 73 percent for tracheal occlusion recipients and 77 percent for the group that did not receive fetal intervention, with no anticipation that continued study would be able to confirm statistically meaningful differences in outcomes in an acceptable timeframe. Infants in the treated group were delivered at a mean gestational age of 30.8 compared to a mean of 37.0 in the standard care group. Survival was significantly greater

regardless of treatment group in infants with LHR >0.90. Consequently subsequent studies have focused on fetuses with LHR <1.0 predicting worse survival.

The fetal surgery trial group had higher rates of prematurity and lower birth weights. Follow-up of those infants has revealed more than half of both those with and without fetal treatment have growth failure and neurodevelopment status is not significantly different (Table 6). This study highlighted the importance of having a concomitant control group as the survival for CDH with postnatal repair had also improved over time from the predicted 38 percent, to 77 percent.

Table 6. Primary outcomes of maternal-fetal surgical procedures for congenital diaphragmatic hernia

Author, Year, Country	Comparison groups (N)	Key outcomes
Randomized trial		
Cortes et al. ^{21,29,38} 2005 U.S.	G1: balloon tracheal occlusion (11) G2: no fetal procedure (13)	<ul style="list-style-type: none"> • Lung-to-head ratios <1.4 enrolled between 22 and 27 weeks' gestation • 8 of 11 (73%) occlusion recipients survived beyond 90 days • 10 of 13 (77%) without fetal surgery survived • Infants with occlusion were more likely to be born preterm • Growth failure (<2 SDs below mean) occurred in 56% of controls and 86% of infants who had occlusion • No neurodevelopmental differences at 1 or 2 years of age between groups
Prospective cohorts		
Cannie et al. ⁴⁵	G1: balloon tracheal occlusion (40) G2: no fetal procedure (18)	<ul style="list-style-type: none"> • No data about fetal deaths; does not include infants born before 32 weeks • Fetuses with balloon occlusion had increase in lung volume in utero relative to untreated • Earlier balloon occlusion (<29 weeks) was associated with greater increase in lung volume • In multivariate models endoscopic occlusion was an independent predictor of survival
Harrison et al. ³¹ 1998 U.S.	G1: open tracheal occlusion (13) G2: fetoscopic occlusion (8) G3: no fetal procedure (13)	<ul style="list-style-type: none"> • All fetuses with isolated left CDH and poor prognosis • 2 of 13 with open surgery survived to discharge • 7 of 8 (88%) endoscopic occlusion recipients survived • 5 of 13 (38%) without fetal surgery survived • Endoscopic approach superior
Harrison et al. ²⁵ 1997 U.S.	G1: open repair (4) G2: no fetal procedure (7)	<ul style="list-style-type: none"> • Repair at 25 weeks • 3 of 4 (75%) with in utero repair survived • 6 of 7 (86%) without fetal surgery survived • Fetal surgery was associated with preterm birth: mean gestational age attained: 32 weeks for surgery; 38 weeks for no fetal surgery
Retrospective cohorts		
Sinha et al. ⁴³ 2009 U.K.	G1: balloon tracheal occlusion (31) G3: no fetal procedure (55)	<ul style="list-style-type: none"> • Balloon occlusion for fetuses with ratio ≤ 1.0 • Analysis includes only liveborn infants • 16 of 31 (52%) with in utero repair survived neonatal course • 35 of 55 (64%) without fetal surgery survived • Lung-to-head ratio and best oxygenation index on first day of life were correlated with oxygenation status best predictor of survival
Saura et al. ⁴¹ 2007 Spain	G1: balloon tracheal occlusion (13) G2: no fetal procedure (6)	<ul style="list-style-type: none"> • Balloon occlusion done for fetuses with ratio <1.1 • Comparison group: 3 with ratio >1.4 and 3 without antenatal diagnosis • 8 of 13 (61%) with occlusion survived • 5 of 6 (83%) with good prognosis or no antenatal diagnosis survived

Table 6. Primary outcomes of maternal-fetal surgical procedures for congenital diaphragmatic hernia (continued)

Author, Year, Country	Comparison groups (N)	Key outcomes
Jani et al. ³⁵ 2005 Belgium	G1: balloon tracheal occlusion (24) G2: no fetal procedure (37)	<ul style="list-style-type: none"> • 12 of 24 (50%) with occlusion survived to 28 days of life • The no fetal surgery group included 5 decisions for termination • 3 of 32 (9%) without fetal surgery survived • Fetal surgery reduced gestational age at birth with mean of 33 weeks
Deprest et al. ²² 2004 Belgium	G1: balloon tracheal occlusion (21) G2: no fetal procedure (17)	<ul style="list-style-type: none"> • Median gestational age at balloon placement: 26 weeks • 10 of 21 (48%) with occlusion survived • 11 of 12 (92%) without fetal surgery survived • 5 cases ended in pregnancy termination
Keller et al. ³⁷ 2003 U.S.	G1: balloon tracheal occlusion (16) G2: no fetal procedure (40)	<ul style="list-style-type: none"> • All fetuses with isolated left CDH and liver herniation and no other anomalies • 11 of 16 (69%) with occlusion survived to discharge • 17 of 40 (43%) of those without fetal surgery survived • Calculation of lung-to-head ratio in CDH is a strong predictor of survival; above ratios of 1.0 risk of death plateaus

CDH=congenital diaphragmatic hernia; SD=standard deviation

Among the cohort studies of tracheal occlusion, survival ranged from 48 percent to 75 percent among treated fetuses and 8 percent to 65 percent among the untreated (Table 6), with the high end likely reflecting less severe disease. The sole well-documented exception to these ranges was the note that a favorable prognosis, as gauged by higher LHR (>1.1), had an 83 percent survival among the untreated.⁴¹ In that cohort there were no treated fetuses who did not have a ratio of less than 1, meaning they were all in the poor prognosis group.

Case series reflect the evolution of methods for treatment with consistent movement toward the improved outcomes observed in the cohorts and trials. In an initial report of eight fetuses using tracheal occlusion there was one survivor.²⁷ The first attempt was done using a foam plug to occlude the trachea in two fetuses which caused tracheomalacia in the first and did not create enough of a seal in the second to prevent hypoplasia.²⁷ In the same report, six subsequent fetuses were treated with a tracheal clip, all six delivered prematurely, and all died from complications of their disease or prematurity or a combination. Another series of 15 open procedures had 5 survivors, and studies of lung specimens suggested fetal lung growth increased but was not uniformly associated with normal tissue structure.^{23,42} Subsequent patient series added further experience that lead up to the trial.²⁹

A number of recent case series reports from Europe and the United States have been published. Endoscopic placement of a specialized balloon originally designed for vascular embolization was reported in 18 of 21 unique publications. Occlusions in Europe are now often performed by obstetric groups with expertise in endoscopic treatment using a new generation of detachable balloons.^{39-41,43-45} Outcomes continue to trend toward favorable survival rates and lower risk of prematurity.

This literature has been focused primarily on short-term outcomes since congenital diaphragmatic hernia has such a high mortality. Long-term infant and maternal outcomes have been evaluated in few studies, with the longest followup of infant outcomes being between 24 months^{21,25} and 48 months.^{23-24,27} Long-term maternal outcomes were addressed carefully in the early U.S. series, and future maternal fertility was documented in one series.³⁰ For CDH, it is important to look at later outcomes since there is a significant postneonatal mortality reported in those groups that continue to follow their cohort.

All but one study provided good documentation of fetal inclusion criteria; only nine adequately described maternal inclusion criteria. The majority of studies did a thorough job of describing surgical approach. Though endoscopic devices are used, most of the procedures were done with a maternal laparotomy incision, often described as a minilaparotomy, prior to placement of trocars through the uterus. Open repairs were the primary use of full hysterotomy in 4 studies, and 6 of 21 papers described completely transcuteaneous approaches. Use of both general and epidural anesthesia was common; some teams added fetal anesthesia and described their approach in publications; seven studies did not address anesthesia. A subset did not address details of the intraoperative and postoperative monitoring of mother and fetus; those that did were comprehensive and helpful in fully understanding the evolving standard of care. Outcomes assessed reflect lack of attention to longer term outcomes and maternal risks (Table 17).

Many questions remain including: What diagnostic approaches best predict prognosis? Which fetuses would benefit from treatment? When in gestation should the occlusive device be placed, and when in the gestation should the occlusive device be removed? The FETO Task group in Europe is using as a control group a multicenter study of 86 fetuses with left-sided CDH and liver herniation, which were managed expectantly and were live born after 30 weeks of gestation. In the control group, the survival rate increased from zero percent for those with LHR of 0.4 to 0.7 to about 15 percent for LHR of 0.8 to 0.9, 65 percent for LHR of 1.0 to 1.5, and 83 percent for LHR of 1.6 or more.⁴⁶ This European series, which continues to add participants, has an 11 percent survival for LHR <1 and can serve as an ongoing reference point for expectations among untreated poor prognosis pregnancies in Europe as it is not possible to directly compare outcomes between Europe and the United States, given the difficulty in reconciling different postnatal survival rates.³⁷ In the United States, multiple centers are working on device development or approval processes for an improved balloon to be used for tracheal occlusion.

Summary of congenital diaphragmatic hernia literature. Case reports comprise the bulk of the CDH literature and reflect movement toward improved outcomes for infants with CDH. The single randomized trial of in utero CDH therapy located for this review similarly reflects improved survival rates for fetuses treated with tracheal occlusion and infants treated at birth. Long-term outcomes, however, are not well reported, and significant questions about fetal treatment for CDH remain.

State of the Science: Myelomeningocele/Spina Bifida

Background. Myelomeningocele (MMC) is a congenital malformation in which the meninges and spinal cord protrude through a defect in the vertebral arches, muscle, and skin. It is the most commonly observed malformation of the central nervous system, affecting more than 1,000 fetuses in the United States annually.⁴⁷ MMC is the most common form of spina bifida, and although it is rarely fatal, individuals affected with it have a range of disabilities, including paraplegia, hydrocephalus, skeletal deformities, bowel and bladder incontinence, and cognitive impairment.

The standard treatment has been to close the defect postnatally, and shunting for hydrocephalus is common.

Table 7. Summary of studies of maternal-fetal surgical procedures for myelomeningocele (MMC)

Author Year	With fetal procedure N	Without fetal procedure N	Fetal inclusion criteria provided?	Maternal inclusion criteria provided?	Comparison group	Outcomes beyond neonatal hospital stay?
Randomized clinical trials						
None						
Prospective cohorts						
Tubbs et al. ⁴⁸⁻⁴⁹ 2003	37	40	Yes	No	No fetal procedure	Yes (36 mos)
Bruner et al. ⁵⁰ 1999	29	23	Yes	No	No fetal procedure	Yes (6 mos)
Retrospective cohorts						
Danzer et al. ⁵¹ 2007	22	16	No	No	No fetal procedure and age matched controls	No
Adelberg et al. ⁵² 2005	14	39	Yes	No	No fetal procedure	No
Hamdan et al. ⁵³ 2004	37	74	No	No	Other preterm infants	No
Tulipan et al. ⁵⁴ 2003	104	189	Yes	No	No fetal procedure	Yes (>12 mos)
Bruner et al. ⁵⁵ 2000	8	--	Yes	No	Endoscopic surgery	Yes (12 mos)
Prospective case series						
None						
Retrospective case series						
Wilson et al. ^{56-59,60,61-65} 2007	54	--	Yes	Yes	NA	Yes (36 mos)
Bruner et al. ⁶⁶⁻⁷¹ 2004	177		Yes	No	NA	Yes (36 mos)
Farmer et al. ⁷²⁻⁷³ 2003	13	--	Yes	No	NA	Yes (45 mos)
Bruner et al. ⁷⁴ 1999	4 (endoscopic)		Yes	No	NA	No
Grand total	262	413	10 of 11	1 of 11		8 of 11

(All patients represented in the total for retrospective cohorts except the Adelberg study are part of the series of patients totaled in the case series.)

Animal research suggested that covering the defect early on could potentially result in better lower extremity and bladder function. Myelomeningocele repair was the first in utero surgery considered for a nonlethal malformation on the basis that its natural history was well known and leads to lifelong disability in the absence of intervention. Furthermore, the defect can be diagnosed prenatally in over 80 percent of cases by maternal serum alpha-fetoprotein and ultrasound; MRI is used to detect specific anomalies and disease process.

The procedure was initially performed by Bruner and colleagues as a closed laparoscopic covering of the spinal defect. The first case was reported in a letter, and a case series describing four fetuses was published in 1999 (the surgeries were conducted between 1994 and 1997).⁷⁴ Half of the fetuses survived, and both survivors required shunting. In a continuation of this work, four fetuses were operated on using an open approach and compared to four done endoscopically,⁵⁵ and the open surgery showed improved outcomes, while the endoscopic

approach had high mortality. The endoscopic approach has been abandoned, and therefore the rest of this overview will focus on literature related to open surgery for MMC repair. Since 1997, more than 200 fetuses with MMC have undergone open surgical repair in the United States.

Included publications. Our search identified 27 publications⁴⁸⁻⁷⁴ that provided outcomes of surgery, two of which were on the use of endoscopic approach,^{55,74} these publications comprise 11 unique studies. These surgeries have taken place at four academic centers in the United States, but to date have not been in the context of a randomized controlled study (RCT). All nine analyses of open surgery are based on four series of patients, although varying study designs were used to analyze the data. For that reason, there are duplicate patients represented in different studies of publications as represented in Table 7. Where authors have presented serial groups of overlapping patients as case series have grown, we focus our discussion on the most complete set, but where there are subanalyses with specific comparisons, those are indicated.

Two studies, including overlapping patients from one center, had concurrent comparisons.^{48,50} The first study analyzed the first 29 cases of open MMC repair at Vanderbilt University Medical Center, and found significant reductions in the need for postnatal shunt placement (51 percent versus 91 percent; $p=0.01$) and reduced hindbrain herniation (38 percent versus 95 percent; $p<0.001$). However, the two prospective studies found greater rates of oligohydramnios among those with in utero repair (48 percent versus 4 percent; $p=0.001$), lower gestational ages in this group (33.2 weeks versus 37 weeks; $p<0.001$)⁵⁰ and no difference in lower extremity function.⁴⁸

Six retrospective cohort analyses were conducted,^{49,51-55} representing three patient populations. Of the five papers that included only open surgery, four used as their comparison group infants who had undergone postnatal repair.^{49,51-52,54} Again, substantially lower rates of postnatal shunt placement were observed (58 percent versus 92 percent) as well as lower incidence of hindbrain herniation (4 percent versus 50 percent).⁴⁹ In a small series at one institution based on 14 repairs, no differences in ventricular progression were observed between the groups.⁵² Two of the academic centers with larger series combined their data and conducted the largest retrospective analysis.⁵⁴ Although results of in utero repair were apparently positive in many of the prior studies, the question had been raised as to whether fetuses selected for in utero repair were fundamentally different than others in features affecting the risk of hydrocephaly, specifically lesion location. With this larger cohort, the investigators were able to stratify their results on lesion location and found statistically significant reductions in shunting relating to repairs of lumbar and sacral lesions, but not thoracic ones. They further observed an age effect whereby there was no improvement in fetuses whose repairs occurred after 25 weeks' gestation, supporting the theory that early intervention is essential.⁵⁴

Case series in these sets of patients showed results generally in line with the comparative studies described above, including rates of shunting about half those seen in postnatal repairs, reversal of hindbrain herniation, and positive rates of cognitive language and personal skills after 3 years (67 percent).^{53,56-71}

Table 8. Primary outcomes of maternal-fetal surgical procedures for MMC

Author, Year, Country	Comparison groups, (N)	Key outcomes
Danzer et al. ⁵¹ 2007 U.S.	G1: in utero repair G2: postnatal repair G3: age-matched non-MMC patients	<ul style="list-style-type: none">• In utero repair was associated with increased normalization of the posterior fossa CSF spaces• Brain thickness was reduced in both pre- and postnatally repaired patients compared to age-matched comparators without MMC
Wilson et al. ⁵⁶⁻⁶⁵ 2007 U.S.	G1: in utero repair (58)	<ul style="list-style-type: none">• 94% of fetuses survived, with a mean age at delivery of 34 weeks, 3 days• 100% demonstrated reversal of hindbrain herniation; 43% required shunting• Better than predicted leg function seen in 57% of thoracic and lumbar patients• At 2 years of age, 30 returned for neurodevelopmental testing• 67% had cognitive language and personal skills in normal range, 20% had mild delays and 13% has significant delays
Adelberg et al. ⁵² 2005 U.S.	G1: in utero repair (14) G2: postnatal repair (39)	<ul style="list-style-type: none">• Study intended to measure ventriculomegaly in utero compared to that associated with postnatal repair• No difference in ventricular progression was observed
Bruner et al. ^{66,67-68,70-71} 2004 U.S.	G1: in utero repair (177)	<ul style="list-style-type: none">• 61/116 fetuses with 12 mos followup required shunt (54%)• Strongest predictor of shunt requirement was upper level lesion, followed by greater gestational age (>25 wks) and ventricular size of >14mm• Among the first 95 infants, no difference in gestational age at delivery based on gestational age at repair (before or after 25 weeks)• Among 9 patients, ultrasound pre- and post- in utero repair showed reversal of preexisting hindbrain herniation
Hamdan et al. ⁵³ 2004 U.S.	G1: infants born prematurely post in utero repair G2: infants born prematurely without MMC	<ul style="list-style-type: none">• Rates of prematurity related complications (RDS, length of stay, IVH) were similar between infants born prematurely, post- in utero surgery and others without MMC born prematurely
Farmer et al. ^{72,73} 2003 U.S.	G1: in utero repair fetoscopic (3); open (10)	<ul style="list-style-type: none">• 56% required shunt by one year compared to 90% in historical controls at the site• 7 patients were examined for bladder function at 1 month• Urodynamic patterns were similar to patients in other studies undergoing postnatal repair
Tubbs et al. ⁴⁸⁻⁴⁹ 2003 U.S.	G1: in utero repair (37) G2: postnatal repair (40)	<ul style="list-style-type: none">• No difference in lower extremity function between G1 and G2• Substantially lower incidence of hindbrain herniation among in utero repair group compared to historical cohort of postnatal repair (4% vs. 50%)⁴⁹• Lower incidence of shunting in in utero repair group compared with historical postnatal repair group (58% vs. 92%)⁴⁹

Table 8. Primary outcomes of surgical repair of MMC (continued)

Author, Year, Country	Comparison groups, (N)	Key outcomes
Tulipan et al. ⁵⁴ 2003 U.S.	G1: in utero repair (104) G2: postnatal repair (189)	<ul style="list-style-type: none"> • Combined data from Vanderbilt Medical Center and Children's Hospital of Philadelphia • Statistically significant reductions in shunting at lumbar and sacral lesion levels, but not for thoracic lesions • No statistically significant differences in fetuses older than 25 weeks gestation
Bruner et al. ⁵⁵ 2000 U.S.	G1: endoscopic repair (4) G2: open (4)	<ul style="list-style-type: none"> • 2 survivors in the endoscopic group compared to 4 in the open surgery group • Both survivors in the endoscopic group required shunting compared to 2 of 4 in the open surgery group
Bruner et al. ⁵⁰ 1999 U.S.	G1: in utero repair (29) G2: postnatal repair (23)	<ul style="list-style-type: none"> • First 29 cases of open surgery at Vanderbilt Medical Center • 51% of in utero cases required shunting compared to 91% of postnatal repairs (p=.01) • Reduced hindbrain herniation among in utero repairs (38% vs. 95%; p<.001) • Greater oligohydramnios among in utero repairs (48% vs. 4%; p=.001) • Gestational age for in utero patients 33.2 vs. 37 for postnatal repair patients (p<.001)
Bruner et al. ⁷⁴ 1999 U.S.	G1: endoscopic repair	<ul style="list-style-type: none"> • 2 of 4 survived past 1 month after delivery

CSF=cerebrospinal fluid; IVH=intraventricular hemorrhage; MMC=myelomeningocele; RDS=respiratory distress syndrome

However, the procedure itself is not benign, and as with any surgery, the risk of maternal morbidity and mortality exists. Limited long-term data are available to assess maternal risks both in the immediate postoperative period and related to longer term fertility and none available in the studies that met inclusion criteria for this review. In addition, fetuses treated in utero routinely deliver prematurely, and outcomes related to prematurity may be the greatest challenge to evaluating the benefit of the surgical repair. Hamdan et al.⁵³ found that rates of prematurity-related complications were no higher among infants born prematurely with MMC after in utero repair compared to those without MMC also born prematurely, suggesting that the procedure is not associated with worse side effects. Nonetheless, absent the in utero repair, patients with MMC could very well have delivered at term. These reasons combined with concerns that past study designs simply do not ensure comparable groups for analysis led the NIH to fund an RCT, which is currently ongoing. Known as the MOMS trial, this study is taking place at three of the centers whose work is represented in this section. The trial will enroll 200 mother-fetus pairs, and at this time, there is a voluntary moratorium in the United States on conducting in utero repair of MMC outside of the trial. Several of our key informants and experts in the literature⁷⁵ suggested that this trial appropriately put a stop to a proliferation of centers doing in utero MMC repair based on enthusiasm but inadequate evidence.

Summary of the MMC literature. As is the case with other in utero repairs, evidence about MMC fetal surgical procedures from more rigorous studies is lacking; much of the MMC literature located for this review comprised retrospective cohorts and case series. Long-term followup of infants treated prenatally is limited, as are outcomes for mothers. No studies included in this review addressed long-term maternal fertility outcomes. Overall trends from

cohorts and case series include reduced shunting after fetal surgical repair of MMC and positive rates of language development and personal skills after three years. The ongoing MOMS trial should augment the MMC evidence base and help to inform families' and clinicians' decisionmaking.

Addendum. As this report was in press, results from the Management of Myelomeningocele Study (MOMS) were published in the New England Journal of Medicine (February 9, 2011). The study's findings add to the body of literature on maternal-fetal surgical procedures for myelomeningocele:

- The RCT reports results from 158 women participating between February 2003 and the trial's early termination based on evidence for the efficacy of prenatal surgery in December 2010. Among these 158 participants, 78 were randomized to prenatal surgery before 26 weeks gestation and 80 to postnatal repair after cesarean delivery at 37 weeks (if undelivered).
- Primary outcomes included a composite of fetal or neonatal death or the need for cerebrospinal fluid (CSF) shunt (placement or meeting criteria for placement) at 12 months of life and a composite score on the Mental Development Index of the Bayley Scales of Infant Development II and motor function at 30 months.
- There were 2 deaths in each group (relative risk [RR], 95 percent confidence interval [CI]: 1.03, 0.14 to 7.10). Overall, 68 percent of prenatal group infants and 98 percent of postnatal group infants either died or required CSF shunt/met shunt criteria by 12 months (RR, 95 percent CI: 0.70, 0.58 to 0.84, $p < 0.001$). Forty percent ($n=31$) of infants in the prenatal group and 82 percent ($n=66$) in the postnatal group required shunt placement ($p < 0.001$).
- Composite scores on the Bayley Mental Development Index were significantly better in the prenatal group compared with the postnatal group ($p=0.007$); motor function and ability to walk without orthotics were also better in the prenatal group as were parent-reported self-care and mobility.
- Prenatal surgery was associated with higher rates of preterm birth, intraoperative complications, maternal transfusion, and uterine scarring. Rates of chorioamniotic membrane separation, spontaneous membrane rupture, and spontaneous labor were higher in prenatal surgery participants.
- Though the trial was stopped early by the study's data safety monitoring board for positive results, the investigators note maternal and fetal risks including preterm delivery and uterine dehiscence.
- This RCT brings the total number of RCTs in the maternal-fetal surgery literature to four; it is the only randomized trial of assessing intervention for myelomeningocele. The study is of additional importance as a model for the field as investigators, working in collaboration with NIH, did not offer the procedure outside the trial during the duration of the study, helping to assure the feasibility of obtaining sufficient participants from around the country to obtain high quality data.

State of the Science: Obstructive Uropathy

Background. A variety of fetal malformations can lead to distention of the urinary bladder; these include urethral atresia (failure of the bladder stem to properly form so urine cannot exit), posterior urethral valves (which in male fetuses can prevent flow of urine through the full length

of the urethra); and megacystis-megaureter-microcolon syndrome (which results from malformation of the organs rather than frank blockage of urine flow), and prune-belly syndrome (which includes lack of development of abdominal muscles, undescended testicles, and urinary anomalies). Other urinary tract anomalies can result in distension of one or both ureters, such as blockage at the junction with the bladder or at any place along the ureter, which conveys urine from the kidney to the bladder. In this case when there is renal function and a ureteral impass, the distended portion of the urinary tract is the ureter or renal pelvis rather than the bladder.

Goals of fetal therapy have emphasized decompression rather than repair of the specific lesion. The goal of decompression of the distended portion of the urinary tract is to protect remaining renal function and to promote lung development. Challenges with increased preterm birth and comparable outcomes with open shunting procedures have resulted in a trend to percutaneous shunting procedures dominating the literature. After a small incision in the maternal skin, generally with local anesthesia only, the shunt is inserted through an introducer sheath into position within the fetal bladder. An internal guide or stylus within the shunt is withdrawn, allowing a prefabricated curl or “pigtail” to form at the distal end that helps hold the device within the fetal bladder. As the introducer is completely withdrawn, a second pigtail forms on the opposite end to hold the shunt outside the fetus and to assure drainage of urine into the amniotic cavity. When the shunt type or method was noted by authors to vary from this, we have indicated the difference.

Included publications. Our search indentified 26 publications representing 25 unduplicated reports about fetal interventions for obstructive uropathy. The publication that duplicates the same study population⁷⁶ is superceded in this summary by the original report.⁷⁷ We did not include reports that only focused on vesicocentesis, because this approach does not reach the degree of complexity to be considered a fetal surgical procedure and is most often reported as a diagnostic procedure to gauge renal function to inform decisions about choice of therapy. We recognize that the 25 identified publications include duplication of individual mothers and babies.

Table 9. Summary of studies of maternal-fetal surgical procedures for obstructive uropathy

Author Year	Shunt procedure N	Without this fetal procedure N	Fetal inclusion criteria?	Maternal inclusion criteria?	Comparison group	Outcome beyond neonatal stay?
Randomized clinical trials						
None						
Prospective cohorts						
Welsh et al. ⁷⁸ 2003	3	10	Yes	No	Hydroablation and/or guidewire passage	Yes
Quintero et al. ⁷⁹ 1995	6	7	Yes	No	No fetal procedure (6); disruption of PUV (1)	No
Johnson et al. ⁸⁰ 1994	15	8	Yes	No	No fetal procedure	Yes (18-66 mos)
Total	24	25	3 of 3	0 of 3	2 of 3 include no treatment	2 of 3
Retrospective cohorts						
Salam et al. ⁸¹ 2006	12	46	Yes	No	No fetal procedure	Yes (mean 47 mos)
Wilson et al. ⁸² 2003	3	3	No	No	No fetal procedure	No
Warne et al. ⁸³ 2002	2	4	No	No	No treatment (All had suspected cloacal anomalies)	Yes (poorly specified)
Holmes et al. ⁸⁴ 2001	9	5	No	No	Bladder marsup- ialization (2); ablations of PUV (2); cutaneous ureterostomy (1)	Yes (mean 139 mos)
McLorie et al. ⁸⁵ 2001	9	3	Yes	No	No fetal procedure	Yes (mean 42 mos)
Freedman et al. ⁸⁶ 1996	28	27	Yes	No	No fetal procedure	No
Cromble- holme et al. ⁸⁷ 1990	19	21	Yes	No	No fetal procedure	No
Harrison et al. ⁷⁷ 1982	5*	21	Yes	No	No fetal procedure	Yes (ad hoc)

Table 9. Summary of studies of maternal-fetal surgical procedures for obstructive uropathy (continued)

Author Year	Shunt procedure N	Without this fetal procedure N	Fetal inclusion criteria?	Maternal inclusion criteria?	Comparison group	Outcome beyond neonatal stay?
Total	87	130	5 of 8	0 of 8	7 of 8 include no treatment	5 of 8
Prospective case series						
Araujo et al. ⁸⁸ 2007	13	NA	Yes	No	NA	No
Craparo et al. ⁸⁹ 2007	12	NA	Yes	No	NA	Yes (3-36 mos)
Biard et al. ⁹⁰ 2005	31	NA	Yes	No	NA	Yes (70 mos)
Makino et al. ⁹¹ 2000	5	NA	Yes	No	NA	Yes (0-48 mos)
Freedman et al. ⁹² 1999	14	NA	Yes	No	NA	Yes (54 mos)
Evans et al. ⁹³ 1991	3	NA	Yes	No	NA	Yes (3-36 mos)
Manning et al. ⁹⁴ 1986	73	NA	No	No	NA	No
Total	151	NA	6 of 7	0 of 7	NA	5 of 7
Retrospective case series						
Gehring et al. ⁹⁵ 2000	3	NA	No	No	NA	No
Shimada et al. ⁹⁶ 1998	6	NA	No	No	NA	Yes (1-14 mos)
Pinckert et al. ⁹⁷ 1994	2	NA	No	No	NA	Yes (2-4 mos)
Bernaschek et al. ⁹⁸ 1994	13	NA	No	No	NA	No
Robichaux et al. ⁹⁹ 1991	2	NA	No	No	NA	No
Crombleholme et al. ¹⁰⁰ 1988	5	NA	No	No	NA	Yes (24-36 mos)
Manning et al. ¹⁰¹ 1983	2	NA	Yes	No	NA	Yes (6 mos)
Total	33	NA	1 of 7	0 of 7	NA	4 of 7

PUV=posterior urethral valves

* Varied therapeutic approaches (vesicoamniotic shunt, transcutaneous catheter drainage, hysterotomy with repair)

Of the 25 publications, 13 originate from research in the United States;^{77,79-80,84,86-87,90,92-93,95,97,99-100} 4 from Europe;^{78,83,89,98} 3 from Canada,^{82,85,101} 2 from Japan,^{91,96} and 1 each from Egypt,⁸¹ Brazil,⁸⁸ and the International Fetal Surgery Registry.⁹⁴

Three publications were prospective cohorts;^{78,80,94} eight were retrospective cohorts;^{77,81-87} seven were prospective case series;⁸⁸⁻⁹⁴ and seven were retrospective case series.⁹⁵⁻¹⁰¹

Prospective cohorts. Among the three prospective cohort studies,^{78,80,94} none restricted to a single underlying pathology. Two groups⁷⁸⁻⁷⁹ performed in utero cystoscopy to evaluate the urinary outflow tract and bladder. Each performed some maneuvers to attempt to establish patency of the urethra when applicable. One group placed transurethral shunts when possible during the cystoscopy⁷⁹ and the other used cystoscopy in a phased process in which recurrence or

persistence of obstruction was the indication for subsequent shunt placement.⁷⁸ Another publication reports the predictive value of urinary electrolyte and protein analysis obtained by vesicocentesis as a prognostic guide to likely disease severity; some fetuses with both poor and good prognosis (based on their hypothesis) received shunts.⁸⁰

In total (Tables 13 and 14), 24 fetuses had placement of shunts in these studies; 11 had hydroablation or other disruption of posterior urethral valves (PUV); 14 fetuses had no fetal intervention; and another 13 pregnancies were terminated given clinical assessments of very poor prognosis. Overall, 53 percent to 66 percent of infants who had shunt placement survived short term (Table 10). Long-term data is scant and no longer than early childhood (Table 10). Prognosis was most easily established for dire cases without urine production and with poor lung development. For cases in which there was fetal urine production, diagnostic testing of fetal urine did not cleanly segregate those who would do well without intervention or the outcomes of intervention. The range of sensitivity for urine markers for predicting “absence of significant underlying renal damage” from last urine specimen obtained was 0.88 to 1.00; specificity ranged from 0.47 to 0.84, with positive predictive values between 0.47 and 0.77.¹⁰² From another vantage point, ability to predict absence of renal dysplasia from urine markers in a related study was reported with sensitivity 0.17 to 1.00, specificity 0.27 to 0.91, and positive predictive value 0.43 to 1.00.⁸⁰ Small sample sizes significantly limit the ability to draw definitive conclusions, but it is helpful to have those cases that received no fetal intervention, or who had alternate interventions, receiving the balance of their care within similar protocols in the care of the same providers. These studies also provide evidence of feasibility of fetal cystoscopy for diagnostic evaluation and in some cases direct treatment of obstruction.

Each group reported on fetal eligibility criteria, none reported maternal inclusion criteria, none reported the approach to maternal anesthesia or analgesia, and none, other than noting ultrasound guidance, provided information about the monitoring of fetal well-being during or immediately after the procedure. One report⁸⁰ noted that 6 of 15 shunt placements required a second procedure to replace the shunt, while others did not comment on this aspect of care. Maternal complications were not systematically documented, and infections were only noted in the context of reasons for poor fetal outcomes on a case-by-case basis, such as noting that an infant died in utero secondary to chorioamnionitis. The status of renal function and need for transplant was well documented in these prospective cohorts, though duration of followup was varied within studies and overall limited. In contrast, pulmonary status was noted by only one report,⁸⁰ and neonatal and early childhood developmental status was not addressed in any of the publications. Table 17 summarizes the outcomes assessed by procedure type.

Retrospective cohorts. Eight studies^{77,81-87} reported on cohorts from clinical medical or fetal surgery program records. One study reports on the urological outcomes of infants known to have been shunt recipients who presented for urologic care in infancy and for whom the denominator of total shunt recipients is unknown so direct comparisons to surgical cohorts are inappropriate.⁸¹ All retrospective cohorts have small number of treated fetuses (2 to 28) and small comparison groups (3 to 46), with a total of 87 shunt recipients and 130 comparison group members in the eight cohorts. With one exception composed of small numbers of varied surgical approaches,⁸⁴ the comparison groups are affected pregnancies without fetal intervention.

Short-term survival to birth and/or hospital discharge ranged from 30 percent in a poor prognosis group, to 88 and 100 percent in the good prognosis group, and 57 to 75 percent for typical obstructive conditions not stratified by risk (Table 10). In the sole cohort of female

infants with cloacal anomalies, both infants who had a shunt placed survived.⁸³ A commonality across studies is that survival is not a sign that risk of renal compromise is low. Risk of renal compromise is 31 percent across all retrospective cohorts, with the majority of smaller cohorts closer to 50 percent (Table 10). Among those infants with renal compromise the plurality progressed to dialysis and transplant. The exceptions were noted early in the history of fetal intervention of obstructive urinary tract conditions—fetuses with unilateral ureteral obstruction do well without intervention, and the majority have normal renal function after postnatal intervention.⁷⁷ and infants with clusters of concomitant anomalies fare worse than those with isolated obstructive conditions.

Five of eight studies described the fetal eligibility criteria used to determine appropriateness for shunt placement; none reported use of any maternal eligibility restrictions. A subset of studies in this group have longer follow-up, one to an average of 11 years.⁸⁴ Three studies do not follow infants past the initial neonatal admission, and two studies poorly specify whether there was a systematic effort to achieve followup through a specific time in childhood; thus it is difficult to know if complete ascertainment of outcomes was obtained (Table 10). No single study in this group was large enough to conduct multivariable analysis to adjust for candidate confounders or modifiers of treatment outcomes; and in aggregate the number of participants would fall short of that needed for meta-regression.

No studies reported maternal inclusion criteria or outcomes in a systematic fashion. One study described the type of anesthesia or analgesia provided for procedures,⁷⁷ and no studies reported on monitoring of fetal well-being during or immediately after procedures beyond ultrasound during the procedure and to check shunt location and obstruction status after procedures. All studies reported on survival to birth and into infancy; seven of eight make note of preterm births and complications associated with prematurity; all make some note of assessment of renal function, and four of eight note pulmonary morbidity and sequelae. Pulmonary outcomes were overwhelmingly those close to birth, such as duration of ventilation. In individual cases, chronic pulmonary dysfunction was noted, but these assessments did not have any apparent uniformity. No retrospective studies had access to information about neurologic status in the neonatal period or later; and a single study reported that half of infants with a history of obstructive uropathy had abnormal growth patterns (diminished height and weight) into childhood.⁸⁵

Table 10. Primary outcomes of maternal-fetal surgical procedures for obstructive uropathy

Author, Year Country	Comparison groups, (N)	Key outcomes
Prospective cohorts		
Welsh et al. ⁷⁶ 2003 U.K.	G1: vesicoamniotic shunt after attempted hydroablation (3) G2: hydroablation and/or guidewire passage through cystoscope (7)	<ul style="list-style-type: none"> • 2 of 3 (66%) shunt recipients survived to infancy • 1 had normal kidney function, 1 poor function at 22 months • 1 of 3 died of complications of preterm premature rupture of membranes at 22 weeks • 6 hydroablation/guidewire procedures achieved technical success/patency of the bladder outlet • 4 of 7 (57%) survived to infancy; 1 pregnancy was terminated; 1 miscarriage (20 weeks), and 1 IUFD

Table 10. Primary outcomes of maternal-fetal surgical procedures for obstructive uropathy (continued)

Author, Year Country	Comparison groups, (N)	Key outcomes
Quintero et al. ⁷⁹ 1995 U.S.	G1: vesicoamniotic shunt (6) G2: no fetal procedure (7)	<ul style="list-style-type: none"> Fetal cystoscopy was possible in 11 of 13 cases, patency established in 1 case 2 transurethral vesicoamniotic shunts placed 4 of 6 (66%) shunt recipients survived to hospital discharge 1 pregnancy terminated after shunt Of the four survivors with shunts, no data is available about renal function at birth or longer term outcomes
Johnson et al. ⁸⁰ 1994 U.S.	G1: vesicoamniotic shunt (15) G2: no fetal procedure (8)	<ul style="list-style-type: none"> 8 of 15 shunt recipients (53%) survived to infancy 3 deaths (one in utero) among those with good antenatal prognosis prior to shunt; 4 among those with poor prognosis Among the 8 fetuses observed, 3 had resolution of obstruction and survived (38%) and 5 died in utero Those shunted had better prognosis based on urinary analysis of fetal renal function During evaluation, prior to decisions about intervention options, 11 pregnancies were terminated; 10 confirmed to have advanced renal fibrosis and dysplasia cloacal dysgenesis at autopsy
Retrospective cohorts		
Salam et al. ⁸¹ 2006 Egypt	G1: vesicoamniotic shunt for PUV (12) G2: no fetal procedure (46)	<ul style="list-style-type: none"> 8 of 12 (66%) shunt recipients survived 1 of 8 had renal insufficiency, 3 had renal failure and are transplanted or candidates Comparison group reflects infants who survived to receive postnatal treatment; survival cannot be calculated 43 of 46 (93%) infants treated achieved normal renal function after treatment of PUV Urodynamic findings for those with antenatal vs. postnatal treatment
Wilson et al. ⁸² 2003 U.S.	G1: vesicoamniotic shunt for PUV (3) G2: other (not defined) (3)	<ul style="list-style-type: none"> Therapy not sufficiently specified to distinguish outcomes across groups 4 infants survived and one had renal failure
Warne et al. ⁸³ 2002 U.K.	G1: vesicoamniotic shunt (2) G2: no fetal intervention (4)	<ul style="list-style-type: none"> All fetuses had suspected cloacal anomalies All survived 2 of 2 shunt recipients survived to birth 1 of 2 had renal failure
Holmes et al. ⁸⁴ 2001 U.S.	G1: vesicoamniotic shunt for PUV (9) G2: bladder marsupialization (2) G3: ablations of PUV (2) G4: cutaneous ureterostomy (1)	<ul style="list-style-type: none"> Outcomes are primarily grouped across all interventions 5 of 14 (36%) infants died in utero; 1 pregnancy was terminated 8 of 14 survived (57%) into childhood 5 of 8 survivors had renal disease; 2 of those five had transplants, 1 was awaiting transplant
McLorie et al. ⁸⁵ 2001 Canada	G1: vesicoamniotic shunt for PUV (9) G2: no fetal procedure (3)	<ul style="list-style-type: none"> 6 of 8 (75%) shunt recipients survived into childhood; 1 pregnancy terminated after shunting None of the untreated infants survived to follow-up 5 of 6 survivors had growth in childhood less than 50% height and weight for age 2 of 6 had long term pulmonary sequelae 3 of 6 had renal impairment; 2 received transplants

Table 10. Primary outcomes of maternal-fetal surgical procedures for obstructive uropathy (continued)

Author, Year Country	Comparison groups, (N)	Key outcomes
Freedman et al. ⁸⁶ 1996 U.S.	G1: vesicoamniotic shunt (28) G2: no fetal intervention (27)	<ul style="list-style-type: none"> • 17 of 28 (61%) shunt recipients survived to discharge • 3 of 17 (18%) survivors post shunt had end stage renal disease and 2 had renal impairment • 5 of 27 (19%) without fetal surgery survived • 1 of 5 survivors without surgery had renal impairment
Crombleholme et al. ⁸⁷ 1990 U.S.	G1: shunt in good prognosis group (9) G2: no fetal procedure in good prognosis group (7) G3: shunt in poor prognosis group (10) G4: no fetal procedure in poor prognosis group (14)	<ul style="list-style-type: none"> • 8 of 9 (88%) shunt recipients in the good prognosis group survived hospital course, 1 pregnancy terminated • 5 of 7 without surgery and good prognosis survived • 3 of 10 (30%) shunt recipients in the poor prognosis group survived • Poor prognosis group without surgery included 11 terminations and 3 fetal or neonatal deaths • In the short term among those with good prognosis, 2 untreated infants have renal insufficiency and none of the shunted infants had renal impairment
Harrison et al. ⁷⁷ 1982 U.S.	G1: no fetal procedure good prognosis (14) G2: decompression with equivocal prognosis (3) G3: no fetal surgery with equivocal prognosis (4) G3: decompression with poor prognosis (5) G3: no fetal procedure poor prognosis (3)	<ul style="list-style-type: none"> • 14 of 14 with good prognosis and no fetal intervention survived to birth • 2 of 3 (66%) with decompression and equivocal prognosis survived; one with renal disease • 4 of 4 with equivocal prognosis and no fetal surgery survived; two with renal disease • 2 of 5 (40%) with poor prognosis and intervention to decompress the outflow tract died, 3 pregnancies were terminated (no survivors) • 3 of 3 with poor prognosis and no surgery died • Infants with unilateral ureteral obstruction did well without intervention, 8 of 8 survived with normal renal function
Prospective case series		
Araujo et al. ⁸⁸ 2007 Brazil	G1: vesicoamniotic shunt (13)	<ul style="list-style-type: none"> • 3 of 13 (23%) required replacement of shunt because the device did not remain properly placed (1) or obstruction was suspected (2) • 1 of 13, a fetus with trisomy 21, died in utero • 12 of 13 survived to one week of age
Craparo et al. ⁸⁹ 2007 Italy	G1: vesicoamniotic shunt (12)	<ul style="list-style-type: none"> • 2 fetuses never re-accumulated amniotic fluid and pregnancies were terminated, both found to have renal dysplasia • 10 of 10 remaining reaccumulated fluid, all survived to discharge • Followup ranged from 3 months to 3 years • 6 had kidney failure with transplant or pending transplant; 4 had normal kidney function

Table 10. Primary outcomes of maternal-fetal surgical procedures for obstructive uropathy (continued)

Author, Year Country	Comparison groups, (N)	Key outcomes
Biard et al. ⁹⁰ 2005 U.S.	G1: vesicoamniotic shunt (31)	<ul style="list-style-type: none"> • 8 of 31 were lost to followup • 23 of 23 live births in the group identified and followed • 21 of 23 (91%) survived to 1 year of age; 2 deaths from pulmonary hypoplasia • Average followup 5.8 years: 12 of 18 with data failure to thrive; 8 of 18 abnormal pulmonary function; 9 of 18 musculoskeletal conditions • 8 of 18 normal renal function; 6 of 18 required transplantation • 11 of 18 (61%) had normal bladder function • Self-reported health-related quality of life was comparable to healthy children
Makino et al. ⁹¹ 2000 Japan	G1: vesicoamniotic shunt (5)	<ul style="list-style-type: none"> • 2 of 5 (40%) survived • 1 survivor had hydrocephalus and normal renal function, the other had a seizure disorder • Both had developmental delay of unclear relation to obstructive syndrome
Freedman et al. ⁹² 1999 U.S.	G1: vesicoamniotic shunt (14)	<ul style="list-style-type: none"> • This paper included outcomes for 14 of 17 members of case series who are more than 2 years old • 3 were lost to follow-up or declined participation • 4 of 14 had pulmonary conditions; 6 of 14 did not have normal voiding function; 3 had renal insufficiency and 5 had renal failure • 3 of 14 had bladder augmentation surgeries
Evans et al. ⁹³ 1991 U.S.	G1: vesicoamniotic shunt (3)	<ul style="list-style-type: none"> • 1 child with normal renal function at age 3 • 1 child with normal renal function and deafness at 3 months • Scheduled shunt placement was not required, decompression resolved megacystis and did not recur
Manning et al. ⁹⁴ 1986 Multinational	G1: vesicoamniotic shunt (73)	<ul style="list-style-type: none"> • 30 of 73 (41%) survived • Procedure-related death rate was 4.6% • 11 pregnancies were terminated • Pulmonary hypoplasia (27) leading cause of death
Retrospective case series		
Gehring et al. ⁹⁵ 2000 U.S.	G1: vesicoamniotic shunt (3)	<ul style="list-style-type: none"> • Reports a series of infants with abdominal wall hernia after shunt above the umbilicus; hernias repaired at birth • 2 of 3 required dialysis
Shimada et al. ⁹⁶ 1998 Japan	G1: vesicoamniotic shunt (6)	<ul style="list-style-type: none"> • Infants entered this series at birth • 4 of 6 had normal pulmonary function • 5 of 6 had abnormal voiding function, including after surgical procedures • 4 of 6 had normal renal function • 2 of 6 had mild to moderate mental retardation
Pinckert et al. ⁹⁷ 1994 U.S.	G1: vesicoamniotic shunt (2)	<ul style="list-style-type: none"> • 1 with peritoneal and nephrostomy shunts had normal growth and normal renal function at 4 months of age • 1 with nephrostomy had abnormal renal function at 2 months of age
Bernaschek et al. ⁹⁸ 1994 Multinational	G1: vesicoamniotic shunt (13)	<ul style="list-style-type: none"> • 7 of 13 (54%) survived • 1 of 13 died in utero, 1 terminated pregnancy, and 2 died in neonatal period • 29 vesicoamniotic, thoracoamniotic, pleuroamniotic, or abdominoamniotic shunts (for a broader range of conditions included in aggregate in paper) required shunt replacement • Procedure-related mortality was 8%

Table 10. Primary outcomes of maternal-fetal surgical procedures for obstructive uropathy (continued)

Author, Year Country	Comparison groups, (N)	Key outcomes
Robichaux et al. ⁹⁹ 1991 U.S.	G1: vesicoamniotic shunt (2)	<ul style="list-style-type: none"> • Reports cases of infants with abdominal wall hernia after shunt • Both had paramedian abdominal defects repaired at birth
Cromblehome et al. ¹⁰⁰ 1988 U.S.	G1: open surgery (5)	<ul style="list-style-type: none"> • All open fetal surgery cases • 2 of 5 died at birth from pulmonary hypoplasia • 1 of 3 survivors had renal failure requiring transplant
Manning et al. ¹⁰¹ 1983 Canada	G1: vesicoamniotic shunt (2)	<ul style="list-style-type: none"> • 1 infant survived and had normal renal function at 6 months of age • 1 infant died of pulmonary hypoplasia within an hour of preterm birth at 30 weeks

IUFD=intrauterine fetal death/in utero fetal demise; PUV=posterior urethral valves

Prospective case series. Seven studies⁸⁸⁻⁹³ including the report from the International Fetal Surgery Registry,⁹⁴ gathered prospective data about 151 treated fetuses, of which 73 were registry cases. Short-term survival ranged from 100 percent in a single report of 3 cases,⁹³ 92 percent in the Brazilian series of 13 cases,⁸⁸ and 91 percent in a larger U.S. series.⁹⁰ However, in that U.S. series, eight infants were lost to followup. Other groups reported less uniformly positive outcomes with survival in 83 percent,⁸⁹ 62 percent,⁹² and 40 percent⁹¹ among infants treated by vesicoamniotic, nephrostomy, or ureteral shunt placement. Need for shunt replacement was only reported by one paper, in which 23 percent of ongoing pregnancies required another procedure. The registry, which reflected care at 20 centers, reported 41 percent survival to birth with a 4.6 percent procedure-related death rate. This number takes into account pregnancy terminations that resulted after failure of the shunt to improve amniotic fluid volume and lung development. If terminations were not counted, the survival rate would be 48 percent.

Two larger studies focused on followup in childhood,^{90,92} with findings consistent with those of smaller reports: shunted infants are at risk of poor growth in infancy; 34 percent to 40 percent will have severe renal disease and require dialysis and transplantation; one-quarter to nearly half do not have normal voiding function, with need for catheterization remaining common even after urologic surgery; one-third to half have pulmonary conditions; 25 percent have recurrent pulmonary infections, and 25 percent have asthma controlled by inhalers. The majority of children will have one or more surgeries for the condition that caused the obstruction. Among 14 parent-child pairs who completed health-related quality of life surveys, the scores were comparable to those of healthy children, suggesting children and families accommodate well to the challenges.⁹⁰

While six of seven studies reported the criteria by which fetuses were selected for intervention, none reported maternal characteristics or eligibility criteria to allow assessment of whether the population of participants was similar to another setting or country. Two studies noted that local anesthesia was used; others did not provide details. None reported beyond ultrasound guidance on the protocol for fetal monitoring during or immediately after the procedure. No studies noted any information about maternal outcomes beyond route of delivery.

Retrospective case series. Seven studies^{95-97,99-101} and one report from multiple European sites⁹⁸ gathered data retrospectively. Two are reports of abdominal wall hernias as a complication of shunt placement. These papers summarized outcomes for five infants, all of whom had repair of the defect at birth; other outcomes information is not the focus of these reports.^{95,99} The remaining five case series include the early reports of these procedures including initial attempts

to define prognostic factors and protocols to select and care for pregnancies complicated by fetal obstructive uropathy. In total, these 5 publications report on 28 infants.

Reported survival was 50, 58, 60, and 100 percent, the last among two cases (Table 10). One of the studies began tracking infants at birth and cannot provide survival data. The studies are concordant with later and larger reports: shunt replacement is common; outcomes of open surgery were similar to percutaneous in a study with five cases; and residual renal impairment and need for dialysis and transplant is common. Details about infant status and childhood are the most limited in this literature. Likewise, details about inclusion criteria and content of care is typically narrative by case, variable, and difficult to compile as is common for case reports.

Summary of obstructive uropathy literature. Positive trends in this literature include larger numbers of participants and increasing momentum from small case series to larger cohorts that include fetuses that received intervention(s) and those that did not. Because the initial reports were in the early 1980s, and nearly a decade was spent in establishing which fetuses might be most likely to benefit, the literature does not yet include detailed comparative followup studies.

Across study designs common elements emerge: those fetuses who present later in gestational age with very little or no amniotic fluid, or those who have no urine production and/or with no lung development are not targets of intervention. With such restrictions, survival is enhanced but far from certain with 50 percent to 88 percent of treated fetuses surviving, and prognosis not predictable with confidence even among those fetuses who can be salvaged. Fetal intervention may not always change the long-term prognosis of renal function; sequelae of posterior urethral valves may not be preventable.⁸⁴ Projections of prognosis are further hindered because though karyotyping is generally required, a proportion of affected infants have clusters of syndromic features that are not readily diagnosed antenatally with confidence and that, when combined with renal or pulmonary compromise, have a synergistic effect in increasing mortality risk and amplifying morbidity experienced among survivors. More than one-third of otherwise normal infants who have only isolated bladder outlet tract obstruction and do not have multiple anomalies or syndromes do not recover normal renal function in childhood, and the majority of those with impaired renal function require dialysis and renal transplantation.

Critical gaps in the literature include complete lack of randomized trials among the groups in which there is clinical uncertainty, including lack of randomized trials making direct comparisons. Studies should continue to enhance description of fetuses enrolled, and must begin to present information about maternal characteristics and selection. Furthermore, multiple key informants expressed concern that intervening for obstructive uropathy may be seen as an “easy” in utero intervention and that therefore it may be escaping into practice in the absence of adequate evidence, methods for selecting patients, or training of physicians. They stressed the need for research and training around identifying appropriate surgical candidates. Finally, patient selection criteria should be carefully assessed and potentially updated.

Systematic and uniform assessments of early neurologic and health outcomes associated with critical illness and prematurity must be tracked, such as risk of ventricular hemorrhage and oxygen dependence. These need be extended to use of reliable tools for uniform assessment of growth and development in childhood. Given the importance of pulmonary sequelae as an outcome, it is quite concerning that little is known about pulmonary outcomes in the short and long term. Renal outcomes are being described and need to be pushed into later childhood and young adulthood; registries and pooled data will be required to gather this valuable information. Differences in needs for neonatal and childhood urologic surgical intervention need to be

examined as do continence outcomes. Health status, functional status, and quality of life will be important components of coordinated followup. A well-rounded picture of the lives of children who do and do not receive fetal intervention is required to fully support care teams and families in informed decisionmaking at a supremely difficult time in which decisions require some degree of dispatch.

State of the Science: Sacrococcygeal Teratoma

Background. Sacrococcygeal teratoma (SCT) is a relatively rare condition affecting approximately 1 in 40,000 fetuses or about 100 infants a year in the United States. As a result of ultrasound use, these tumors are increasingly recognized antenatally. The outcomes of prenatally diagnosed, uncomplicated survivors to term are generally good. However, those fetuses with large, vascular tumors have a high incidence of prenatal mortality from high-output cardiac failure or spontaneous hemorrhage into or rupture of the growing tumor. Fetal surgical procedures for SCT have focused on the small subgroup of fetuses with SCT and hydrops because untreated cases are expected to die in utero or at birth. All series report 100 percent mortality.¹⁰³⁻¹⁰⁹ In severe cases, SCT with hydrops is associated with maternal risks. Mothers of fetuses with hydrops can develop mirror syndrome, which is a severe form of preeclampsia and can be associated with placentomegaly. Mirror syndrome is a maternal contraindication to fetal approaches since the mother is critically ill and delivery has been felt to be indicated for maternal health. Consequently, decisions to intervene need to be made when the fetus is documented to be critically ill while the mother is still in good health.

Table 11. Summary of studies of maternal-fetal surgical procedures for sacrococcygeal teratoma

Author Year	Open resection N	Other or no surgery N	Fetal inclusion criteria?	Maternal inclusion criteria?	Comparison group	Outcomes beyond neonatal hospital stay?
Randomized clinical trials and prospective cohorts						
None						
Retrospective cohorts						
Grethel et al. ¹¹⁰ 2007	6	42	Yes*	No	RFA (7); no fetal procedure (35)	No
Danzer et al. ¹¹¹ 2006	4	26	Yes	No	No fetal procedure	Yes (20-72 mos)
Hedrick et al. ¹¹² 2004						
Makin et al. ¹¹³ 2006	0	29	Yes	No	Varied interventions (8)‡;no fetal procedure (21)	Yes (8-86 mos)
Westerburg et al. ¹⁰⁸ 2000	7*	10	Yes	No	No fetal procedure	No
Schmidt et al. ¹⁰⁷ 1989						
Total	17	109	4 of 4	0 of 4	4 of 4	2 of 4
Retrospective case series						
Paek et al. ¹¹⁴ 2001	0	4	Yes	No	No, all case RFA	Yes (12 mos)
Grand Total	17	113	5 of 5	0 of 5	4 of 5	3 of 5

RFA = radiofrequency ablation; * less detail for those without intervention; ‡ laser ablation, alcohol sclerosis, shunt placement for PUV

Included publications. We identified seven publications^{107-108,110-114} that included fetal surgical procedures from five distinct populations of pregnancies affected by SCT. Procedures were associated with three fetal surgery groups based in an academic medical center. Two programs are in the United States, the other in the United Kingdom. Because this report is focused on surgical interventions, we have not included descriptions of percutaneous decompression of the SCT¹¹⁵ without shunt placement or other concomitant fetal intervention. Randomized clinical trials and prospective cohorts have not been reported. Four retrospective cohorts and one case series (Table 11) have examined varied maternal-fetal interventions, including 10 cases of open fetal surgery,^{110,112} 11 cases of radiofrequency ablation,^{110,114} 4 of laser vessel ablation,¹¹³ and 3 of alcohol sclerosis.¹¹³ Another publication reports in the broad category of “fetal intervention” for seven cases without specific details.¹⁰⁸ In total, these studies include 130 fetuses with antenatal diagnosis of SCT, with 94 cases without fetal intervention or with only cyst aspiration. Overall, the expectant management cases are less severe (Table 12).

Table 12. Primary outcomes of maternal-fetal surgical procedures for sacrococcygeal teratoma

Author, Year, Country	Comparison groups, (N)	Key outcomes
Retrospective cohorts		
Grethel et al. ¹¹⁰ 2007 U.S.	G1: open fetal procedure (6) G2: percutaneous radiofrequency ablation (7) G3: no fetal procedure (35)	<ul style="list-style-type: none"> • 2 of 6 with open surgery survived; all 4 deaths were among fetuses with hydrops • 2 of 7 with RFA survived; 3 deaths were among fetuses with hydrops and 2 among those without hydrops • Among those without fetal intervention and no hydrops there were five terminations and 16 of 17 remaining survived • Among those without fetal intervention and hydrops there were four terminations and 1 survivor who was delivered preterm at 25 weeks at the onset of hydrops
Danzer et al. ¹¹¹ 2006 Hedrick et al. ¹¹² 2004 U.S.	G1: open fetal procedure (4) G2: no fetal surgery or cyst aspiration only (26)	<ul style="list-style-type: none"> • 3 of 4 fetuses survived open surgery (75%) and delivered between 27 and 31 weeks • 4 of 26 fetal deaths with 4 additional terminations. • 50% survived without intervention excluding terminations • 90% of fetuses with other procedures, amnioreduction, amnioinfusion, and cyst aspiration, survived
Makin et al. ¹¹³ 2006 UK	G1: laser vessel ablation (4) G2: alcohol sclerosis (3) G3: vesicoamniotic shunt (1) G4: no fetal procedure (21)	<ul style="list-style-type: none"> • 1 of 4 with laser ablation survived • 0 of 3 with alcohol sclerosis survived • 1 of 1 shunt recipient survived • 21 of 21 without fetal surgery for SCT survived ; 23 infants total survived to have definitive surgery including 2 of 8 with fetal surgery and 21 without • Median followup of 39 months
Westerburg et al. ¹⁰⁸ 2000 Schmidt et al. ¹⁰⁷ 1989 U.S.	G1: “fetal intervention“ (7) G2: no fetal procedure (10)	<ul style="list-style-type: none"> • 3 of 7 with unspecified fetal intervention (43%) survived; all had hydrops • 1 of 5 fetuses with hydrops and no intervention survived; infant was delivered at detection of hydrops at 32 weeks • 2 of 5 with hydrops had pregnancy termination • 5 of 5 without hydrops and no intervention survived • Survival excluding terminations was 6 of 10 (60%)
Retrospective case series		
Paek et al. ¹¹⁴ 2001 U.S.	G1: radiofrequency ablation (4)	<ul style="list-style-type: none"> • 2 of 4 survived to birth • 2 deaths attributed to attempts to ablate larger portions of mass • 2 survivors had ablation targeted to only major feeder vessels

RFA=radiofrequency ablation

Alcohol sclerosis was the least studied, and all three reported cases died. Radiofrequency ablation was also rarely reported; four of seven infants survived (Table 12). Of the five fetuses or infants that died after radiofrequency ablation, death was associated with hydrops in three cases, occurred in two infants without hydrops, and was associated with aggressive use of radiofrequency ablation to debulk tumor rather than ablate vessels only in two cases. The group that examined outcomes of radiofrequency ablation reports subsequent cases have only targeted major vessels, and both fetuses treated after this change survived.¹¹⁴ Laser vessel ablation in four cases with hydrops failed to salvage the fetuses and all died in utero or at birth.¹¹³

For open fetal procedures, the aggregate survival rates were 33 percent to 75 percent;^{110,112} both reported fetuses without hydrops survived in one group, and three of three without hydrops survived in the other. All fetal and neonatal deaths occurred among those with hydrops or with prodromal cardiovascular changes concerning for developing hydrops. In the comparison groups without fetal intervention or with only cyst aspiration to facilitate delivery, all cases with hydrops died, with the exception of two infants who were delivered promptly near the time that progression to hydrops was detected by frequent ultrasound surveillance. These infants were delivered at 25 and 32 weeks, respectively.^{108,110} Infants in both the intervention and no fetal intervention groups had complex hospital courses related to surgical intervention for the SCT. All who survived to surgery and who did not have fetal resection had surgery.

Long-term followup is limited; two groups provide only birth outcomes, and three provide longer term information out to 6 to 7 years of age.¹¹²⁻¹¹³ Chronic lung disease related to prematurity and recurrence of tumor has been sporadically reported in both fetal intervention and no fetal treatment groups. Of 22 surviving infants in all groups of the British cohort, the median hospital stay was 14 days and median followup is 39 months. Three cases were lost to followup after one year and were alive at that time; the remainder were known to be alive. One child had developmental delay, one had chronic constipation, and three needed cosmetic scar revision. None of the children, including six who were younger than 2 years of age, had other urologic or neurologic sequelae.¹¹³

All studies provided sufficient detail to understand the status of the infants included for procedures. Less information about antenatal course was available in some cases about the SCT cases that did not have interventions. One report included insufficient information about the nature of the procedures done. The latter paper was focused on predicting the occurrence of hydrops and thus presented limited intervention and outcome data. No studies characterized maternal inclusion criteria, though three did provide some information about maternal obstetrical complications and perioperative complications.

Summary of the SCT literature. Consistent with other newer fetal interventions, this literature will benefit over time from the anticipated transition to uniform, prospective data collection. Standardized classification systems and consistent assessment of similar case features will allow aggregation across sites and ultimately enough cases will be compiled to begin to stratify outcomes by risk group and to design the next generation of research to fully understand infant, childhood, and young adult outcomes including use of multivariable models and clinical trials. Other challenges for SCT include a need to focus on the optimal timing of fetal interventions and early and reliable detection of fetuses which will or are developing hydrops or cardiac decompensation. The overriding comment from key informants was related to the importance of very careful patient selection. SCTs do not necessarily need to be addressed in utero, and in the absence of incipient hydrops, treatment should be postponed until the postnatal period. The

“right” patients for this procedure are extraordinarily rare—even the site with the greatest experience reports doing fewer than 10.

State of the Science: Thoracic Lesions

Background. Congenital pulmonary airway malformations (CPAM), which include congenital cystic adenomatoid malformation (CCAM) and bronchopulmonary sequestration (BPS), are congenital anomalies of the lung that share the characteristic of a segment of lung being replaced by abnormally developing tissue. CCAMs can have connections to the pulmonary tree and contain air. The tissue is served by blood vessels in the pulmonary circulation.¹¹⁶ BPS does not connect to airway and has blood flow from branches off the aorta as well as the pulmonary circulation. Antenatal diagnosis is most often made by ultrasound.

Only a small subset of patients with congenital pulmonary airway malformations are candidates for in utero treatment. In this subset, the mass is large enough and in such an anatomically critical position that the fetal mediastinum is compressed, leading to impaired venous return with resulting fetal hydrops secondary to cardiac failure. When this occurs early enough in gestational age that delivery and postnatal treatment are not an option, in utero treatment is a possible solution. The majority of CPAMs, however, do not have an indication for prenatal treatment as the outcomes are excellent, with the tumors often regressing throughout pregnancy and causing no neonatal or early childhood symptoms.

Oftentimes the more difficult judgments to be made during pregnancy are the frequency with which these tumors should be monitored in order to detect the small percentage that will cause fetal harm in order to know when to intervene. Distinguishing between these conditions is difficult and some would argue clinically irrelevant until after birth. The final common pathway that leads to consideration of fetal intervention is the same—fetal hydrops—whether the lesion is considered a pure CCAM, BPS, or a hybrid lesion.

There are presently no useful predictors of outcome for thoracic lesions, and serial evaluations are essential to determine course. Hydrops in the fetus results from obstruction of the vena cava and cardiac compression caused by mediastinal shift.¹¹⁷ The decision to intervene in utero is often based on the natural history reports that hydrops marks a transition to fetal demise. At times large pleural effusions occur without CCAM or BPS; the natural history of these effusions is even less well understood. We did not include interventions for isolated pleural effusions in this review; neither did we include papers that only reported thoracentesis as a treatment.

Included publications. No randomized trials have focused on maternal-fetal intervention for CCAMs or BPS (Table 13). Our search identified 17 publications in which the authors focused on lesions thought antenatally to be CCAMs or in which the anomalies were simply classified as thoracic or pulmonary masses. They included: 13 publications about 6 distinct cohorts,^{24,110,117-127} and 4 case series reports^{88,98,128-129} about 3 distinct study populations from a total of 7 academic groups in the United States, South America, Europe, and Japan. Collectively, their participants represent approximately 401 fetuses believed to have CCAMs, of which 54 had thoracoamniotic shunting and 3 had open procedures, with the goal of decompressing the lung lesion. Two retrospective cohorts focused on a total of 13 fetuses with bronchopulmonary sequestration.^{120,130} Fetal intervention for both CCAMs and BPS are summarized in Table 14.

Table 13. Summary of cohort and case series studies of maternal-fetal surgical procedures for thoracic lesions

Author Year	With fetal shunting N	Without this procedure N	Fetal inclusion criteria?	Maternal inclusion criteria?	Comparison group	Outcomes beyond neonatal hospital stay?
Cohorts						
Morris et al. ¹²⁷ 2009	3 shunt 3 open	38	Yes	No	High risk lesion without surgery (7) All types of lesions who received steroids (9)	Yes (≥ 5 mos)
Merchant et al. ¹²⁵ 2007*	9	19	Yes	No	Ineligible for fetal surgery (13); matched no fetal surgery (6)	Yes (1.5-9 mos)
Grethel et al. ¹¹⁰ 2007*	9	154	Yes	No	No fetal surgery (129); open fetal surgery (25)	Yes (1 mos)
Morikawa et al. ¹²⁶ 2003*	2	2	Yes	No	No fetal surgery (2)	Yes (24-36 mos)
Adzick et al. ^{24,117,120-124} 1998*	6	114	Yes	No	No fetal surgery (101); open fetal surgery (13)	Yes (12-84 mos)
Adzick et al. ¹²⁰ 1998	2	1	Yes	No	No fetal surgery	No
Dommergues et al. ¹¹⁸⁻¹¹⁹ 1997*	9	17	Yes	No	No fetal surgery	Yes (5-36 mos)
Becmeur et al. ¹³⁰ 1997	1	9	Yes	No	No fetal surgery	No
Total	44	354	8 of 8	0 of 8	8 of 8 include no fetal surgery	6 of 8
Case series						
Araujo et al. ⁸⁸ 2007*	2	NA	Yes	No	NA	No
Wilson et al. ¹²⁸ 2004*	10	NA	Yes	No	NA	No
Golaszewski et al. ¹²⁹ 1998* Bernaschek et al. ⁹⁸ 1994*	4	NA	Yes	No	NA	Yes (mean 30 mos)
Total	16	NA	3 of 3	0 of 3	NA	1 of 3

*CCAM studies

The total literature available included 88 infants with untreated hydrops associated with CCAM. Of these infants, five survived (5.7 percent); four of these improved after a course of steroids. The intervention literature suggests a 54 percent overall survival to birth after maternal-fetal intervention, with survival as low as 20 percent to 33 percent among fetuses with hydrops.^{110,120} In cohorts, 44 percent to 100 percent of infants who had thoracoamniotic shunts placed survived to birth or through neonatal hospitalization.^{110,118,126-128}

Table 14. Primary outcomes of maternal-fetal surgical procedures for thoracic lesions

Author, Year, Country	Comparison groups (N)	Key outcomes
Prospective cohorts: CCAM		
Dommergues et al. ¹¹⁸ 1997	G1: thoracoamniotic shunt (9)	<ul style="list-style-type: none"> All 9 fetuses receiving thoracoamniotic shunt were hydropic All 17 fetuses in no fetal surgery group were nonhydropic 5 of 9 (55%) fetuses receiving thoracoamniotic shunt died; all had pulmonary hypoplasia at autopsy 1 patient had PROM within 48 hours of shunt placement and delivered at 31 weeks (infant died) 3 of 12 pregnancies assigned to receive thoracoamniotic shunt terminated the pregnancy 17 of 17 nonhydropic fetuses assigned to no fetal surgery group survived 11 of 17 (65%) of no fetal surgery cases the lesion was < 50% of the thorax 11 of 17 of infants in no fetal surgery group had to undergo postnatal surgery
Revillon et al. ¹¹⁹ 1993 France	G2: no fetal procedure (17)	
Retrospective cohorts: CCAM		
Morris et al. ¹²⁷ 2009	G1: open fetal surgery (3) G2: thoracoamniotic shunt (3) G3: High risk no procedure (7)	<ul style="list-style-type: none"> 3 of 3 fetuses with open fetal surgery died intraoperatively or in utero 2 of 3 with thoracoamniotic shunt survived 4 of 7 infants with hydrops survived without prenatal intervention 4 of 4 survivors without procedure responded well to prenatal steroids; 3 who died did not respond
Adzick et al. ¹²⁰⁻¹²² 1998, 1994, 1993	G1: thoracoamniotic shunt (6)	<ul style="list-style-type: none"> 3 of 3 nonhydropic fetuses survived after shunt placement, with 1 requiring ECMO for 4 days and 1 requiring high-frequency ventilation for 2 weeks 2 of 3 (66%) hydropic fetuses survived after shunt placement 8 of 13 (62%) fetuses undergoing open fetal lobectomy survived at up to 7 years follow-up Mean postoperative pregnancy duration was 8 weeks (range: 2-13 weeks) 76 of 101 fetuses in the no fetal surgery group did not have hydrops; 100% survived (66 of 76 received postnatal resection) 25 of 101 fetuses in the no fetal surgery group were hydropic; 100% died 4 of 4 infants who had open fetal surgery had normal neurodevelopment at up to 47 mos
Cha et al. ¹²³ 1997	G2: open fetal lobectomy (13)	
Kuller et al. ¹²⁴ 1992	G3: no fetal procedure (101)	
Harrison et al. ¹¹⁷ 1990		
Gibbs et al. ²⁴ 1998 U.S.		
Grethel et al. ¹¹⁰ 2007 U.S.	G1: thoracoamniotic shunt (9) G2: open fetal procedure (25) G3: no fetal procedure (129)	<ul style="list-style-type: none"> 5 of 9 (45%) fetuses who received thoracoamniotic shunt survived (1 of 5 with hydrops survived) 14 of 25 (56%) who had open fetal surgery survived (13 of 23 with hydrops survived) 113 of 129 (87%) who were in the no fetal surgery group survived (0 of 14 with hydrops survived)

Table 14. Primary outcomes of maternal-fetal surgical procedures for thoracic lesions (continued)

Author, Year, Country	Comparison groups (N)	Key outcomes
Retrospective cohorts: CCAM		
Merchant et al. ¹²⁵ 2007 U.S.	G1: thoracoamniotic shunt for macrocystic CCAM (9) G2: no fetal surgery-CCAMs did not require prenatal shunt (13) G3: gestation, volume, and CVR-matched CCAM who did not require prenatal shunt (6)	<ul style="list-style-type: none"> All infants underwent surgical resection of CCAMs within first month of life G1: 2 of 9 (22%) had significant chest wall deformity with rib deformity and rib thinning; 2 of 9 had rib fractures G2: 13 of 13 had normal chest radiographs immediately after resection of CCAM without rib deformity, thinning, or fractures G3: 2 of 6 had no rib deformity on chest radiographs; 4 of 6 had symmetric, minimal rib thinning
Morikawa et al. ¹²⁶ 2003 Japan	G1: thoracoamniotic shunt (2) G2: no fetal procedure (2)	<ul style="list-style-type: none"> G1: 2 of 2 infants survived and were well at 2 yrs G2: 2 of 2 infants survived and were well at 2 and 3 yrs G1: Gestational age was 37-40 weeks G2: Gestational age 30-37 weeks All 4 infants underwent postnatal surgery for CCAM
Retrospective cohorts: BPS		
Adzick et al. ¹²⁰ 1998 U.S.	G1: thoracoamniotic shunt (2) G2: no fetal procedure (1)	<ul style="list-style-type: none"> 2 of 2 infants with thoracoamniotic shunt survived but required ventilator support and postnatal extralobar pulmonary sequestration resection 1 infant without fetal surgery was diagnosed at 34 weeks' gestation and died of pulmonary hypoplasia after postnatal resection and ECMO for 3 weeks
Becmeur et al. ¹³⁰ 1997 France	G1: pleuro-amniotic shunt (1) G2: no fetal procedure (9)	<ul style="list-style-type: none"> 1 infant received pleuro-amniotic shunt at 30 weeks gestational age 6 of 9 infants who received no fetal surgery had absolute or relative regression of the thoracic mass Definitive diagnosis of BPS was done after birth (9) by MRI or US 8 of 10 infants had other congenital malformations
Case series: CCAM		
Araujo et al. ⁸⁸ 2007 Brazil	G1: thoracoamniotic shunt (2)	<ul style="list-style-type: none"> 2 of 2 fetuses survived to one week of age
Wilson et al. ¹²⁸ 2004 U.S.	G1: thoracoamniotic shunting (10)	<ul style="list-style-type: none"> 7 of 10 (70%) infants survived 2 of 10 (20%) infants died during the neonatal period 1 of 10 fetuses died in utero 6 of 10 fetuses were hydropic 5 of 10 fetuses had polyhydramnios 3 fetuses had both hydrops and polyhydramnios All survivors had resection of CCAM in first 3 days of life
Golaszewski et al. ¹²⁹ 1998 Bernaschek et al. ⁹⁸ 1994 Austria, Germany	G1: thoracoamniotic shunting (4)	<ul style="list-style-type: none"> 0 of 4 fetuses died in utero 3 of 4 (75%) infants survived the perinatal period 1 of 4 delivered preterm 1 of 4 infants had occlusion of the shunt 1 week after shunt placement and required thoracocentesis four times in 10 days

BPS=bronchopulmonary sequestration; CCAM=Congenital Cystic Adenomatoid Malformation; ECMO=Extracorporeal Membrane Oxygenation; MRI=Magnetic Resonance Imaging; PROM=Preterm rupture of membranes; US=ultrasound

A team treating 13 fetuses with open fetal surgery achieved 61 percent survival through seven years of followup, with normal neurodevelopmental followup for the 4 infants with formal evaluation up to 47 months of age. In the same group of patients from this surgical group, all infants without hydrops survived, and 66 of 76 (87 percent) required postnatal resection.^{24,117,120-124} This is similar to 56 percent survival reported for open surgery by another team who operated

on 25 fetuses, of which 23 had hydrops.¹¹⁰ Another group reported intraoperative death or fetal demise in three cases of open fetal surgery in the setting of hydrops.¹²⁷ Uniform survival of infants without hydrops has been reported by several groups.^{118-119,125-127}

Among fetuses with shunts for BPS three of three survived; however, as for CCAMs, a number of fetuses, in one series 67 percent, have spontaneous regression of the lesion in utero or after birth and do not require resection. The proportion of infants requiring surgery for resection of the lesions may not be reduced by fetal intervention. Outcomes beyond survival have been examined in only a few series. Merchant and colleagues¹²⁵ reported chest wall and rib deformities in two of nine patients treated with fetal shunts. Gibbs and colleagues²⁴ reported on neurologic outcomes of 11 infants with open fetal surgery for all types of lesions; 9 were developing normally.

Fetal inclusion criteria or detailed case descriptions are included in each of the identified publications; reporting of anesthesia approach is also well described. Subsequent surgical intervention in both those infants treated as fetuses and after birth is nearly complete. However, information about factors related to maternal selection and complications is meager. Length of followup is highly variable, with infants followed up past the newborn hospital stay in 7 of 16 publications; 4 provided any neurologic outcomes in infancy or childhood; and none provide formal evaluation of pulmonary function in childhood.

Summary of thoracic lesions literature. The literature on congenital lung lesions is dominated by reports of isolated or repeated use of thoracocentesis, which was not a maternal-fetal surgical intervention directly addressed by this report. This smaller body of literature about open maternal-fetal surgeries and thoracoamniotic shunt placement reflects a wide range of differences in spectrum of fetuses treated. Over time, interest has evolved in the direction of treating only those infants with poor prognosis as indicated by fetal hydrops. While logical, this creates lack of comparability of infants who received and did not receive fetal treatment. Other aspects of changes in contemporary care may also be influencing how cohorts and case series are interpreted. Recent advances in the CCAM literature include the report of three cases of a novel therapy involving percutaneous fetal sclerotherapy in 2008.¹³¹ Additionally, some infants with large CCAMs may respond to in utero medical treatment with steroids.^{110,127} Combined, the two teams have reported seven infants with CCAM and hydrops, with resolution of the lesion in all seven. Currently a multicenter trial is being organized at the University of California, San Francisco, the Fetal Care Center of Cincinnati, and the Children's Hospital of Philadelphia, which will randomize select infants with CCAM to steroid or no steroid treatment. Future interventions may also have failure to respond to steroids as an entry criterion.

State of the Science: Twin-Twin Transfusion Syndrome

Background. In twin-to-twin transfusion syndrome (TTTS), twins share a single chorionic membrane and therefore a single placenta, but have separate amniotic sacs. Approximately 15 percent of monochorionic, diamniotic twin pregnancies are affected by TTTS,¹³² and therefore, estimates based on CDC data are that theoretical incidence of TTTS would be about 1.38 to 1.86 cases per 1,000 live births.¹³³ Although incidence studies have found lower numbers, these numbers are probably a reflection of early deaths of affected fetuses in utero that therefore do not get recognized as TTTS pregnancies.

Most pregnancies presenting with severe TTTS prior to 26 weeks and not undergoing some sort of therapy will end with dual fetal demise.¹³² When both twins do survive, there is often

severe neurologic compromise in survivors as well as other organ failure, including cardiac conditions. Approximately 25 percent of surviving fetuses in a monochorionic twin pair in which one dies will suffer CNS injury.

Diagnostic criteria for TTTS have evolved to include: same-sex fetuses with a single placenta with lack of lambda sign in early pregnancy; oligohydramnios in the donor sac (<2 cm maximum vertical pocket); and polyhydramnios in the recipient sac (>8 cm maximum vertical pocket at less than 20 weeks or >10 cm after 20 weeks).

After diagnosis, the most common approach to assessing severity in TTTS is the Quintero staging system.¹³⁴

- Stage I: The fetal bladder of the donor twin remains visible sonographically.
- Stage II: The bladder of the donor twin is collapsed and not visible by ultrasound.
- Stage III: Critically abnormal fetal Doppler studies noted. This may include absent or reversed end-diastolic velocity in the umbilical artery, absent or reverse flow in the ductus venosus, or pulsatile flow in the umbilical vein.
- Stage IV: Fetal hydrops present.
- Stage V: Demise of one or both twins.

In 1990, Baldwin and Wittman¹³⁵ presented three prenatally diagnosed twin pairs with in utero TTTS for which they attempted selective reduction. They postulated the importance of a vascular separation. Later that year, De Lia et al reported the first fetal surgery to treat the underlying pathology.¹³⁶

Four primary approaches exist for intervening in TTTW:

- Serial amnioreduction to relieve intra-amniotic pressure and uterine size, and thus prolong the pregnancy. Although the mechanism by which it works is not entirely clear, amnioreduction has been associated with a 50–60 percent survival rate of at least one fetus.¹³⁷
- Termination of the sicker twin, which is likely to rescue the healthier one and is accomplished by cord occlusion, radio frequency ablation, or ligation. This is only used in the presence of significant birth defects.
- Septostomy, in which the intervening membranes is punctured to attempt to increase amniotic fluid in the oligohydramniotic sac, was performed but has largely been abandoned as a therapy.¹³⁸
- Laser ablation of communicating vessels is performed either selectively or non-selectively to attempt to protect one twin from hemodynamic disturbances in the other twin. In nonselective ablation, all vessels crossing the dividing membrane are ablated, whereas selective ablation is limited to vessels shown to be communicating between the two fetuses. Selective ablation is most common today, and is the focus of this section of the technical brief. Gaining access to the uterus can be accomplished in three ways: laparotomy to expose the uterus, laparoscopic placement of the fetoscope, and ultrasound-guided placement of the fetoscope.

Table 15. Summary of trials and cohort studies of laser ablation for twin-twin transfusion syndrome (TTTS)

Author Year	With laser ablation N	Without laser or other procedure N	Fetal inclusion criteria?	Maternal inclusion criteria?	Comparison group	Outcomes beyond neonatal hospital stay?
Randomized controlled trials						
Cromble- holme et al. ¹³⁹ 2007	20	20	Yes	No	Amnioreduction	Yes (30 days postnatal)
Senat et al. ¹⁴⁰ 2004	72	70	Yes	No	Amnioreduction	Yes (7-12 mos)
Total	92	90	2 of 2	0 of 2	2 of 2	2 of 2
Prospective cohorts						
Chmait et al. ¹⁴¹⁻¹⁴² 2010	99	--	Yes	No	Sequential vs. nonsequential laser ablation	No
Quintero et al. ¹⁴³ 2007	193	--*	Yes	No	Sequential vs. nonsequential laser ablation	No
Gardiner et al. ¹⁴⁴ 2003	13	14	Yes	No	Symptomatic management	Yes (mean 11.1 mos)
Total	305	14	3 of 3	3 of 3	2 of 3	1 of 3
Retrospective cohorts						
Habli et al. ¹⁴⁵ 2008	26	26	Yes	No	Amnioreduction (15), radio- frequency ablation (4), no fetal surgery (7)	No
Lenclen et al. ¹⁴⁶⁻¹⁴⁷ 2007	101	36	Yes	No	Amnioreduction	No
Middeldorp et al. ¹⁴⁸⁻¹⁴⁹ 2007	20	30	Yes	No	Conservative management	Yes
Santiago et al. ¹⁵⁰ 2006	16	--	No	No	Prior amnioreduction	No
Quintero et al. ¹⁵¹ 2003	95	78	Yes	No	Amnioreduction	No
Quintero et al. ¹⁵² 2000	92	--	Yes	No	Selective vs. nonselective	No
Total	345	160	5 of 6	0 of 6	6 of 6	1 of 6

*These cohorts reflect differences in laser ablation approach (e.g. selective vs. nonselective) or prior intervention (e.g. with or without prior amnioreduction) as the basis for comparisons across groups.

Included publications. We searched specifically for literature on laser treatment for TTTS; therefore, we defined cohort studies as those that included comparisons either of types of laser to other types of treatment or to no treatment. Studies in which all participants received laser treatment were considered case series even if the data were presented for separate groups, such as by severity.

The treatment literature evaluating laser ablation for TTTS included 2 RCTs,¹³⁹⁻¹⁴⁰ 3 prospective cohorts,^{141,143-144} 7 retrospective cohorts^{142,145-152} and 73 case series (Table 15). Although we attempted to group “families” of publications in which specific pregnancies may be reported in duplicate, we were unable to do so definitively, and there is likely substantial overlap

among the populations in the studies. Our best estimate is that approximately 1,790 pregnancies treated with laser ablation for TTTS have been reported in the literature. Of the 77 papers, 42 specified using selective laser ablation and 14 nonselective, including 3 that reported using both (sometimes in direct comparison). Of 54 studies reporting the type of anesthesia used, 15 used general, 26 used local and 13 used epidural.

Until 2000, all publications were case series, with the first RCT reported in 2004. The vast majority of studies (including all of the newer ones) that report surgical approach indicate that they used a percutaneous approach with a fetoscope. All but one of the reports using laparotomy to gain access to the uterus were by the same group, early in the series. This may reflect advances in instrumentation which improved minimally invasive access surgery during this time. Some laparotomy cases were done to gain access to an anteriorly placed placenta without transplacental fetoscope placement.

Both RCTs¹³⁹⁻¹⁴⁰ used amnioreduction as their comparison group. One required that pregnancies first have an amnioreduction prior to randomization¹³⁹ The other excluded patients with prior invasive treatment.¹⁴⁰ Only pregnancies in which initial amnioreduction was non-therapeutic were enrolled in the study. Both studies were stopped before completion under standard stopping rules at planned interim analyses. The earlier study¹⁴⁰ had a higher rate of survival at 7 to 12 months of age of at least one twin in the laser group relative to the amnioreduction group (p=.002). Although survival rates were higher among lower Quintero-staged pregnancies in general, there was still greater survival among higher Quintero-staged pregnancies in the laser group. Cerebral lesions were also significantly less likely in the laser group compared to amnioreduction (7 percent of survivors in laser versus 35 percent of survivors in AR; p=.02).

In the Crombleholme study, there was a statistically significant increase in fetal mortality among recipient twins treated with laser (63 percent) versus amnioreduction (12.5 percent), but no difference in survival at 30 days. There was also no difference in survival among donor twins. Small numbers, however, make these results difficult to assess.

Nonetheless, the studies cannot be directly compared: the Senat study, which had more positive outcomes for laser intervention included women with any Quintero stage TTTS, whereas the Crombleholme study excluded women with stage 1 TTTS, thus focusing on a more severely impaired group. The Senat study also included pregnancies up to gestational ages of 26 weeks, compared to an upper limit of 22 weeks in the Crombleholme study.

Of the nine cohort studies, three were prospective and six were retrospective. Five included data that allowed comparisons of amnioreduction to laser ablation.^{144-146,148,151} Two compared selective to nonselective approaches,^{143,152} and one considered whether having had a prior amnioreduction conferred risk of worse outcomes on pregnancies undergoing laser ablation.¹⁵⁰

The five studies that included data allowing for a comparison between amnioreduction and laser showed mixed results (Table 16), but because these studies were all nonrandomized, this could very well reflect unmeasured differences in study populations or differences in laser technique or experience. In one of the two studies that did not demonstrate a survival benefit for laser relative to AR,¹⁴⁸ however, substantially higher morbidity was observed among the neonates who had been treated with AR. One study¹⁴⁷ followed a subset of twins from another retrospective cohort¹⁴⁶ and found similar neurodevelopmental outcomes in survivors treated with laser as seen in a group of dichorionic twins. Survivors of amnioreduction had increased neurodevelopmental delay at 2 years, as measured by the Ages and Stages questionnaire.

Table 16. Primary outcomes of trials and cohort studies of laser ablation for TTTS

Author, Year, Country	Comparison groups, (N)	Key outcomes
Chavira et al. ¹⁴² 2009 U.S.	G1: very short cervical length, 0.5-1.9 cm (10) G2: moderate cervical length, 2-2.5 cm (13) G3: normal cervical length, >2.5 cm (76)	<ul style="list-style-type: none"> • 3/10 patients in the very short cervical length group had prior AR and 8/10 underwent cerclage • No significant differences among groups in gestational age at delivery, 30-day neonatal survival, or latency from time of surgery to delivery • Overall at least 1 neonatal survivor in 90 of 99 cases (91%), dual survival in 71/99 cases (72%)
Habli et al. ¹⁴⁵ 2008 U.S.	G1: SFLP (26) G2: AR (15) G3: RFA (4), G4: expectant management (7)	<ul style="list-style-type: none"> • No significant difference in donor or recipient survival rate (p=0.058) or gestational age at delivery among treatment groups (p=.5)
Crombleholme et al. ¹³⁹ 2007 U.S.	G1: SFLP (20) G2: AR (20)	<ul style="list-style-type: none"> • No significant difference in 30-day postnatal survival between donors or recipients by group • No difference in 30-day survival of one or both twins on a per-pregnancy basis • Significant increase in fetal recipient mortality in the SFLP arm, offset by increased recipient neonatal mortality in the AR arm • Echocardiographic abnormality in recipient twin; CVPS most significant (p=0.055) predictor of recipient mortality by logistic regression
Lenclen et al. ¹⁴⁶⁻¹⁴⁷ 2007 France	G1: laser ablation (101) G2: amnioreduction (36) G3: unattended dichorionic twins delivered at 24-34 weeks of gestation (242)	<ul style="list-style-type: none"> • Death or severe cerebral lesions more frequent in the amnioreduction group than laser or dichorionic groups • No significant difference in overall neonatal outcome between laser and normal dichorionic neonates • Neonatal morbidity higher in laser neonates delivered at <30 weeks' gestation when due to failed laser therapy • Neurodevelopmental delays greater at 2 years in G2 compared with the other 2 groups
Middeldorp et al. ¹⁴⁸⁻¹⁴⁹ 2007 Netherlands	G1: laser surgery, presenting after 26 weeks of gestation (10) G2: conservative management (30)	<ul style="list-style-type: none"> • No significant difference was found between groups in the median gestational age at birth • Long term neurodevelopmental delay in 0% of G1 vs. 23% of G2 (p=.03) • Major neonatal morbidity occurred more often in the amniodrainage group (26%) than laser surgery group (7%), (p=0.04) • No significant difference in rates of severe cerebral injury (p=1.00), neonatal mortality (p=0.54), or overall adverse outcome (p=0.83) between groups
Quintero et al. ¹⁴³ 2007 U.S.	G1: selective laser photocoagulation of communicating vessels (SLPCV) (56) G2: sequential SLPCV (137)	<ul style="list-style-type: none"> • Pregnancies in which sequential SLPCV (G2) was done were more likely (p=.02) to have 2 surviving fetuses (73% vs. 57%) • Differences for at least one surviving fetus were non-significant

Table 16. Primary outcomes of trials and cohort studies of laser ablation for TTTS (continued)

Author, Year, Study Type, Country	Comparison groups, (N)	Key outcomes
Santiago et al. ¹⁵⁰ 2006 Spain	G1: laser without prior AR (10) G2: laser with prior AR (6)	<ul style="list-style-type: none"> No substantial differences in survival rates between the groups, but the sample size was small
Senat et al. ¹⁴⁰ 2004 France, Belgium, Switzerland	G1: selective laser SFLP therapy (72) G2: amnioreduction (70)	<ul style="list-style-type: none"> Neonatal survival greater in G1 vs. G2 (p=0.0009) Survival to 6 months of age was greater in G1 vs. G2 (p=0.002) Incidence of cystic periventricular leukomalacia was lower in G1 vs. G2 at 6 months (p=0.003)
Gardiner et al. ¹⁴⁴ 2003 UK, Germany	G1: TTTS treated symptomatically (14) G2: laser ablation (13) G3: pregnancies w/ monochorionic twins w/o TTTS (12) G4: normal dichorionic twins (11)	<ul style="list-style-type: none"> Gestational age and birthweight slightly greater in G2 than G1 but no assessment of statistical significance for comparison No significant differences in blood pressure or intrauterine growth between G1 and G2
Quintero et al. ¹⁵¹ 2003 U.S., Australia	G1: SFLP (95) G2: serial amnioreduction (173)	<ul style="list-style-type: none"> Likelihood of at least one surviving infant was correlated inversely with stage in G2 but not G1 G1 was 2.4 times more likely to have at least one survivor than G2 Neurologic morbidity related to stage in G2 but not G1 Neurologic morbidity significantly higher in G2 vs. G1
Quintero et al. ¹⁵² 2000 U.S.	G1: SFLP G2: nonselective laser	<ul style="list-style-type: none"> Higher survival of at least one fetus in selective (83%) vs. nonselective (61%) (p=0.04)

AR=amnioreduction; CVPS=cardiovascular profile score; RFA=radiofrequency ablation; SFLP=selective laser photocoagulation; SLPCV= selective laser photocoagulation of communicating vessels; TTTS=Twin-twin transfusion syndrome

Two studies by the same group examined modifications to the general technique: selective versus nonselective¹⁵² and sequential versus nonsequential approaches.¹⁴³ Both selective and sequential approaches were associated with greater survival rates. In a retrospective comparison of 16 patients referred for laser, some of whom had a prior amnioreduction, there was no difference between patients who had or had not had prior AR. Finally, one prospective cohort¹⁴² found no difference in outcomes of laser treatment by cervical length at admission.

The many case series available in this literature are helpful in surveying the range of success rates and in identifying potential harms associated with treatment.¹⁵³ Preterm premature rupture of membranes is the most commonly noted short-term harm, with a range of 4 percent¹⁵⁴ to 28 percent.¹⁵⁵ Longer term developmental outcomes in the infants have been examined in a small number of studies, and although a high rate of neurodevelopmental impairment is noted,¹⁵⁶ none of these studies included a treatment comparison group, so the relative benefit or harm of laser treatment on these outcomes is unknown.

Experts in treatment for TTTS stressed the importance of very stringent techniques, particularly in mapping the vessels and incorporating checks and balances into the process; mapping techniques and the need for stringent processes, however, are not well evaluated in the literature and likely warrant further study. Two key informants spoke to their concerns that complications are substantially higher outside of the larger centers, but without a system for documenting outcomes and outside of the research enterprise, actual rates cannot be captured.

Summary of the TTTS literature. Case series comprise the bulk of TTTS literature discussed in this review. Two RCTs meeting our criteria compared amnioreduction to laser ablation; similarly, five of the eight cohort studies reported here compared laser ablation and amnioreduction. Consensus about the superiority of vascular ablation procedures versus amnioreduction is developing, but as in other fetal procedures, small sample sizes and differences between study groups limit comparisons. The TTTS literature also lacks substantial long-term fetal and maternal outcomes data.

Discussion

State of the Science

The crosscutting focus of this review is summarizing the state of the field of maternal-fetal surgical procedures, broadly defined to include topics such as training of providers, access to care, and strength of the research literature for understanding the anticipated effectiveness of fetal approaches in practice. Stakeholders requesting the report were specifically interested in instances in which strong comparative research suggests superiority of maternal-fetal surgical procedures over intervention at birth for reducing fetal, intrapartum, and neonatal mortality and for preserving organ function. However in compiling this literature it is apparent that, while developing rapidly, the research on fetal surgical procedures has not achieved the typical level of quality of studies and aggregate strength of the evidence used to reach definitive conclusions about care and policy.

Favorable signs include the substantive leadership of U.S. researchers across each of the topics considered. For each target condition, there are both fetal surgical centers and associated research enterprises engaged in the full spectrum of academic endeavor, from animal research, development of surgical interventions, and refinements, to patient care, surgical training, bioethics forums, and reporting of results in the scientific literature. The majority of fetal surgical innovations arose in the United States, and the momentum of the literatures suggest continued growth of expertise alongside a commitment to assuring forthright examination of the outcomes of maternal-fetal surgical care. All publications across both the United States and internationally reflected the involvement of tertiary care academic medical centers, and scholarly work is clearly woven into the fabric of maternal-fetal surgery care. Thus, available data are likely to be relevant to care and trends in the United States.

Randomized trials, a total of three published in two topics (CDH and TTTS), are rare. Experts and authors in this area rightly point out both the desirability of randomized trials and the factors that mitigate success of trials, including small numbers of fetuses with specific conditions, need for methodologic advancement for study of this topic, patients who span the country while academic research centers are sparsely distributed, insufficient mechanisms to absorb the costs of care for participants who are participating in research, lack of national research infrastructure to coordinate trials, and in some instances, competing availability of procedures outside the trial.¹⁵⁷⁻¹⁵⁸ When conducted, the results have had influence in redirecting the field. The finding that open fetal repair of CDH did not improve outcomes compared to repair at birth, helped focus continued development of interventions on less invasive approaches that now include comparison of approaches for balloon tracheal occlusion. Trials suggesting superiority of laser ablation of vessels to serial amnioreduction also refocused the field on comparisons of less invasive approaches.

Prospective studies, with the potential to standardize protocols and elements of data collection and outcome measurement, are also few. Eleven of 166 total study populations (7 percent) were classified as prospective cohorts for this count. We erred on the side of inclusiveness, counting all use of research registries that prospectively capture individual case data, whether local or multisite, as prospective data collection. Retrospective cohorts, a total of 36, made up 22 percent of the total study populations reported in the literature. Retrospective

studies were less likely to compare to fetal interventions and most likely to have historical comparison groups.

Cohort studies have fundamental challenges with comparability of the comparison group because the decision to act or defer intervention until the postnatal timeframe is often entangled with clinically assessed prognosis. Infants who were expected to do well without intervention would be less likely to have fetal surgery and would potentially do better than those who received fetal surgery. Conversely, those who were felt to have grim survivability are often noted to have been offered termination or to have had treatment withheld secondary to perceived futility. The latter scenario overestimates the benefit of fetal intervention compared to those with extremely poor prognosis. The number of cases with similar characteristics between those who received surgery and those who did not accept referral to procedures is rarely reported. The total number in the literature is insufficient to make estimates that are legitimately comparable. Furthermore, data collection is often imbalanced, with greater detail available for the cases that underwent surgery than those that did not.

Few cohort studies were large and thorough enough to conduct appropriately powered multivariable analysis to adjust for candidate confounders or modifiers of treatment outcomes. TTTS was the exception, and findings from this area, which reflect greater numbers of pregnancies in individual studies available to aggregate, are more secure. Consensus is developing that vascular ablation procedures are superior to serial amnioreduction, and attention has turned to evaluating selective versus nonselective approaches to targeting vessels. For the majority of the conditions of interest, aggregating the number of participants would still fall short of that needed for metaregression, and key confounders and modifiers of outcomes appear not to be available uniformly across research groups.

Case series dominate the maternal-fetal surgical procedures literature, making up 70 percent of the included studies. This dominance of descriptive work is not an indictment, rather a natural consequence of the arrival of the fetus as a surgical candidate within the last 3 decades.

As expected, the literature for each type of approach reflects initial case reports of technical aspects of the surgery, followed by publications about selection criteria, then prognostics, and then conversion to including a comparison group and transitioning to cohort analyses. Increments of followup lengthen and the status of early cases is typically updated beyond infancy into childhood in later publications. This natural evolution of the field shows in the trend toward rising numbers cohort and prospective studies as we approach contemporary timeframes.

The strength of protocol-based research lies in gathering comparable information across an entire study population. The opportunity to use standardized timing of assessment, similar lengths of followup for those included in the analysis, or validated assessment tools for evaluation of characteristics such as neonatal and childhood developmental status is not yet being optimized. Twenty-eight percent of the publications report outcomes to birth only, and followup into childhood is meager. Outcomes of crucial interest such as neurodevelopmental status and quality of life for children and their families are rarely reported (Table 17). Complications of prematurity, a frequent sequelae of maternal-fetal surgical procedures or the conditions themselves, are not well reported. Surprisingly, gaps also exist in the reporting of the functional status of the target organ for which the procedure was done (i.e. need for renal transplant among infants with vesicoamniotic shunt placement).

Other notable gaps include sparse information about anesthesia care, intra-operative monitoring of mother and fetus, postoperative care, and specialized nursing considerations. Near-

absence of maternal outcome assessment, including a significant lack of data on future maternal reproductive health, is especially concerning.¹⁵⁹⁻¹⁶¹ The single publication that examined maternal outcomes across the spectrum of maternal-fetal surgical procedures for 187 women, reported 26 percent of women having open fetal procedures had an intensive care stay and 2.3 percent were intubated.¹⁶² The team found across open, endoscopic, and percutaneous approaches combined that preterm labor resulting in birth affected 27 percent of pregnancies and preterm premature rupture of membranes 44 percent, with cesarean birth being the route of delivery for 70 percent. These and other details, such as the fact that 29 percent of women remained hospitalized until birth, are crucial to providing comprehensive anticipatory guidance during the process of informed decisionmaking about maternal-fetal surgical procedures.

Table 17. Counts of studies reporting outcomes of maternal-fetal surgical procedures

Procedure (total number of studies)	Fetal and Infant						Maternal				
	Survival to birth	Preterm birth	Neonatal deaths	Pulmonary status	Neonatal neurologic status	Developmental status in infancy or childhood	Mortality or intensive care	Infections and wound healing complications	Length of stay	Uterine rupture (index or later pregnancy)	Subsequent fertility or reproductive outcomes
Cardiac malformations											
Atrial septoplasty (3)	3	2	3								
Aortic valvuloplasty (8)	5	5	5				4	3			
Pulmonary valvuloplasty (2)	1	1	1								
Congenital diaphragmatic hernia											
Hysterotomy (8)	6	6	6	--	4	4	4	4	3	2	2
Laparoscopic (12)	10	10	10	--	2	3	4	4	2	2	1
Percutaneous (6)	6	6	6	--			3	2	1		
Myelomeningocele											
Hysterotomy (9)	6	7	6	--	7	3	4	1		1	
Obstructive uropathy											
Vesicoamniotic or other shunt (24)	24	23	24	10	1	5		1			
Hysterotomy with repair (3)	3	3	3	2				1			1
Sacroccygeal teratoma											
Hysterotomy (3)	3	3	3				1	1			
Laparoscopic (1)	1	1	1								
Percutaneous (5)	4	4	4				2	1			
Thoracic lesions											
Thoracoamniotic shunt (9)	8	6	8	--	1	1					
Open resection (3)	3	2	3	--	1	1	1				
Twin-twin transfusion syndrome											
Laser ablation (84)	67	61	48	1	19	13	4	10			

NOTE: This table summarizes whether or not the publications considered these key outcomes, not the number of outcomes themselves. Some publications include more than one intervention and are counted under each intervention.

Despite these weaknesses, the overall momentum is toward more robust research and rigorous, more consistent documentation of outcomes over longer periods of time. All three trials

were conducted in the last decade, and each decade since the 1980s, the number of cohort studies has increased, with a threefold increase between 33 cohorts in the 2000s compared to 11 in the 1990s. Experts concurred in discussions as well as in the literature that they are eager to develop consensus measures as well as mechanisms to make implementation of common protocols and larger studies, both trials and prospective cohorts, increasingly possible.

The field is also benefitting from the contributions of groups like International Fetal Medicine and Surgery Society, the North American Fetal Therapy Network, and the International Fetal Surgery Registry. Large-scale collaborations promote not only aggregation of more participants but also standardization of measures, extended duration of followup, and emphasis on multisite trial research prioritization. Ongoing trials such as the National Institutes of Health Management of Myelomeningocele Study (MOMS) have also had beneficial effects on promoting strategies that enhance feasibility of study of rare conditions, such as commitments to provide the procedure under study only within trials and coordinating regional access.

Challenges and Opportunities

Fetal surgery teams, related research groups, professional associations, government agencies, and individual consumers with an affected fetus have a vested interest in the continued growth and sophistication of the study of outcomes of maternal-fetal surgical procedures. A number of challenges are presented, both individually and in combination:

- Relative rareness of specific anomalies, with no regional or national method to identify or consolidate new cases to be offered protocol involvement
- Need to accumulate cases over long periods of time, during which changes in other aspects of care such as innovations in neonatal care or pediatric surgery can change the benefit equation for fetal intervention or during which new surgical tools are introduced
- Variation in clinical care and research classifications of fetal anomalies and in accuracy of antenatal diagnosis, with limited diagnostic accuracy literature to draw on that reflects the general population of pregnant women in the United States
- Observation in some conditions that spontaneous regression or stabilization occurs
- Less than full agreement between staging or severity assessment systems and outcomes indicating prognosis is at present not fully discoverable from clinical assessments
- Changes in the spectrum of disease, to include previously undetected and possibly less severe cases, as imaging becomes more and more advanced with the result of reducing comparability to prior natural history studies of anticipated outcomes
- Continuing evolution of in utero interventions, which can complicate comparisons among interventions and outcomes
- Overrepresentation of higher socioeconomic status patients who have some or partial coverage for costs and may not have generalizable risks or outcomes compared to expected population-level outcomes
- Need for a strong assessment of models of care, including the potential for regionalization of care
- Training programs for the next generation of maternal-fetal surgeons, including assessment of whether formal training programs, accreditation or certification are appropriate

Strategies to reduce evidence gaps include:

- Continued development of consensus on operational definitions to uniformly classify and describe severity of conditions
- Enhanced attention to collection of common data elements using uniform approaches, especially for measurement of strong predictors of outcome and for the outcomes themselves
- Use of valid and reliable tools, common in pediatric and developmental biology research, to more globally assess infant and child health status with the long-term goal of ultimately having followup into young adulthood and later to include functional status and quality of life measures
- Cooperative data sharing with these common data elements to include plans for assessing issues of diagnostic accuracy, changing natural history, and prognosis, as well as large-scale multivariable data analysis comparing outcomes
- Use of such analyses to inform the conduct of the most pressing clinical trials in which there is scientific equipoise
- Investment in research infrastructure, external to any one site, that can facilitate achieving these aims
- New methods for funding and sharing cost and liability risk for the conduct of maternal-fetal treatment research
- Establishment of an accepted and consistent set of ethical standards for conduct of research in maternal-fetal procedures

In our discussions with experts across the country, they universally discussed the need for a considered approach to the potential for regionalized care, the need for appropriate and rigorous training, the potential for a move toward a nationally accredited field, and the desire to continue to push the science forward with as much rigor and ethical practice as possible. The coherence of the overall agenda^{157-158, 163} and the determination of those with a stake in understanding fetal surgical procedures are strong assurances that the scientific community will continue to build knowledge to inform care when infrastructure and consensus needs are overcome.

References and Included Studies

1. Ashburn DA, Blackstone EH, Wells WJ, et al. Determinants of mortality and type of repair in neonates with pulmonary atresia and intact ventricular septum. *J Thorac Cardiovasc Surg* 2004 Apr;127(4):1000-1007; discussion 1007-1008.
2. Shinebourne EA, Rigby ML and Carvalho JS. Pulmonary atresia with intact ventricular septum: from fetus to adult: congenital heart disease. *Heart* 2008 Oct;94(10):1350-1357.
3. Tulzer G, Arzt W, Franklin RC, et al. Fetal pulmonary valvuloplasty for critical pulmonary stenosis or atresia with intact septum. *Lancet* 2002 Nov 16;360(9345):1567-1568.
4. Mizrahi-Arnaud A, Tworetzky W, Bulich LA, et al. Pathophysiology, management, and outcomes of fetal hemodynamic instability during prenatal cardiac intervention. *Pediatr Res* 2007 Sep;62(3):325-330.
5. McElhinney DB, Marshall AC, Wilkins-Haug LE, et al. Predictors of technical success and postnatal biventricular outcome after in utero aortic valvuloplasty for aortic stenosis with evolving hypoplastic left heart syndrome. *Circulation* 2009 Oct 13;120(15):1482-1490.
6. McElhinney DB, Benson CB, Brown DW, et al. Cerebral blood flow characteristics and biometry in fetuses undergoing prenatal intervention for aortic stenosis with evolving hypoplastic left heart syndrome. *Ultrasound Med Biol* 2010 Jan;36(1):29-37.
7. Wilkins-Haug LE, Tworetzky W, Benson CB, et al. Factors affecting technical success of fetal aortic valve dilation. *Ultrasound Obstet Gynecol* 2006 Jul;28(1):47-52.
8. Marshall AC, Tworetzky W, Bergersen L, et al. Aortic valvuloplasty in the fetus: technical characteristics of successful balloon dilation. *J Pediatr* 2005 Oct;147(4):535-539.
9. Tworetzky W, Wilkins-Haug L, Jennings RW, et al. Balloon dilation of severe aortic stenosis in the fetus: potential for prevention of hypoplastic left heart syndrome: candidate selection, technique, and results of successful intervention. *Circulation* 2004 Oct 12;110(15):2125-2131.
10. Kohl T, Sharland G, Allan LD, et al. World experience of percutaneous ultrasound-guided balloon valvuloplasty in human fetuses with severe aortic valve obstruction. *Am J Cardiol* 2000 May 15;85(10):1230-1233.
11. Maxwell D, Allan L and Tynan MJ. Balloon dilatation of the aortic valve in the fetus: a report of two cases. *Br Heart J* 1991 May;65(5):256-258.
12. Marshall AC, van der Velde ME, Tworetzky W, et al. Creation of an atrial septal defect in utero for fetuses with hypoplastic left heart syndrome and intact or highly restrictive atrial septum. *Circulation* 2004 Jul 20;110(3):253-258.
13. Marshall AC, Levine J, Morash D, et al. Results of in utero atrial septoplasty in fetuses with hypoplastic left heart syndrome. *Prenat Diagn* 2008 Nov;28(11):1023-1028.
14. Allan LD, Maxwell DJ, Carminati M, et al. Survival after fetal aortic balloon valvuloplasty. *Ultrasound Obstet Gynecol* 1995 Feb;5(2):90-91.
15. Hospital stays, hospital charges, and in-hospital deaths among infants with selected birth defects—United States, 2003. *MMWR Morb Mortal Wkly Rep* 2007 Jan 19;56(2):25-29.
16. National Center on Birth Defects and Developmental Disabilities. Metropolitan Atlanta Congenital Defects Program 2004 Annual Report. Atlanta, GA: Centers for Disease Control and Prevention; 2004.
17. Quintero RA, Huhta J, Suh E, et al. In utero cardiac fetal surgery: laser atrial septotomy in the treatment of hypoplastic left heart syndrome with intact atrial septum. *Am J Obstet Gynecol* 2005 Oct;193(4):1424-1428.

18. Glatz JA, Tabbutt S, Gaynor JW, et al. Hypoplastic left heart syndrome with atrial level restriction in the era of prenatal diagnosis. *Ann Thorac Surg* 2007 Nov;84(5):1633-1638.
19. Rudolph CD, Rudolph AM, Hostetter MK, et al., editors. *Rudolph's pediatrics*. New York: McGraw-Hill, Medical Pub Div; 2003.
20. Butler N, Claireaux AE. Congenital diaphragmatic hernia as a cause of perinatal mortality. *Lancet* 1962 Mar 31;1(7231):659-663.
21. Cortes RA, Keller RL, Townsend T, et al. Survival of severe congenital diaphragmatic hernia has morbid consequences. *J Pediatr Surg* 2005 Jan;40(1):36-45; discussion 45-46.
22. Deprest J, Gratacos E, Nicolaidis KH. Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia: evolution of a technique and preliminary results. *Ultrasound Obstet Gynecol* 2004 Aug;24(2):121-126.
23. Flake AW, Crombleholme TM, Johnson MP, et al. Treatment of severe congenital diaphragmatic hernia by fetal tracheal occlusion: clinical experience with fifteen cases. *Am J Obstet Gynecol* 2000 Nov;183(5):1059-1066.
24. Gibbs DL, Piecuch RE, Graf JL, et al. Neurodevelopmental outcome after open fetal surgery. *J Pediatr Surg* 1998 Aug;33(8):1254-1256.
25. Harrison MR, Adzick NS, Bullard KM, et al. Correction of congenital diaphragmatic hernia in utero VII: a prospective trial. *J Pediatr Surg* 1997 Nov;32(11):1637-1642.
26. Harrison MR, Adzick NS, Flake AW, et al. Correction of congenital diaphragmatic hernia in utero: VI. Hard-earned lessons. *J Pediatr Surg* 1993 Oct;28(10):1411-1417; discussion 1417-1418.
27. Harrison MR, Adzick NS, Flake AW, et al. Correction of congenital diaphragmatic hernia in utero VIII: Response of the hypoplastic lung to tracheal occlusion. *J Pediatr Surg* 1996 Oct;31(10):1339-1348.
28. Harrison MR, Albanese CT, Hawgood SB, et al. Fetoscopic temporary tracheal occlusion by means of detachable balloon for congenital diaphragmatic hernia. *Am J Obstet Gynecol* 2001 Sep;185(3):730-733.
29. Harrison MR, Keller RL, Hawgood SB, et al. A randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic hernia. *N Engl J Med* 2003 Nov 13;349(20):1916-1924.
30. Harrison MR, Langer JC, Adzick NS, et al. Correction of congenital diaphragmatic hernia in utero, V. Initial clinical experience. *J Pediatr Surg* 1990 Jan;25(1):47-55; discussion 56-57.
31. Harrison MR, Mychaliska GB, Albanese CT, et al. Correction of congenital diaphragmatic hernia in utero IX: fetuses with poor prognosis (liver herniation and low lung-to-head ratio) can be saved by fetoscopic temporary tracheal occlusion. *J Pediatr Surg* 1998 Jul;33(7):1017-1022; discussion 1022-1023.
32. Harrison MR, Sydorak RM, Farrell JA, et al. Fetoscopic temporary tracheal occlusion for congenital diaphragmatic hernia: prelude to a randomized, controlled trial. *J Pediatr Surg* 2003 Jul;38(7):1012-1020.
33. Heerema AE, Rabban JT, Sydorak RM, et al. Lung pathology in patients with congenital diaphragmatic hernia treated with fetal surgical intervention, including tracheal occlusion. *Pediatr Dev Pathol* 2003 Nov-Dec;6(6):536-546.
34. Hubbard AM, Adzick NS, Crombleholme TM, et al. Left-sided congenital diaphragmatic hernia: value of prenatal MR imaging in preparation for fetal surgery. *Radiology* 1997 Jun;203(3):636-640.
35. Jani J, Gratacos E, Greenough A, et al. Percutaneous fetal endoscopic tracheal occlusion (FETO) for severe left-sided congenital diaphragmatic hernia. *Clin Obstet Gynecol* 2005 Dec;48(4):910-922.
36. Jani JC, Nicolaidis KH, Gratacos E, et al. Fetal lung-to-head ratio in the prediction of survival in severe left-sided diaphragmatic hernia treated by fetal endoscopic tracheal occlusion (FETO). *Am J Obstet Gynecol* 2006 Dec;195(6):1646-1650.

37. Keller RL, Glidden DV, Paek BW, et al. The lung-to-head ratio and fetoscopic temporary tracheal occlusion: prediction of survival in severe left congenital diaphragmatic hernia. *Ultrasound Obstet Gynecol* 2003 Mar;21(3):244-249.
38. Keller RL, Hawgood S, Neuhaus JM, et al. Infant pulmonary function in a randomized trial of fetal tracheal occlusion for severe congenital diaphragmatic hernia. *Pediatr Res* 2004 Nov;56(5):818-825.
39. Kohl T, Gembruch U, Filsinger B, et al. Encouraging early clinical experience with deliberately delayed temporary fetoscopic tracheal occlusion for the prenatal treatment of life-threatening right and left congenital diaphragmatic hernias. *Fetal Diagn Ther* 2006;21(3):314-318.
40. Peralta CF, Jani JC, Van Schoubroeck D, et al. Fetal lung volume after endoscopic tracheal occlusion in the prediction of postnatal outcome. *Am J Obstet Gynecol* 2008 Jan;198(1):60e1-60e5.
41. Saura L, Castanon M, Prat J, et al. Impact of fetal intervention on postnatal management of congenital diaphragmatic hernia. *Eur J Pediatr Surg* 2007 Dec;17(6):404-407.
42. Danzer E, Davey MG, Kreiger PA, et al. Fetal tracheal occlusion for severe congenital diaphragmatic hernia in humans: a morphometric study of lung parenchyma and muscularization of pulmonary arterioles. *J Pediatr Surg* 2008 Oct;43(10):1767-1775.
43. Sinha CK, Islam S, Patel S, et al. Congenital diaphragmatic hernia: prognostic indices in the fetal endoluminal tracheal occlusion era. *J Pediatr Surg* 2009 Feb;44(2):312-316.
44. Peiro JL, Carreras E, Guillen G, et al. Therapeutic indications of fetoscopy: a 5-year institutional experience. *J Laparoendosc Adv Surg Tech A* 2009 Apr;19(2):229-236.
45. Cannie MM, Jani JC, De Keyzer F, et al. Evidence and patterns in lung response after fetal tracheal occlusion: clinical controlled study. *Radiology* 2009 Aug;252(2):526-533.
46. Jani J, Keller RL, Benachi A, et al. Prenatal prediction of survival in isolated left-sided diaphragmatic hernia. *Ultrasound Obstet Gynecol* 2006 Jan;27(1):18-22.
47. Mathews TJ, Honein MA and Erickson JD. Spina bifida and anencephaly prevalence—United States, 1991-2001. *MMWR Recomm Rep* 2002 Sep 13;51(RR-13):9-11.
48. Tubbs RS, Chambers MR, Smyth MD, et al. Late gestational intrauterine myelomeningocele repair does not improve lower extremity function. *Pediatr Neurosurg* 2003 Mar;38(3):128-132.
49. Tulipan N, Bruner JP, Hernanz-Schulman M, et al. Effect of intrauterine myelomeningocele repair on central nervous system structure and function. *Pediatr Neurosurg* 1999 Oct;31(4):183-188.
50. Bruner JP, Tulipan N, Paschall RL, et al. Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus. *JAMA* 1999 Nov 17;282(19):1819-1825.
51. Danzer E, Johnson MP, Bebbington M, et al. Fetal head biometry assessed by fetal magnetic resonance imaging following in utero myelomeningocele repair. *Fetal Diagn Ther* 2007;22(1):1-6.
52. Adelberg A, Blotzer A, Koch G, et al. Impact of maternal-fetal surgery for myelomeningocele on the progression of ventriculomegaly in utero. *Am J Obstet Gynecol* 2005 Sep;193(3 Pt 1):727-731.
53. Hamdan AH, Walsh W, Bruner JP, et al. Intrauterine myelomeningocele repair: effect on short-term complications of prematurity. *Fetal Diagn Ther* 2004 Jan-Feb;19(1):83-86.
54. Tulipan N, Sutton LN, Bruner JP, et al. The effect of intrauterine myelomeningocele repair on the incidence of shunt-dependent hydrocephalus. *Pediatr Neurosurg* 2003 Jan;38(1):27-33.
55. Bruner JP, Tulipan NB, Richards WO, et al. In utero repair of myelomeningocele: a comparison of endoscopy and hysterotomy. *Fetal Diagn Ther* 2000 Mar-Apr;15(2):83-88.
56. Johnson MP, Sutton LN, Rintoul N, et al. Fetal myelomeningocele repair: short-term clinical outcomes. *Am J Obstet Gynecol* 2003 Aug;189(2):482-487.

57. Johnson MP, Gerdes M, Rintoul N, et al. Maternal-fetal surgery for myelomeningocele: neurodevelopmental outcomes at 2 years of age. *Am J Obstet Gynecol* 2006 Apr;194(4):1145-1150; discussion 1150-1152.
58. Koh CJ, DeFilippo RE, Borer JG, et al. Bladder and external urethral sphincter function after prenatal closure of myelomeningocele. *J Urol* 2006 Nov;176(5):2232-2236.
59. Danzer E, Johnson MP, Wilson RD, et al. Fetal head biometry following in-utero repair of myelomeningocele. *Ultrasound Obstet Gynecol* 2004 Nov;24(6):606-611.
60. Wilson RD, Johnson MP, Bebbington M, et al. Does a myelomeningocele sac compared to no sac result in decreased postnatal leg function following maternal fetal surgery for spina bifida aperta? *Fetal Diagn Ther* 2007;22(5):348-351.
61. Mazzola CA, Albright AL, Sutton LN, et al. Dermoid inclusion cysts and early spinal cord tethering after fetal surgery for myelomeningocele. *N Engl J Med* 2002 Jul 25;347(4):256-259.
62. Sutton LN, Adzick NS, Bilaniuk LT, et al. Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele. *JAMA* 1999 Nov 17;282(19):1826-1831.
63. Danzer E, Adzick NS, Rintoul NE, et al. Intradural inclusion cysts following in utero closure of myelomeningocele: clinical implications and follow-up findings. *J Neurosurg Pediatr* 2008 Dec;2(6):406-413.
64. Danzer E, Finkel RS, Rintoul NE, et al. Reversal of hindbrain herniation after maternal-fetal surgery for myelomeningocele subsequently impacts on brain stem function. *Neuropediatrics* 2008 Dec;39(6):359-362.
65. Danzer E, Gerdes M, Bebbington MW, et al. Lower extremity neuromotor function and short-term ambulatory potential following in utero myelomeningocele surgery. *Fetal Diagn Ther* 2009;25(1):47-53.
66. Bruner JP, Tulipan N, Reed G, et al. Intrauterine repair of spina bifida: preoperative predictors of shunt-dependent hydrocephalus. *Am J Obstet Gynecol* 2004 May;190(5):1305-1312.
67. Hamdan AH, Walsh W, Heddings A, et al. Gestational age at intrauterine myelomeningocele repair does not influence the risk of prematurity. *Fetal Diagn Ther* 2002 Mar-Apr;17(2):66-68.
68. Mangels KJ, Tulipan N, Bruner JP, et al. Use of bipedicular advancement flaps for intrauterine closure of myeloschisis. *Pediatr Neurosurg* 2000 Jan;32(1):52-56.
69. Tulipan N, Hernanz-Schulman M, Lowe LH, et al. Intrauterine myelomeningocele repair reverses preexisting hindbrain herniation. *Pediatr Neurosurg* 1999 Sep;31(3):137-142.
70. Tulipan N, Bruner JP. Myelomeningocele repair in utero: a report of three cases. *Pediatr Neurosurg* 1998 Apr;28(4):177-180.
71. Tulipan N, Hernanz-Schulman M, Bruner JP. Reduced hindbrain herniation after intrauterine myelomeningocele repair: A report of four cases. *Pediatr Neurosurg* 1998 Nov;29(5):274-278.
72. Farmer DL, von Koch CS, Peacock WJ, et al. In utero repair of myelomeningocele: experimental pathophysiology, initial clinical experience, and outcomes. *Arch Surg* 2003 Aug;138(8):872-878.
73. Holmes NM, Nguyen HT, Harrison MR, et al. Fetal intervention for myelomeningocele: effect on postnatal bladder function. *J Urol* 2001 Dec;166(6):2383-2386.
74. Bruner JP, Richards WO, Tulipan NB, et al. Endoscopic coverage of fetal myelomeningocele in utero. *Am J Obstet Gynecol* 1999 Jan;180(1 Pt 1):153-158.
75. Chervenak FA, McCullough LB, Birnbach DJ. Ethical issues in fetal surgery research. *Best Pract Res Clin Anaesthesiol* 2004 Jun;18(2):221-230.
76. Golbus MS, Harrison MR, Filly RA. Prenatal diagnosis and treatment of fetal hydronephrosis. *Semin Perinatol* 1983 Apr;7(2):102-108.

77. Harrison MR, Golbus MS, Filly RA, et al. Management of the fetus with congenital hydronephrosis. *J Pediatr Surg* 1982 Dec;17(6):728-742.
78. Welsh A, Agarwal S, Kumar S, et al. Fetal cystoscopy in the management of fetal obstructive uropathy: experience in a single European centre. *Prenat Diagn* 2003 Dec 30;23(13):1033-1041.
79. Quintero RA, Johnson MP, Romero R, et al. In-utero percutaneous cystoscopy in the management of fetal lower obstructive uropathy. *Lancet* 1995 Aug 26;346(8974):537-540.
80. Johnson MP, Bukowski TP, Reitleman C, et al. In utero surgical treatment of fetal obstructive uropathy: a new comprehensive approach to identify appropriate candidates for vesicoamniotic shunt therapy. *Am J Obstet Gynecol* 1994 Jun;170(6):1770-1776; discussion 1776-1779.
81. Salam MA. Posterior urethral valve: Outcome of antenatal intervention. *Int J Urol* 2006 Oct;13(10):1317-1322.
82. Wilson RD, Johnson MP. Prenatal ultrasound guided percutaneous shunts for obstructive uropathy and thoracic disease. *Semin Pediatr Surg* 2003 Aug;12(3):182-189.
83. Warne S, Chitty LS, Wilcox DT. Prenatal diagnosis of cloacal anomalies. *BJU Int* 2002 Jan;89(1):78-81.
84. Holmes N, Harrison MR, Baskin LS. Fetal surgery for posterior urethral valves: long-term postnatal outcomes. *Pediatrics* 2001 Jul;108(1):E7.
85. McLorie G, Farhat W, Khoury A, et al. Outcome analysis of vesicoamniotic shunting in a comprehensive population. *J Urol* 2001 Sep;166(3):1036-1040.
86. Freedman AL, Bukowski TP, Smith CA, et al. Fetal therapy for obstructive uropathy: diagnosis specific outcomes [corrected]. *J Urol* 1996 Aug;156(2 Pt 2):720-723; discussion 723-724.
87. Crombleholme TM, Harrison MR, Golbus MS, et al. Fetal intervention in obstructive uropathy: prognostic indicators and efficacy of intervention. *Am J Obstet Gynecol* 1990 May;162(5):1239-1244.
88. Araujo Junior E, Guimaraes Filho HA, Saito M, et al. Percutaneous fetal surgery using epidural catheter: preliminary experience acquired from 24 cases. *Arch Gynecol Obstet* 2007 Jul;276(1):29-33.
89. Craparo FJ, Rustico M, Tassis B, et al. Fetal serum beta2-microglobulin before and after bladder shunting: a 2-step approach to evaluate fetuses with lower urinary tract obstruction. *J Urol* 2007 Dec;178(6):2576-2579.
90. Biard JM, Johnson MP, Carr MC, et al. Long-term outcomes in children treated by prenatal vesicoamniotic shunting for lower urinary tract obstruction. *Obstet Gynecol* 2005 Sep;106(3):503-508.
91. Makino Y, Kobayashi H, Kyono K, et al. Clinical results of fetal obstructive uropathy treated by vesicoamniotic shunting. *Urology* 2000 Jan;55(1):118-122.
92. Freedman AL, Johnson MP, Smith CA, et al. Long-term outcome in children after antenatal intervention for obstructive uropathies. *Lancet* 1999 Jul 31;354(9176):374-377.
93. Evans MI, Sacks AJ, Johnson MP, et al. Sequential invasive assessment of fetal renal function and the intrauterine treatment of fetal obstructive uropathies. *Obstet Gynecol* 1991 Apr;77(4):545-550.
94. Manning FA, Harrison MR, Rodeck C. Catheter shunts for fetal hydronephrosis and hydrocephalus. Report of the International Fetal Surgery Registry. *N Engl J Med* 1986 Jul 31;315(5):336-340.
95. Gehring JE, Cain MP, Casale AJ, et al. Abdominal wall hernia: an uncommon complication of in utero vesicoamniotic shunt placement. *Urology* 2000 Aug 1;56(2):330.
96. Shimada K, Hosokawa S, Tohda A, et al. Follow-up of children after fetal treatment for obstructive uropathy. *Int J Urol* 1998 Jul;5(4):312-316.

97. Pinckert TL, Kiernan SC. In utero nephrostomy catheter placement. *Fetal Diagn Ther* 1994 Sep-Oct;9(5):348-352.
98. Bernaschek G, Deutinger J, Hansmann M, et al. Feto-amniotic shunting—report of the experience of four European centres. *Prenat Diagn* 1994 Sep;14(9):821-833.
99. Robichaux III AG, Mandell J, Greene MF, et al. Fetal abdominal wall defect: a new complication of vesicoamniotic shunting. *Fetal Diagn Ther* 1991;6(1-2):11-13.
100. Crombleholme TM, Harrison MR, Langer JC, et al. Early experience with open fetal surgery for congenital hydronephrosis. *J Pediatr Surg* 1988 Dec;23(12):1114-1121.
101. Manning FA, Harman CR, Lange IR, et al. Antepartum chronic fetal vesicoamniotic shunts for obstructive uropathy: A report of two cases. *Am J Obstet Gynecol* 1983 Apr 1;145(7):819-822.
102. Johnson MP, Corsi P, Bradfield W, et al. Sequential urinalysis improves evaluation of fetal renal function in obstructive uropathy. *Am J Obstet Gynecol* 1995 Jul;173(1):59-65.
103. Neubert S, Trautmann K, Tanner B, et al. Sonographic prognostic factors in prenatal diagnosis of SCT. *Fetal Diagn Ther* 2004 Jul-Aug;19(4):319-326.
104. Flake AW. Fetal sacrococcygeal teratoma. *Semin Pediatr Surg*. 1993 May;2(2):113-120.
105. Chisholm CA, Heider AL, Kuller JA, et al. Prenatal diagnosis and perinatal management of fetal sacrococcygeal teratoma. *Am J Perinatol* 1999;16(1):47-50.
106. Uchiyama M, Iwafuchi M, Naitoh M, et al. Sacrococcygeal teratoma: a series of 19 cases with long-term follow-up. *Eur J Pediatr Surg* 1999 Jun;9(3):158-162.
107. Schmidt KG, Silverman NH, Harison MR, et al. High-output cardiac failure in fetuses with large sacrococcygeal teratoma: diagnosis by echocardiography and Doppler ultrasound. *J Pediatr* 1989 Jun;114(6):1023-1028.
108. Westerburg B, Feldstein VA, Sandberg PL, et al. Sonographic prognostic factors in fetuses with sacrococcygeal teratoma. *J Pediatr Surg* 2000 Feb;35(2):322-325; discussion 325-326.
109. Bond SJ, Harrison MR, Schmidt KG, et al. Death due to high-output cardiac failure in fetal sacrococcygeal teratoma. *J Pediatr Surg*. 1990 Dec;25(12):1287-1291.
110. Grethel EJ, Wagner AJ, Clifton MS, et al. Fetal intervention for mass lesions and hydrops improves outcome: a 15-year experience. *J Pediatr Surg* 2007 Jan;42(1):117-123.
111. Danzer E, Hubbard AM, Hedrick HL, et al. Diagnosis and characterization of fetal sacrococcygeal teratoma with prenatal MRI. *AJR Am J Roentgenol* 2006 Oct;187(4):W350-W356.
112. Hedrick HL, Flake AW, Crombleholme TM, et al. Sacrococcygeal teratoma: prenatal assessment, fetal intervention, and outcome. *J Pediatr Surg* 2004 Mar;39(3):430-438; discussion 430-438.
113. Makin EC, Hyett J, Ade-Ajayi N, et al. Outcome of antenatally diagnosed sacrococcygeal teratomas: single-center experience (1993-2004). *J Pediatr Surg* 2006 Feb;41(2):388-393.
114. Paek BW, Jennings RW, Harrison MR, et al. Radiofrequency ablation of human fetal sacrococcygeal teratoma. *Am J Obstet Gynecol* 2001 Feb;184(3):503-507.
115. Kay S, Khalife S, Laberge JM, et al. Prenatal percutaneous needle drainage of cystic sacrococcygeal teratomas. *J Pediatr Surg* 1999 Jul;34(7):1148-1151.
116. Pumberger W, Hormann M, Deutinger J, et al. Longitudinal observation of antenatally detected congenital lung malformations (CLM): natural history, clinical outcome and long-term follow-up. *Eur J Cardiothorac Surg* 2003 Nov;24(5):703-711.
117. Harrison MR, Adzick NS, Jennings RW, et al. Antenatal intervention for congenital cystic adenomatoid malformation. *Lancet* 1990 Oct 20;336(8721):965-967.

118. Dommergues M, Louis-Sylvestre C, Mandelbrot L, et al. Congenital adenomatoid malformation of the lung: when is active fetal therapy indicated? *Am J Obstet Gynecol* 1997 Oct;177(4):953-958.
119. Revillon Y, Jan D, Plattner V, et al. Congenital cystic adenomatoid malformation of the lung: prenatal management and prognosis. *J Pediatr Surg* 1993 Aug;28(8):1009-1011.
120. Adzick NS, Harrison MR, Crombleholme TM, et al. Fetal lung lesions: management and outcome. *Am J Obstet Gynecol* 1998 Oct;179(4):884-889.
121. Adzick NS. Fetal cystic adenomatoid malformation of the lung: diagnosis, perinatal management, and outcome. *Semin Thorac Cardiovasc Surg* 1994 Oct;6(4):247-252.
122. Adzick NS, Harrison MR, Flake AW, et al. Fetal surgery for cystic adenomatoid malformation of the lung. *J Pediatr Surg* 1993 Jun;28(6):806-812.
123. Cha I, Adzick NS, Harrison MR, et al. Fetal congenital cystic adenomatoid malformations of the lung: a clinicopathologic study of eleven cases. *Am J Surg Pathol* 1997 May;21(5):537-544.
124. Kuller JA, Yankowitz J, Goldberg JD, et al. Outcome of antenatally diagnosed cystic adenomatoid malformations. *Am J Obstet Gynecol* 1992 Oct;167(4 Pt 1):1038-1041.
125. Merchant AM, Peranteau W, Wilson RD, et al. Postnatal chest wall deformities after fetal thoracoamniotic shunting for congenital cystic adenomatoid malformation. *Fetal Diagn Ther* 2007;22(6):435-439.
126. Morikawa M, Yamada H, Okuyama K, et al. Prenatal diagnosis and fetal therapy of congenital cystic adenomatoid malformation type I of the lung: a report of five cases. *Congenit Anom (Kyoto)* 2003 Mar;43(1):72-78.
127. Morris LM, Lim FY, Livingston JC, et al. High-risk fetal congenital pulmonary airway malformations have a variable response to steroids. *J Pediatr Surg* 2009 Jan;44(1):60-65.
128. Wilson RD, Baxter JK, Johnson MP, et al. Thoracoamniotic shunts: fetal treatment of pleural effusions and congenital cystic adenomatoid malformations. *Fetal Diagn Ther* 2004 Sep-Oct;19(5):413-420.
129. Golaszewski T, Bettelheim D, Eppel W, et al. Cystic adenomatoid malformation of the lung: prenatal diagnosis, prognostic factors and fetal outcome. *Gynecol Obstet Invest* 1998;46(4):241-246.
130. Becmeur F, Donato L, Horta-Geraud P, et al. Pulmonary sequestrations. *Pediatr Pulmonol Suppl* 1997;16:129-130.
131. Bermudez C, Perez-Wulff J, Arcadipane M, et al. Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung. *Fetal Diagn Ther* 2008;24(3):237-240.
132. Johnson A, Moise Jr KJ. Improving survival in twin-twin transfusion syndrome. *Contemporary OB/GYN* 2006;51(12):54-59.
133. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2003. *Natl Vital Stat Rep* 2005 Sep 8;54(2):1-116.
134. Quintero RA, Morales WJ, Allen MH, et al. Staging of twin-twin transfusion syndrome. *J Perinatol* 1999 Dec;19(8 Pt 1):550-555.
135. Baldwin VJ, Wittmann BK. Pathology of intragestational intervention in twin-to-twin transfusion syndrome. *Pediatr Pathol* 1990;10(1-2):79-93.
136. De Lia JE, Cruikshank DP, Keye Jr WR. Fetoscopic neodymium:YAG laser occlusion of placental vessels in severe twin-twin transfusion syndrome. *Obstet Gynecol* 1990 Jun;75(6):1046-1053.
137. Chescheir NC. *Maternal-Fetal Surgery: Where Are We and How Did We Get Here?* *Obstet Gynecol* 2009;113(3):717-731.
138. Moise Jr KJ, Dorman K, Lamvu G, et al. A randomized trial of amnioreduction versus septostomy in the treatment of twin-twin transfusion syndrome. *Am J Obstet Gynecol* 2005 Sep;193(3 Pt 1):701-707.

139. Crombleholme TM, Shera D, Lee H, et al. A prospective, randomized, multicenter trial of amnioreduction vs selective fetoscopic laser photocoagulation for the treatment of severe twin-twin transfusion syndrome. *Am J Obstet Gynecol* 2007 Oct;197(4):396e1-396e9.
140. Senat MV, Deprest J, Boulvain M, et al. Endoscopic laser surgery versus serial amnioreduction for severe twin-to-twin transfusion syndrome. *N Engl J Med* 2004 Jul 8;351(2):136-144.
141. Chmait RH, Khan A, Benirschke K, et al. Perinatal survival following preferential sequential selective laser surgery for twin-twin transfusion syndrome. *J Matern Fetal Neonatal Med* 2010 Jan;23(1):10-16.
142. Chavira ER, Khan A, Korst LM, et al. Are patients with twin-twin transfusion syndrome and a very short cervix candidates for laser surgery? *J Ultrasound Med* 2009 May;28(5):633-639.
143. Quintero RA, Ishii K, Chmait RH, et al. Sequential selective laser photocoagulation of communicating vessels in twin-twin transfusion syndrome. *J Matern Fetal Neonatal Med* 2007 Oct;20(10):763-768.
144. Gardiner HM, Taylor MJ, Karatza A, et al. Twin-twin transfusion syndrome: the influence of intrauterine laser photocoagulation on arterial distensibility in childhood. *Circulation* 2003 Apr 15;107(14):1906-1911.
145. Habli M, Livingston J, Harmon J, et al. The outcome of twin-twin transfusion syndrome complicated with placental insufficiency. *Am J Obstet Gynecol* 2008 Oct;199(4):424e1-424e6.
146. Lenclen R, Paupe A, Ciarlo G, et al. Neonatal outcome in preterm monochorionic twins with twin-to-twin transfusion syndrome after intrauterine treatment with amnioreduction or fetoscopic laser surgery: comparison with dichorionic twins. *Am J Obstet Gynecol* 2007 May;196(5):450e1-450e7.
147. Lenclen R, Ciarlo G, Paupe A, et al. Neurodevelopmental outcome at 2 years in children born preterm treated by amnioreduction or fetoscopic laser surgery for twin-to-twin transfusion syndrome: comparison with dichorionic twins. *Am J Obstet Gynecol* 2009 Sep;201(3):291e1-291e5.
148. Middeldorp JM, Lopriore E, Sueters M, et al. Twin-to-twin transfusion syndrome after 26 weeks of gestation: is there a role for fetoscopic laser surgery? *BJOG* 2007 Jun;114(6):694-698.
149. Wagner MM, Lopriore E, Klumper FJ, et al. Short- and long-term outcome in stage 1 twin-to-twin transfusion syndrome treated with laser surgery compared with conservative management. *Am J Obstet Gynecol* 2009 Sep;201(3):286e1-286e6.
150. Santiago JC, Ramos-Corpas DJ, Castillo MJ. Endoscopic laser surgery after therapeutic amniocentesis in the treatment of severe twin-twin transfusion syndrome. *Int J Gynaecol Obstet* 2006 Mar;92(3):262-263.
151. Quintero RA, Dickinson JE, Morales WJ, et al. Stage-based treatment of twin-twin transfusion syndrome. *Am J Obstet Gynecol* 2003 May;188(5):1333-1340.
152. Quintero RA, Comas C, Bornick PW, et al. Selective versus non-selective laser photocoagulation of placental vessels in twin-to-twin transfusion syndrome. *Ultrasound Obstet Gynecol* 2000 Sep;16(3):230-236.
153. Habli M, Bombrys A, Lewis D, et al. Incidence of complications in twin-twin transfusion syndrome after selective fetoscopic laser photocoagulation: a single-center experience. *Am J Obstet Gynecol* 2009 Oct;201(4):417e1-417e7.
154. Chang J, Tracy Jr TF, Carr SR, et al. Port insertion and removal techniques to minimize premature rupture of the membranes in endoscopic fetal surgery. *J Pediatr Surg* 2006 May;41(5):905-909.

155. Yamamoto M, El Murr L, Robyr R, et al. Incidence and impact of perioperative complications in 175 fetoscopy-guided laser coagulations of chorionic plate anastomoses in fetofetal transfusion syndrome before 26 weeks of gestation. *Am J Obstet Gynecol* 2005 Sep;193(3 Pt 2):1110-1116.
156. Lopriore E, Middeldorp JM, Sueters M, et al. Long-term neurodevelopmental outcome in twin-to-twin transfusion syndrome treated with fetoscopic laser surgery. *Am J Obstet Gynecol* 2007 Mar;196(3):231 e1-e4.
157. Moise Jr KJ, Johnson A, Carpenter RJ, et al. Fetal intervention: providing reasonable access to quality care. *Obstet Gynecol* 2009 Feb;113(2 Pt 1):408-410.
158. Chescheir NC, Socol M. The National Institutes of Health Workshop on Fetal Treatment: needs assessment and future directions. *Obstet Gynecol* 2005 Oct;106(4):828-833.
159. Wilson RD, Johnson MP, Flake AW, et al. Reproductive outcomes after pregnancy complicated by maternal-fetal surgery. *Am J Obstet Gynecol* 2004 Oct;191(4):1430-1436.
160. Farrell JA, Albanese CT, Jennings RW, et al. Maternal fertility is not affected by fetal surgery. *Fetal Diagn Ther* 1999 May-Jun;14(3):190-192.
161. Longaker MT, Golbus MS, Filly RA, et al. Maternal outcome after open fetal surgery. A review of the first 17 human cases. *JAMA* 1991 Feb 13;265(6):737-741.
162. Golombeck K, Ball RH, Lee H, et al. Maternal morbidity after maternal-fetal surgery. *Am J Obstet Gynecol* 2006 Mar;194(3):834-839.
163. Harrison MR. Fetal surgery: trials, tribulations, and turf. *J Pediatr Surg* 2003 Mar;38(3):275-282.

Acronyms/Abbreviations

AHRQ	Agency for Healthcare Research and Quality
AR	Amnioreduction
ASD	Atrial septal defect
BPS	Bronchopulmonary sequestration
CCAM	Congenital cystic adenomatoid malformation
CDC	Centers for Disease Control and Prevention
CDH	Congenital diaphragmatic hernia
CM	Chiari malformation
CPAM	Congenital Pulmonary Airway Malformation
CSF	Cerebrospinal fluid
CVPS	Cardiovascular Profile Score
DNA	Deoxyribonucleic acid
ECMO	Extracorporeal membrane oxygenation
EPC	Evidence-based Practice Center
FETO	Fetoscopic tracheal occlusion
FHI	Fetal hemodynamic instability
G	Group
HLHS	Hypoplastic left heart syndrome
IUFD	Intrauterine fetal death/In utero fetal demise
IVH	Intraventricular hemorrhage
LHR	Lung-to-head ratio
MeSH	Medical Subject Headings
MMC	Myelomeningocele
mo/mos	Months
MOMS	Management of Myelomeningocele Study
MRI	Magnetic resonance imaging
NA	Not applicable
NIH	National Institutes of Health
PROM	Premature rupture of membranes
PUV	Posterior urethral valves
RCT	Randomized controlled trial
RDS	Respiratory Distress Syndrome
RFA	Radiofrequency ablation
SD	Standard deviation
SFLP	Selective fetoscopic laser photocoagulation
SLPCV	Selective laser photocoagulation of communicating vessels
TTTS	Twin-twin transfusion syndrome
U.S.	United States
UK	United Kingdom
US	Ultrasound

Appendix A. Exact Search Strings

Table 1. PubMed search strategies (last updated May 12, 2010)

Preliminary search terms		Preliminary search results
#1 General fetal surgery search	(fetus/surgery[mh:noexp] OR fetal heart/surgery[mh] OR fetal diseases/surgery[mh] OR fetal surgery[tiab]) AND eng[la] AND humans[mh]	1,426
#2 Sacrococcygeal teratoma	(sacroccygeal teratoma OR sacrococcygeal region[mh]) AND (fetus[tiab] OR fetal[tiab]) AND (surgery OR surgical OR fetoscopy OR fetoscopic) AND eng[la] AND humans[mh]	138
#3 Congenital diaphragmatic hernia	(hernia, diaphragmatic[mh] OR diaphragmatic hernia[tiab]) AND (fetoscopy OR fetoscopic[tiab] OR "fetal therapies"[mh]) AND eng[la] AND humans[mh]	68
#4 Congenital cystic adenomatoid malformation, bronchopulmonary sequestration	(cystic adenomatoid malformation of lung, congenital[mh] OR bronchopulmonary sequestration[mh] OR adenomatoid[tiab] OR bronchopulmonary sequestration[tiab]) AND (intrauterine[tiab] OR in utero[tiab] OR fetoscopy OR fetoscopic[tiab] OR "fetal therapies"[mh]) AND eng[la] AND humans[mh]	136
#5 Obstructive uropathy	(uropathy[tiab] OR urologic diseases[mh] OR urinary tract[mh]) AND (fetoscopy OR fetoscopic[tiab] OR "fetal therapies"[mh]) AND eng[la] AND humans[mh]	39
#6 Myelomeningocele	(meningomyelocele OR myelomeningocele) AND (intrauterine[tiab] OR in utero[tiab] OR fetoscopy OR fetoscopic[tiab] OR "fetal therapies"[mh]) AND eng[la] AND humans[mh]	127
#7 Twin-twin transfusion syndrome	fetofetal transfusion[mh] AND (laser therapy[mh] OR fetoscopy OR fetoscopic OR "fetal therapies"[mh]) AND eng[la] AND humans[mh]	300
#8 Cardiac malformations	(fetal heart[mh] OR heart[mh] OR heart septal defects[mh] OR hypoplastic left heart syndrome[mh] OR aortic valve stenosis[mh] OR pulmonary valve stenosis[mh] OR pulmonary atresia[mh]) AND (fetoscopy OR fetoscopic[tiab] OR "fetal therapies"[mh]) AND eng[la] AND humans[mh]	74
#9	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8	2,020
#10	#9 AND letter[pt]	119*
#11	#9 AND comment[pt]	78
#12	#9 AND editorial[pt]	39
#13	#9 AND review[pt]	485**
#14	#9 AND news[pt]	9
#15	#9 AND practice guideline[pt]	4
#16	#9 NOT (#10 OR #11 OR #12 OR #13 OR #14 OR #15)	1,364***

Key: [mh] Medical Subject Heading; [tiab] title/abstract; [la] language; [mh:noexp] MeSH heading, not exploded

*Note: 34 of these letters include case reports; these have been included in the EndNote database

**Note: 52 of these reviews include case reports; these have been included in the EndNote database.

*** The EndNote database includes these 1,364 references, along with the 34 letters with case reports and the 52 reviews with case reports, bringing the overall pool of items retrieved by the PubMed searches to 1,450.

Update EndNote database from 5/12/10 includes 37 new items added to the database since the previous search update on 1/13/10.

Appendix B. Sample Data Abstract Forms

Technical Brief on Maternal-Fetal Surgery Abstract Review Form

First Author, Year: _____ Reference # _____

Abstractor Initials: _____

Primary Inclusion/Exclusion Criteria																			
1. Original research (exclude editorials, commentaries, reviews, etc)	Yes	No	Cannot Determine																
2. Study published in English	Yes	No	Cannot Determine																
3. Human study population	Yes	No	Cannot Determine																
4. Eligible study size ($N \geq 2$)	Yes	No	Cannot Determine																
5. Related to one or more of the following:	Yes	No	Cannot Determine																
<table border="0"> <tr> <td>a. ___ Sacrococcygeal teratoma</td> <td>i. ___ Hydrocephalus</td> </tr> <tr> <td>b. ___ Congenital diaphragmatic hernia</td> <td>j. ___ Ovarian cysts</td> </tr> <tr> <td>c. ___ Congenital cystic adenomatoid malformation</td> <td>k. ___ Amniotic band</td> </tr> <tr> <td>d. ___ Bronchopulmonary sequestration</td> <td>l. ___ Maternal outcomes of maternal-fetal surgery</td> </tr> <tr> <td>e. ___ Obstructive uropathy</td> <td>m. ___ Anesthesia care for maternal-fetal surgery</td> </tr> <tr> <td>f. ___ Myelomeningocele</td> <td>n. ___ Intraoperative maternal and fetal monitoring for maternal-fetal surgery</td> </tr> <tr> <td>g. ___ Twin-twin transfusion syndrome</td> <td>o. ___ Other _____</td> </tr> <tr> <td>h. ___ Cardiac malformations</td> <td></td> </tr> </table>				a. ___ Sacrococcygeal teratoma	i. ___ Hydrocephalus	b. ___ Congenital diaphragmatic hernia	j. ___ Ovarian cysts	c. ___ Congenital cystic adenomatoid malformation	k. ___ Amniotic band	d. ___ Bronchopulmonary sequestration	l. ___ Maternal outcomes of maternal-fetal surgery	e. ___ Obstructive uropathy	m. ___ Anesthesia care for maternal-fetal surgery	f. ___ Myelomeningocele	n. ___ Intraoperative maternal and fetal monitoring for maternal-fetal surgery	g. ___ Twin-twin transfusion syndrome	o. ___ Other _____	h. ___ Cardiac malformations	
a. ___ Sacrococcygeal teratoma	i. ___ Hydrocephalus																		
b. ___ Congenital diaphragmatic hernia	j. ___ Ovarian cysts																		
c. ___ Congenital cystic adenomatoid malformation	k. ___ Amniotic band																		
d. ___ Bronchopulmonary sequestration	l. ___ Maternal outcomes of maternal-fetal surgery																		
e. ___ Obstructive uropathy	m. ___ Anesthesia care for maternal-fetal surgery																		
f. ___ Myelomeningocele	n. ___ Intraoperative maternal and fetal monitoring for maternal-fetal surgery																		
g. ___ Twin-twin transfusion syndrome	o. ___ Other _____																		
h. ___ Cardiac malformations																			

Retain for:

___ BACKGROUND/DISCUSSION

___ ETHICS

___ REVIEW OF REFERENCES

___ Other _____

COMMENTS:

**Technical Brief on Maternal-Fetal Surgery
Full-Text Review Form**

First Author, Year: _____ Reference # _____

Abstractor Initials: _____

Primary Inclusion/Exclusion Criteria																			
1. Original research (exclude editorials, commentaries, reviews, etc)	Yes	No	Cannot Determine																
2. Study published in English	Yes	No	Cannot Determine																
3. Human study population	Yes	No	Cannot Determine																
4. Eligible study size (N ≥ 2)	Yes	No	Cannot Determine																
5. Related to one or more of the following (select all that apply):	Yes	No	Cannot Determine																
<table border="0"> <tr> <td>a. ___ Sacrococcygeal teratoma</td> <td>i. ___ Hydrocephalus</td> </tr> <tr> <td>b. ___ Congenital diaphragmatic hernia</td> <td>j. ___ Ovarian cysts</td> </tr> <tr> <td>c. ___ Congenital cystic adenomatoid malformation</td> <td>k. ___ Amniotic band</td> </tr> <tr> <td>d. ___ Bronchopulmonary sequestration</td> <td>l. ___ Maternal outcomes of maternal-fetal surgery</td> </tr> <tr> <td>e. ___ Obstructive uropathy</td> <td>m. ___ Anesthesia care for maternal-fetal surgery</td> </tr> <tr> <td>f. ___ Myelomeningocele</td> <td>n. ___ Intraoperative maternal and fetal monitoring for maternal-fetal surgery</td> </tr> <tr> <td>g. ___ Twin-twin transfusion syndrome</td> <td>o. ___ Other _____</td> </tr> <tr> <td>h. ___ Cardiac malformations</td> <td></td> </tr> </table>				a. ___ Sacrococcygeal teratoma	i. ___ Hydrocephalus	b. ___ Congenital diaphragmatic hernia	j. ___ Ovarian cysts	c. ___ Congenital cystic adenomatoid malformation	k. ___ Amniotic band	d. ___ Bronchopulmonary sequestration	l. ___ Maternal outcomes of maternal-fetal surgery	e. ___ Obstructive uropathy	m. ___ Anesthesia care for maternal-fetal surgery	f. ___ Myelomeningocele	n. ___ Intraoperative maternal and fetal monitoring for maternal-fetal surgery	g. ___ Twin-twin transfusion syndrome	o. ___ Other _____	h. ___ Cardiac malformations	
a. ___ Sacrococcygeal teratoma	i. ___ Hydrocephalus																		
b. ___ Congenital diaphragmatic hernia	j. ___ Ovarian cysts																		
c. ___ Congenital cystic adenomatoid malformation	k. ___ Amniotic band																		
d. ___ Bronchopulmonary sequestration	l. ___ Maternal outcomes of maternal-fetal surgery																		
e. ___ Obstructive uropathy	m. ___ Anesthesia care for maternal-fetal surgery																		
f. ___ Myelomeningocele	n. ___ Intraoperative maternal and fetal monitoring for maternal-fetal surgery																		
g. ___ Twin-twin transfusion syndrome	o. ___ Other _____																		
h. ___ Cardiac malformations																			

Does it provide any of the following data?	
___ Operational definition of fetal diagnoses	___ Comparator used _____
___ Type of surgery _____	___ Length of follow up _____
___ Maternal inclusion criteria	___ Outcomes measured for fetus
___ Training of providers/specialized expertise and equipment in the study hospital(s)	___ Outcomes measured for mother
___ Study country _____	___ Adverse events/harms/safety issues reported for fetus
___ Study size (N= _____)	___ Adverse events/harms/safety issues reported for mother
___ Study setting	
___ Study design	
a. ___ RCT	d. ___ Case series
b. ___ Cohorts with comparison	e. ___ Case report
c. ___ Case-control	f. ___ Literature review of case reports

Retain for:

___ BACKGROUND/DISCUSSION

___ ETHICS

___ REVIEW OF REFERENCES

___ Other _____

COMMENTS:

Appendix C. Excluded Studies

Full-text Article Exclusion Criteria Codes for Database

X-1: Not original research

X-3: Non-human study population

X-5: Ineligible study size (N <2)

X-6: Not related to selected conditions and/or not related to fetal surgery for selected conditions

X-7: Unable to obtain full-text

X-8: Case series of twin-twin transfusion syndrome

1. Crafoord C. Classics in thoracic surgery. Correction of aortic coarctation. *Ann Thorac Surg* 1980;30(3):300-302. X-1, X-6
2. Dor V, et al. Anomalous origin of left coronary artery from pulmonary artery. Evolution of right and left coronary circulation after surgical correction in four cases with delayed control. *Thorac Cardiovasc Surg* 1980;28(1):51-56. X-6
3. Doty DB, et al. Hypoplastic left heart syndrome: successful palliation with a new operation. *J Thorac Cardiovasc Surg* 1980;80(1):148-152. X-5
4. Fernhoff PM, Marion JP, Priest JH. Limitations of amniography in the prenatal diagnosis of spina bifida. *Am J Med Genet* 1980;7(3):369-373. X-5
5. Gomez R, et al. Management of patent ductus arteriosus in preterm babies. *Ann Thorac Surg* 1980;29(5):459-463. X-6
6. Harrison MR, Jester JA, Ross NA. Correction of congenital diaphragmatic hernia in utero. I. The model: intrathoracic balloon produces fatal pulmonary hypoplasia. *Surgery* 1980;88(1):174-182. X-3, X-5
7. Kirks DR, et al. Aneurysm of the ductus arteriosus in the neonate. *AJR Am J Roentgenol* 1980;134(3):573-576. X-5, X-6
8. Osathanondh R, et al. Ultrasonically guided transabdominal encephalocentesis. *J Reprod Med* 1980;25(3):125-128. X-5, X-6
9. Schifrin BS, Platt LD. Modified technique for monitoring fetal heart rate during intrauterine transfusion. *Am J Obstet Gynecol* 1980;138(8):1220-1222. X-1
10. Spirer Z. The role of the spleen in immunity and infection. *Adv Pediatr* 1980;27:55-88. X-6
11. Verma U, et al. Sinusoidal fetal heart rate patterns in severe Rh disease. *Obstet Gynecol* 1980;55(5):666-669. X-6
12. Barclay WR, et al. The ethics of in utero surgery. *JAMA* 1981;246(14):1551-1552, 1554-1555. X-1
13. Birnholz JC, Frigoletto FD. Antenatal treatment of hydrocephalus. *N Engl J Med* 1981;304(17):1021-1023. X-5
14. Brambati B, Pardi G. The intraventricular conduction time of fetal heart in pregnancies complicated by rhesus haemolytic disease. *Br J Obstet Gynaecol* 1981;88(12):1233-1240. X-6
15. Canty TG, Leopold GR, Wolf DA. Maternal ultrasonography for the antenatal diagnosis of surgically significant neonatal anomalies. *Ann Surg* 1981;194(3):353-365. X-6

16. Clewell WH, et al. Placement of ventriculo-amniotic shunt for hydrocephalus in a fetus. *N Engl J Med* 1981;305(16):955. X-1
17. Cottrell AJ, Holden MP, Hunter S. Interrupted aortic arch type A associated with congenitally corrected transposition of great arteries and ventricular septal defect. Successful direct aortic anastomosis and pulmonary artery banding in an infant. *Br Heart J* 1981;46(6):671-674. X-5
18. Harrison MR, Golbus MS, Filly RA. Management of the fetus with a correctable congenital defect. *JAMA* 1981;246(7):774-777. X-1
19. Hodgen GD. Antenatal diagnosis and treatment of fetal skeletal malformations. With emphasis on in utero surgery for neural tube defects and limb bud regeneration. *JAMA* 1981;246(10):1079-1083. X-1
20. Pontius RG, et al. Illusions leading to surgical closure of the distal left pulmonary artery instead of the ductus arteriosus. *J Thorac Cardiovasc Surg* 1981;82(1):107-113. X-6
21. Williams Jr TE, Beach TP, Kilman JW. Pharmacological blood pressure reduction as an adjunct in the operation for patent ductus arteriosus. *Ann Thorac Surg* 1981;31(1):90-91. X-6
22. Ethics, future of fetal surgery uncertain. *Ob Gyn News* 1982;17(11):3, 27. X-1
23. Berkowitz RL, et al. Fetal urinary tract obstruction: what is the role of surgical intervention in utero? *Am J Obstet Gynecol* 1982;144(4):367-375. X-1
24. Canty TG, Wolf DA. Maternal ultrasound in neonatal surgery. *Pediatr Ann* 1982;11(11):888-889, 891-894. X-1
25. Clewell WH, et al. A surgical approach to the treatment of fetal hydrocephalus. *N Engl J Med* 1982;306(22):1320-1325. X-5
26. Eggert LD, et al. Surgical treatment of patent ductus arteriosus in preterm infants. Four-year experience with ligation in the newborn intensive care unit. *Pediatr Cardiol* 1982;2(1):15-18. X-6
27. Friedman WF, Heiferman MF. Clinical problems of postoperative pulmonary vascular disease. *Am J Cardiol* 1982;50(3):631-636. X-1, X-6
28. Frigoletto Jr FD, Birnholz JC, Greene MF. Antenatal treatment of hydrocephalus by ventriculoamniotic shunting. *JAMA* 1982;248(19):2496-2497. X-5
29. Golbus MS, et al., In utero treatment of urinary tract obstruction. *Am J Obstet Gynecol* 1982;142(4):383-388. X-5
30. Graham D, et al. The role of sonography in the prenatal diagnosis and management of encephalocele. *J Ultrasound Med* 1982;1(3):111-115. X-5
31. Grunebaum AN, Sedlis A. Adenomatoid tumor of the uterus simulating interstitial pregnancy. *Obstet Gynecol* 1982;59(6 Suppl):87S-88S. X-5, X-6
32. Harrison MR, et al., Fetal surgery for congenital hydronephrosis. *N Engl J Med* 1982;306(10):591-593. X-5
33. Harrison MR, et al. Fetal surgical treatment. *Pediatr Ann* 1982;11(11):896-899, 901-903. X-6
34. Hecht F, Hecht BK, O'Keefe D. Sacrococcygeal teratoma: prenatal diagnosis with elevated alpha-fetoprotein and acetylcholinesterase in amniotic fluid. *Prenat Diagn* 1982;2(3):229-231. X-5

35. Karp LE. Fetal surgery. *Am J Med Genet* 1982;13(4):357-358. X-1
36. Kirkinen P, et al. Repeated transabdominal renocenteses in a case of fetal hydronephrotic kidney. *Am J Obstet Gynecol* 1982;142(8):1049-1052. X-5
37. Laks H. Advances in the repair of complex congenital heart disease. *Pediatr Ann* 1982;11(11):926-927, 930-931. X-6
38. Levine AH, Imai PK. Intrauterine treatment of fetal hydronephrosis. *AORN J* 1982;35(4):655-662. X-1
39. Marsden DE, Chang AS, Shin KS. Decapitation and vaginal delivery for impacted transverse lie in late labour: reports of 4 cases. *Aust N Z J Obstet Gynaecol* 1982;22(1):46-49. X-6
40. Petres RE, Redwine FO, Cruikshank, DP. Congenital bilateral chylothorax. Antepartum diagnosis and successful intrauterine surgical management. *JAMA* 1982;248(11):1360-1361. X-5
41. Rayburn WF. Surveillance techniques other than ultrasonography for detecting fetal malformations. *J Reprod Med* 1982;27(9): 565-568. X-1
42. Robertson JA. The right to procreate and in utero fetal therapy. *J Leg Med* 1982;3(3):333-366. X-1
43. Roth A, et al. Patent ductus arteriosus in a 67-year-old woman: late diagnosis and surgical closure. *Isr J Med Sci* 1982;18(9):952-954. X-5
44. Ruddick W, Wilcox W. Operating on the fetus. *Hastings Cent Rep* 1982;12(5):10-14. X-1
45. Samberg I, et al. Early vaginal delivery of hydrocephalus after transabdominal encephalocentesis. *Int J Gynaecol Obstet* 1982;20(3): 227-229. X-5
46. Vallancien G, et al. Percutaneous nephrostomy in utero. *Urology* 1982;20(6):647-649. X-5
47. Whittemore R, Hobbins JC, Engle MA. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. *Am J Cardiol* 1982;50(3):641-651. X-6
48. In utero fetal surgery. Resolution 73 (I-81) council on scientific affairs. *JAMA*, 1983. 250(11): 1443-1444. X-1
49. Alverson DC, et al. Effect of patent ductus arteriosus on left ventricular output in premature infants. *J Pediatr* 1983;102(5):754-757. X-6
50. Antsaklis A, et al. Prenatal diagnosis of hemoglobinopathies in twin pregnancies by double simultaneous fetoscopy. *Prenat Diagn* 1983;3(1): 21-27. X-6
51. Bland RS, et al. Gonococcal ventriculitis associated with ventriculoamniotic shunt placement. *Am J Obstet Gynecol* 1983;147(7): 781-784. X-5
52. Blane CE, et al. Nonobstructive fetal hydronephrosis: sonographic recognition and therapeutic implications. *Radiology* 1983;147(1): 95-99. X-6
53. Cohen RA, Moskowitz PS, McCallum WD. Sonographic diagnosis of cystic adenomatoid malformation in-utero. *Prenat Diagn* 1983;3(2):139-143. X-5
54. Collins FS, Mahoney MJ. Hydrocephalus and abnormal digits after failed first-trimester prostaglandin abortion attempt. *J Pediatr* 1983;102(4):620-621. X-5

55. Daskalopoulos DA, et al., Fatal pulmonary artery banding in truncus arteriosus with anomalous origin of circumflex coronary artery from right pulmonary artery. *Am J Cardiol* 1983;52(10): 1363-1364. X-5, X-6
56. Depp R, et al. Fetal surgery for hydrocephalus: successful in utero ventriculoamniotic shunt for Dandy-Walker syndrome. *Obstet Gynecol* 1983;61(6):710-714. X-5
57. DeVore GR, Dixon JA, Hobbins JC, Fetoscope-directed neodymium-YAG laser: a potential tool for fetal surgery. *Am J Obstet Gynecol* 1983;145(3):379-380. X-3, X-5, X-6
58. Donovan P. When does personhood begin? *Fam Plann Perspect* 1983;15(1): 40-44. X-1
59. Edwards WR. A fetal sacrococcygeal tumor obstructing labor after attempted home confinement. *Obstet Gynecol* 1983;61(3 Suppl):19S-20S. X-5
60. Elias S, Annas GJ. Perspectives on fetal surgery. *Am J Obstet Gynecol* 1983;145(7):807-812. X-1, X-3
61. Farkas A, Eidelman AI, Gale R. Transient perinatal urinary retention: a cautionary note for the fetal surgeon. *Am J Obstet Gynecol* 1983;147(4): 461-462. X-5
62. Fletcher JC. Emerging ethical issues in fetal therapy. *Prog Clin Biol Res* 1983;128:293-318. X-1
63. Gilmore A. Is the fetus a patient? *Can Med Assoc J* 1983;128(12):1472, 1475-1476. X-1
64. Goldman EB. Fetal versus maternal rights: who is the patient? *Mich Hosp* 1983;19(4):23-25. X-1
65. Hertogs K, et al., The safety of fetoscopy: (I). Effect of umbilical vessel puncture on the fetal heart rate and cord histology. *Prenat Diagn* 1983;3(2):91-96. X-6
66. Johnson ML, et al. Fetal hydrocephalus: diagnosis and management. *Semin Perinatol* 1983;7(2): 83-89. X-1
67. Labbe R, et al. Fetal brain transplant: reduction of cognitive deficits in rats with frontal cortex lesions. *Science* 1983;221(4609):470-472. X-3
68. Lenow JL. The fetus as a patient: emerging rights as a person? *Am J Law Med* 1983;9(1): 1-29. X-1
69. Mintz MC, Mennuti M, Fishman M. Prenatal aspiration of sacrococcygeal teratoma. *AJR Am J Roentgenol* 1983;141(2): 367-368. X-5
70. Norwood WI, Lang P, Hansen DD. Physiologic repair of aortic atresia-hypoplastic left heart syndrome. *N Engl J Med* 1983;308(1): 23-26. X-5, X-6
71. Onitsuka T, et al. Echographic detection and successful excision of pulmonary cyst in a fetus. *Jpn J Surg* 1983;13(3):254-257. X-5
72. Redwine FO, Petres RE, Cruikshank DP. Reversal of polyhydramnios by drainage of a fetal renal cyst. A case report. *J Reprod Med* 1983;28(6):421-423. X-5
73. Schaaps JP, Thoumsin H, Lambotte R. Intrauterine unilateral nephrostomy. *Am J Obstet Gynecol* 1983;146(1):105-106. X-5
74. Soper RT. President's address: the Pandora's box of antenatal surgery. *Am Surg* 1983;49(6):285-289. X-1
75. Vintzileos AM, et al. Unilateral fetal hydronephrosis: successful in utero surgical management. *Am J Obstet Gynecol* 1983;145(7):885-886. X-5

76. Weinberg SR. A maternal duty to protect fetal health? *Indiana Law J* 1983;58(3):531-546. X-1
77. Bannister CM. Fetal neurosurgery—a new challenge on the horizon. *Dev Med Child Neurol* 1984;26(6):827-830. X-1
78. Boehm FH. Management of the unanticipated neural tube defect in late pregnancy. *Clin Obstet Gynecol* 1984;27(1):78-83. X-1
79. Burakovsky VI, Falkovsky GE, Ivanitsky AV. Surgical repair of truncus arteriosus. *Pediatr Cardiol* 1984;5(2):111-114. X-6
80. Chervenak FA, Romero R. Is there a role for fetal cephalocentesis in modern obstetrics? *Am J Perinatol* 1984;1(2):170-173. X-1
81. Crowley P, O’Herlihy C, Boylan P. The value of ultrasound measurement of amniotic fluid volume in the management of prolonged pregnancies. *Br J Obstet Gynaecol* 1984;91(5):444-448. X-6
82. Dao, AH, Netsky MG. Human tails and pseudotails. *Hum Pathol* 1984;15(5):449-453. X-5, X-6
83. Dunn P. Surgery for the unborn: a nurse’s own story. *Nurs Life* 1984;4(5):19-21. X-1
84. Golladay ES, Mollitt DL. Surgically correctable fetal hydrops. *J Pediatr Surg* 1984;19(1):59-62. X-6
85. Kindregan C. Compulsory fetal surgery: an issue for the future. *Report Hum Reprod Law* 1984;Reports:111-112. X-1
86. Kramer SA, Kelalis PP. Approach to the foetus with congenital hydronephrosis. *Ann Acad Med Singapore* 1984;13(4):565-570. X-1
87. Lowe TW, et al. Sinusoidal fetal heart rate pattern after intrauterine transfusion. *Obstet Gynecol* 1984;64(3 Suppl):21S-25S. X-1
88. Matthews AL, Costello AJ, Scott JA. The fetus as a patient: some preliminary data from the first year of a fetal medicine and surgery program. *Birth Defects Orig Artic Ser* 1984;20(6):192-196. X-6
89. McFadyen IR. Obstruction of the fetal urinary tract: a role for surgical intervention in utero? *Br Med J (Clin Res Ed)* 1984;288(6415):459-462. X-6
90. Nicolini U, Hertogs K, Rodeck CH. Sinusoidal rhythm caused by fetal hemorrhage during fetoscopy. *J Perinat Med* 1984;12(1):39-42. X-5
91. Puri P, Gorman F. Lethal nonpulmonary anomalies associated with congenital diaphragmatic hernia: implications for early intrauterine surgery. *J Pediatr Surg* 1984;19(1):29-32. X-6
92. Reedy NJ, Ford KL, Depp R. Intrauterine fetal surgery: a nursing challenge. *JOGN Nurs* 1984;13(5):291-295. X-1
93. Rudeen RL, Elliott JP. In utero management of fetal urinary tract obstruction: case report. *Mil Med* 1984;149(2):87-88. X-5
94. Seeds JW, et al. Hydramnios and maternal renal failure: relief with fetal therapy. *Obstet Gynecol*, 1984;64(3 Suppl):26S-29S. X-5
95. Seeds JW, et al. Recurrent idiopathic fetal hydrops: results of prenatal therapy. *Obstet Gynecol* 1984;64(3 Suppl):30S-33S. X-5

96. Shalev E, et al. External bladder—amniotic fluid shunt for fetal urinary tract obstruction. *Obstet Gynecol* 1984;63(3 Suppl):31S-34S. X-5
97. Spicer RL, et al. Repair of truncus arteriosus in neonates with the use of a valveless conduit. *Circulation* 1984;70(3 Pt 2):I26-I29. X-6
98. Spirnak JP, et al. Incidental fetal hydronephrosis: clinical implication. *Urology* 1984;24(1):105-108. X-6
99. Weissman MN, Green BA, Morse B. In-utero gunshot wound to the head. Use of intraoperative ultrasonography for localization of an intracerebral projectile. *Surg Neurol* 1984;21(4):347-350. X-5, X-6
100. Williamson RA, et al. Heterogeneity of prenatal onset hydrocephalus: management and counseling implications. *Am J Med Genet* 1984;17(2):497-508. X-6
101. Adzick NS, et al. Diaphragmatic hernia in the fetus: prenatal diagnosis and outcome in 94 cases. *J Pediatr Surg* 1985;20(4):357-361. X-6
102. Avni EF, Rodesch F, Schulman CC. Fetal uropathies: diagnostic pitfalls and management. *J Urol* 1985;134(5):921-925. X-6
103. Bowman JM. Alloimmunization in twin pregnancies. *Am J Obstet Gynecol* 1985;153(1):7-13. X-6
104. Chervenak FA, et al. Diagnosis and management of fetal teratomas. *Obstet Gynecol* 1985;66(5):666-671. X-6
105. Engelhardt Jr HT. Current controversies in obstetrics: wrongful life and forced fetal surgical procedures. *Am J Obstet Gynecol* 1985;151(3):313-318. X-1
106. Fitzsimons RB, Keohane C, Galvin J. Prune belly syndrome with ultrasound demonstration of reduction of megacystis in utero. *Br J Radiol* 1985;58(688):374-376. X-5, X-6
107. Gaffney SE. Intrauterine fetal surgery: the ramifications for nurses. *MCN Am J Matern Child Nurs* 1985;10(4):250-254. X-1
108. Glick PL, et al. Management of the fetus with congenital hydronephrosis II: Prognostic criteria and selection for treatment. *J Pediatr Surg* 1985;20(4):376-387. X-6
109. Harrison MR, et al. Fetal diaphragmatic hernia: fetal but fixable. *Semin Perinatol* 1985;9(2):103-112. X-1
110. Holzgreve W, et al. Sonographic demonstration of fetal sacrococcygeal teratoma. *Prenat Diagn* 1985;5(4):245-257. X-6
111. Inturrisi M, Perry SE, May KA. Fetal surgery for congenital hydronephrosis. *J Obstet Gynecol Neonatal Nurs* 1985;14(4):271-276. X-1
112. Kaufmann CL, Williams PR. Fetal surgery: the social implications of medical and surgical treatment of the unborn child. *Women Health* 1985;10(1):25-37. X-1
113. Kirkinen P, Jouppila P. Perinatal aspects of pregnancy complicated by fetal ovarian cyst. *J Perinat Med* 1985;13(5):245-251. X-6
114. Moniz CF, et al. Normal reference ranges for biochemical substances relating to renal, hepatic, and bone function in fetal and maternal plasma throughout pregnancy. *J Clin Pathol* 1985;38(4):468-472. X-6
115. Murray TH. Ethical issues in fetal surgery. *Bull Am Coll Surg* 1985;70(6):6-10. X-1

116. Nakayama DK, et al. Prenatal diagnosis and natural history of the fetus with a congenital diaphragmatic hernia: initial clinical experience. *J Pediatr Surg* 1985;20(2):118-124. X-1, X-5, X-6
117. Ott DA, et al. Surgical treatment for the type II and III truncus: complete division of the truncal root with primary repair using absorbable suture. *Ann Thorac Surg* 1985;40(2):201-204. X-6
118. Phelan JP, et al. The role of external version in the intrapartum management of the transverse lie presentation. *Am J Obstet Gynecol* 1985;151(6):724-726. X-6
119. Platt LD, DeVore GR. Modification of fetal intraventricular amniotic shunt. *Am J Obstet Gynecol* 1985;152(8):1044-1045. X-3, X-5, X-6
120. Reynolds JE, et al. Fetal hydrocephalus: a case of ventricular-amniotic shunting. *South Med J* 1985;78(2):203-204. X-5
121. Saunders RL, et al. A cranial nail for fetal shunting. *Childs Nerv Syst* 1985;1(3):185-187. X-5
122. Smith RJ. Preventive surgery for congenital deformities of the hand. *Hand Clin* 1985;1(3):373-382. X-6
123. Stolar CJ, Altman RP. Research in pediatric surgery. *World J Surg* 1985;9(2):321-328. X-1
124. Appelman Z, Golbus MS. The management of fetal urinary tract obstruction. *Clin Obstet Gynecol* 1986;29(3):483-489. X-1
125. Blank RH. Emerging notions of women's rights and responsibilities during gestation. *J Leg Med* 1986;7(4):441-469. X-1
126. Chiamonte RM, et al. Implications of hydronephrosis in the newborn with myelodysplasia. *J Urol* 1986;136(2):427-429. X-6
127. Edwards MS. An evaluation of the in utero neurosurgical treatment of ventriculomegaly. *Clin Neurosurg* 1986;33:347-357. X-3
128. Flake AW, et al. Fetal sacrococcygeal teratoma. *J Pediatr Surg* 1986;21(7):563-566. X-6
129. Flake AW, et al. Ureteropelvic junction obstruction in the fetus. *J Pediatr Surg* 1986;21(12):1058-1063. X-6
130. Fletcher JC. Drawing moral lines in fetal therapy. *Clin Obstet Gynecol* 1986;29(3):595-602. X-1
131. Friedman M. Factors influencing parathyroid allotransplantation in rats. *Laryngoscope* 1986;96(9 Pt 2 Suppl 39):1-16. X-3
132. Gregorios JB, et al. Spinal cord tumors presenting with neural tube defects. *Neurosurgery* 1986;19(6):962-966. X-6
133. Hardy K. Prospects for fetal surgery. *Aust N Z J Surg* 1986;56(4):295-297. X-1
134. Harman CR. Bioethical issues in perinatology—is the future now? *Fetal Ther* 1986;1(4):217-222. X-1
135. Haroutunian V, et al. Animal models of Alzheimer's disease: behavior, pharmacology, transplants. *Can J Neurol Sci* 1986;13(4 Suppl):385-393. X-3
136. Harrison MR, et al. Fetal diaphragmatic hernia: pathophysiology, natural history, and outcome. *Clin Obstet Gynecol* 1986;29(3):490-501. X-6

137. Holschneider AM, Baumgartner M, Mascott C. Consequences of antenatal diagnosis for pediatric surgery. *Prog Pediatr Surg* 1986;19:184-196. X-6
138. Lundell BP, Sonesson SE, Cotton RB. Ductus closure in preterm infants. Effects on cerebral hemodynamics. *Acta Paediatr Scand Suppl* 1986;329:140-147. X-6
139. Manning FA. International Fetal Surgery Registry: 1985 update. *Clin Obstet Gynecol* 1986;29(3):551-557. X-1
140. Marek J, Dvoracek J. Renal changes in vesicoureteral reflux—human reflux nephropathy. *Zentralbl Allg Pathol* 1986;132(5-6):413-422. X-6
141. Michejda M, Pringle K. Fascination with the mystery of new life in utero. *Fetal Ther* 1986;1(1):3-7. X-1
142. Michejda M, Queenan JT, McCullough D. Present status of intrauterine treatment of hydrocephalus and its future. *Am J Obstet Gynecol* 1986;155(4):873-882. X-3
143. Nicolaides KH, Rodeck CH, Gosden CM. Rapid karyotyping in non-lethal fetal malformations. *Lancet* 1986;1(8476):283-287. X-6
144. Paine LL, Payton RG, Johnson TR. Auscultated fetal heart rate accelerations. Part I. Accuracy and documentation. *J Nurse Midwifery* 1986;31(2):68-72. X-1
145. Perry SE, Inturrisi M, Filly RA. Meeting the challenge of fetal surgery. *Dimens Crit Care Nurs* 1986;5(4):196-205. X-1
146. Pober BR, Greene MF, Holmes LB. Complexities of intraventricular abnormalities. *J Pediatr* 1986;108(4):545-551. X-6
147. Pretorius DH, et al. Diagnosis of brain neuropathology in utero. *Neuroradiology* 1986;28(5-6):386-397. X-6
148. Pringle KC. Fetal surgery: it has a past, has it a future? *Fetal Ther* 1986;1(1):23-31. X-1
149. Robertson JA. Legal issues in prenatal therapy. *Clin Obstet Gynecol* 1986;29(3):603-611. X-1
150. Seeds JW, Jones FD. Lipomyelomeningocele: prenatal diagnosis and management. *Obstet Gynecol* 1986;67(3 Suppl):34S-37S. X-5
151. Stauffer UG. Management of prenatally diagnosed congenital malformations—actual problems and the importance of an interdisciplinary team approach. *Prog Pediatr Surg* 1986;19:127-142. X-5
152. Weiner C, et al. Antenatal diagnosis and palliative treatment of nonimmune hydrops fetalis secondary to pulmonary extralobar sequestration. *Obstet Gynecol* 1986;68(2):275-280. X-5
153. Weiner C, et al. In utero bladder diversion—problems with patient selection. *Fetal Ther* 1986;1(4):196-202. X-5
154. Chayen B, Rifkin MD. Cephalocentesis. Guidance with an endovaginal probe and endovaginal needle placement. *J Ultrasound Med* 1987;6(4):221-223. X-5
155. Clark SL, et al. Successful fetal therapy for cystic adenomatoid malformation associated with second-trimester hydrops. *Am J Obstet Gynecol* 1987;157(2):294-295. X-5
156. Colodny AH. Antenatal diagnosis and management of urinary abnormalities. *Pediatr Clin North Am* 1987;34(5):1365-1381. X-1

157. Gross TL, et al. Shoulder dystocia: a fetal-physician risk. *Am J Obstet Gynecol* 1987;156(6):1408-1418. X-6
158. Harrison MR, et al. Fetal hydronephrosis: selection and surgical repair. *J Pediatr Surg* 1987;22(6):556-558. X-5
159. Holzgreve W, et al. Experience with 8 cases of prenatally diagnosed sacrococcygeal teratomas. *Fetal Ther* 1987;2(2):88-94. X-6
160. Kiwanuka AI, Moore WM. The changing incidence of caesarean section in the health district of Central Manchester. *Br J Obstet Gynaecol* 1987;94(5):440-444. X-6
161. Langer JC, Harrison MR, Adzick NS. Congenital diaphragmatic hernia: current controversies in prenatal and postnatal management. *Fetal Ther* 1987;2(4):209-215. X-5
162. Manning FA. Fetal surgery for obstructive uropathy: rational considerations. *Am J Kidney Dis* 1987;10(4):259-267. X-1, X-3
163. Murray TH. Moral obligations to the not-yet born: the fetus as patient. *Clin Perinatol* 1987;14(2):329-343. X-1
164. Nakamura Y, et al. Nonimmunologic hydrops fetalis: a clinicopathological study of 50 autopsy cases. *Pediatr Pathol* 1987;7(1):19-30. X-6
165. Nicolini U, Rodeck CH, Fisk NM. Shunt treatment for fetal obstructive uropathy. *Lancet* 1987;2(8571):1338-1339. X-5, X-6
166. Rauscher K. Fetal surgery: a developing legal dilemma. *St Louis Univ Law J* 1987;31(3):775-795. X-1
167. Redwine FO. Fetal medicine and surgery. *Med Sect Proc* 1987;69-75. X-1
168. Shurtleff DB, et al. The outcome of pregnancies diagnosed as having a fetus with meningocele. *Z Kinderchir* 1987;42(Suppl 1):50-52. X-6
169. Silver RK, Huff RW. Intrapartum management of the fetus with idiopathic hydrocephalus. *Am J Perinatol* 1987;4(1):16-19. X-5
170. Thomassen-Brepols LJ. Psychological implications of fetal diagnosis and therapy. *Fetal Ther* 1987;2(3):169-174. X-1
171. Varga DA, et al. Vaginal delivery impeded by a large fetal sacrococcygeal teratoma: anesthetic considerations. *Anesth Analg* 1987;66(12):1325-1327. X-6
172. Wilkins IA, et al. The nonpredictive value of fetal urinary electrolytes: preliminary report of outcomes and correlations with pathologic diagnosis. *Am J Obstet Gynecol* 1987;157(3):694-698. X-5
173. Wilkinson LG, et al. Surgical problems in the fetus: a multidisciplinary approach. *Am J Surg* 1987;154(6):685-687. X-1
174. Ardinger HH, et al. Verification of the fetal valproate syndrome phenotype. *Am J Med Genet* 1988;29(1):171-185. X-6
175. Ash KM, Mibashan RS, Nicolaidis KH. Diagnosis and treatment of fetomaternal hemorrhage in a fetus with homozygous von Willebrand's disease. *Fetal Ther* 1988;3(4):189-191. X-5, X-6
176. Blott M, Nicolaidis KH, Greenough A. Postnatal respiratory function after chronic drainage of fetal pulmonary cyst. *Am J Obstet Gynecol* 1988;159(4):858-859. X-5, X-6

177. Cassady G. Relation between persistent patency of the ductus arteriosus and retinopathy of prematurity. *Birth Defects Orig Artic Ser* 1988;24(1):53-65. X-6
178. Clewell WH. Congenital hydrocephalus: treatment in utero. *Fetal Ther* 1988;3(1-2):89-97. X-1
179. Fine C, Adzick NS, Doubilet PM. Decreasing size of a congenital cystic adenomatoid malformation in utero. *J Ultrasound Med* 1988;7(7):405-408. X-5
180. Fuglestad SJ, et al. Surgical pathology of the truncal valve: a study of 12 cases. *Am J Cardiovasc Pathol* 1988;2(1):39-47. X-6
181. Hage ML, et al. Changing rates of cesarean delivery: the Duke experience, 1978-1986. *Obstet Gynecol* 1988;72(1):98-101. X-6
182. Johnson JW, et al. Abdominal rescue after incomplete delivery secondary to large fetal sacrococcygeal teratoma. *Obstet Gynecol* 1988;71(6 Pt 2):981-984. X-6
183. Johnston PW. The diagnostic value of alpha-fetoprotein in an infant with sacrococcygeal teratoma. *J Pediatr Surg* 1988;23(9):862-863. X-5, X-6
184. McKone RC, Weesner KM. Determination of the time of closure of the ductus arteriosus in severely ill premature infants. *Clin Pediatr (Phila)* 1988;27(3):135-139. X-6
185. Pendl G. Symposium on ethics and morals related to antenatal treatment of pediatric neurosurgical disorders. Treatment of fetuses in utero—an opinion from central Europe. *Childs Nerv Syst* 1988;4(3):158-160. X-1
186. Purkiss S, Brereton RJ, Wright VM. Surgical emergencies after prenatal treatment for intra-abdominal abnormality. *Lancet* 1988;1(8580):289-290. X-5, X-6
187. Raimondi AJ. Shunts, indications, problems, and characteristics. *Childs Nerv Syst* 1988;4(6):321-324. X-1
188. Rodeck CH, et al. Long-term in utero drainage of fetal hydrothorax. *N Engl J Med* 1988;319(17):1135-1138. X-6
189. Saltzman DH, Adzick NS, Benacerraf BR. Fetal cystic adenomatoid malformation of the lung: apparent improvement in utero. *Obstet Gynecol* 1988;71(6 Pt 2):1000-1002. X-6
190. Urig MA, et al. Twin-twin transfusion syndrome: the surgical removal of one twin as a treatment option. *Fetal Ther* 1988;3(4):185-188. X-5
191. Westgren M, Selbing A, Stangenberg M. Fetal intracardiac transfusions in patients with severe rhesus isoimmunisation. *Br Med J (Clin Res Ed)* 1988;296(6626):885-886. X-6
192. Baisden CE, et al. Ductus diverticulum aneurysm and coronary stenosis: repair using circulatory arrest. *Ann Thorac Surg* 1989;48(3):432-433. X-5
193. Beluffi G, et al. Congenital cystic adenomatoid malformation of the lung. Presentation of 16 cases. *Rofo*, 1989;150(5):523-530. X-6
194. Bernaschek G, et al. Intrauterine treatment of a fetal pulmonary cyst by chorioamniotic shunt. *Arch Gynecol Obstet* 1989;244(2):129-132. X-5, X-6
195. Cassady G, et al. A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth. *N Engl J Med* 1989;320(23):1511-1516. X-6

196. Copel, J.A., et al., Fetal cardiac output in the isoimmunized pregnancy: a pulsed Doppler-echocardiographic study of patients undergoing intravascular intrauterine transfusion. *Am J Obstet Gynecol* 1989;161(2):361-365. X-6
197. Davies RP, et al. Ultrasonic detection of subdiaphragmatic pulmonary sequestration in utero and postnatal diagnosis by fine-needle aspiration biopsy. *J Ultrasound Med* 1989;8(1):47-49. X-6
198. Drugan A, et al. The natural history of prenatally diagnosed cerebral ventriculomegaly. *JAMA* 1989;261(12):1785-1788. X-6,
199. Drugan A, et al. First trimester diagnosis and early in utero treatment of obstructive uropathy. *Acta Obstet Gynecol Scand* 1989;68(7):645-649. X-5
200. Fadel HE. Antenatal diagnosis of fetal intracranial anomalies. *J Child Neurol* 1989;4(Suppl):S107-S112. X-1
201. Galligan BR, et al. Preparation of packed red cells suitable for intravascular transfusion in utero. *Transfusion* 1989;29(2):179-181. X-6
202. Gembruch U, et al. Fetal complete heart block: antenatal diagnosis, significance and management. *Eur J Obstet Gynecol Reprod Biol* 1989; 31(1):9-22. X-6
203. Hutson J. Fetal surgery at the crossroads. *Indian J Pediatr* 1989;56(5):570-572. X-1
204. Johnsen D, Wilder MJ. Webster and women's equality. *Am J Law Med* 1989;15(2-3):178-184. X-1
205. Johnson MD, et al. Fetal surgery and general anesthesia: a case report and review. *J Clin Anesth*, 1989;1(5):363-367. X-5, X-6
206. Langer JC, et al. Gastrointestinal tract obstruction in the fetus. *Arch Surg* 1989;124(10):1183-1186; discussion 1187. X-6
207. Langer JC, et al. Fetal hydrops and death from sacrococcygeal teratoma: rationale for fetal surgery. *Am J Obstet Gynecol* 1989;160(5 Pt 1):1145-1150. X-5
208. Lodeiro JG, et al. Antenatal diagnosis of epignathus with neonatal survival. A case report. *J Reprod Med* 1989;34(12):997-999. X-5
209. Norris MC, Joseph J, Leighton BL. Anesthesia for perinatal surgery. *Am J Perinatol* 1989. 6(1):39-40. X-5
210. Nugent CE, Hayashi RH, Rubin J. Prenatal treatment of type I congenital cystic adenomatoid malformation by intrauterine fetal thoracentesis. *J Clin Ultrasound* 1989;17(9):675-677. X-5
211. Ouimet A, Russo P. Fetus in fetu or not? *J Pediatr Surg* 1989;24(9):926-927. X-5
212. Robie GF, Payne Jr GG, Morgan MA. Selective delivery of an acardiac, acephalic twin. *N Engl J Med* 1989;320(8):512-513. X-5, X-6
213. Rosner F, et al. Fetal therapy and surgery. Fetal rights versus maternal obligations. *N Y State J Med* 1989;89(2):80-84. X-1
214. Rostain AL, Bhutani VK. Ethical dilemmas of neonatal--perinatal surgery. *Clin Perinatol* 1989;16(1):275-302. X-1
215. Sano K. Quo vadis, neurochirurgia paediatrica? *Childs Nerv Syst* 1989;5(1):3-8. X-1

216. Schmidt KG, et al. High-output cardiac failure in fetuses with large sacrococcygeal teratoma: diagnosis by echocardiography and Doppler ultrasound. *J Pediatr* 1989;114(6):1023-1028. X-6
217. Sepulveda WH. Prenatal sonographic diagnosis of congenital sacrococcygeal teratoma and management. *J Perinat Med* 1989;17(2):93-97. X-5, X-6
218. Touraine JL. New strategies in the treatment of immunological and other inherited diseases: allogeneic stem cells transplantation. *Bone Marrow Transplant* 1989;4(Suppl 4):139-141. X-6
219. Barbero-Marcial M, et al. A technique for correction of truncus arteriosus types I and II without extracardiac conduits. *J Thorac Cardiovasc Surg* 1990;99(2):364-369. X-6
220. Dado DV, Kernahan DA, Gianopoulos JG. Intrauterine repair of cleft lip: what's involved. *Plast Reconstr Surg* 1990;85(3):461-465; discussion 466-467. X-6
221. Fischer RL, et al. Chronic, massive fetomaternal hemorrhage treated with repeated fetal intravascular transfusions. *Am J Obstet Gynecol* 1990;162(1):203-204. X-5
222. Fisk NM, et al. Fetofetal transfusion syndrome: do the neonatal criteria apply in utero? *Arch Dis Child* 1990;65(7 Spec No):657-661. X-6
223. Giorlandino C, et al. Successful intrauterine therapy of a large fetal ovarian cyst. *Prenat Diagn* 1990;10(7):473-475. X-5
224. Goldstein P, et al. Ventriculoamniotic shunt for treatment of hydrocephalus in one of twins: medical, ethical and legal considerations. *Fetal Diagn Ther* 1990;5(2):84-91. X-5
225. Grannum PA, Copel JA. Invasive fetal procedures. *Radiol Clin North Am* 1990;28(1):217-226. X-1
226. Gruenewald SM, et al. Diagnosis and treatment of antenatal uropathies. *J Paediatr Child Health* 1990;26(3):142-147. X-6
227. Harrison MR. Fetal surgery. *West J Med* 1990;153(6):648. X-1
228. Harrison MR, et al. Successful repair in utero of a fetal diaphragmatic hernia after removal of herniated viscera from the left thorax. *N Engl J Med* 1990;322(22):1582-1584. X-5
229. Hefez DS, et al. The paralysis associated with myelomeningocele: clinical and experimental data implicating a preventable spinal cord injury. *Neurosurgery* 1990;26(6):987-992. X-3
230. Hogge WA, et al. Diagnosis and management of prenatally detected myelomeningocele: a preliminary report. *Am J Obstet Gynecol* 1990;163(3):1061-1064; discussion 1064-5. X-6
231. Leon Sosa, RR, Moore PJ. Sacrococcygeal teratomas in the fetus and newborn. *Int J Gynaecol Obstet* 1990;32(1):61-66. X-6
232. Naruse I, Kameyama Y. Fetal laser surgery in genetic polydactyly mice. *Teratology* 1990;41(6):731-735. X-3
233. Oi SZ, et al. Factors affecting prognosis of intrauterine hydrocephalus diagnosed in the third trimester--computerized data analysis on controversies in fetal surgery. *Neurol Med Chir (Tokyo)* 1990;30(7):456-461. X-6
234. Rizzo G, et al. Effects of intravascular fetal blood transfusion on fetal intracardiac Doppler velocity waveforms. *Am J Obstet Gynecol* 1990;163(4 Pt 1):1231-1238. X-6

235. Sherer DM, et al. Prenatal sonographic diagnosis and subsequent management of fetal adnexal torsion. *J Ultrasound Med* 1990;9(3):161-163. X-5
236. Silverman NH, Schmidt KG. Ventricular volume overload in the human fetus: observations from fetal echocardiography. *J Am Soc Echocardiogr* 1990;3(1):20-29. X-6
237. Steinhardt G, et al. Long-term survival in an infant with urethral atresia. *J Urol* 1990;143(2):336-337. X-5
238. Strauss RP, Davis JU. Prenatal detection and fetal surgery of clefts and craniofacial abnormalities in humans: social and ethical issues. *Cleft Palate J* 1990;27(2):176-182; discussion 182-183. X-1
239. Wood M.K. Repair of ductus diverticulum aneurysm. *Ann Thorac Surg* 1990;49(1):169. X-5, X-6
240. Bosman G, et al. Prenatal diagnosis, management and outcome of fetal uretero-pelvic junction obstruction. *Ultrasound Med Biol* 1991;17(2):117-120. X-6
241. Brandt ML, et al. Surgical indications in antenatally diagnosed ovarian cysts. *J Pediatr Surg* 1991;26(3):276-281; discussion 281-282. X-6
242. Brown D, Andersen HF, Elkins TE. An analysis of the ACOG and AAP ethics statements on conflicts in maternal-fetal care. *J Clin Ethics* 1991;2(1):19-22; discussion 23-24. X-1
243. Cochrane D, et al. The effects of labor and delivery on spinal cord function and ambulation in patients with meningomyelocele. *Childs Nerv Syst* 1991;7(6):312-315. X-6
244. Dainiak N. In utero transplantation of hematopoietic stem cells. *Blood Cells* 1991;17(2):376-378. X-3
245. Dildy III GA, et al. Porencephalic cyst: a complication of fetal intravascular transfusion. *Am J Obstet Gynecol* 1991;165(1):76-78. X-5
246. Gau GS, Napier K, Bhundia J. Use of a tissue adhesive to repair fetal bodies after dissection. *J Clin Pathol* 1991;44(9):759-760. X-6
247. Harrison MR, Adzick NS. The fetus as a patient. Surgical considerations. *Ann Surg* 1991;213(4):279-291; discussion 277-278. X-1
248. King PA, et al. Recurrent congenital chylothorax. *Prenat Diagn* 1991;11(10):809-811. X-6
249. Knopoff KA. Can a pregnant woman morally refuse fetal surgery? *Calif Law Rev* 1991;79(2):499-540. X-1
250. Krummel TM, et al. Characteristics of fetal repair. *Prog Clin Biol Res* 1991;365: 167-176. X-1
251. Lammers PK, Palmer PN. Surgeons discuss ambulatory surgery, legislative concerns, dangers of transfusions, surgical advances. *AORN J* 1991;53(1):16-29. X-1
252. Levine AH. Fetal surgery. In utero repair of congenital diaphragmatic hernia. *AORN J* 1991;54(1):16-19, 22-27, 30-32. X-1
253. Morykwas MJ, et al. *Monodelphis domestica*: a model for early developmental wound healing. *Ann Plast Surg* 1991;27(4):327-331. X-3
254. Nakayama DK, et al. The newborn with hydrops and sacrococcygeal teratoma. *J Pediatr Surg* 1991;26(12):1435-1438. X-6

255. Neilson IR, et al. Congenital adenomatoid malformation of the lung: current management and prognosis. *J Pediatr Surg* 1991;26(8):975-980; discussion 980-981. X-6
256. Organ Jr CH, Henderson VJ. Surgery. *JAMA* 1991;265(23):3172-3175. X-1
257. Ronderos-Dumit D, et al. Uterine-peritoneal amniotic fluid leakage: an unusual complication of intrauterine shunting. *Obstet Gynecol* 1991;78(5 Pt 2):913-915. X-5
258. Sakala EP, Leon ZA, Rouse GA. Management of antenatally diagnosed fetal ovarian cysts. *Obstet Gynecol Surv* 1991;46(7):407-414. X-6
259. Sonek JD, Foley MR, Iams JD. Spontaneous regression of a large intrathoracic fetal lesion before birth. *Am J Perinatol* 1991;8(1):41-43. X-5
260. Touraine JL. Stem cell transplantation in primary immunodeficiency, with special reference to the first prenatal, in utero, transplants. *Allergol Immunopathol (Madr)* 1991;19(2):49-51. X-6
261. Touraine JL, et al. In utero transplantation of hemopoietic stem cells in humans. *Transplant Proc* 1991;23(1 Pt 2):1706-1708. X-6
262. Weiner CP, et al. Management of fetal hemolytic disease by cordocentesis. II. Outcome of treatment. *Am J Obstet Gynecol* 1991;165(5 Pt 1):1302-1307. X-6
263. Weintraub WH. What's new in surgery for 1991? Pediatric surgery. *Bull Am Coll Surg* 1991;76(1):40-42, 79. X-1
264. Weston MJ, Andrews H. Case report: in-utero aspiration of sacrococcygeal cyst. *Clin Radiol* 1991;44(2):119-120. X-5, X-6
265. Yilmaz AT, et al. Ligation in adult persistent ductus arteriosus. *J Cardiovasc Surg (Torino)* 1991;32(5):575-580. X-6
266. Abbott JF, et al. Prenatal diagnosis of vestigial tail. *J Ultrasound Med* 1992;11(1):53-55. X-5, X-6,
267. Adzick NS, Longaker MT. Scarless fetal healing. Therapeutic implications. *Ann Surg* 1992;215(1):3-7. X-1
268. Andersen K, Kaad PH. Congenital sideroblastic anaemia with intrauterine symptoms and early lethal outcome. *Acta Paediatr* 1992;81(8):652-653. X-5, X-6
269. Balci S, et al. Meckel Gruber syndrome: a case diagnosed in utero. *Turk J Pediatr* 1992;34(3):179-185. X-5, X-6
270. Bayer I, Samuel N, Chaimoff C. Surgical emergency in the fetus as indication for cesarean section. *Int J Gynaecol Obstet* 1992;39(4):333-334. X-6
271. Boglino C, et al. Neurotensin localization in adenomatoid cystic malformation versus normal lung: preliminary report of six consecutive cases. *J Pediatr Surg* 1992;27(1):57-60. X-6
272. Budorick NE, et al. Spontaneous improvement of intrathoracic masses diagnosed in utero. *J Ultrasound Med* 1992;11(12):653-662. X-6
273. dell'Agnola CA, et al. Prenatal ultrasonography and early surgery for congenital cystic disease of the lung. *J Pediatr Surg* 1992;27(11):1414-1417. X-6
274. Ginsberg NA, et al. Term birth after midtrimester hysterotomy and selective delivery of an acardiac twin. *Am J Obstet Gynecol* 1992;167(1):33-37. X-5

275. Gladstone DJ, et al. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. *Reprod Toxicol* 1992;6(3):257-261. X-6
276. Hosoda Y, et al. Characteristics and management of patients with fetal neuroblastoma. *J Pediatr Surg* 1992;27(5):623-625. X-5, X-6
277. Jennings RW, et al. New techniques in fetal surgery. *J Pediatr Surg* 1992;27(10):1329-1333. X-3
278. Mandell J, et al. Aspiration of bilateral perinephric urinomas and vesicoamniotic shunt placement in fetal bladder outlet obstruction. *J Ultrasound Med* 1992;11(12):679-682. X-5
279. Muller-Leisse C, et al. Ovarian cysts in the fetus and neonate—changes in sonographic pattern in the follow-up and their management. *Pediatr Radiol* 1992;22(6):395-400. X-6
280. Murphy JJ, Blair GK, Fraser GC. Coagulopathy associated with large sacrococcygeal teratomas. *J Pediatr Surg* 1992;27(10):1308-1310. X-6
281. Otamiri G, et al. Neurological adaptation of infants delivered by emergency or elective cesarean section. *Acta Paediatr* 1992;81(10):797-801. X-6
282. Pearl JM, et al. Repair of conotruncal abnormalities with the use of the valved conduit: improved early and midterm results with the cryopreserved homograft. *J Am Coll Cardiol* 1992;20(1):191-196. X-6
283. Prasad K, Radhakrishnan S, Sinha N. Extensive calcification of pulmonary arteries with left-to-right shunting across the arterial duct. *Int J Cardiol* 1992;35(3):419-421. X-5, X-6
284. Rosseau GL, McCullough DC, Joseph AL. Current prognosis in fetal ventriculomegaly. *J Neurosurg* 1992;77(4):551-555. X-6
285. Schaupp W, et al. Reconstruction of the arteria carotis communis in newborn following extracorporeal membrane oxygenation (ECMO). *Eur J Pediatr Surg* 1992;2(2):78-80. X-6
286. Slavin S, et al. Clinical application of intrauterine bone marrow transplantation for treatment of genetic diseases--feasibility studies. *Bone Marrow Transplant* 1992;9(Suppl 1):189-190. X-6
287. Tanaka M, et al. Intravascular pancuronium bromide infusion for prenatal diagnosis of twin-twin transfusion syndrome. *Fetal Diagn Ther* 1992;7(1):36-40. X-5
288. Thomas RL. Prenatal diagnosis of giant cystic hygroma: prognosis, counselling, and management; case presentation and review of the recent literature. *Prenat Diagn* 1992;12(11):919-923. X-5, X-6
289. Touraine JL. Rationale and results of in utero transplants of stem cells in humans. *Bone Marrow Transplant* 1992;10(Suppl 1):121-126. X-6
290. Zaninovic AC, et al. Congenital bladder rupture and urine ascites secondary to a sacrococcygeal teratoma. *Pediatr Radiol* 1992;22(7):509-511. X-5
291. Belik J, et al. Fetal ductus arteriosus ligation. Pulmonary vascular smooth muscle biochemical and mechanical changes. *Circ Res* 1993;72(3):588-596. X-3
292. Benya EC, et al. Cystic sonographic appearance of extralobar pulmonary sequestration. *Pediatr Radiol* 1993;23(8):605-607. X-5, X-6

293. Brus F, et al. Non-immune hydrops fetalis and bilateral pulmonary hypoplasia in a newborn infant with extralobar pulmonary sequestration. *Acta Paediatr* 1993;82(4):416-418. X-5, X-6
294. Cowles T, Furman P, Wilkins I. Prenatal diagnosis of Dandy-Walker malformation in a family displaying X-linked inheritance. *Prenat Diagn* 1993;13(2):87-91. X-5, X-6
295. Delius R, et al. Venovenous compares favorably with venoarterial access for extracorporeal membrane oxygenation in neonatal respiratory failure. *J Thorac Cardiovasc Surg* 1993;106(2):329-338. X-6
296. Dumez Y, et al. Prenatal management of congenital cystic adenomatoid malformation of the lung. *J Pediatr Surg* 1993;28(1):36-41. X-6
297. Flake AW. Fetal sacrococcygeal teratoma. *Semin Pediatr Surg*, 1993;2(2):113-120. X-6
298. Gonen R, et al. The effect of drainage of fetal chylothorax on cardiac and blood vessel hemodynamics. *J Clin Ultrasound* 1993;21(4):265-268. X-5
299. Hawkins E, et al. Occult malignancy in neonatal sacrococcygeal teratomas. A report from a Combined Pediatric Oncology Group and Children's Cancer Group study. *Am J Pediatr Hematol Oncol* 1993;15(4):406-409. X-6
300. Heffez DS, et al. Intrauterine repair of experimental surgically created dysraphism. *Neurosurgery* 1993;32(6):1005-1010. X-3, X-6
301. Howell LJ, Adzick NS, Harrison MR. The Fetal Treatment Center. *Semin Pediatr Surg* 1993;2(2):143-146. X-1
302. Jelsema RD, et al. Prenatal diagnosis of congenital diaphragmatic hernia not amenable to prenatal or neonatal repair: Brachmann-de Lange syndrome. *Am J Med Genet* 1993;47(7):1022-1023. X-5
303. Kum CK, Wong YC, Prabhakaran K. Management of fetal sacrococcygeal teratoma. *Ann Acad Med Singapore* 1993;22(3):377-380. X-6
304. MacMahon RA, et al. In utero repair of diaphragmatic hernia. *J Paediatr Child Health* 1993;9(5):393-395. X-6
305. Majid AA. Closure of the patent ductus arteriosus with a Ligaclip through a minithoracotomy. *Chest* 1993;103(5):1512-1514. X-6
306. Malnofski MJ, et al. Prenatal ultrasonic diagnosis of retroperitoneal cystic lymphangioma. *J Ultrasound Med* 1993;12(7):427-429. X-6
307. Mashiach R, et al. Antenatal ultrasound diagnosis of congenital cystic adenomatoid malformation of the lung: spontaneous resolution in utero. *J Clin Ultrasound* 1993;21(7):453-457. X-5, X-6
308. Meagher SE, et al. Disappearing lung echogenicity in fetal bronchopulmonary malformations: a reassuring sign? *Prenat Diagn* 1993;13(6):495-501. X-6
309. Nyberg DA, et al. Prenatal sonographic findings of trisomy 18: review of 47 cases. *J Ultrasound Med* 1993;12(2):103-113. X-6
310. Obwegeser R, Deutinger J, Bernaschek G. Fetal pulmonary cyst treated by repeated thoracocentesis. *Am J Obstet Gynecol* 1993;169(6):1622-1624. X-5
311. Ruiz CE, et al. Brief report: stenting of the ductus arteriosus as a bridge to cardiac transplantation in infants with the hypoplastic left-heart syndrome. *N Engl J Med* 1993;328(22):1605-1608. X-6

312. Shalev E, Peleg D. Fetal cardiac resuscitation. *Lancet* 1993;341(8840):305-306. X-5, X-6
313. Taguchi M, et al. Prenatal diagnosis of congenital cystic adenomatoid malformation of the lung. *Fetal Diagn Ther* 1993;8(2):114-118. X-5, X-6
314. Tariq TA, Korejo R. Evaluation of the role of craniotomy in developing countries. *J Pak Med Assoc* 1993;43(2):30-32. X-6
315. Touraine JL. In utero fetal liver cell transplantation in the treatment of immunodeficient or thalassemic human fetuses. *Transfus Sci* 1993;14(3):299-304. X-6
316. Turco AE, et al. Prenatal testing in a fetus at risk for autosomal dominant polycystic kidney disease and autosomal recessive junctional epidermolysis bullosa with pyloric atresia. *Am J Med Genet* 1993;47(8):1225-1230. X-5, X-6
317. Verloes A, et al. Brachymorphism-onychodysplasia-dysphalangism syndrome. *J Med Genet* 1993;30(2):158-161. X-5, X-6
318. Walton JM, et al. Fetal tumors associated with hydrops: the role of the pediatric surgeon. *J Pediatr Surg* 1993;28(9):1151-1153. X-6
319. Westaby S, et al. Replacement of the thoracic aorta with collagen-impregnated woven Dacron grafts. Early results. *J Thorac Cardiovasc Surg* 1993;106(3):427-433. X-6
320. Wilson JM, DiFiore JW, Peters CA. Experimental fetal tracheal ligation prevents the pulmonary hypoplasia associated with fetal nephrectomy: possible application for congenital diaphragmatic hernia. *J Pediatr Surg* 1993;28(11):1433-1439; discussion 1439-1440. X-3, X-6
321. Blachar A, et al. Evaluation of prenatally diagnosed hydronephrosis by morphometric measurements of the kidney. *Pediatr Radiol* 1994;24(2):131-134. X-6
322. Crombleholme TM, Murray TA, Harris BH. Diagnosis and management of fetal neuroblastoma. *Curr Opin Obstet Gynecol* 1994;6(2):199-202. X-5, X-6
323. DiFiore JW, et al. Experimental fetal tracheal ligation reverses the structural and physiological effects of pulmonary hypoplasia in congenital diaphragmatic hernia. *J Pediatr Surg* 1994;29(2):248-256; discussion 256-257. X-3, X-6
324. Dumez Y, et al. Meckel-Gruber syndrome: prenatal diagnosis at 10 menstrual weeks using embryoscopy. *Prenat Diagn* 1994;14(2):141-144. X-5
325. Elami A, Laks H, Pearl JM. Truncal valve repair: initial experience with infants and children. *Ann Thorac Surg* 1994;57(2):397-401; discussion 402. X-6
326. Geirsson RT, Palsson G. Prenatal thoracocentesis may be lifesaving in congenital chylothorax. *J Perinat Med* 1994;22(5):447-448. X-5, X-6
327. Hecher K, Sullivan ID, Nicolaides KH. Temporary iatrogenic fetal tricuspid valve atresia in a case of twin to twin transfusion syndrome. *Br Heart J* 1994;72(5):457-460. X-5
328. Hedrick MH, et al. Plug the lung until it grows (PLUG): a new method to treat congenital diaphragmatic hernia in utero. *J Pediatr Surg* 1994;29(5):612-617. X-3
329. Hershkovitz E, et al. Prenatal ultrasonic diagnosis of nonhypertrophic pyloric stenosis associated with intestinal malrotation. *J Clin Ultrasound* 1994;22(1):52-54. X-6
330. Hill AE, Beattie F. Does caesarean section delivery improve neurological outcome in open spina bifida? *Eur J Pediatr Surg* 1994;4(Suppl 1):32-34. X-6

331. Holzgreve W, et al. A simpler technique for umbilical-cord blockade of an acardiac twin. *N Engl J Med* 1994;331(1):56-57. X-5
332. Inoue M, et al. Antenatal diagnosis of sacrococcygeal teratoma with hydrops fetalis; a case report. *Eur J Pediatr Surg* 1994;4(2):125-127. X-5, X-6
333. Kaw YT. Congenital cystic adenomatoid malformation of the lung. Report of a case with cytologic findings. *Acta Cytol* 1994;38(2):275-278. X-5, X-6
334. Liu HY, et al. Clinical outcome and management of prenatally diagnosed primary megaureters. *J Urol* 1994;152(2 Pt 2):614-617. X-6
335. MacGillivray TE, et al. Vascular changes with in utero correction of diaphragmatic hernia. *J Pediatr Surg* 1994;29(8):992-996. X-6
336. McCullagh M, et al. Accuracy of prenatal diagnosis of congenital cystic adenomatoid malformation. *Arch Dis Child* 1994;71(2):F111-F113. X-6
337. Porreco RP, et al. Palliative fetal surgery for diaphragmatic hernia. *Am J Obstet Gynecol* 1994;170(3):833-884. X-5
338. Quintero RA, et al. Brief report: umbilical-cord ligation of an acardiac twin by fetoscopy at 19 weeks of gestation. *N Engl J Med* 1994;330(7):469-471. X-5
339. Rodeck CH, Roberts LJ. Successful treatment of fetal cardiac arrest by left ventricular exchange transfusion. *Fetal Diagn Ther* 1994;9(4):213-217. X-5, X-6
340. Sakala EP, et al. Spontaneous, in utero regression of antenatally diagnosed solid fetal chest masses. A report of two cases. *J Reprod Med* 1994;39(7):531-536. X-6
341. Sakala EP, Perrott WS, Grube GL. Sonographic characteristics of antenatally diagnosed extralobar pulmonary sequestration and congenital cystic adenomatoid malformation. *Obstet Gynecol Surv* 1994;49(9):647-655. X-1
342. Sharara FI, Khoury AN. Prenatal diagnosis of a giant cavernous hemangioma in association with nonimmune hydrops. A case report. *J Reprod Med* 1994;39(7):547-549. X-5
343. Skupski DW, et al. Rapid exclusion of chromosomal aneuploidies by fluorescence in situ hybridization prior to fetal surgery for obstructive uropathy—a case report. *Fetal Diagn Ther* 1994;9(5):353-356. X-5
344. Thorpe-Beeston JG, Nicolaidis KH. Cystic adenomatoid malformation of the lung: prenatal diagnosis and outcome. *Prenat Diagn* 1994;14(8):677-688. X-6
345. Weiner CP, Ludomirski A. Diagnosis, pathophysiology, and treatment of chronic twin-to-twin transfusion syndrome. *Fetal Diagn Ther* 1994;9(5):283-290. X-6
346. Westgren M, Ringden O. Fetal to fetal transplantation. *Acta Obstet Gynecol Scand* 1994;73(5):371-372. X-1, X-6
347. Wilson RD, et al. In utero decompression of umbilical cord angiomyxoma followed by vaginal delivery. *Am J Obstet Gynecol* 1994;171(5):1383-1385. X-5
348. Achiron R, et al. Fetal lung hyperechogenicity: prenatal ultrasonographic diagnosis, natural history and neonatal outcome. *Ultrasound Obstet Gynecol* 1995;6(1):40-42. X-6
349. Aguirre OA, et al. Resolution of unilateral fetal hydrothorax with associated non-immune hydrops after intrauterine thoracentesis. *Ultrasound Obstet Gynecol* 1995;5(5):346-348. X-5

350. Allan LD, et al. Survival after fetal aortic balloon valvoplasty. *Ultrasound Obstet Gynecol* 1995;5(2):90-91. X-5
351. Barret J, et al. The prognostic factors in the prenatal diagnosis of the echogenic fetal lung. *Prenat Diagn* 1995;15(9):849-853. X-1
352. Bromley B, et al. Fetal lung masses: prenatal course and outcome. *J Ultrasound Med* 1995;14(12):927-936; quiz 1378. X-6
353. Brown MF, et al. Successful prenatal management of hydrops, caused by congenital cystic adenomatoid malformation, using serial aspirations. *J Pediatr Surg* 1995;30(7):1098-1099. X-5
354. Chisholm JC, et al. Persistent hemolysis after transcatheter occlusion of a patent ductus arteriosus: surgical ligation of the duct over the occlusion device. *Pediatr Cardiol* 1995;16(4):194-196. X-6
355. Crombleholme TM, et al. Amniotic band syndrome in fetal lambs. I: Fetoscopic release and morphometric outcome. *J Pediatr Surg* 1995;30(7):974-978. X-3
356. De DH, Pezzella AT. Aneurysm following ligation of patent ductus arteriosus. *Tex Heart Inst J* 1995;22(4):324-326. X-6
357. Elchalal U, et al. Prenatal diagnosis of acute bladder distension associated with fetal sacrococcygeal teratoma—a case report. *Prenat Diagn* 1995;15(12):1160-1164. X-5
358. Foley MR, et al. Use of the Foley Cordostat grasping device for selective ligation of the umbilical cord of an acardiac twin: a case report. *Am J Obstet Gynecol* 1995;172(1 Pt 1):212-214. X-5
359. Hashim E, et al. Reversible tracheal obstruction in the fetal sheep: effects on tracheal fluid pressure and lung growth. *J Pediatr Surg* 1995;30(8):1172-1177. X-3
360. Hecher K, Ville Y, Nicolaides KH. Color Doppler ultrasonography in the identification of communicating vessels in twin-twin transfusion syndrome and acardiac twins. *J Ultrasound Med* 1995;14(1):37-40. X-6
361. Hsu KF, et al. Complete intrauterine resolution of fetal congenital cystic adenomatoid malformation of the lung type III. *J Ultrasound Med* 1995;14(11):871-875. X-6
362. King SJ, Pilling DW, Walkinshaw S. Fetal echogenic lung lesions: prenatal ultrasound diagnosis and outcome. *Pediatr Radiol* 1995;25(3):208-210. X-6
363. Luks FI. Fetal surgery. *Baillieres Clin Obstet Gynaecol* 1995;9(3):571-577. X-1
364. Meagher SE, et al. Successful outcome with serial amniocenteses for polyhydramnios complicating cystic adenomatoid malformation of the lung. *Aust N Z J Obstet Gynaecol* 1995;35(3):326-328. X-5
365. Meuli M, et al. Creation of myelomeningocele in utero: a model of functional damage from spinal cord exposure in fetal sheep. *J Pediatr Surg* 1995;30(7):1028-1032; discussion 1032-1033. X-3
366. Meuli-Simmen C, et al. Fetal reconstructive surgery: experimental use of the latissimus dorsi flap to correct myelomeningocele in utero. *Plast Reconstr Surg* 1995;96(5):1007-1011. X-3
367. Millicovsky G, Lazar ML. Spina bifida: role of neural tissue damage during pregnancy in producing spinal paralysis. *Obstet Gynecol* 1995;86(2):300-301. X-1

368. Morrow RJ, et al. Midtrimester thoracoamniotic shunting for the treatment of fetal hydrops. *Fetal Diagn Ther* 1995;10(2):92-94. X-5
369. Munoz H, et al. Prenatal sonographic findings of a large fetal cardiac fibroma. *J Ultrasound Med* 1995;14(6):479-481. X-5
370. Parilla BV, Chen GW. Fetal thoracentesis for cystic adenomatoid malformation of the lung. *Am J Obstet Gynecol* 1995;172(2 Pt 1):717. X-5
371. Quintero RA, et al. Percutaneous fetal cystoscopy and endoscopic fulguration of posterior urethral valves. *Am J Obstet Gynecol* 1995;172(1 Pt 1):206-209. X-5
372. Robertson FM, et al. Devascularization and staged resection of giant sacrococcygeal teratoma in the premature infant. *J Pediatr Surg* 1995;30(2):309-311. X-5
373. Shipley III CF, Simmons CL, Nelson GH. Intrauterine diagnosis of hydrothorax in a fetus who had a combination chylothorax and pulmonary sequestration after delivery. *J Perinatol* 1995;15(3):237-239. X-5
374. Taguchi T, et al. Antenatal diagnosis and surgical management of congenital cystic adenomatoid malformation of the lung. *Fetal Diagn Ther* 1995;10(6):400-407. X-6
375. Uchiyama M, et al. A huge immature cervical teratoma in a newborn: report of a case. *Surg Today* 1995;25(8):737-740. X-6
376. Watanabe M, et al. Left aortic arch with right descending aorta and right ligamentum arteriosum associated with d-TGA and large VSD: surgical treatment of a rare form of vascular ring. *J Pediatr Surg* 1995;30(9):1363-1365. X-5
377. Welch CR, et al. Needle modifications for invasive fetal procedures. *Obstet Gynecol* 1995;85(1):113-117. X-6
378. Willcourt RJ, et al. Laparoscopic ligation of the umbilical cord of an acardiac fetus. *J Am Assoc Gynecol Laparosc* 1995;2(3):319-321. X-5
379. Ahmad FK, et al. Isolated unilateral fetal pleural effusion: the role of sonographic surveillance and in utero therapy. *Fetal Diagn Ther* 1996;11(6):383-389. X-5
380. Blanch G, et al. Internalization of pleuroamniotic shunt causing neonatal demise. *Fetal Diagn Ther* 1996;11(1):32-36. X-5
381. Bloechle M, et al. Neuroectodermal cyst may be a rare differential diagnosis of fetal sacrococcygeal teratoma: first case report of a prenatally observed neuroectodermal cyst. *Ultrasound Obstet Gynecol* 1996;7(1):64-67. X-5, X-6
382. Chen CP, et al. Ultrasound-guided fluid aspiration and prenatal diagnosis of duplicated hydrometrocolpos with uterus didelphys and septate vagina. *Prenat Diagn* 1996;16(6):572-576. X-5
383. Crombleholme, TM, et al. Prenatal diagnosis and the pediatric surgeon: the impact of prenatal consultation on perinatal management. *J Pediatr Surg* 1996;31(1):156-162; discussion 162-163. X-6
384. Crombleholme TM, et al. Fetoscopic cord ligation to prevent neurological injury in monozygous twins. *Lancet* 1996;348(9021):191. X-5
385. dell'Agnola C, et al. Advantages of prenatal diagnosis and early surgery for congenital cystic disease of the lung. *J Perinat Med* 1996;24(6):621-631. X-6
386. DiFederico EM, Harrison M, Matthay MA. Pulmonary edema in a woman following fetal surgery. *Chest* 1996;109(4):1114-1117. X-5

387. Flake AW. Fetal surgery for congenital diaphragmatic hernia. *Semin Pediatr Surg* 1996;5(4):266-274. , X-5
388. Gundogdu HZ, Senocak ME. Intrauterine intussusception due to Meckel's diverticulum as a cause of ileal atresia: analysis of 2 cases. *Eur J Pediatr Surg* 1996;6(1):52-54. X-6
389. Habal MB. Perspectives on what's new in plastic surgery. The new millennium. *Clin Plast Surg* 1996;23(1):1-2. X-1
390. Haddad B, et al. The congenital mesoblastic nephroma: a case report of prenatal diagnosis. *Fetal Diagn Ther* 1996;11(1):61-66. X-5
391. Hecher K, Hackeloer BJ. Intrauterine endoscopic laser surgery for fetal sacrococcygeal teratoma. *Lancet* 1996;347(8999):470. X-5
392. Hutchins GM, et al. Acquired spinal cord injury in human fetuses with myelomeningocele. *Pediatr Pathol Lab Med* 1996;16(5):701-712. X-6
393. Johnson JA, et al. Prenatal diagnosis of a fetal ventricular diverticulum associated with pericardial effusion: successful outcome following pericardiocentesis. *Prenat Diagn* 1996;16(10):954-957. X-5
394. Katz VL, et al. Fetal ovarian torsion appearing as a solid abdominal mass. *J Perinatol* 1996;16(4):302-304. X-5, X-6
395. Kaufman GE, D'Alton ME, Crombleholme TM. Decompression of fetal axillary lymphangioma to prevent dystocia. *Fetal Diagn Ther* 1996;11(3):218-220. X-5
396. Kubota M, et al. Clinical characteristics and natural history of antenatally diagnosed fetal uropathy. An analysis of 55 cases. *Fetal Diagn Ther* 1996;11(4):275-285. X-6
397. Kuller JA, et al. Cesarean delivery for fetal malformations. *Obstet Gynecol Surv* 1996;51(6):371-375. X-1, X-6
398. Lin RY, Adzick NS. The role of the fetal fibroblast and transforming growth factor-beta in a model of human fetal wound repair. *Semin Pediatr Surg* 1996;5(3):165-174. X-6
399. Mas M, Fontes J, Salcedo J. Ultrasonographic diagnosis of a twisted fetal ovarian cyst in utero. *Int J Gynaecol Obstet* 1996;52(2):185-186. X-5, X-6
400. Metkus AP, et al. Sonographic predictors of survival in fetal diaphragmatic hernia. *J Pediatr Surg* 1996;31(1):148-111; discussion 151-152. X-6
401. Mikulandra F, Perisa M, Stojnic E. When is fetal macrosomia (> or = 4500 g) an indication for caesarean section? *Zentralbl Gynakol* 1996;118(8):441-447. X-6
402. Miller JA, Corteville JE, Langer JC. Congenital cystic adenomatoid malformation in the fetus: natural history and predictors of outcome. *J Pediatr Surg* 1996;31(6):805-808. X-6
403. Noia G, et al. Double shunt in a case of fetal low-level obstructive uropathy. *Fetal Diagn Ther* 1996;11(5):313-317. X-5
404. Petrikovsky B, et al. Single-needle insertion technique for thoracocentesis for bilateral pleural effusions. *Fetal Diagn Ther* 1996;11(1):26-31. X-5
405. Skarsgard ED, et al. Fetal endoscopic tracheal occlusion ('Fetendo-PLUG') for congenital diaphragmatic hernia. *J Pediatr Surg* 1996;31(10):1335-1338. X-3
406. Smulian JC, et al. Color and duplex Doppler sonographic investigation of in utero spontaneous regression of pulmonary sequestration. *J Ultrasound Med* 1996;15(11):789-792. X-6

407. Tomlinson MW, et al. Correction of hemodynamic abnormalities by vesicoamniotic shunting in familial congenital megacystis. *Fetal Diagn Ther* 1996;11(1):46-49. X-5
408. VanderWall KJ, et al. Fetal endoscopic ('Fetendo') tracheal clip. *J Pediatr Surg* 1996;31(8):1101-1103; discussion 1103-1104. X-3
409. Adzick NS, et al. A rapidly growing fetal teratoma. *Lancet* 1997;349(9051):538. X-5
410. Bakos O. Intrauterine cephalocentesis: a case report. *Fetal Diagn Ther* 1997;12(5):296-297. X-5
411. Barrett JF, et al. Fetal urine production rates following intrauterine transfusion. *Fetal Diagn Ther* 1997;12(6):343-347. X-6
412. Bromley B, Benacerraf BR. Unilateral lung hypoplasia: report of three cases. *J Ultrasound Med* 1997;16(9):599-601. X-6
413. Bruch SW, et al. Prenatal therapy for pericardial teratomas. *J Pediatr Surg* 1997;32(7):1113-1115. X-6
414. Cacciari A, et al. A series of 17 cases of congenital cystic adenomatoid malformation of the lung: management and outcome. *Eur J Pediatr Surg* 1997;7(2):84-89. X-6
415. Cass DL, et al. Cystic lung lesions with systemic arterial blood supply: a hybrid of congenital cystic adenomatoid malformation and bronchopulmonary sequestration. *J Pediatr Surg* 1997;32(7):986-990. X-5
416. Conte S, et al. One-stage repair of truncus arteriosus, CAVC, and TAPVC. *Ann Thorac Surg* 1997;63(6):1781-1783. X-5
417. Conte S, et al. Double-homograft repair of truncus arteriosus with severe truncal valve dysfunction. *Scand Cardiovasc J* 1997;31(4):245-247. X-5
418. Coplen DE. Prenatal intervention for hydronephrosis. *J Urol* 1997;157(6):2270-2277. X-1
419. d'Udekem Y, Rubay JE, Sluysmans T. A case of neonatal ductus arteriosus aneurysm. *Cardiovasc Surg* 1997;5(3):338-339. X-5
420. Fung TY, et al. Abdomino-amniotic shunting in isolated fetal ascites with polyhydramnios. *Acta Obstet Gynecol Scand* 1997;76(7):706-707. X-5
421. Gaiser RR, Cheek TG, Kurth CD. Anesthetic management of cesarean delivery complicated by ex utero intrapartum treatment of the fetus. *Anesth Analg* 1997;84(5):1150-1153. X-6
422. Graf JL, et al. Fetal hydrops after in utero tracheal occlusion. *J Pediatr Surg* 1997;32(2):214-215; discussion 216. X-5
423. Hecher K, Hackeloer BJ, Ville Y. Umbilical cord coagulation by operative microendoscopy at 16 weeks' gestation in an acardiac twin. *Ultrasound Obstet Gynecol* 1997;10(2):130-132. X-5
424. Ito M, et al. Aspiration of giant hepatic cyst in the fetus in utero. *Fetal Diagn Ther* 1997;12(4):221-225. X-5
425. Kimber CP, et al. Antenatal intestinal vascular accident with subsequent small bowel atresia: case report. *Ultrasound Obstet Gynecol* 1997;10(3):212-214. X-6
426. Kohl T, et al. Fetoscopic and open transumbilical fetal cardiac catheterization in sheep. Potential approaches for human fetal cardiac intervention. *Circulation* 1997;95(4):1048-1053. X-3

427. Liberati M, et al. Cardiotocographic and Doppler velocimetric patterns, pre- and post-thoracentesis, in a case of fetal hydrothorax. *Clin Exp Obstet Gynecol* 1997;24(2):109-111. X-5
428. Lipshutz GS, et al. Prospective analysis of lung-to-head ratio predicts survival for patients with prenatally diagnosed congenital diaphragmatic hernia. *J Pediatr Surg* 1997;32(11):1634-1636. X-6
429. Meuli M, et al. The spinal cord lesion in human fetuses with myelomeningocele: implications for fetal surgery. *J Pediatr Surg* 1997;32(3):448-452. X-6
430. Morris C. Technology and the legal discourse of fetal autonomy. *UCLA Womens Law J* 1997;8(1):47-97. X-1
431. Mychaliska GB, et al. Operating on placental support: the ex utero intrapartum treatment procedure. *J Pediatr Surg* 1997;32(2):227-230; discussion 230-231. X-6
432. O'Toole SJ, et al. Tracheal ligation: the dark side of in utero congenital diaphragmatic hernia treatment. *J Pediatr Surg* 1997;32(3):407-410. X-3
433. Ozmen MN, et al. Prenatal diagnosis of gastric duplication cyst. *J Ultrasound Med* 1997;16(3):219-222. X-6
434. Rani R, Cameron A, Munro F. Prenatal diagnosis and management of urethral obstruction. *J Obstet Gynaecol Res* 1997;23(1):59-62. X-6
435. Samuel M, Burge DM, Griffiths DM. Prenatal diagnosis of laryngotracheoesophageal clefts. *Fetal Diagn Ther* 1997;12(5):260-265. X-6
436. Sanal M, et al. Fetus in fetu and cystic rectal duplication in a newborn. *Eur J Pediatr Surg* 1997;7(2):120-121. X-5
437. Sener T, et al. Ultrasonographic detection of single umbilical artery: a simple marker of fetal anomaly. *Int J Gynaecol Obstet* 1997;58(2):217-221. X-6
438. Shih HH, et al. Mature teratoma arising from an intra-abdominal undescended testis presenting as a fetal abdominal mass. *Ultrasound Obstet Gynecol* 1997;10(3):209-211. X-5
439. Sklansky M, et al. Intrapericardial teratoma in a twin fetus: diagnosis and management. *Obstet Gynecol* 1997;89(5 Pt 2):807-809. X-5
440. Tabsh KM, Theroux NL. Obstructive fetal hydronephrosis managed by amnioinfusions and bladder aspirations. *Obstet Gynecol* 1997;90(4 Pt 2):679-680. X-5
441. VanderWall KJ, et al. Fetendo-clip: a fetal endoscopic tracheal clip procedure in a human fetus. *J Pediatr Surg* 1997;32(7):970-972. X-5
442. Winderl LM, Silverman RK. Prenatal identification of a completely cystic internal sacrococcygeal teratoma (type IV). *Ultrasound Obstet Gynecol* 1997;9(6):425-428. X-5
443. Winters WD, et al. Congenital masses of the lung: changes in cross-sectional area during gestation. *J Clin Ultrasound* 1997;25(7):372-377. X-6
444. Wittman BK, et al. Complications of long-term drainage of fetal pleural effusion: case report and review of the literature. *Am J Perinatol* 1997;14(8):443-447. X-6
445. Adzick NS, et al. Successful fetal surgery for spina bifida. *Lancet* 1998;352(9141):1675-1676. X-5

446. Arabin B, et al. Treatment of twin-twin transfusion syndrome by laser and digoxin. Biophysical and angiographic evaluation. *Fetal Diagn Ther* 1998;13(3):141-146. X-5
447. Arias F, et al. Treatment of acardiac twinning. *Obstet Gynecol* 1998;91(5 Pt 2):818-821. X-5
448. Armentano G, et al. Fetal ovarian cysts: prenatal diagnosis and management. Report of two cases and review of literature. *Clin Exp Obstet Gynecol* 1998;25(3):88-91. X-6
449. Asano M, et al. Modified subclavian flap aortoplasty for coarctation repair in patients less than three months of age. *Ann Thorac Surg* 1998;66(2):588-589. X-6
450. Bakos O, Ewald U, Lindgren PG. Fetal cardiocentesis in care of severe Kell immunisation. *Fetal Diagn Ther* 1998;13(6):372-374. X-5
451. Bannister CM, Russell SA, Rimmer S. Pre-natal brain development of fetuses with a myelomeningocele. *Eur J Pediatr Surg* 1998;8(Suppl 1):15-17. X-6
452. Borghi F, et al. Embryologic bases of extended radical resection in pancreatic cancer. *Arch Surg* 1998;133(3):297-301. X-6
453. Bryant DR, et al. Limited usefulness of fetal weight in predicting neonatal brachial plexus injury. *Am J Obstet Gynecol* 1998;179(3 Pt 1):686-689. X-6
454. Chen CP, et al. Perinatal findings in a male fetus with congenital megacystis and anorectal malformations. *Fetal Diagn Ther* 1998;13(6):348-351. X-5
455. Chisholm CA, et al. Prenatal diagnosis and perinatal management of fetal sacrococcygeal teratoma. *Am J Perinatol* 1998;15(8):503-505. X-6
456. Davis CF, Sabharwal AJ. Management of congenital diaphragmatic hernia. *Arch Dis Child Fetal Neonatal Ed* 1998;79(1):F1-F3. X-1
457. Deprest JA, et al. Experience with fetoscopic cord ligation. *Eur J Obstet Gynecol Reprod Biol* 1998;81(2):157-164. X-6
458. Eapen RS, Rowland DG, Franklin WH. Effect of prenatal diagnosis of critical left heart obstruction on perinatal morbidity and mortality. *Am J Perinatol* 1998;15(4):237-242. X-6
459. Garcia AM, Morgan III WM, and Bruner JP. In utero decompression of a cystic grade IV sacrococcygeal teratoma. *Fetal Diagn Ther* 1998;13(5):305-308. X-5
460. Graf JL, et al. A surprising histological evolution of preterm sacrococcygeal teratoma. *J Pediatr Surg* 1998;33(2):177-179. X-6
461. Hamada Y, et al. Rapid enlargement of a choledochal cyst: antenatal diagnosis and delayed primary excision. *Pediatr Surg Int* 1998;13(5-6):419-421. X-5, X-6
462. Holterman AX, et al. The natural history of sacrococcygeal teratomas diagnosed through routine obstetric sonogram: a single institution experience. *J Pediatr Surg* 1998;33(6):899-903. X-6
463. Housley HT, Harrison MR. Fetal urinary tract abnormalities. Natural history, pathophysiology, and treatment. *Urol Clin North Am* 1998;25(1):63-73. X-1
464. Howarth GR, et al. Management of early onset severe twin-twin transfusion syndrome in the absence of fetoscopic equipment by exteriorisation, ligation and replacement of the umbilical cord of the sacrificed twin. *S Afr Med J* 1998;88(3):286. X-5

465. Hubbard AM, Crombleholme TM. Anomalies and malformations affecting the fetal/neonatal chest. *Semin Roentgenol* 1998;33(2):117-125. X-1
466. Jamjoom AB, et al. Factors affecting the outcome of foetal hydrocephaly. *Acta Neurochir (Wien)* 1998;140(11):1121-1125. X-6
467. Jikuya T, et al. Aortic dissection extending from ductus diverticulum aneurysm. *Jpn J Thorac Cardiovasc Surg* 1998;46(7):595-598. X-5
468. Kuga T, et al. Prune belly syndrome with penile and urethral agenesis: report of a case. *J Pediatr Surg* 1998;33(12):1825-1828. X-5
469. Lewis KM, et al. Complications of intrauterine placement of a vesicoamniotic shunt. *Obstet Gynecol* 1998;91(5 Pt 2):825-827. X-5
470. Martinez Ferro M, et al. Intrathoracic alimentary tract duplication cysts treated in utero by thoracoamniotic shunting. *Fetal Diagn Ther* 1998;13(6):343-347. X-6
471. Pschera H. Current status in intrauterine fetal stem cell therapy. *J Obstet Gynaecol Res* 1998;24(6):419-424. X-1
472. Reyes C, et al. Delayed repair of congenital diaphragmatic hernia with early high-frequency oscillatory ventilation during preoperative stabilization. *J Pediatr Surg* 1998;33(7):1010-1014; discussion 1014-1016. X-6
473. Riskin-Mashiah S, et al. In utero diagnosis of intrapericardial teratoma: a case for in utero open fetal surgery. *Prenat Diagn* 1998;18(12):1328-1330. X-5
474. Shapiro E, et al. Altered smooth muscle development and innervation in the lower genitourinary and gastrointestinal tract of the male human fetus with myelomeningocele. *J Urol* 1998;160(3 Pt 2):1047-1053; discussion 1079. X-6
475. Shimazaki Y, et al. Ruptured aneurysm of the ductus diverticulum into the pulmonary artery in a man: a successful repair. *J Card Surg* 1998;13(2):146-149. X-5
476. Sistino JJ. Foetal bypass: concepts and controversies. *Perfusion* 1998;13(2):111-117. X-6
477. Stelnicki EJ, et al. The in utero repair of Tessier number 7 lateral facial clefts created by amniotic band-like compression. *J Craniofac Surg* 1998;9(6):557-562; discussion 563. X-3
478. Stone CA, Quinn MW, Saxby PJ. Congenital skin loss following Nd:YAG placental photocoagulation. *Burns* 1998;24(3):275-277. X-5
479. Thakral CL, Maji DC, Sajwani MJ. Fetus-in-fetu: a case report and review of the literature. *J Pediatr Surg* 1998;33(9):1432-1434. X-5, X-6
480. van Gemert MJ, Major AL, Scherjon SA. Placental anatomy, fetal demise and therapeutic intervention in monochorionic twins and the transfusion syndrome: new hypotheses. *Eur J Obstet Gynecol Reprod Biol* 1998;78(1):53-62. X-6
481. Van Peborgh, P, et al. Management of a case of twin-to-twin transfusion syndrome by a combined surgical approach. *Fetal Diagn Ther* 1998;13(2):75-78. X-5
482. Wilhelm C, et al. Ventriculomegaly diagnosed by prenatal ultrasound and mental development of the children. *Fetal Diagn Ther* 1998;13(3):162-166. X-6
483. Wilkinson C, et al. Is a rising caesarean section rate inevitable? *Br J Obstet Gynaecol* 1998;105(1):45-52. X-6

484. Ethical guidelines on human reproduction and women's health. FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. *J Reprod Med* 1999;44(5):482-486. X-1
485. Part III: pulmonary lesions—congenital cystic adenomatoid malformation (CCAM) or extralobar pulmonary sequestration (EPS). *Tecnologica MAP Suppl* 1999:15-16. X-1
486. Part II: congenital diaphragmatic hernia. *Tecnologica MAP Suppl* 1999:14-15. X-1
487. Part I: bilateral urinary tract obstruction. *Tecnologica MAP Suppl* 1999:12-13. X-1
488. Fetal surgery for prenatally diagnosed malformations. *Tecnologica MAP Suppl* 1999:11-12. X-1
489. al-Kouatly HB, Skupski DW. Intrauterine sling: a complication of the stuck twin syndrome. *Ultrasound Obstet Gynecol* 1999;14(6):419-421. X-5
490. Anandakumar C, et al. Direct intrauterine fetal therapy in a case of bronchopulmonary sequestration associated with non-immune hydrops fetalis. *Ultrasound Obstet Gynecol* 1999;13(4):263-265. X-5
491. Anteby EY, Sternhell K, Dicke JM. The fetus with gastroschisis managed by a trial of labor: antepartum and intrapartum complications. *J Perinatol* 1999;19(7):521-524. X-6
492. Bagolan P, et al. Cystic adenomatoid malformation of the lung: clinical evolution and management. *Eur J Pediatr* 1999;158(11):879-882. X-6
493. Baskin LS. Fetal genital anatomy reconstructive implications. *J Urol* 1999;162(2):527-529. X-6
494. Brookes JA, et al. Three-dimensional imaging of the postmortem fetus by MRI: early experience. *Fetal Diagn Ther* 1999;14(3):166-171. X-6
495. Chisholm CA, et al. Prenatal diagnosis and perinatal management of fetal sacrococcygeal teratoma. *Am J Perinatol* 1999;16(1):47-50. X-6
496. Chisholm CA, et al. Prenatal diagnosis and perinatal management of fetal sacrococcygeal teratoma. *Am J Perinatol* 1999;16(2):89-92. X-6
497. Chuileannain FN, Woodrow N, de Crespigny L. Prenatal diagnosis and management of sacrococcygeal teratoma. *Aust N Z J Obstet Gynaecol* 1999;39(4):497-501. X-6
498. Dommergues M, et al. The reasons for termination of pregnancy in the third trimester. *Br J Obstet Gynaecol* 1999;106(4):297-303. X-6
499. Evrard V, et al. Congenital parenchymatous malformations of the lung. *World J Surg* 1999;23(11):1123-1132. X-6
500. Flake AW, Crombleholme TM, Adzick NS. The current status and future potential of fetal intervention: image is everything. *Comput Med Imaging Graph* 1999;23(1):51-57. X-1
501. Gonen R, et al. Intrapartum drainage of fetal pleural effusion. *Prenat Diagn* 1999;19(12):1124-1126. X-6
502. Gotte K, et al. Congenital nasal hemangiopericytoma: intrauterine, intraoperative, and histologic findings. *Ann Otol Rhinol Laryngol* 1999;108(6):589-593. X-6
503. Hamada Y, et al. Prenatally diagnosed cystic neuroblastoma. *Pediatr Surg Int* 1999;15(1):71-74. X-5, X-6

504. Hirose H, et al. Spontaneously developed aneurysm of the ductus arteriosus in an adult. *Ann Vasc Surg* 1999;13(2):229-231. X-5, X-6
505. Hornung TS, et al. Neonatal ductus arteriosus aneurysm causing nerve palsies and airway compression: surgical treatment by decompression without excision. *Pediatr Cardiol* 1999;20(2):158-160. X-5, X-6
506. Howell LJ, Adzick NS. The essentials of a fetal therapy center. *Semin Perinatol* 1999;23(6):535-540. X-1
507. Howell LJ, Dunphy PM. Fetal surgery: exploring the challenges in nursing care. *J Obstet Gynecol Neonatal Nurs* 1999;28(4):427-432. X-5
508. Imamura M, et al. Improving early and intermediate results of truncus arteriosus repair: a new technique of truncal valve repair. *Ann Thorac Surg* 1999;67(4):1142-1146. X-6
509. Liechty KW, et al. Elevated platelet-derived growth factor-B in congenital cystic adenomatoid malformations requiring fetal resection. *J Pediatr Surg* 1999;34(5):805-809; discussion 809-810. X-6
510. Liechty KW, et al. The ex utero intrapartum treatment procedure for a large fetal neck mass in a twin gestation. *Obstet Gynecol* 1999;93(5 Pt 2):824-825. X-5
511. Liu SL, et al. 19-year follow-up of fetal myelomeningocele brought to term. *Eur J Pediatr Surg* 1999;9(Suppl 1):12-14. X-6
512. Lopoo JB, et al. Natural history of fetuses with cleft lip. *Plast Reconstr Surg* 1999;103(1):34-38. X-6
513. Lundvall L, Skibsted L, Graem N. Limb necrosis associated with twin-twin transfusion syndrome treated with YAG-laser coagulation. *Acta Obstet Gynecol Scand* 1999;78(4):349-350. X-5
514. Okamura M, et al. Fetal sacrococcygeal teratoma visualized by ultra-fast T2 weighted magnetic resonance imaging. *Int J Gynaecol Obstet* 1999;65(2):191-193. X-6
515. Porter HJ. Pulmonary hypoplasia. *Arch Dis Child Fetal Neonatal Ed* 1999;81(2):F81-F83. X-1
516. Ranzini AC, et al. Prenatal sonographic diagnosis of uterine rupture following open fetal surgery. *Obstet Gynecol* 1999;93(5 Pt 2):826-827. X-5
517. Schmidt M, et al. Magnetic resonance imaging of ductus arteriosus Botalli apertus in adulthood. *Int J Cardiol* 1999;68(2):225-229. X-6
518. Schreiber C, et al. Morphologic spectrum of Ebstein's malformation: revisitation relative to surgical repair. *J Thorac Cardiovasc Surg* 1999;117(1):148-155. X-6
519. Schwarzler P, et al. Trisomy 10: first-trimester features on ultrasound, fetoscopy and postmortem of a case associated with increased nuchal translucency. *Ultrasound Obstet Gynecol* 1999;13(1):67-70. X-5
520. Sergi C, et al. Huge fetal sacrococcygeal teratoma with a completely formed eye and intratumoral DNA ploidy heterogeneity. *Pediatr Dev Pathol* 1999;2(1):50-57. X-5, X-6
521. Suzuki T, Fukuda T, Ito T. Modified end-to-end anastomosis combined with subclavian flap aortoplasty for repair of coarctation of the aorta with extended hypoplasia of the aortic isthmus. *J Card Surg* 1999;14(5):359-362. X-6
522. Takeuchi K, et al. Management of acute chylothorax with hydrops fetalis diagnosed in the third trimester of pregnancy. *Fetal Diagn Ther* 1999;14(5):264-265. X-5

523. Tame JD, et al. Level of postoperative analgesia is a critical factor in regulation of myometrial contractility after laparotomy in the pregnant baboon: implications for human fetal surgery. *Am J Obstet Gynecol* 1999;180(5):1196-1201. X-3
524. Tomita H, et al. Stretching of the ductus: an important factor in determining the outcome of coil occlusion. *Jpn Circ J* 1999;63(8):593-596. X-6
525. Tseng JJ, et al. In utero diagnosis of cardiac hemangioma. *Ultrasound Obstet Gynecol* 1999;13(5):363-365. X-5
526. Uchiyama M, et al. Sacrococcygeal teratoma: a series of 19 cases with long-term follow-up. *Eur J Pediatr Surg* 1999;9(3):158-162. X-6
527. Urban BA, et al. Helical CT amniography of congenital diaphragmatic hernia. *AJR Am J Roentgenol* 1999;172(3):809-812. X-6
528. van Leeuwen, K, et al. Prenatal diagnosis of congenital cystic adenomatoid malformation and its postnatal presentation, surgical indications, and natural history. *J Pediatr Surg* 1999;34(5):794-798; discussion 798-799. X-6
529. Weinzweig J, et al. The fetal cleft palate: II. Scarless healing after in utero repair of a congenital model. *Plast Reconstr Surg* 1999;104(5):1356-1364. X-3
530. Treatment of twin-twin transfusion syndrome (TTTS) with aggressive amnioreduction and/or fetoscopic laser therapy. *Tecnologica MAP Suppl* 2000;34-37. X-1
531. Agnew T. Before their time. Surgery on the unborn is a reality. But can it be justified when a baby's life is not at risk? *New Sci* 2000;166(2237):18-19. X-1
532. Arena S, et al. A case of non-immune hydrops fetalis with congenital cystic adenomatoid malformation of the left lung in a twin. *Minerva Pediatr* 2000;52(5-6):307-312. X-5
533. Arenholtz J. A case of fetus-in-fetu. *Radiol Technol* 2000;71(6):605. X-6
534. Bannister CM. Suggested goals for intrauterine surgery for the repair of myelomeningoceles. *Eur J Pediatr Surg* 2000;10(Suppl 1):42. X-1
535. Brown R, Nicolaidis K. Constriction band of the arm following insertion of a pleuro-amniotic shunt. *Ultrasound Obstet Gynecol* 2000;15(5):439-440. X-5
536. Bruner JP, Jarnagin BK, Reinisch L. Percutaneous laser ablation of fetal congenital cystic adenomatoid malformation: too little, too late? *Fetal Diagn Ther* 2000;15(6):359-363. X-5
537. Bui TH, et al. Successful EXIT (ex utero intrapartum treatment) procedure in a fetus diagnosed prenatally with congenital high-airway obstruction syndrome due to laryngeal atresia. *Eur J Pediatr Surg* 2000;10(5):328-333. X-5
538. Carpentieri DF, et al. Subdiaphragmatic pulmonary sequestration: a case report with review of the literature. *J Perinatol* 2000;20(1):60-62. X-5
539. Chiba T, et al. In utero repair of rectal atresia after complete resection of a sacrococcygeal teratoma. *Fetal Diagn Ther* 2000;15(3):187-190. X-5
540. Chiba Y. Fetal intervention. *Ultrasound Med Biol* 2000;26(Suppl 1):S135-S136. X-1
541. Coakley FV, et al. Normal and hypoplastic fetal lungs: volumetric assessment with prenatal single-shot rapid acquisition with relaxation enhancement MR imaging. *Radiology* 2000;216(1):107-111. X-6

542. Crane JM. Fetal bladder outlet obstruction caused by ureterocele. *Obstet Gynecol* 2000;95(6 Pt 2):1040. X-5
543. De Santis M, et al. Congenital cystic adenomatoid malformation of the lung: antenatal ultrasound findings and fetal-neonatal outcome. Fifteen years of experience. *Fetal Diagn Ther* 2000;15(4):246-250. X-6
544. Deprest JA, et al. Bipolar coagulation of the umbilical cord in complicated monochorionic twin pregnancy. *Am J Obstet Gynecol* 2000;182(2):340-345. X-6
545. Drake C. Internet resources for researching twin-to-twin transfusion syndrome. *AORN J* 2000;71(4):894, 896. X-6
546. Dyamenahalli U, et al. Isolated ductus arteriosus aneurysm in the fetus and infant: a multi-institutional experience. *J Am Coll Cardiol* 2000;36(1):262-269. X-6
547. Easley ME, Schon LC. Peripheral nerve vein wrapping for intractable lower extremity pain. *Foot Ankle Int* 2000;21(6):492-500. X-6
548. Farley CL, Cox LA, Long BW. Ultrasound and twin-twin transfusion syndrome. *Radiol Technol* 2000;72(2):95-100. X-1
549. Feldstein VA, et al. Twin-twin transfusion syndrome: the 'Select' procedure. *Fetal Diagn Ther* 2000;15(5):257-261. X-5
550. Galinkin JL, et al. Anesthesia for fetoscopic fetal surgery: twin reverse arterial perfusion sequence and twin-twin transfusions syndrome. *Anesth Analg* 2000;91(6):1394-1397. X-5
551. Goto M, et al. Sacrococcygeal teratoma with hydrops fetalis and bilateral hydronephrosis. *J Perinat Med* 2000;28(5):414-418. X-5
552. Graf JL, et al. Successful fetal sacrococcygeal teratoma resection in a hydropic fetus. *J Pediatr Surg* 2000;35(10):1489-1491. X-5
553. Graf JL, et al. Successful resuscitation during fetal surgery. *J Pediatr Surg* 2000;35(9):1388-1389. X-5
554. Grisar-Granovsky S, et al. Mid-trimester thoracoamniotic shunting for the treatment of fetal primary pleural effusions in a twin pregnancy. a case report. *Fetal Diagn Ther* 2000;15(4):209-211. X-5
555. Guadalupi P, Spadoni I, Vanini V. Repair of hemitruncus with autologous arterial ring and valved bioconduit. *Ann Thorac Surg* 2000;70(5):1708-1710. X-5, X-6
556. Harnett MJ, Hurley R. Anesthesia for fetal intervention. *Anesth Analg* 2000;91(2):500. X-5
557. Holzbeierlein J, et al. The urodynamic profile of myelodysplasia in childhood with spinal closure during gestation. *J Urol* 2000;164(4):1336-1339. X-6
558. Irwin BH, Vane DW. Complications of intrauterine intervention for treatment of fetal obstructive uropathy. *Urology* 2000;55(5):774. X-5
559. Kabra M, et al. Fraser-cryptophthalmos syndrome. *Indian J Pediatr* 2000;67(10):775-778. X-6
560. Khadaroo RG, et al. Fetus-in-fetu presenting as cystic meconium peritonitis: diagnosis, pathology, and surgical management. *J Pediatr Surg* 2000;35(5):721-723. X-5

561. Koike T, et al. Severe hypoproteinemia in a fetus after pleuro-amniotic shunts with double-basket catheters for treatment of chylothorax. *J Obstet Gynaecol Res* 2000;26(5):373-376. X-5
562. Leeners B, et al. Prune-belly syndrome: therapeutic options including in utero placement of a vesicoamniotic shunt. *J Clin Ultrasound* 2000;28(9):500-507. X-6
563. Leistikow EA, et al. Isolated large third-trimester intracranial cyst on fetal ultrasound: fact or fiction? *Pediatrics* 2000;106(4):844-848. X-6
564. Lwakatare F, et al. Ultrafast fetal MR images of sacrococcygeal teratoma: a case report. *Comput Med Imaging Graph* 2000;24(1):49-52. X-5
565. Mangels KJ, et al. Fetal MRI in the evaluation of intrauterine myelomeningocele. *Pediatr Neurosurg* 2000;32(3):124-131. X-6
566. Matias A, Montenegro N, Areias JC. Anticipating twin-twin transfusion syndrome in monochorionic twin pregnancy. Is there a role for nuchal translucency and ductus venosus blood flow evaluation at 11-14 weeks? *Twin Res* 2000;3(2):65-70. X-6
567. Mauldin J. Prenatal diagnosis and fetal therapy--what lies in future? *Indian J Pediatr* 2000;67(12): 899-905. X-6
568. Meslin EM. Of clones, stem cells, and children: issues and challenges in human research ethics. *J Womens Health Gend Based Med* 2000;9(8):831-841. X-1
569. Nicolini U, et al. A new approach to prenatal treatment of extralobar pulmonary sequestration. *Prenat Diagn* 2000;20(9):758-760. X-5
570. Okie S. Over the tiniest patients, big ethical questions: fetal surgery's growing reach raises issues of need and risks. *Washington Post* 2000;A1, A16. X-1
571. Olutoye OO, et al. Prenatal diagnosis and management of congenital lobar emphysema. *J Pediatr Surg* 2000;35(5):792-795. X-6
572. Poutamo J, et al. Diagnosing fetal urinary tract abnormalities: benefits of MRI compared to ultrasonography. *Acta Obstet Gynecol Scand* 2000;79(1):65-71. X-6
573. Quintero RA, et al. Fetal hydrolaparoscopy and endoscopic cystotomy in complicated cases of lower urinary tract obstruction. *Am J Obstet Gynecol* 2000;183(2):324-330; discussion 330-333. X-5
574. Quintero RA, et al. Minimally invasive intraluminal tracheal occlusion in a human fetus with left congenital diaphragmatic hernia at 27 weeks' gestation via direct fetal laryngoscopy. *Prenat Neonat Med* 2000;5:134-140. X-4
575. Quintero RA, et al. Successful in utero endoscopic ablation of posterior urethral valves: a new dimension in fetal urology. *Urology* 2000;55(5):774. X-5
576. Robinson JN, et al. Predictors of episiotomy use at first spontaneous vaginal delivery. *Obstet Gynecol* 2000;96(2):214-218. X-6
577. Sapin E, et al. Transabdominal amnioinfusion to avoid fetal demise and intestinal damage in fetuses with gastroschisis and severe oligohydramnios. *J Pediatr Surg* 2000;35(4):598-600. X-6
578. Schild RL, et al. Diagnosis of a fetal mesoblastic nephroma by 3D-ultrasound. *Ultrasound Obstet Gynecol* 2000;15(6):533-536. X-5, X-6

579. Schwarz RE, et al. A carcinoembryonic antigen-secreting adenocarcinoma arising within a retrorectal tailgut cyst: clinicopathological considerations. *Am J Gastroenterol* 2000;95(5):1344-1347. X-5
580. Simon EM, et al. Fast MR imaging of fetal CNS anomalies in utero. *AJNR Am J Neuroradiol* 2000;21(9):1688-1698. X-6
581. Sittig SE, Asay GF. Congenital cystic adenomatoid malformation in the newborn: two case studies and review of the literature. *Respir Care* 2000;45(10):1188-1195. X-6
582. Smith RP, et al. Pain and stress in the human fetus. *Eur J Obstet Gynecol Reprod Biol* 2000;92(1):161-165. X-1
583. Srinivasan S. Fetal echocardiography. *Indian J Pediatr* 2000;67(7):515-521. X-6
584. Stelnicki EJ, et al. Nerve dependency in scarless fetal wound healing. *Plast Reconstr Surg* 2000;105(1):140-147. X-3
585. Thorp JA, et al. Decompression of fetal cardiac tamponade caused by congenital capillary hemangioma of the pericardium. *Obstet Gynecol* 2000;96(5 Pt 2):816-817. X-5
586. van Gemert MJ, Umur A. Trends of discordant fetal growth in monochorionic twin pregnancies. *Phys Med Biol* 2000;45(8):N85-N93. X-6
587. Ward VM, Langford K, Morrison G. Prenatal diagnosis of airway compromise: EXIT (ex utero intra-partum treatment) and foetal airway surgery. *Int J Pediatr Otorhinolaryngol* 2000;53(2):137-141. X-6
588. Yasukochi S, Satomi G. Fetal diagnosis of common arterial trunk with interrupted aortic arch using color power Doppler angiography. *Cardiol Young* 2000;10(1):54-56. X-5
589. Austin JC, et al. Vesicoamniotic shunt in a female fetus with the prune belly syndrome. *J Urol* 2001;166(6):2382. X-5
590. Bartha JL, Comino-Delgado R. Fetal chylothorax response to maternal dietary treatment. *Obstet Gynecol* 2001;97(5 Pt 2):820-823. X-5, X-6
591. Bliton MJ, Zaner RM. Over the cutting edge: how ethics consultation illuminates the moral complexity of open-uterine fetal repair of spina bifida and patients' decision making. *J Clin Ethics* 2001;12(4):346-360. X-1
592. Carr SR, Plevyak MP. Contemporary evaluation and management of twin-twin transfusion syndrome. *Med Health R I* 2001;84(5):165-168. X-1
593. Cheatham JP. Intervention in the critically ill neonate and infant with hypoplastic left heart syndrome and intact atrial septum. *J Interv Cardiol* 2001;14(3):357-366. X-1, X-5
594. Coakley FV. Role of magnetic resonance imaging in fetal surgery. *Top Magn Reson Imaging* 2001;12(1):39-51. X-1, X-6
595. Cooper R, et al. Endoscopic documentation of unintentional perforation of the dividing membrane during amnioreduction for twin-twin transfusion syndrome. *Fetal Diagn Ther* 2001;16(2):101-104. X-5
596. Domanovic D, Završnik T, Vesel S. Autologous placental blood transfusion after a planned neonatal pacemaker implantation. *Transfus Med* 2001;11(6):459-461. X-5, X-6
597. Hamada H, et al. Successful treatment of primary fetal hydrothorax with hydrops by pleuroamniotic shunt placement. *Arch Gynecol Obstet* 2001;265(1):53-54. X-5

598. Han SJ, Hwang EH. The development of fetal surgery. *Yonsei Med J* 2001;42(6):602-608. X-1
599. Howe EG. Unicorns, Carravaggio, and fetal surgery. *J Clin Ethics* 2001;12(4):333-345. X-1
600. Izquierdo LA, et al. In utero demonstration of aberrant systemic blood supply in lung sequestration: a case report. *Bol Asoc Med P R* 2001 93(1-12):32-34. X-5
601. Jenkin G, et al. Physiological and regulatory roles of activin A in late pregnancy. *Mol Cell Endocrinol* 2001;180(1-2):131-138. X-6
602. Jolly M, et al. Interstitial laser: a new surgical technique for twin reversed arterial perfusion sequence in early pregnancy. *BJOG* 2001;108(10):1098-1102. X-6
603. Jouannic JM, et al. Successful intrauterine shunting of a sacrococcygeal teratoma (SCT) causing fetal bladder obstruction. *Prenat Diagn* 2001;21(10):824-826. X-5
604. Kamata S, et al. Operative management for sacrococcygeal teratoma diagnosed in utero. *J Pediatr Surg* 2001;36(4):545-548. X-6
605. Kashani AH, Hutchins GM. Meningeal-cutaneous relationships in anencephaly: evidence for a primary mesenchymal abnormality. *Hum Pathol* 2001;32(5):553-558. X-6
606. Kathary N, et al. MRI imaging of fetal neck masses with airway compromise: utility in delivery planning. *Pediatr Radiol* 2001;31(10):727-731. X-6
607. Kitano Y, et al. BAPS prize-1999: Lung growth induced by prenatal tracheal occlusion and its modifying factors: a study in the rat model of congenital diaphragmatic hernia. *J Pediatr Surg* 2001;36(2):251-259. X-3
608. Kohl T. Congenital heart disease. Mending the tiniest hearts. *Lancet* 2001;358(Suppl):S17. X-1
609. Levine D, et al. Progressive fetal bronchial obstruction caused by a bronchogenic cyst diagnosed using prenatal MR imaging. *AJR Am J Roentgenol* 2001;176(1):49-52. X-6
610. Lipitz S, et al. A comparative study of multifetal pregnancy reduction from triplets to twins in the first versus early second trimesters after detailed fetal screening. *Ultrasound Obstet Gynecol* 2001;18(1):35-38. X-6
611. Longaker MT, et al. Fetal wound healing: progress report and future directions. *Surgery* 2001;130(5):785-787. X-1
612. Loo CK, et al. Cytologic findings in a fetal intracranial teratoma. A case report. *Acta Cytol* 2001;45(2):227-232. X-5
613. Lu GC, et al. Lethal pulmonary hypoplasia after in-utero myelomeningocele repair. *Obstet Gynecol* 2001;98(4):698-701. X-5
614. Luks FI. Fetal surgery. *Med Health R I* 2001;84(5):169-170. X-1
615. Luks FI, et al. Preoperative planning with magnetic resonance imaging and computerized volume rendering in twin-to-twin transfusion syndrome. *Am J Obstet Gynecol* 2001;185(1):216-219. X-6
616. Lyerly AD, et al. Attitudes of maternal-fetal specialists concerning maternal-fetal surgery. *Am J Obstet Gynecol* 2001;185(5):1052-1058. X-6

617. Mavroudis C, Backer CL. Surgical management of severe truncal insufficiency: experience with truncal valve remodeling techniques. *Ann Thorac Surg* 2001;72(2):396-400. X-6
618. McBride ME, et al. Hypogammaglobulinemia complicating chylothorax after cardiac surgery in two infants. *J Cardiothorac Vasc Anesth* 2001;15(3):358-361. X-6
619. Midrio P, et al. EXIT procedure in a twin gestation and review of the literature. *Am J Perinatol* 2001;18(7):357-362. X-5, X-6
620. Murphy DJ, et al. Ex-utero intrapartum treatment for cervical teratoma. *BJOG* 2001;108(4):429-430. X-6
621. Park HW. Embryological background for fetal surgery. *Yonsei Med J* 2001;42(6):609-614. X-6
622. Pumberger W, Moroder W, Wiesbauer P. Intraabdominal extralobar pulmonary sequestration exhibiting cystic adenomatoid malformation: prenatal diagnosis and characterization of a left suprarenal mass in the newborn. *Abdom Imaging* 2001;26(1):28-31. X-5
623. Quintero RA, et al. Selective photocoagulation of communicating vessels in the treatment of monochorionic twins with selective growth retardation. *Am J Obstet Gynecol* 2001;185(3):689-696. X-6
624. Quintero RA, et al. In-utero treatment of fetal bladder-outlet obstruction by a ureterocele. *Lancet* 2001;357(9272):1947-1948. X-5
625. Rypens F, et al. Fetal lung volume: estimation at MR imaging-initial results. *Radiology* 2001;219(1):236-241. X-6
626. Sbragia L, et al. Outcome of prenatally diagnosed solid fetal tumors. *J Pediatr Surg* 2001;36(8):1244-1247. X-6
627. Siu BL, et al. Aneurysmal dilatation of the ductus arteriosus in a neonate. *Pediatr Cardiol* 2001;22(5):403-405. X-5
628. Tseng JJ, Chou MM, Ho ES. In utero sonographic diagnosis of a communicating enteric duplication cyst in a giant omphalocele. *Prenat Diagn* 2001;21(7):540-542. X-5
629. Turgut F, et al. In utero MR imaging and management of foetal hydrocephalus and NTDs in the third trimester. *J Neurosurg Sci* 2001;45(3):189-192. X-6
630. Umur A, van Gemert MJ, Ross MG. Fetal urine and amniotic fluid in monochorionic twins with twin-twin transfusion syndrome: simulations of therapy. *Am J Obstet Gynecol* 2001;185(4):996-1003. X-3
631. Van Overmeire B, et al. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. *Clin Pharmacol Ther* 2001;70(4):336-343. X-6
632. Wermenski K, et al. [Prenatal diagnosis of a brain tumour--an example of diagnostic and therapeutical algorithm]. *Med Wieku Rozwoj* 2001;5(1):59-64. X-5
633. Young BK, et al. Endoscopic ligation of umbilical cord at 19 week's gestation in monoamniotic monochorionic twins discordant for hypoplastic left heart syndrome. *Fetal Diagn Ther* 2001;16(1):61-64. X-5
634. Antonelli PJ, et al. Fetal central auditory system metabolic response to cochlear implant stimulation. *Otolaryngol Head Neck Surg* 2002;127(3):131-137. X-3, X-6

635. Avni FE, et al. MR imaging of fetal sacrococcygeal teratoma: diagnosis and assessment. *AJR Am J Roentgenol* 2002;178(1):179-183. X-6
636. Axt-Fliedner R, et al. Prenatal diagnosis of sacrococcygeal teratoma: a review of cases between 1993 and 2000. *Clin Exp Obstet Gynecol* 2002;29(1):15-18. X-6
637. Berge SJ, et al. Natural history of 70 fetuses with a prenatally diagnosed orofacial cleft. *Fetal Diagn Ther* 2002;17(4):247-251. X-6
638. Boltshauser E, et al. Vanishing cerebellum in myelomeningocele. *Eur J Paediatr Neurol* 2002;6(2):109-113. X-6
639. Bouchard S, et al. The EXIT procedure: experience and outcome in 31 cases. *J Pediatr Surg* 2002;37(3):418-426. X-6
640. Breyssem L, et al. Postnatal cranial ultrasonographic findings in fetofetal transfusion syndrome. *Eur Radiol* 2002;12(12):2926-2932. X-6
641. Cauldwell CB. Anesthesia for fetal surgery. *Anesthesiol Clin North America* 2002;20(1):211-226. X-1
642. Chan FY, et al. Limb constriction as a complication of intra-uterine vesico-amniotic shunt: fetoscopic release. *Fetal Diagn Ther* 2002;17(5):315-320. X-5
643. Chan KL, et al. Factors affecting outcomes of prenatally-diagnosed tumours. *Prenat Diagn* 2002;22(5):437-443. X-6
644. Chao AS, et al. Application of monopolar thermocoagulation in an acardiac fetus. *Prenat Diagn* 2002;22(6):499-500. X-6
645. Chen CP, et al. Sonographic findings in a case of congenital pyloric diaphragm. *Ultrasound Obstet Gynecol* 2002;19(5):528-529. X-6
646. Chervenak FA, McCullough LB. A comprehensive ethical framework for fetal research and its application to fetal surgery for spina bifida. *Am J Obstet Gynecol* 2002;187(1):10-14. X-1
647. Correia-Pinto J, et al. In utero meconium exposure increases spinal cord necrosis in a rat model of myelomeningocele. *J Pediatr Surg* 2002;37(3):488-492. X-3
648. Crombleholme TM, et al. Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. *J Pediatr Surg* 2002;37(3):331-338. X-6
649. De Paepe ME, et al. Demonstration of placental vascular anatomy in monozygotic twin gestations. *Pediatr Dev Pathol* 2002;5(1):37-44. X-3
650. Donofrio MT. Images in cardiovascular medicine. Premature closure of the foramen ovale and ductus arteriosus in a fetus with transposition of the great arteries. *Circulation* 2002;105(11):e65-e66. X-5
651. Eddleman KA, et al. Selective termination of anomalous fetuses in multifetal pregnancies: two hundred cases at a single center. *Am J Obstet Gynecol* 2002;187(5):1168-1172. X-6
652. Fesslova V, et al. Spectrum and outcome of atrioventricular septal defect in fetal life. *Cardiol Young* 2002;12(1):18-26. X-6
653. Frader JE. Surgical fetal interventions: innovation and research. *Account Res* 2002;9(3-4):193-198. X-1

654. Fundaro C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. *AIDS* 2002;16(2):299-300. X-5, X-6
655. Futagi Y, et al. Neurodevelopmental outcome in children with fetal hydrocephalus. *Pediatr Neurol* 2002;27(2):111-116. X-6
656. Gatti JM, Kirsch AJ, Massad CA. Antenatal intervention: jeopardizing life or limb? *Urology* 2002;60(4):697. X-5
657. Henrich W, et al. Prenatal sonographic findings of thalamic cavernous angioma. *Ultrasound Obstet Gynecol* 2002;19(5):518-522. X-5, X-6
658. Herndon CD, Casale AJ. Early second trimester intervention in a surviving infant with postnatally diagnosed urethral atresia. *J Urol* 2002;168(4 Pt 1):1532-1533. X-5
659. Howell LJ, et al. Management of fetal airway obstruction: an innovative strategy. *MCN Am J Matern Child Nurs* 2002;27(4):238-243. X-5
660. Hutson JM. 35th annual meeting of the pacific association of pediatric surgeons. *J Pediatr Surg* 2002;37(12):1775. X-1
661. Jesudason EC. Challenging embryological theories on congenital diaphragmatic hernia: future therapeutic implications for paediatric surgery. *Ann R Coll Surg Engl* 2002;84(4):252-259. X-3
662. Kazez A, et al. Sacrococcygeal heart: a very rare differentiation in teratoma. *Eur J Pediatr Surg* 2002;12(4):278-280. X-5, X-6
663. Lam YH, Tang MH, Shek TW. Thermocoagulation of fetal sacrococcygeal teratoma. *Prenat Diagn* 2002;22(2):99-101. X-5
664. Lenfant C. Report of the Task Force on Research in Pediatric Cardiovascular Disease. *Circulation* 2002;106(9):1037-1042. X-1
665. Leung EC, et al. Spinal lipoma misinterpreted as a meningomyelocele on antenatal MRI scan in a baby girl. *Childs Nerv Syst* 2002;18(6-7):361-363. X-5
666. Lurie S, Gur D, Glezerman M. Argon beam coagulation during caesarean section. *BJOG* 2002;109(12):1415. X-6
667. Machin GA. Rejoinder to meta-analysis of twin-twin transfusion by Skupski et al. *Twin Res* 2002;5(1):5-7. X-1
668. Midrio P, et al. Prenatal diagnosis of terminal myelocystocele in the fetal surgery era: case report. *Neurosurgery* 2002;50(5):1152-1154; discussion 1154-1155. X-5
669. Noah MM, et al. Short-term maternal outcomes that are associated with the EXIT procedure, as compared with cesarean delivery. *Am J Obstet Gynecol* 2002;186(4):773-777. X-6
670. Paek BW, et al. Successful fetal intervention for congenital high airway obstruction syndrome. *Fetal Diagn Ther* 2002;17(5):272-276. X-5
671. Pan HS, et al. Fetal meconium peritonitis in single and twin pregnancy. Two cases report. *Arch Gynecol Obstet* 2002;266(4):229-231. X-6
672. Petratos PB, et al. Ex vivo evaluation of human fetal membrane closure. *Lasers Surg Med* 2002;30(1):48-53. X-3, X-5, X-6
673. Quintero RA, et al. Fetoscopic demonstration of perimortem feto-fetal hemorrhage in twin-twin transfusion syndrome. *Ultrasound Obstet Gynecol* 2002;20(6):638-639. X-5

674. Quintero RA, et al. Operative fetoscopy via telesurgery. *Ultrasound Obstet Gynecol* 2002;20(4):390-391. X-5
675. Rakowski E. Who should pay for bad genes? *Calif Law Rev* 2002;90(5):1345-1414. X-1
676. Rintoul NE, et al. A new look at myelomeningoceles: functional level, vertebral level, shunting, and the implications for fetal intervention. *Pediatrics* 2002;109(3):409-413. X-6
677. Savulescu J. The embryonic stem cell lottery and the cannibalization of human beings. *Bioethics* 2002;16(6):508-529. X-1
678. Soothill P, et al. Ultrasound-guided, intra-abdominal laser to treat acardiac pregnancies. *BJOG* 2002;109(3):352-354. X-6
679. Suri V, et al. Pregnancy in a noncommunicating horn of a unicornuate uterus with fetal salvage. *Acta Obstet Gynecol Scand* 2002;81(5):473-474. X-5
680. Sydorak RM, et al. Prenatal resection of a fetal pericardial teratoma. *Fetal Diagn Ther* 2002;17(5):281-285. X-5
681. Tashjian DB, Konefal SH. Hypertrophic pyloric stenosis in utero. *Pediatr Surg Int* 2002;18(5-6):539-540. X-5, X-6
682. Tsao K, et al. Selective reduction of acardiac twin by radiofrequency ablation. *Am J Obstet Gynecol* 2002;187(3):635-640. X-6
683. Tseng D, Curran TJ, Silen ML. Minimally invasive management of the prenatally torsed ovarian cyst. *J Pediatr Surg* 2002;37(10):1467-1469. X-6
684. Williams HJ, Johnson KJ. Imaging of congenital cystic lung lesions. *Paediatr Respir Rev* 2002;3(2):120-127. X-1
685. Afolabi IR. Sacrococcygeal teratoma: a case report and a review of literature. *Pac Health Dialog* 2003;10(1):57-61. X-5, X-6
686. Apfel HD. Fetal intervention: Halacha's response to a new bioethical dilemma. *J Halacha Contemporary Society* 2003;(46):9-40. X-1
687. Arzt W, et al. Invasive intrauterine treatment of pulmonary atresia/intact ventricular septum with heart failure. *Ultrasound Obstet Gynecol* 2003;21(2):186-188. X-5
688. Beuls E, et al. The Arnold-Chiari type II malformation at midgestation. *Pediatr Neurosurg* 2003;39(3):149-158. X-5
689. Beuls EA, et al. In vitro high-field magnetic resonance imaging-documented anatomy of a fetal myelomeningocele at 20 weeks' gestation. A contribution to the rationale of intrauterine surgical repair of spina bifida. *J Neurosurg* 2003;98(2 Suppl):210-214. X-5
690. Bliton MJ. Ethics: "life before birth" and moral complexity in maternal-fetal surgery for spina bifida. *Clin Perinatol* 2003;30(3):449-464, v-vi. X-1
691. Bruner JP. In their footsteps: a brief history of maternal-fetal surgery. *Clin Perinatol* 2003;30(3):439-447. X-1
692. Budts W, Gewillig M, Van de Werf F. Left-to-right shunting in common congenital heart defects: which patients are eligible for percutaneous interventions? *Acta Cardiol* 2003;58(3):199-205. X-1
693. Cannon JW, et al. Real-time three-dimensional ultrasound for guiding surgical tasks. *Comput Aided Surg* 2003;8(2):82-90. X-1

694. Chan FY, et al. Fetal endoscopic telesurgery using an Internet Protocol connection: clinical and technical challenges. *J Telemed Telecare* 2003;9(Suppl 2):S12-S14. X-3
695. Chen CP, et al. Second-trimester evaluation of fetal sacrococcygeal teratoma using three-dimensional color Doppler ultrasound and magnetic resonance imaging. *Prenat Diagn* 2003;23(7):602-603. X-6
696. Chervenak FA, McCullough LB. An ethical framework for fetal research. *Med Ethics* 2003;10(1):1-2. X-1
697. Christensen G, et al. Embryonic and neonatal cardiac gene transfer in vivo. *Methods Mol Biol* 2003;219:169-178. X-3
698. Eckoldt F, et al. Meconium peritonitis and pseudo-cyst formation: prenatal diagnosis and post-natal course. *Prenat Diagn* 2003;23(11):904-908. X-6
699. Farmer DL, Hirose S. Fetal intervention for complications of monochorionic twinning. *World J Surg* 2003;27(1):103-107. X-1
700. Fesslova V, Villa L, Kustermann A. Long-term experience with the prenatal diagnosis of cardiac anomalies in high-risk pregnancies in a tertiary center. *Ital Heart J* 2003;4(12):855-864. X-6
701. Ford NM. Fetal surgery: the wisdom of Solomon. *Ethics Medics* 2003;28(8):3-4. X-1
702. Fujiki Y, et al. Successful multilineage engraftment of human cord blood cells in pigs after in utero transplantation. *Transplantation* 2003;75(7):916-922. X-3
703. Gallot D, Laurichesse H, Lemery D. Selective feticide in monochorionic twin pregnancies by ultrasound-guided umbilical cord occlusion. *Ultrasound Obstet Gynecol* 2003;22(5):484-488. X-6
704. George TM, Cummings TJ. The immunohistochemical profile of the myelomeningocele placode: is the placode normal? *Pediatr Neurosurg* 2003;39(5):234-239. X-3
705. Goodwin RP. Two craniotomy arguments don't make it. *J Med Philos* 2003;28(1):79-88. X-1
706. Graf JL, Albanese CT. Fetal sacrococcygeal teratoma. *World J Surg* 2003;27(1):84-86. X-1
707. Grebille AG, et al. Pericardial teratoma complicated by hydrops: successful fetal therapy by thoracoamniotic shunting. *Prenat Diagn* 2003;23(9):735-739. X-5
708. Groves A, Cameron H, Barrett M. Intra-abdominal lymphangioma: further images of prenatal diagnosis. *Ultrasound Obstet Gynecol* 2003;22(1):97-98. X-6
709. Harrison MR. Fetal surgery: trials, tribulations, and turf. *J Pediatr Surg* 2003;38(3):275-282. X-1
710. Hata N, et al. Three-dimensional volume rendering of fetal MR images for the diagnosis of congenital cystic adenomatoid malformation. *Acad Radiol* 2003;10(3):309-312. X-5, X-6
711. Hedrick HL. Ex utero intrapartum therapy. *Semin Pediatr Surg* 2003;12(3):190-195. X-6
712. Herini E, et al. Clinical features of infants with subependymal germinolysis and choroid plexus cysts. *Pediatr Int* 2003;45(6):692-696. X-6
713. Hirose S, Farmer DL. Fetal surgery for sacrococcygeal teratoma. *Clin Perinatol* 2003;30(3):493-506. X-1

714. Ho NK. Neonatology in Singapore: the way we were, the way forward. *Ann Acad Med Singapore* 2003;32(3):311-317. X-1
715. Ibrahim D, et al. Newborn with an open posterior hip dislocation and sciatic nerve injury after intrauterine radiofrequency ablation of a sacrococcygeal teratoma. *J Pediatr Surg* 2003;38(2):248-250. X-5
716. Kolas T, et al. Indications for cesarean deliveries in Norway. *Am J Obstet Gynecol* 2003;188(4):864-870. X-6
717. Lam H, Yates R, Jauniaux E. Successful early in utero management of fetal hydrothorax in a twin pregnancy. *Prenat Diagn* 2003;23(3):221-224. X-5
718. Lim FY, et al. Congenital high airway obstruction syndrome: natural history and management. *J Pediatr Surg* 2003;38(6):940-945. X-6
719. Lowenstein L, et al. In utero diagnosis of bladder perforation with urinary ascites. A case report. *Fetal Diagn Ther* 2003;18(3):179-182. X-5
720. Lysterly AD, Mahowald MB. Maternal-fetal surgery for treatment of myelomeningocele. *Clin Perinatol* 2003;30(1):155-165. X-1
721. Lyon HM, Holmes LB, Huang T. Multiple congenital anomalies associated with in utero exposure of phenytoin: possible hypoxic ischemic mechanism? *Birth Defects Res A Clin Mol Teratol* 2003;67(12):993-996. X-5
722. Markhardt BK, Farmer DL, Filly RA. Presumptive intrahepatic congenital cystic adenomatoid malformation. *J Ultrasound Med* 2003;22(5):531-536. X-5
723. Markov D, Jacquemyn Y, Leroy Y. Bilateral cleft lip and palate associated with increased nuchal translucency and maternal cocaine abuse at 14 weeks of gestation. *Clin Exp Obstet Gynecol* 2003;30(2-3):109-110. X-5, X-6
724. Michel-Behnke I, et al. Stenting of the ductus arteriosus and banding of the pulmonary arteries: basis for various surgical strategies in newborns with multiple left heart obstructive lesions. *Heart* 2003;89(6):645-650. X-6
725. Noia G, et al. A novel route of transplantation of human cord blood stem cells in preimmune fetal sheep: the intracelomic cavity. *Stem Cells* 2003;21(6):638-646. X-3, X-6
726. Oepkes D, et al. Congenital high airway obstruction syndrome successfully managed with ex-utero intrapartum treatment. *Ultrasound Obstet Gynecol* 2003;22(4):437-439. X-5, X-6
727. Oi S. Diagnosis, outcome, and management of fetal abnormalities: fetal hydrocephalus. *Childs Nerv Syst* 2003;19(7-8):508-516. X-6
728. Oi S. Current status of prenatal management of fetal spina bifida in the world: worldwide cooperative survey on the medico-ethical issue. *Childs Nerv Syst* 2003;19(7-8):596-599. X-1
729. Pierre-Kahn A, Sonigo P. Lumbosacral lipomas: in utero diagnosis and prognosis. *Childs Nerv Syst* 2003;19(7-8):551-554. X-6
730. Reitsma AM, Moreno JD. Maternal-fetal research and human research protections policy. *Clin Perinatol* 2003;30(1):141-153. X-1

731. Rosen MA, Andreae MH, Cameron AG. Nitroglycerin for fetal surgery: fetoscopy and ex utero intrapartum treatment procedure with malignant hyperthermia precautions. *Anesth Analg* 2003;96(3):698-700, table of contents. X-5, X-6
732. Salomon LJ, et al. Fetal thoracoamniotic shunting as the only treatment for pulmonary sequestration with hydrops: favorable long-term outcome without postnatal surgery. *Ultrasound Obstet Gynecol* 2003;21(3):299-301. X-5
733. Schmidt S, et al. Operative fetoscopic management of intrauterine obstructive uropathia by urethral stent. *J Perinat Med* 2003;31(4):313-316. X-5
734. Senat MV, et al. The value of middle cerebral artery peak systolic velocity in the diagnosis of fetal anemia after intrauterine death of one monochorionic twin. *Am J Obstet Gynecol* 2003;189(5):1320-1324. X-6
735. Sepulveda W, Corral E, Gutierrez J. A simple device for vascular occlusion of acardiac twins. *Ultrasound Obstet Gynecol* 2003;21(4):386-388. X-6
736. Sinha A, Sarin YK, Sengar, M., Magnetic Resonance Imaging (MRI) in the diagnosis of fetus-in-fetu. *Indian Pediatr* 2003;40(1):63-64. X-6
737. Sonigo-Cohen P, et al. Prenatal diagnosis of diastematomyelia. *Childs Nerv Syst* 2003;19(7-8):555-560. X-6
738. Soothill PW, Bartha JL, Tizard J. Ultrasound-guided laser treatment for fetal bladder outlet obstruction resulting from ureterocele. *Am J Obstet Gynecol* 2003;188(4):1107-1108. X-5
739. Stanley JD. Fetal surgery and wrongful death actions on behalf of the unborn: an argument for a social standard. *Vanderbilt Law Rev* 2003;56(5):1523-1555. X-1
740. Sutton LN, Adzick NS, Johnson MP. Fetal surgery for myelomeningocele. *Childs Nerv Syst* 2003;19(7-8):587-591. X-1
741. Valla JS, et al. Congenital seminal vesicle cyst: prenatal diagnosis and postnatal laparoscopic excision with an attempt to preserve fertility. *BJU Int* 2003;91(9):891-892. X-6
742. Weinstein AS, Goldstein RB, Barkovich AJ. In utero disappearance of the corpus callosum secondary to extensive brain injury. *J Ultrasound Med* 2003;22(8):837-840. X-6
743. Young AJ, et al. Engraftment of human cord blood-derived stem cells in preimmune ovine fetuses after ultrasound-guided in utero transplantation. *Am J Obstet Gynecol* 2003;189(3):698-701. X-3
744. Berge SJ, et al. Diagnosis and management of cervical teratomas. *Br J Oral Maxillofac Surg* 2004;42(1):41-45. X-6
745. Burdis L, Koch DD. The use of cardiopulmonary bypass and extracorporeal membrane oxygenation for support during removal of two teratomas and hydrops fetalis. *J Extra Corpor Technol* 2004;36(2):182-184. X-5
746. Carr SR, et al. Antenatal necrotic injury in severe twin-to-twin transfusion syndrome. A case and review. *Fetal Diagn Ther* 2004;19(4):370-372. X-5
747. Chen CP, et al. Second-trimester diagnosis of complete trisomy 9 associated with abnormal maternal serum screen results, open sacral spina bifida and congenital diaphragmatic hernia, and review of the literature. *Prenat Diagn* 2004;24(6):455-462. X-6

748. Fieni S, et al. Twin-twin transfusion syndrome: a review of treatment option. *Acta Biomed* 2004;75(Suppl 1):34-39. X-3
749. Fountain-Dommer RR, et al. Outcome following, and impact of, prenatal identification of the candidates for the Norwood procedure. *Cardiol Young* 2004;14(1):32-38. X-6
750. Hamrick SE, Brook MM, Farmer DL. Fetal surgery for congenital diaphragmatic hernia and pulmonary sequestration complicated by postnatal diagnosis of transposition of the great arteries. *Fetal Diagn Ther* 2004;19(1):40-42. X-5
751. Harrison MR. The University of California at San Francisco Fetal Treatment Center: a personal perspective. *Fetal Diagn Ther* 2004;19(6):513-524. X-1
752. Hirose S, et al. The ex utero intrapartum treatment procedure: Looking back at the EXIT. *J Pediatr Surg* 2004;39(3):375-380; discussion 375-380. X-6
753. Hofmann R, et al. Fetoscopic placement of a transurethral stent for intrauterine obstructive uropathy. *J Urol* 2004;171(1):384-386. X-5
754. Hsu YR, Lee SY. Prenatal diagnosis of congenital cystic adenomatoid malformation. *Chang Gung Med J* 2004;27(1):61-65. X-5, X-6
755. Huber A, et al. Amniotic fluid and maternal blood characteristics in severe mid-trimester twin-twin transfusion syndrome. *Fetal Diagn Ther* 2004;19(6):504-509. X-6
756. Iqbal N, Durrani Z. Management of sacrococcygeal teratoma of the fetus. *J Coll Physicians Surg Pak* 2004;14(8):506-507. X-5
757. Isaacs Jr H. Perinatal (fetal and neonatal) germ cell tumors. *J Pediatr Surg* 2004;39(7):1003-1013. X-6
758. Kanbur NO, et al. Diastematomyelia: a case with familial aggregation of neural tube defects. *ScientificWorld Journal* 2004;4:847-852. X-5
759. Keller TM, et al. MR assessment of fetal lung development using lung volumes and signal intensities. *Eur Radiol* 2004;14(6):984-989. X-6
760. Kuroda T, et al. Prenatal diagnosis and management of abdominal diseases in pediatric surgery. *J Pediatr Surg* 2004;39(12):1819-1822. X-6
761. Meyns B, et al. The Contegra conduit in the right ventricular outflow tract induces supralvalvular stenosis. *J Thorac Cardiovasc Surg* 2004;128(6):834-840. X-6
762. Miller TE, et al. Recurrent third-trimester fetal loss and maternal mosaicism for long-QT syndrome. *Circulation* 2004;109(24):3029-3034. X-5, X-6
763. Neubert S, et al. Sonographic prognostic factors in prenatal diagnosis of SCT. *Fetal Diagn Ther* 2004;19(4):319-326. X-6
764. Noia G, et al. The intracoelomic route: a new approach for in utero human cord blood stem cell transplantation. *Fetal Diagn Ther* 2004;19(1):13-22. X-3
765. Ogle BM, et al. Spontaneous fusion of cells between species yields transdifferentiation and retroviral transfer in vivo. *FASEB J* 2004;18(3):548-550. X-6
766. Okada T, et al. Postnatal management for prenatally diagnosed choledochal cysts. *J Pediatr Surg* 2004;39(7):1055-1058. X-6
767. Omeroglu S, et al. Intrauterine structure of foot muscles in talipes equinovarus due to high-level myelomeningocele: a light microscopic study in fetal cadavers. *J Pediatr Orthop B* 2004;13(4):263-267. X-6

768. Peek GJ, Elliott MJ. Fetal surgery for congenital diaphragmatic hernia. *Pediatrics* 2004;113(6):1810-1811. X-1
769. Picone O, et al. Thoracoamniotic shunting for fetal pleural effusions with hydrops. *Am J Obstet Gynecol* 2004;191(6):2047-2050. X-6
770. Pirovano S, et al. Mutations of the T-cell receptor constant region after in utero stem cell transplantation. *Immunogenetics* 2004;56(3):214-219. X-6
771. Porreco RP. Percutaneous ultrasonographically guided ablation of an acardiac twin. *Am J Obstet Gynecol* 2004;190(2):572-574. X-5
772. Preciado DA, et al. Intrapartum management of severe fetal airway obstruction. *J Otolaryngol* 2004;33(5):283-288. X-6
773. Rushford MP, et al. Prenatal sonographic detection of meckel diverticulum in utero with postnatal radiologic and surgical confirmation. *J Ultrasound Med* 2004;23(2):319-321. X-6
774. Saito N, et al. Successful endovascular repair of an aneurysm of the ductus diverticulum with a branched stent graft: case report and review of literature. *J Vasc Surg* 2004;40(6):1228-1233. X-5, X-6
775. Sentilhes L, et al. Favourable outcome of a tight constriction band secondary to amniotic band syndrome. *Prenat Diagn* 2004;24(3):198-201. X-5, X-6
776. Sepulveda W, et al. Intrafetal alcohol chemosclerosis of acardiac twins: a multicenter experience. *Fetal Diagn Ther* 2004;19(5):448-452. X-6
777. Sepulveda W, et al. Successful sonographically guided laser ablation of a large acardiac twin at 26 weeks' gestation. *J Ultrasound Med* 2004;23(12):1663-1666. X-5
778. Shevell T, et al. Radiofrequency ablation in a monochorionic twin discordant for fetal anomalies. *Am J Obstet Gynecol* 2004;190(2):575-576. X-5
779. Sival DA, et al. Neonatal loss of motor function in human spina bifida aperta. *Pediatrics* 2004;114(2):427-434. X-6
780. Sutton LN, Adzick NS, Fetal surgery for myelomeningocele. *Clin Neurosurg* 2004;51:155-62. X-1
781. Taylor MJ, Talbert D, Fisk NM. Pseudo-arterio-arterial anastomoses in twin-twin transfusion syndrome. *Placenta* 2004;25(8-9):742-747; discussion 748-752. X-3
782. Tworetzky W, Marshall AC. Fetal interventions for cardiac defects. *Pediatr Clin North Am* 2004;51(6):1503-1513, vii. X-1, X-5
783. Warner BW. What's new in pediatric surgery. *J Am Coll Surg* 2004;199(2):273-285. X-1
784. Wax JR, et al. Gravid uterus exteriorization at cesarean delivery for prenatally diagnosed placenta previa-accreta. *Am J Perinatol* 2004;21(6):311-313. X-6
785. Weisz B, et al. Tailored management of twin reversed arterial perfusion (TRAP) sequence. *Ultrasound Obstet Gynecol* 2004;23(5):451-455. X-6
786. Wright JD, et al. Prenatally diagnosed human caudal appendage: a case report. *J Reprod Med* 2004;49(7):566-568. X-5
787. Respecting women's rights and fetal value: reflections on the question of fetal anesthesia. *Conscience* 2005;26(3):39-40. X-1

788. Adama van Scheltema PN, et al. Biochemical composition of amniotic fluid in pregnancies complicated with twin-twin transfusion syndrome. *Fetal Diagn Ther* 2005;20(3):186-189. X-6
789. Al-Ojaimi EH. Successful intrauterine aspiration of a large fetal ovarian cyst. *Saudi Med J* 2005;26(2):308-310. X-5
790. Asabe K, Oka Y, Shirakusa T. Fetal case of congenital cystic adenomatoid malformation of the lung: fetal therapy and a review of the published reports in Japan. *Congenit Anom (Kyoto)* 2005;45(3):96-101. X-5
791. Berg C, et al. The syndrome of left isomerism: sonographic findings and outcome in prenatally diagnosed cases. *J Ultrasound Med* 2005;24(7):921-931. X-6
792. Bliton MJ. Parental hope confronting scientific uncertainty: a test of ethics in maternal-fetal surgery for spina bifida. *Clin Obstet Gynecol* 2005;48(3):595-607. X-6
793. Brumfield SS, Fausett MB, Fries MH. Intrauterine fetal resuscitation following complications of closed fetal surgery. *Fetal Diagn Ther* 2005;20(4):272-274. X-5
794. Celiker A, et al. Transcatheter closure of patent ductus arteriosus with Nit-Occlud coils. *Catheter Cardiovasc Interv* 2005;65(4):569-576. X-6
795. Chen CP, et al. Prenatal magnetic resonance imaging demonstration of the systemic feeding artery of a pulmonary sequestration associated with in utero regression. *Prenat Diagn* 2005;25(8):721-723. X-6
796. Chescheir NC, D'Alton M. Evidence-based medicine and fetal treatment: how to get involved. *Obstet Gynecol* 2005;106(3):610-613. X-1
797. Chescheir NC, Socol M. The National Institutes of Health Workshop on Fetal Treatment: needs assessment and future directions. *Obstet Gynecol* 2005;106(4):828-833. X-1
798. Chua JH, et al. Fetus-in-fetu in the pelvis: report of a case and literature review. *Ann Acad Med Singapore* 2005;34(10):646-649. X-5, X-6
799. Cohen-Overbeek TE, et al. Mild renal pyelectasis in the second trimester: determination of cut-off levels for postnatal referral. *Ultrasound Obstet Gynecol* 2005;25(4):378-383. X-6
800. Comparetto C, et al. Fetal and neonatal ovarian cysts: what's their real meaning? *Clin Exp Obstet Gynecol* 2005;32(2):123-125. X-6
801. Cortes RA, et al. Pre-emptive placement of a presealant for amniotic access. *Am J Obstet Gynecol* 2005;193(3 Pt 2):1197-1203. X-6
802. Cunat V, et al. Congenital diaphragmatic hernia associated with esophageal atresia, tracheoesophageal fistula, and truncus arteriosus in a premature newborn. *Pediatr Surg Int* 2005;21(8):684-686. X-5, X-6
803. del Rio M, et al. Successful selective termination at 17 weeks' gestation in monochorionic monoamniotic twin pregnancy affected by twin-twin transfusion syndrome and discordant for hypoplastic left heart syndrome. *Prenat Diagn* 2005;25(13):1223-1225. X-5
804. El Kady D, et al. Congenital cardiac left ventricular aneurysm with pericardial effusion: early prenatal diagnosis and intervention. *J Ultrasound Med* 2005;24(7):1011-1015. X-5, X-6

805. Eschertzhuber S, et al. Verifying correct endotracheal intubation by measurement of end-tidal carbon dioxide during an ex utero intrapartum treatment procedure. *Anesth Analg* 2005;101(3):658-660, table of contents. X-5, X-6
806. Ewert P. Challenges encountered during closure of patent ductus arteriosus. *Pediatr Cardiol* 2005;26(3):224-229. X-6
807. Fayn E, et al. Ultrasonic biophysical measurements in the normal human fetus for optimal design of the monolithic fetal pacemaker. *Am J Cardiol* 2005;95(10):1267-1270. X-6
808. Galili O, Mogilner J. Type IV sacrococcygeal teratoma causing urinary retention: a rare presentation. *J Pediatr Surg* 2005;40(2):E18-E20. X-5
809. Gardiner HM, et al. Images in cardiovascular medicine. Pericardiocentesis at 14 weeks: effective treatment of pericardial effusion complicating right ventricular diverticulum. *Circulation* 2005;112(9):e120. X-5
810. Gezer A, Simsek YO, Gani, H. Elective cesarean section for preterm intrauterine growth retarded fetuses. *Int J Gynaecol Obstet* 2005;88(2):138-139. X-6
811. Gonzalez-Abreu EE. Parental voices: For Angeline: A mother's reflection and emotional struggle with the loss of a typical child and how she stumbles into an unexpected world of special needs and the people who live there. *Clin Obstet Gynecol* 2005;48(3):518-526. X-1
812. Gonzalez-Abreu MM. Parental voices: You get what you get and you don't get upset: a child's answer to life's biggest challenges. *Clin Obstet Gynecol* 2005;48(3):527-533. X-1
813. Hedrick HL, et al. The ex utero intrapartum therapy procedure for high-risk fetal lung lesions. *J Pediatr Surg* 2005;40(6):1038-1043; discussion 1044. X-6
814. Huisman TA, et al. Magnetic resonance imaging of the fetoplacental unit after fetoscopic laser coagulation for twin-to-twin transfusion syndrome. *Acta Radiol* 2005;46(3):328-330. X-1
815. Illanes S, et al. Prenatal diagnosis of echogenic lung: evolution and outcome. *Ultrasound Obstet Gynecol* 2005;26(2):145-149. X-6
816. Jung E, et al. Successful outcome following prenatal intervention in a female fetus with bladder outlet obstruction. *Prenat Diagn* 2005;25(12):1107-1110. X-5
817. Kanamori Y, et al. A case of intrapericardial diaphragmatic hernia with a massive pericardial effusion: fetal diagnosis and therapy. *J Pediatr Surg* 2005;40(11):e43-e55. X-5
818. Kennedy D, Kennedy L. Parental voices: our journey of grace. *Clin Obstet Gynecol* 2005;48(3):534-539. X-1
819. Kim SK, et al. Successful vesicoamniotic shunting of posterior urethral valves in the first trimester of pregnancy. *Ultrasound Obstet Gynecol* 2005;26(6):666-668. X-5
820. Kim YT, et al. Treatment of congenital cystic adenomatoid malformation-does resection in the early postnatal period increase surgical risk? *Eur J Cardiothorac Surg* 2005;27(4):658-661. X-6
821. Kinnick V. Twin-to-twin transfusion syndrome. *AWHONN Lifelines* 2005;9(6):512, 509-511. X-1, X-5

822. Kohl T, et al. Fetal transesophageal echocardiography: clinical introduction as a monitoring tool during cardiac intervention in a human fetus. *Ultrasound Obstet Gynecol* 2005;26(7): 780-785. X-5
823. Kolditz DP, et al. Low-energy radiofrequency catheter ablation as therapy for supraventricular tachycardia in a premature neonate. *Eur J Pediatr* 2005;164(9):559-562. X-5
824. Leung WC, et al. Unexpected intrauterine death following resolution of hydrops fetalis after betamethasone treatment in a fetus with a large cystic adenomatoid malformation of the lung. *Ultrasound Obstet Gynecol* 2005;25(6):610-612. X-5
825. Leva E, et al. The role of the surgeon in the case of a giant neck mass in the EXIT procedure. *J Pediatr Surg* 2005;40(4):748-750. X-6
826. Lonjon M, et al. Prenatal diagnosis of a craniopharyngioma: a new case with radical surgery and review. *Childs Nerv Syst* 2005;21(3):177-180. X-5, X-6
827. Lyons A. Parental voices: One father's thoughts on fetal surgery. *Clin Obstet Gynecol* 2005;48(3):540-547. X-1
828. Matias A, Ramalho C, Montenegro N. Search for hemodynamic compromise at 11-14 weeks in monochorionic twin pregnancy: is abnormal flow in the ductus venosus predictive of twin-twin transfusion syndrome? *J Matern Fetal Neonatal Med* 2005;18(2):79-86. X-6
829. McAuliffe FM, et al. Cardiac diverticulum with pericardial effusion: report of two new cases treated by in-utero pericardiocentesis and a review of the literature. *Ultrasound Obstet Gynecol* 2005;25(4):401-404. X-6
830. McCullough LB, Coverdale JH, Chervenak FA. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. *Am J Obstet Gynecol* 2005;193(3 Pt 2):901-907. X-6
831. Merchant AM, et al. Management of fetal mediastinal teratoma. *J Pediatr Surg* 2005;40(1):228-231. X-5
832. Mittermayer C, et al. Prenatal magnetic resonance imaging as a useful adjunctive to ultrasound-enhanced diagnosis in case of a giant foetal tumour of the neck. *Ultraschall Med* 2005;26(1):46-50. X-6
833. Mohammadi S, et al. Surgery for right ventricle to pulmonary artery conduit obstruction: risk factors for further reoperation. *Eur J Cardiothorac Surg* 2005;28(2):217-222. X-6
834. Prefumo F, et al. Fetal congenital cardiac diverticulum with pericardial effusion: two cases with different presentations in the first trimester of pregnancy. *Ultrasound Obstet Gynecol* 2005;25(4):405-408. X-6
835. Quintero RA, et al. In utero cardiac fetal surgery: laser atrial septotomy in the treatment of hypoplastic left heart syndrome with intact atrial septum. *Am J Obstet Gynecol* 2005;193(4):1424-1428. X-5
836. Quintero RA, et al. Management of twin-twin transfusion syndrome in pregnancies with iatrogenic detachment of membranes following therapeutic amniocentesis and the role of interim amniopatch. *Ultrasound Obstet Gynecol* 2005;26(6):628-633. X-6

837. Rahbar R, et al. Fetal surgery in otolaryngology: a new era in the diagnosis and management of fetal airway obstruction because of advances in prenatal imaging. *Arch Otolaryngol Head Neck Surg* 2005;131(5):393-398. X-6
838. Ramdas A, Chopra R. FNAC diagnosis of a pre-sacral chordoma: a case report. *Indian J Pathol Microbiol* 2005;48(2):250-251. X-5
839. Rothschild BB, Estroff SE, Churchill LR. The cultural calculus of consent. *Clin Obstet Gynecol* 2005;48(3):574-594. X-1
840. Saitoh A, et al. Myelomeningocele in an infant with intrauterine exposure to efavirenz. *J Perinatol* 2005;25(8):555-556. X-5, X-6
841. Sikkil E, et al. Fetal cardiac contractility before and after intrauterine transfusion. *Ultrasound Obstet Gynecol* 2005;26(6):611-617. X-6
842. Stewart DL, Cook LN. Current management of congenital diaphragmatic hernia. *J Ky Med Assoc* 2005;103(2):47-53. X-6
843. Talabani H, et al. Fetal anal incontinence evaluated by amniotic fluid digestive enzyme assay in myelomeningocele spina bifida. *Pediatr Res* 2005;58(4):766-770. X-6
844. van den Wijngaard JP, et al. Simulation of therapy in a model of a nonhydropic and hydropic recipient in twin-twin transfusion syndrome. *Am J Obstet Gynecol* 2005;193(6):1972-1980. X-3
845. von Koch CS, et al. Myelomeningocele: characterization of a surgically induced sheep model and its central nervous system similarities and differences to the human disease. *Am J Obstet Gynecol* 2005;193(4):1456-1462. X-3
846. Wasant P, Sathienkijkanchai A. Neural tube defects at Siriraj Hospital, Bangkok, Thailand—10 years review (1990-1999). *J Med Assoc Thai* 2005;88(Suppl 8):S92-S99. X-6
847. Wilkins-Haug LE, et al. In-utero intervention for hypoplastic left heart syndrome—a perinatologist's perspective. *Ultrasound Obstet Gynecol* 2005;26(5):481-486. X-1
848. Williamson J, Williamson S. Parental voices: the positive impact of medical professionals. *Clin Obstet Gynecol* 2005;48(3):512-517. X-1
849. Young BK, et al. Combined sonographic and endoscopic umbilical cord occlusion in twin and triplet gestations. *J Perinat Med* 2005;33(6):530-533. X-6
850. Zaner RM. Parental voices: Randal Lewis Morris was born. *Clin Obstet Gynecol* 2005;48(3):548-561. X-1
851. Zeng F, et al. Identification and characterization of engrafted human cells in human/goat xenogeneic transplantation chimerism. *DNA Cell Biol* 2005;24(7):403-409. X-3, X-6
852. Zhang P, et al. Fetal laryngeal stenosis/atresia and congenital high airway obstructive syndrome (CHAOS): a case report. *J Perinatol* 2005;25(6):426-428. X-5, X-6
853. Ames WA, et al. Long-term use of the laryngeal mask airway in a neonate. *Anesth Analg* 2006;103(3):792. X-6
854. Ayzen M, et al. Monochorionic twin gestation complicated by a sacrococcygeal teratoma with hydrops--optimal timing of delivery allows for survival of the unaffected twin. *J Pediatr Surg* 2006;41(8):e11-e13. X-5
855. Bader R, et al. Fetal pericardial teratoma: presentation of two cases and review of literature. *Am J Perinatol* 2006;23(1):53-58. X-5

856. Barini R, et al. Abruptio placentae during fetal myelomeningocele repair. *Fetal Diagn Ther* 2006;21(1):115-117. X-5
857. Basu A, et al. Fetus in fetu or differentiated teratomas? *Indian J Pathol Microbiol* 2006;49(4):563-565. X-6
858. Brown JW, et al. Valved bovine jugular vein conduits for right ventricular outflow tract reconstruction in children: an attractive alternative to pulmonary homograft. *Ann Thorac Surg* 2006;82(3):909-916. X-6
859. Chan DF, et al. Ex utero intrapartum treatment (EXIT) for congenital giant ranula. *Acta Paediatr* 2006;95(10):1303-1305. X-6
860. Chu GM, et al. Ex-utero intrapartum treatment: a controlled approach to the management of anticipated airway problems in the newborn. *Hong Kong Med J* 2006;12(5):381-384. X-6
861. Colmant C, et al. Second-trimester diagnosis of mucopolysaccharidosis type IV a presenting as hydrops fetalis. *Prenat Diagn* 2006;26(8):750-752. X-6
862. Danzer E, et al. Diagnosis and characterization of fetal sacrococcygeal teratoma with prenatal MRI. *AJR Am J Roentgenol* 2006;187(4):W350-W356. X-6
863. Dogan OF, et al. Spontaneous regression of left upper lobe emphysema after division of large ductus arteriosus in an infant. *Turk J Pediatr* 2006;48(3):269-271. X-5, X-6
864. Fujimura J, et al. Management of a suprasellar arachnoid cyst identified using prenatal sonography. *J Clin Ultrasound* 2006;34(2):92-94. X-5, X-6
865. Galindo A, et al. Pulmonary balloon valvuloplasty in a fetus with critical pulmonary stenosis/atresia with intact ventricular septum and heart failure. *Fetal Diagn Ther* 2006;21(1):100-104. X-5
866. Ghazi L, et al. Rapid growth of a fetal sacrococcygeal teratoma in an HIV-infected woman: a case report. *J Reprod Med* 2006;51(5):431-434. X-5
867. Gohlke BC, et al. Cord blood leptin and IGF-I in relation to birth weight differences and head circumference in monozygotic twins. *J Pediatr Endocrinol Metab* 2006;19(1):3-9. X-6
868. Hayashi S, et al. Manifestation of mirror syndrome after fetoscopic laser photocoagulation in severe twin-twin transfusion syndrome. *Fetal Diagn Ther* 2006;21(1):51-54. X-5
869. Hecher K, et al. Twin reversed arterial perfusion: fetoscopic laser coagulation of placental anastomoses or the umbilical cord. *Ultrasound Obstet Gynecol* 2006;28(5):688-691. X-6
870. Hinds R, et al. Variable degree of liver involvement in siblings with PiZZ alpha-1-antitrypsin deficiency-related liver disease. *J Pediatr Gastroenterol Nutr* 2006;43(1):136-138. X-6
871. Ishii K, et al. An experience of laser surgery for feto-fetal transfusion syndrome complicated with unexpected feto-fetal hemorrhage in a case of monochorionic triamniotic triplets. *Fetal Diagn Ther* 2006;21(4):339-342. X-5
872. Kaczmarek I, et al. Complete autologous reconstruction of the aorta and the pulmonary bifurcation in truncus arteriosus communis. *Eur J Cardiothorac Surg* 2006;30(4):675-677. X-6

873. Kim N, Friedberg MK, Silverman NH. Diagnosis and prognosis of fetuses with double outlet right ventricle. *Prenat Diagn* 2006;26(8):740-745. X-6
874. Koh CJ, et al. Bladder and external urethral sphincter function after prenatal closure of myelomeningocele. *J Urol* 2006;176(5):2232-2236. X-6
875. Kohl T, et al. Fetoscopic and ultrasound-guided decompression of the fetal trachea in a human fetus with Fraser syndrome and congenital high airway obstruction syndrome (CHAOS) from laryngeal atresia. *Ultrasound Obstet Gynecol* 2006;27(1):84-88; discussion 88. X-5, X-6
876. Kohl T, et al. Analysis of the stepwise clinical introduction of experimental percutaneous fetoscopic surgical techniques for upcoming minimally invasive fetal cardiac interventions. *Surg Endosc* 2006;20(7):1134-1143. X-3
877. Kohl T, et al. Images in cardiovascular medicine. Intraamniotic fetal echocardiography: a new fetal cardiovascular monitoring approach during human fetoscopic surgery. *Circulation* 2006;114(21):e594-e596. X-5
878. Kuczkowski KM. Images in Anesthesia: Ex utero intrapartum treatment (EXIT procedure): fetal airway management. *Can J Anaesth* 2006;53(11):1117. X-6
879. Kwak DW, et al. Clinical experiences of fetal ovarian cyst: diagnosis and consequence. *J Korean Med Sci* 2006;21(4):690-694. X-6
880. Lewi L, et al. Diagnosis and management of heterokaryotypic monochorionic twins. *Am J Med Genet A* 2006;140(3):272-275. X-6
881. Liao H, et al. Fetus support manipulator with flexible balloon-based stabilizer for endoscopic intrauterine surgery. *Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv* 2006;9(Pt 1):412-419. X-3
882. Mair R, et al. En bloc rotation of the truncus arteriosus--an option for anatomic repair of transposition of the great arteries, ventricular septal defect, and left ventricular outflow tract obstruction. *J Thorac Cardiovasc Surg* 2006;131(3):740-741. X-6
883. Makikallio K, et al. Fetal aortic valve stenosis and the evolution of hypoplastic left heart syndrome: patient selection for fetal intervention. *Circulation* 2006;113(11):1401-1405. X-6
884. Martino F, et al. Teratomas of the neck and mediastinum in children. *Pediatr Surg Int* 2006;22(8):627-634. X-6
885. Ong SS, et al. Laser ablation of foetal microcystic lung lesion: successful outcome and rationale for its use. *Fetal Diagn Ther* 2006;21(5):471-474. X-5
886. Ozcan T, et al. Use of middle cerebral artery peak systolic velocity and intrauterine transfusion for management of twin-twin transfusion and single fetal intrauterine demise. *J Matern Fetal Neonatal Med* 2006;19(12):807-809. X-5
887. Paladini D, et al. Diagnosis, characterization and outcome of congenitally corrected transposition of the great arteries in the fetus: a multicenter series of 30 cases. *Ultrasound Obstet Gynecol* 2006;27(3):281-285. X-6
888. Phaloprakarn C, Pott Bartsch EM, Harrison MR. Residual congenital cystic adenomatoid malformation and thoracic scar deformation after fetal surgery: a case report. *J Pediatr Surg* 2006;41(2):e11-e14. X-5

889. Pitkanen OM, et al. Borderline left ventricles in prenatally diagnosed atrioventricular septal defect or double outlet right ventricle: echocardiographic predictors of biventricular repair. *Am Heart J* 2006;152(1):163e1-163e7. X-6
890. Portmann-Lanz CB, et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. *Am J Obstet Gynecol* 2006;194(3):664-673. X-1
891. Poulou T, Fox R, Booth A. Unrecognised 180 degree torsion of a pregnant uterus. *J Obstet Gynaecol* 2006;26(1):70-71. X-6
892. Qureshi SA. Catheterization in neonates with pulmonary atresia with intact ventricular septum. *Catheter Cardiovasc Interv* 2006;67(6):924-931. X-6
893. Rashid N, et al. Effects of prostacyclin and milrinone on pulmonary hemodynamics in newborn lambs with persistent pulmonary hypertension induced by ductal ligation. *Pediatr Res* 2006;60(5):624-629. X-3, X-6
894. Ronderos-Dumit D, et al. Endoscopic release of limb constriction rings in utero. *Fetal Diagn Ther* 2006;21(3):255-258. X-5
895. Rosenberg E, Sheiner E, Holcberg G. Neurofibromatosis type 1 and masses of the appendix: a case report. *J Reprod Med* 2006;51(7):578-580. X-5
896. Scarlett MD, Tha MW. Russell-Silver syndrome: anaesthetic implications and management. *West Indian Med J* 2006;55(2):127-129. X-5, X-6
897. Singh AS, et al. Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. *Oncol Rep* 2006;15(3):519-524. X-3
898. Sy ED, et al. Spontaneous rupture of fetal sacrococcygeal teratoma. *Fetal Diagn Ther* 2006;21(5):424-427. X-5
899. Tjoa ML, et al. Circulating cell-free fetal messenger RNA levels after fetoscopic interventions of complicated pregnancies. *Am J Obstet Gynecol* 2006;195(1):230-235. X-6
900. Truitt AK, et al. Perinatal management of congenital cystic lung lesions in the age of minimally invasive surgery. *J Pediatr Surg* 2006;41(5):893-896. X-6
901. Viggiano MB, et al. Prenatal catheter placement for fetal cystic adenomatoid pulmonary malformation: a case report. *Fetal Diagn Ther* 2006;21(2):194-197. X-5
902. Williams C. Dilemmas in fetal medicine: premature application of technology or responding to women's choice? *Sociol Health Illn* 2006;28(1):1-20. X-1
903. Woodard TD, Yong S, Hotaling AJ. The Ex Utero Intrapartum Treatment (EXIT) procedure used for airway control in a newborn with cervical fetus in fetu: a rare case. *Int J Pediatr Otorhinolaryngol* 2006;70(11):1989-1994. X-5
904. Yamaguchi Y, et al. Spontaneous rupture of sacrococcygeal teratoma associated with acute fetal anemia. *Ultrasound Obstet Gynecol* 2006;28(5):720-722. X-5
905. York DG, Wolfe H, von Allmen D. Fetal abdomino-perineal lymphangioma: differential diagnosis and management. *Prenat Diagn* 2006;26(8):692-695. X-5
906. Ziaei S, et al. Effect of bacterial vaginosis on premature rupture of membranes and related complications in pregnant women with a gestational age of 37-42 weeks. *Gynecol Obstet Invest* 2006;61(3):135-138. X-6
907. Akinturk H, et al. Hybrid transcatheter-surgical palliation: basis for univentricular or biventricular repair: the Giessen experience. *Pediatr Cardiol* 2007;28(2):79-87. X-6

908. Anagnostopoulos PV, et al. Neonatal mitral and tricuspid valve repair for in utero papillary muscle rupture. *Ann Thorac Surg* 2007;83(4):1458-1462. X-6
909. Aslanabadi S, et al. A neonate with cleft palate and a fetal mass in the oral cavity: a rare case of an oral fetus-in-fetu. *Int J Pediatr Otorhinolaryngol* 2007;71(10):1617-1622. X-5, X-6
910. Baschat AA, Harman CR. Acute intrapartum twin-to-twin transfusion following successful fetoscopic laser ablation. *Am J Perinatol* 2007;24(4):203-205. X-5
911. Bataille D, et al. In utero urinary bladder rupture: a case report. *Acta Chir Belg* 2007;107(4):429-431. X-5, X-6
912. Boucherat O, et al. Surfactant maturation is not delayed in human fetuses with diaphragmatic hernia. *PLoS Med* 2007;4(7):e237. X-6
913. Chang YL, et al. Transient chorioamniotic membrane separation after fetoscope guide laser therapy for twin-twin transfusion syndrome: a case report. *Fetal Diagn Ther* 2007;22(3):180-182. X-5
914. Chow PC, et al. Management and outcome of antenatally diagnosed congenital cystic adenomatoid malformation of the lung. *Hong Kong Med J* 2007;13(1):31-39. X-6
915. Ciardelli V, et al. Endoscopic fetal surgery: in vitro thermic effect of electrosurgical units. *Prenat Diagn* 2007;27(2):170-173. X-3, X-5
916. Delsing B, et al. Risk of persistent pulmonary hypertension of the neonate in twin-to-twin transfusion syndrome. *Neonatology* 2007;92(2):134-138. X-6
917. Farrell JA. Fetal treatment center: history, infrastructure, and nursing perspective. *J Perinat Neonatal Nurs* 2007;21(1):11-19; quiz 20-21. X-1
918. Finamore PS, et al. Mirror syndrome associated with sacrococcygeal teratoma: a case report. *J Reprod Med* 2007;52(3):225-227. X-5
919. George RB, et al. Case series: Combined spinal epidural anesthesia for Cesarean delivery and ex utero intrapartum treatment procedure. *Can J Anaesth* 2007;54(3):218-222. X-6
920. Glatz JA, et al. Hypoplastic left heart syndrome with atrial level restriction in the era of prenatal diagnosis. *Ann Thorac Surg* 2007;84(5):1633-1638. X-6
921. Harmath A, et al. Congenital lung malformations in the second trimester: prenatal ultrasound diagnosis and pathologic findings. *J Clin Ultrasound* 2007;35(5):250-255. X-6
922. Hirayama Y, et al. Sacral parasite with histopathological features of an unequally conjoined twin. *Pediatr Surg Int* 2007;23(7):715-720. X-5, X-6
923. Isnard M, et al. Successful intrauterine therapy for congenital cystic adenomatoid malformation of the lung. A case report. *Fetal Diagn Ther* 2007;22(5):325-329. X-5
924. JP VDW, Ross MG, MJ VANG. Twin-twin transfusion syndrome modeling. *Ann N Y Acad Sci* 2007;1101:215-234. X-3
925. Kamphuis MM, et al. Secondary infertility as a late complication of vesico-amniotic shunt therapy. *Prenat Diagn* 2007;27(4):362-364. X-5
926. Kilby M, et al. PLUTO trial protocol: percutaneous shunting for lower urinary tract obstruction randomised controlled trial. *BJOG* 2007;114(7):904-905, e1-4. X-1

927. Kiziltan HT, et al. Repair of aortic coarctation and aneurysm of ductus arteriosus in the presence of right-sided arch and descending aorta. *J Card Surg* 2007;22(5):440-442. X-5, X-6
928. Kunisaki SM, et al. Ex utero intrapartum treatment with extracorporeal membrane oxygenation for severe congenital diaphragmatic hernia. *J Pediatr Surg* 2007;42(1):98-104; discussion 104-106. X-6
929. Kunisaki SM, et al. Large fetal congenital cystic adenomatoid malformations: growth trends and patient survival. *J Pediatr Surg* 2007;42(2):404-410. X-6
930. Kunisaki SM, et al. Ex utero intrapartum treatment with placement on extracorporeal membrane oxygenation for fetal thoracic masses. *J Pediatr Surg* 2007;42(2):420-425. X-6
931. Lang E, et al. Ex utero intrapartum treatment (EXIT) procedure and simultaneous excision of oral teratoma. *Ir Med J* 2007;100(10):632-633. X-5
932. Lee H, et al. Efficacy of radiofrequency ablation for twin-reversed arterial perfusion sequence. *Am J Obstet Gynecol* 2007;196(5):459e1-459e4. X-6
933. Livingston JC, et al. Intrafetal radiofrequency ablation for twin reversed arterial perfusion (TRAP): a single-center experience. *Am J Obstet Gynecol* 2007;197(4):399e1-399e3. X-6
934. Livingston JC, et al. Mirror syndrome: a novel approach to therapy with fetal peritoneal-amniotic shunt. *Obstet Gynecol* 2007;110(2 Pt 2):540-543. X-5
935. Lopriore E, et al. Assessment of fetofetal transfusion flow through placental arteriovenous anastomoses in a unique case of twin-to-twin transfusion syndrome. *Placenta* 2007;28(2-3):209-211. X-5
936. Majhi AK, et al. Fetus in fetu--a mystery in medicine. *ScientificWorldJournal* 2007;7:252-257. X-5, X-6
937. Marinoni E, et al. Intravaginal gemeprost and second-trimester pregnancy termination in the scarred uterus. *Int J Gynaecol Obstet* 2007;97(1):35-39. X-6
938. Matsui H, Gardiner H. Fetal intervention for cardiac disease: the cutting edge of perinatal care. *Semin Fetal Neonatal Med* 2007;12(6):482-489. X-1
939. Mota R, et al. Evolving indications for the EXIT procedure: the usefulness of combining ultrasound and fetal MRI. *Fetal Diagn Ther* 2007;22(2):107-111. X-6
940. Nezafati MH, Soltani G, Vedadian A. Video-assisted ductal closure with new modifications: minimally invasive, maximally effective, 1,300 cases. *Ann Thorac Surg* 2007;84(4):1343-1348. X-6
941. Oepkes D, et al. Successful ultrasound-guided laser treatment of fetal hydrops caused by pulmonary sequestration. *Ultrasound Obstet Gynecol* 2007;29(4):457-459. X-5
942. Okutomi T, Saito M, Kuczkowski KM. The use of potent inhalational agents for the ex-utero intrapartum treatment (exit) procedures: what concentrations? *Acta Anaesthesiol Belg* 2007;58(2):97-99. X-5
943. Pachydakis A, Belgaumkar PV, Patel R. Intra-partum transvaginal cranial decompression of intracranial teratoma. *J Obstet Gynaecol* 2007;27(1):85-86. X-5
944. Pedreira DA, et al. Validation of the ovine fetus as an experimental model for the human myelomeningocele defect. *Acta Cir Bras* 2007;22(3):168-173. X-3, X-6

945. Peranteau WH, et al. Effect of maternal betamethasone administration on prenatal congenital cystic adenomatoid malformation growth and fetal survival. *Fetal Diagn Ther* 2007;22(5):365-371. X-1
946. Peterson EC, et al. Epidural metastases from endodermal sinus tumor arising from benign sacral teratoma. Case report and review of the literature. *J Neurosurg* 2007;107(4 Suppl):303-306. X-5, X-6
947. Quintero R, et al. Fetal laryngoscopy and lung biopsy in a case of bilateral lethal congenital cystic adenomatoid malformation of the lung. *Fetal Pediatr Pathol* 2007;26(5-6):229-234. X-5
948. Rocha G, et al. Congenital cystic adenomatoid malformation of the lung—the experience of five medical centres. *Rev Port Pneumol* 2007;13(4):511-523. X-5
949. Rogers TN, et al. Solitary liver cysts in children: not always so simple. *J Pediatr Surg* 2007;42(2):333-339. X-6
950. Ruano R, et al. Percutaneous intrauterine laser ablation of the abnormal vessel in pulmonary sequestration with hydrops at 29 weeks' gestation. *J Ultrasound Med* 2007;26(9):1235-1241. X-5
951. Sanchez e Oliveira Rde C, et al. Biosynthetic cellulose induces the formation of a neoduramater following pre-natal correction of meningomyelocele in fetal sheep. *Acta Cir Bras* 2007;22(3):174-181. X-6
952. Santiago-Munoz PC, et al. Outcomes of pregnancies with fetal gastroschisis. *Obstet Gynecol* 2007;110(3):663-668. X-6
953. Santolaya-Forgas J, et al. A study to determine if human umbilical cord hematopoietic stem cells can survive in baboon extra-embryonic celomic fluid: a prerequisite for determining the feasibility of in-utero stem cell xeno-transplantation via celocentesis. *Fetal Diagn Ther* 2007;22(2):131-135. X-3
954. Sekarski N, et al. Right ventricular outflow tract reconstruction with the bovine jugular vein graft: 5 years' experience with 133 patients. *Ann Thorac Surg* 2007;84(2):599-605. X-6
955. Shimabukuro F, et al. A case of congenital high airway obstruction syndrome managed by ex utero intrapartum treatment: case report and review of the literature. *Am J Perinatol* 2007;24(3):197-201. X-6
956. Sierra J, et al. Right ventricular outflow tract reconstruction: what conduit to use? Homograft or Contegra? *Ann Thorac Surg* 2007;84(2):606-610; discussion 610-611. X-6
957. Sista AK, Filly RA. Paradoxical movement of abdominal contents: a real-time sonographic finding indicating a congenital diaphragmatic hernia. *J Ultrasound Med* 2007;26(11):1617-1619. X-6
958. Thoannes H, Visseaux H, Malinovsky JM. Labour analgesia and scabies. *Int J Obstet Anesth* 2007;16(3):293-294. X-6
959. van den Wijngaard JP, et al. Modeling severely discordant hematocrits and normal amniotic fluids after incomplete laser therapy in twin-to-twin transfusion syndrome. *Placenta* 2007;28(7):611-615. X-3
960. Ville Y. Twin-to-twin transfusion syndrome: time to forget the Quintero staging system? *Ultrasound Obstet Gynecol* 2007;30(7):924-927. X-1

961. Wataganara T, et al. Fetal neck myofibroma. *J Med Assoc Thai* 2007;90(2):376-380. X-5
962. Yamamoto M, et al. Intrathoracic pressure in congenital chylothorax: keystone for the rationale of thoracoamniotic shunting? *Fetal Diagn Ther* 2007;22(3):169-171. X-5
963. Yoshinaga T, et al. Neural stem cell transplantation in a model of fetal alcohol effects. *J Neural Transm Suppl* 2007(72):331-337. X-3
964. Zambelli H, et al. Successful developmental outcome in intrauterine myelomeningocele repair. *Childs Nerv Syst* 2007;23(1):123-126. X-5
965. Zambelli H, et al. Assessment of neurosurgical outcome in children prenatally diagnosed with myelomeningocele and development of a protocol for fetal surgery to prevent hydrocephalus. *Childs Nerv Syst* 2007;23(4):421-425. X-6
966. Akcurin G, et al. Giant aneurysm of the ductus arteriosus. *Anadolu Kardiyol Derg* 2008;8(4):E28-E29. X-1
967. Al-Anazi A, Al-Mejhim F, Al-Qahtani N. In utero ventriculo-amniotic shunt for hydrocephalus. *Childs Nerv Syst* 2008;24(2):193-195. X-4, X-5
968. Arbell D, et al. Prepartum sonographic demonstration of 'to-and-fro' motion in fetal intestinal obstruction: a novel sign for immediate postnatal surgery. *Ultrasound Obstet Gynecol* 2008;32(1):112-114. X-5
969. Baldassarre ME, et al. A case of fetal midgut volvulus and jejunal atresia: nutritional support and maintenance of mucosal function and integrity. *Immunopharmacol Immunotoxicol* 2008;30(3):601-608. X-5
970. Butera G, et al. Percutaneous treatment of ductal origin of the distal pulmonary artery in low-weight newborns. *J Invasive Cardiol* 2008;20(7):354, 356. X-6
971. Cabral AC, et al. Cardiofemoral index as an ultrasound marker of fetal anemia in isoimmunized pregnancy. *Int J Gynaecol Obstet* 2008;100(1):60-64. X-6
972. Calvaruso D, et al. Images in cardiovascular medicine: right ventricular outflow tract reconstruction with contegra bovine valved conduit. *Circulation* 2008;118(15):e519-e520. X-5
973. Chakraborty A, et al. Toward reducing shunt placement rates in patients with myelomeningocele. *J Neurosurg Pediatrics* 2008;1(5):361-365. X-6
974. Chang LC, Kuczkowski KM. The ex utero intrapartum treatment procedure: anesthetic considerations. *Arch Gynecol Obstet* 2008;277(1):83-85. X-5
975. Clifton MS, et al. Fetoscopic transuterine release of posterior urethral valves: a new technique. *Fetal Diagn Ther* 2008;23(2):89-94. X-5
976. Croti UA, et al. The use of decellularized homograft monocuspid in the treatment of truncus arteriosus by Barbero Marcial technique. *Rev Bras Cir Cardiovasc* 2008;23(2):290-291. X-5
977. Davis J, Fernando JJ. Successful management of prenatal hydrops fetalis in a mother with HIV. *Int J STD AIDS* 2008;19(4):281-282. X-5, X-6
978. Delahaye S, et al. Prenatal diagnosis of dumbbell neuroblastoma. *Ultrasound Obstet Gynecol* 2008;31(1):92-95. X-6
979. Encinas Hernandez JL, et al. Brain malformations in the sheep model of myelomeningocele are similar to those found in human disease: preliminary report. *Pediatr Surg Int* 2008;24(12):1335-1340. X-3, X-4

980. Fadler KM, Askin DF. Sacrococcygeal teratoma in the newborn: a case study of prenatal management and clinical intervention. *Neonatal Netw* 2008;27(3):185-191. X-5
981. Galantowicz M, et al. Hybrid approach for hypoplastic left heart syndrome: intermediate results after the learning curve. *Ann Thorac Surg* 2008;85(6):2063-2070; discussion 2070-2071. X-6
982. Gardiner HM. In-utero intervention for severe congenital heart disease. *Best Pract Res Clin Obstet Gynaecol* 2008;22(1):49-61. X-1, X-5
983. Gillham J, et al. An unusual complication of in utero pleuro-amniotic shunting for fetal pleural effusion. *Eur J Obstet Gynecol Reprod Biol* 2008;140(2):285-286. X-5
984. Grgic O, Radakovic B, Barisic D. Hyperreactio luteinalis could be a risk factor for development of HELLP syndrome: case report. *Fertil Steril* 2008;90(5):2008 e13-e16. X-5
985. Guillot PV, et al. Transplantation of human fetal mesenchymal stem cells improves glomerulopathy in a collagen type I alpha 2-deficient mouse. *J Pathol* 2008;214(5):627-636. X-3
986. Henaine R, et al. Fate of the truncal valve in truncus arteriosus. *Ann Thorac Surg* 2008;85(1):172-178. X-6
987. Hickey EJ, et al. Jugular venous valved conduit (Contegra) matches allograft performance in infant truncus arteriosus repair. *Eur J Cardiothorac Surg* 2008;33(5):890-898. X-6
988. Holcroft CJ, et al. Large fetal sacrococcygeal teratomas: could early delivery improve outcome? *Fetal Diagn Ther* 2008;24(1):55-60. X-6
989. Ibele A, Flake A, Shaaban A. Survival of a profoundly hydropic fetus with a sacrococcygeal teratoma delivered at 27 weeks of gestation for maternal mirror syndrome. *J Pediatr Surg* 2008;43(8):e17-e20. X-5
990. Ishii K, et al. Anemia in a recipient twin unrelated to twin anemia-polycythemia sequence subsequent to sequential selective laser photocoagulation of communicating vessels for twin-twin transfusion syndrome. *Prenat Diagn* 2008;28(3):262-263. X-5
991. Kim A, et al. A rare case of posterior urethral valve and pleural effusion in Down syndrome with successful intrauterine shunt. *Fetal Diagn Ther* 2008;24(4):372-375. X-4, X-5
992. Kuwashima S, et al. MR imaging appearance of laryngeal atresia (congenital high airway obstruction syndrome): unique course in a fetus. *Pediatr Radiol* 2008;38(3):344-347. X-5, X-6
993. Lewi L, et al. The outcome of monochorionic diamniotic twin gestations in the era of invasive fetal therapy: a prospective cohort study. *Am J Obstet Gynecol* 2008;199(5):514e1-514e8. X-6
994. Lewi L, et al. The role of ultrasound examination in the first trimester and at 16 weeks' gestation to predict fetal complications in monochorionic diamniotic twin pregnancies. *Am J Obstet Gynecol* 2008;199(5):493e1-493e7. X-6
995. Liao H, et al. Fetus-supporting flexible manipulator with balloon-type stabilizer for endoscopic intrauterine surgery. *Int J Med Robot* 2008;4(3):214-223. X-5

996. Lopriore E, et al. Fetoscopic laser treatment of twin-to-twin transfusion syndrome followed by severe twin anemia-polycythemia sequence with spontaneous resolution. *Am J Obstet Gynecol* 2008;198(2):e4-e7. X-5
997. Matsubara M, et al. Resolution of mirror syndrome after successful fetoscopic laser photocoagulation of communicating placental vessels in severe twin-twin transfusion syndrome. *Prenat Diagn* 2008;28(12):1167-1168. X-4
998. Morikawa M, et al. Ileal atresia after fetoscopic laser photocoagulation for twin-to-twin transfusion syndrome—a case report. *Prenat Diagn* 2008;28(11):1072-1074. X-4
999. Morota N, Ihara S. Postnatal ascent of the cerebellar tonsils in Chiari malformation Type II following surgical repair of myelomeningocele *J Neurosurg Pediatrics* 2008;2(3):188-193. X-6
1000. Nakata M, et al. Fetoscopic laser photocoagulation of placental communicating vessels for twin-reversed arterial perfusion sequence. *J Obstet Gynaecol Res* 2008;34(4 Pt 2):649-652. X-5
1001. Nejat F, Kazmi SS, Ardakani SB. Congenital brain tumors in a series of seven patients. *Pediatr Neurosurg* 2008;44(1):1-8. X-6
1002. Okada T, et al. Management and outcome in prenatally diagnosed sacrococcygeal teratomas. *Pediatr Int* 2008;50(4):576-580. X-5
1003. Okawa T, et al. Repeated paracentesis in a fetus with meconium peritonitis with massive ascites: a case report. *Fetal Diagn Ther* 2008;24(2):99-102. X-5
1004. Papadias A, et al. Comparison of prenatal and postnatal MRI findings in the evaluation of intrauterine CNS anomalies requiring postnatal neurosurgical treatment. *Childs Nerv Syst* 2008;24(2):185-192. X-5
1005. Park CS, et al. Lecompte operation: is it still a viable option for truncus arteriosus? *J Thorac Cardiovasc Surg* 2008;136(5):1384-1386, 1386e1-1386e2. X-6
1006. Park JS, et al. Intrauterine midgut volvulus without malrotation: diagnosis from the 'coffee bean sign'. *World J Gastroenterol* 2008;14(9):1456-1458. X-5, X-6
1007. Pedreira DA, et al. Gasless fetoscopy: a new approach to endoscopic closure of a lumbar skin defect in fetal sheep. *Fetal Diagn Ther* 2008;23(4):293-298. X-3
1008. Phi JH, et al. Congenital subependymal giant cell astrocytoma: clinical considerations and expression of radial glial cell markers in giant cells. *Childs Nerv Syst* 2008;24(12):1499-1503. X-4, X-5
1009. Pilla CB, et al. Hybrid management for hypoplastic left heart syndrome : an experience from Brazil. *Pediatr Cardiol* 2008;29(3):498-506. X-6
1010. Quintero RA, et al. In utero fetal oximetry via visible light spectroscopy in twin-twin transfusion syndrome. *Am J Obstet Gynecol* 2008;199(6):639e1-639e4. X-5
1011. Ramanah R. et al. The uterosacral complex: ligament or neurovascular pathway? Anatomical and histological study of fetuses and adults. *Int Urogynecol J Pelvic Floor Dysfunct* 2008;19(11):1565-1570. X-5
1012. Ramos E, Marlin AE, Gaskill SJ. Congenital dermoid tumor in a child at initial myelomeningocele closure: an etiological discussion. *J Neurosurg Pediatr* 2008;2(6):414-415. X-4

1013. Rizkalla HF, et al. Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy. *Int J Gynecol Pathol* 2008;27(1):74-78. X-6
1014. Robinson MB, Crombleholme TM, Kurth CD. Maternal pulmonary edema during fetoscopic surgery. *Anesth Analg* 2008;107(6):1978-1980. X-5
1015. Ruano R, et al. To shunt or not to shunt a pulmonary adenomatoid cystic malformation after 33 weeks of gestation: a case report. *Sao Paulo Med J* 2008;126(4):239-241. X-4
1016. Sago H, et al. Endoscopic fetal urethrotomy for anterior urethral valves: a preliminary report. *Fetal Diagn Ther* 2008;24(2):92-95. X-5
1017. Salomon LJ, et al. Emergency cerclage in cases of twin-to-twin transfusion syndrome with a short cervix at the time of surgery and relationship to perinatal outcome. *Prenat Diagn* 2008;28(13):1256-1261. X-5
1018. Santo S, et al. Prenatal ultrasonographic diagnosis of abdominal cystic lymphangioma: a case report. *J Matern Fetal Neonatal Med* 2008;21(8):565-566. X-5
1019. Saygili-Yilmaz ES, et al. Prenatal diagnosis of type I sacrococcygeal teratoma and its management. *Clin Exp Obstet Gynecol* 2008;35(2):153-155. X-5
1020. Shinebourne EA, Rigby ML, Carvalho, J.S., Pulmonary atresia with intact ventricular septum: from fetus to adult: congenital heart disease. *Heart* 2008;94(10):1350-1357. X-6
1021. Sival DA, et al. Spinal hemorrhages are associated with early neonatal motor function loss in human spina bifida aperta. *Early Hum Dev* 2008;84(7):423-431. X-6
1022. Sueters M, et al. Fetal cardiac output in monochorionic twins. *Ultrasound Obstet Gynecol* 2008;32(6):807-812. X-5
1023. Tofigh AM, et al. Fetus in fetu: report of a case and literature review. *Int J Surg* 2008;6(6):e94-e96. X-4
1024. Turgut M. Pediatric neurosurgical techniques in the 15th century. *J Clin Neurosci* 2008;15(10):1085-1090. X-1
1025. Turgut M. Surgical instruments utilized in foetal hydrocephalus to prevent the mother's death at the time of Serefeddin Sabuncuoglu (1385-1468 AD). *Childs Nerv Syst* 2008;24(7):783. X-4, X-5
1026. van Gemert MJ, et al. Simulated sequential laser therapy of twin-twin transfusion syndrome. *Placenta* 2008;29(7):609-613. X-3
1027. van Gemert MJ, et al. Arterio-venous flow between monochorionic twins determined during intra-uterine transfusion. *Phys Med Biol* 2008;53(7):N109-N117. X-6
1028. Vladareanu R. Progress in obstetrics or the road to the promised land. *J Med Life* 2008;1(1):55-59. X-1, X-4, X-5
1029. Vogler SA, et al. Closed gastroschisis: total parenteral nutrition-free survival with aggressive attempts at bowel preservation and intestinal adaptation. *J Pediatr Surg* 2008;43(6):1006-1010. X-6
1030. Wang Y, et al. Management of nuchal cord with multiple loops. *Obstet Gynecol* 2008;112(2 Pt 2):460-461. X-5
1031. Williams H. Gender, head size and disease: a hypothesis related to posterior fossa growth. *Med Hypotheses* 2008;70(6):1108-1111. X-1

1032. Wilson RD, Chitty LS. Anomalies of the fetal thorax and abdomen: diagnosis, management and outcome. *Prenat Diagn* 2008;28(7):567. X-1
1033. Woerner A, et al. Neonatological and pulmonological management of bilateral pulmonary sequestration in a neonate. *World J Pediatr* 2008;4(4):301-304. X-4
1034. Yamashita H, et al. Miniature bending manipulator for fetoscopic intrauterine laser therapy to treat twin-to-twin transfusion syndrome. *Surg Endosc* 2008;22(2):430-435. X-3
1035. Zampieri N, et al. Foetal and neonatal ovarian cysts: a 5-year experience. *Arch Gynecol Obstet* 2008;277(4):303-306. X-6
1036. Zani A, et al. Not all symptoms disappear after vascular ring division: a pathophysiological interpretation. *Pediatr Cardiol* 2008;29(3):676-678. X-5, X-6
1037. Zhou C, et al. Changes in atrial natriuretic peptide levels during cardiac bypass in the fetal goat. *Artif Organs* 2008;32(12):956-961. X-3, X-4, X-5
1038. Abi-Nader K, et al. Successful outcome after prenatal treatment of a cardiac diverticulum with massive pericardial effusion. *Fetal Diagn Ther* 2009;25(1):148-152. X-4, X-5
1039. Alkazaleh F, Saleem M., Badran E. Intrathoracic displacement of pleuroamniotic shunt after successful in utero treatment of fetal hydrops secondary to hydrothorax. Case report and review of the literature. *Fetal Diagn Ther* 2009;25(1):40-43. X-4, X-5
1040. Allegaert K, et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. *Am J Obstet Gynecol* 2009;200(2):170e1-170e7. X-5
1041. Alsaid B, et al. Coexistence of adrenergic and cholinergic nerves in the inferior hypogastric plexus: anatomical and immunohistochemical study with 3D reconstruction in human male fetus. *J Anat* 2009;214(5):645-654. X-5
1042. Arlikar JD, et al. Fetus in fetu: two case reports and review of literature. *Pediatr Surg Int* 2009;25(3):289-292. X-5
1043. Ballard HO, et al. An embolic complication in a donor twin with severe twin-twin transfusion syndrome after fetoscopic intervention. *J Perinatol* 2009;29(3):250-251. X-4
1044. Benirschke K. The monozygotic twinning process, the twin-twin transfusion syndrome and acardiac twins. *Placenta* 2009;30(11):923-928. X-1, X-3, X-4
1045. Butwick A, Aleshi P, Yamout I. Obstetric hemorrhage during an EXIT procedure for severe fetal airway obstruction. *Can J Anaesth* 2009;56(6):437-442. X-4, X-5
1046. Cavoretto P, et al. Early diagnosis, follow-up, and prenatal treatment of a case of TRAP sequence occurring in a dichorionic triamniotic triplet pregnancy. *J Clin Ultrasound* 2009;37(6):350-353. X-4, X-5
1047. Chelli Bouaziz M, et al. Extralobar pulmonary sequestration revealed by prenatal hydrothorax. *Tunis Med* 2009;87(10):712-715. X-4
1048. Clyman R, et al. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. *J Pediatr* 2009;154(6):873-876. X-5
1049. Danzer E, et al. In utero meconium passage in fetuses and newborns with myelomeningocele. *J Neurosurg Pediatr* 2009;3(2):141-146. X-5
1050. De Lia JE, et al. Placental laser surgery for severe previable fetofetal transfusion syndrome in triplet gestation. *Am J Perinatol* 2009;26(8):559-564. X-5

1051. Deprest JA, et al. Antenatal prediction of lung volume and in-utero treatment by fetal endoscopic tracheal occlusion in severe isolated congenital diaphragmatic hernia. *Semin Fetal Neonatal Med* 2009;14(1):8-13. X-1, X-3, X-4
1052. Deprest JA, et al. Current controversies in prenatal diagnosis 4: Should fetal surgery be done in all cases of severe diaphragmatic hernia? *Prenat Diagn* 2009;29(1):15-19. X-1, X-4
1053. Draper H, et al. Long-term functional results following resection of neonatal sacrococcygeal teratoma. *Pediatr Surg Int* 2009;25(3):243-246. X-5
1054. Ellwood D. As good as it gets in fetal therapy? *Aust N Z J Obstet Gynaecol* 2009;49(1):1. X-1
1055. Fenghua W, et al. Does intervention in utero preserve the obstructed kidneys of fetal lambs? A histological, cytological, and molecular study. *Pediatr Res* 2009;66(2):145-148. X-3, X-5
1056. Fichera A, et al. Severe brain damage from twin-twin transfusion syndrome treated with serial amnioreductions after 26 weeks: a case to reconsider the gestational age limits of laser therapy. *Fetal Diagn Ther* 2009;25(2):203-205. X-4
1057. Filipchuck D, Avdimiretz L. The ex utero intrapartum treatment (EXIT) procedure for fetal head and neck masses. *AORN J* 2009;90(5):661-672; quiz 673-676. X-4
1058. Fox CE, et al. Reversed twin-to-twin transfusion syndrome following successful laser therapy. *Fetal Diagn Ther* 2009;26(2):115-118. X-4
1059. Fox CE, et al. Maternal serum markers of placental damage in uncomplicated dichorionic and monochorionic pregnancies in comparison with monochorionic pregnancies complicated by severe twin-to-twin transfusion syndrome and the response to fetoscopic laser ablation. *Eur J Obstet Gynecol Reprod Biol* 2009;144(2):124-129. X-5
1060. Guida M, et al. Spinal dysraphism in an early missed abortion: embryofetoscopic diagnosis. *J Minim Invasive Gynecol* 2009;16(6):768-771. X-4, X-5
1061. Hache JJ, Emery SP, Vallejo MC. Bilateral fetal hydrothorax requiring intrauterine fetal thoracoamniotic shunts: anesthetic considerations and management. *ScientificWorldJournal* 2009;9:435-440. X-4, X-5
1062. Harada K, et al. ICG fluorescence endoscope for visualization of the placental vascular network. *Minim Invasive Ther Allied Technol* 2009;18(1):1-5. X-1, X-3, X-4
1063. Hartnick CJ, et al. Case records of the Massachusetts General Hospital. Case 7-2009. A pregnant woman with a large mass in the fetal oral cavity. *N Engl J Med* 2009;360(9):913-921. X-4, X-5
1064. Henry PY, et al. Extrauterine Intrapartum Treatment (EXIT) in bilateral primary fetal hydrothorax. *Indian J Pediatr* 2009;76(1):99-101. X-5
1065. Herway C, et al. Fetal intraperitoneal transfusion for iatrogenic twin anemia-polycythemia sequence after laser therapy. *Ultrasound Obstet Gynecol* 2009;33(5):592-594. X-4
1066. Hidaka N, et al. Prenatal diagnosis of trisomy 16 mosaicism manifested as pulmonary artery stenosis. *J Clin Ultrasound* 2009;37(2):107-111. X-4, X-5
1067. Jancelewicz T, Harrison MR. A history of fetal surgery. *Clin Perinatol* 2009;36(2):227-236, vii. X-1, X-3, X-4, X-5

1068. Jelin E, Jelin AC, Lee H. Sacrococcygeal teratoma with spinal canal invasion prenatally diagnosed. *J Pediatr Surg* 2009;44(4):E9-E11. X-1, X-4
1069. Jesudian V, Ravikumar R, Kumar RS. Isolation of the left subclavian artery-origin from the left pulmonary artery by way of ductus arteriosus: multidetector row computed tomographic angiographic imaging. *Pediatr Cardiol* 2009;30(4):549-550. X-4, X-5
1070. Jimenez JS, et al. Conservative management of retained trophoblastic tissue and placental polyp with diagnostic ambulatory hysteroscopy. *Eur J Obstet Gynecol Reprod Biol* 2009;145(1):89-92. X-4, X-5
1071. Joshi M, et al. Foetus in fetu with common bile duct injury: a case report and review of literature. *ANZ J Surg* 2009;79(9):651-652. X-4, X-5
1072. Kalu E, Richardson R. Retained foetal bones: an intrauterine cause of chronic pelvic pain. *Arch Gynecol Obstet* 2009;279(2):233-234. X-4, X-5
1073. Kohl T, et al. Is there a therapeutic role for fetoscopic surgery in the prenatal treatment of gastroschisis? A feasibility study in sheep. *Surg Endosc* 2009;23(7):1499-1505. X-3, X-4, X-5
1074. Kohl T, et al. Percutaneous fetoscopic laser decompression of congenital high airway obstruction syndrome (CHAOS) from laryngeal atresia via a single trocar—current technical constraints and potential solutions for future interventions. *Fetal Diagn Ther* 2009;25(1):67-71. X-4, X-5
1075. Koszutski T, et al. Babies with myelomeningocele in Poland: parents' attitudes on fetal surgery versus termination of pregnancy. *Childs Nerv Syst* 2009;25(2):207-210. X-1, X-4
1076. Kuehnl A, et al. Floating caval thrombus arising from the ovarian vein. *Ann Vasc Surg* 2009;23(5):688e7-688e9. X-4, X-5
1077. Lambretti S. Fetal surgery. *Radiol Technol* 2009;81(2):194-198. X-1
1078. Lee H. Fetal surgery is a multidisciplinary field that relies on the participation and expertise of a variety of clinicians and support staff. Preface. *Clin Perinatol* 2009;36(2):xv-xvi. X-1, X-2, X-3, X-4
1079. Leung TY, et al. Urgent cesarean delivery for fetal bradycardia. *Obstet Gynecol* 2009;114(5):1023-1028. X-5
1080. Liao H, et al. Fast image mapping of endoscopic image mosaics with three-dimensional ultrasound image for intrauterine fetal surgery. *Minim Invasive Ther Allied Technol* 2009;18(6):332-340. X-1, X-3, X-4
1081. Lopriore E, et al. Residual anastomoses in twin-to-twin transfusion syndrome treated with selective fetoscopic laser surgery: localization, size, and consequences. *Am J Obstet Gynecol* 2009;201(1):66e1-66e4. X-5
1082. Lopriore E, et al. Quantification of feto-fetal transfusion rate through a single placental arterio-venous anastomosis in a monochorionic twin pregnancy. *Placenta* 2009;30(3):223-225. X-4
1083. Mah VK, et al. Absolute vs relative improvements in congenital diaphragmatic hernia survival: what happened to "hidden mortality." *J Pediatr Surg* 2009;44(5):877-882. X-5
1084. McCann SM, Emery SP, Vallejo MC. Anesthetic management of a parturient with fetal sacrococcygeal teratoma and mirror syndrome complicated by elevated hCG and subsequent hyperthyroidism. *J Clin Anesth* 2009;21(7):521-524. X-4

1085. Moise Jr KJ, et al. Fetal intervention: providing reasonable access to quality care. *Obstet Gynecol* 2009;113(2 Pt 1):408-410. X-1
1086. Morris LM, Lim FY, Crombleholme TM. Ex utero intrapartum treatment procedure: a peripartum management strategy in particularly challenging cases. *J Pediatr* 2009;154(1):126-131 e3. X-5
1087. Morris LM, et al. Severe micrognathia: indications for EXIT-to-Airway. *Fetal Diagn Ther* 2009;26(3):162-166. X-5
1088. Mychaliska GB, et al. Giant pulmonary sequestration: the rare case requiring the EXIT procedure with resection and ECMO. *Fetal Diagn Ther* 2009;25(1):163-166. X-1, X-3, X-4, X-5
1089. Nagao Y, et al. Improved efficacy and safety of in utero cell transplantation in sheep using an ultrasound-guided method. *Cloning Stem Cells* 2009;11(2):281-285. X-3, X-4, X-5
1090. Odibo AO, et al. Selective laser photocoagulation versus serial amniodrainage for the treatment of twin-twin transfusion syndrome: a cost-effectiveness analysis. *J Perinatol* 2009;29(8):543-547. X-5
1091. O'Donoghue K, et al. Transfusional fetal complications after single intrauterine death in monochorionic multiple pregnancy are reduced but not prevented by vascular occlusion. *BJOG* 2009;116(6):804-812. X-5
1092. Parlakgumus HA, Tarim E, Ezer SS. Antenatal diagnosis of sacrococcygeal teratoma—two different case reports. *Ginekol Pol* 2009;80(6):445-448. X-4, X-5, NO FETAL INTERVENTION
1093. Puvanachandra N, Clifford L, Gaston H. Retinopathy of prematurity in twin-twin transfusion syndrome. *J Pediatr Ophthalmol Strabismus* 2009;46(4):226-227. X-4
1094. Ruano R, Duarte S, Zugaib M. Percutaneous laser ablation of sacrococcygeal teratoma in a hydropic fetus with severe heart failure—too late for a surgical procedure? *Fetal Diagn Ther* 2009;25(1):26-30. X-4
1095. Ruano R, et al. Four-dimensional ultrasonographic imaging of fetal lower urinary tract obstruction and guidance of percutaneous cystoscopy. *Ultrasound Obstet Gynecol* 2009;33(2):250-252. X-4, X-5
1096. Said S, et al. Prenatal diagnosis of massive fetal tongue teratoma followed by successful, ex-utero intra-partum treatment. *J Obstet Gynaecol* 2009;29(1):55-57. X-4, X-5
1097. Scott CK, et al. Ductal arteriosus aneurysm, right aortic arch, and isolated left subclavian artery in a neonate. *Congenit Heart Dis* 2009;4(3):187-189. X-4, X-5
1098. Seki T, et al. Blood flow measurement system for fetoscopic laser photocoagulation of chorionic plate anastomosing vessels (FLPC). *Minim Invasive Ther Allied Technol* 2009;18(6):350-355. X-3
1099. Simpson JM. Fetal cardiac interventions: worth it? *Heart* 2009;95(20):1653-1655. X-1
1100. Slodki M, et al. Fetal echocardiography before and after prenatal aspiration of a fetal ovarian cyst. *Ginekol Pol* 2009;80(8):629-631. X-4, X-5
1101. Slodki M, et al. Hydrothorax treated in utero and monitored by fetal echocardiography. *Ginekol Pol* 2009;80(5):386-389. X-1, X-4, X-5

1102. Soldado F, et al. Fetoscopic release of extremity amniotic bands with risk of amputation. *J Pediatr Orthop* 2009;29(3):290-293. X-3, X-4, X-5
1103. Soldado F, et al. Fetal surgery of extremity amniotic bands: an experimental model of in utero limb salvage in fetal lamb. *J Pediatr Orthop* 2009;29(1):98-102. X-3, X-4, X-5
1104. Steffensen TS, et al. Massive pericardial effusion treated with in utero pericardioamniotic shunt in a fetus with intrapericardial teratoma. *Fetal Pediatr Pathol* 2009;28(5):216-231. X-4, X-5
1105. Sumie M, et al. Two cases of reversal of twin-twin transfusion syndrome diagnosed by measuring hourly fetal urine production. *J Obstet Gynaecol Res* 2009;35(5):983-986. X-5
1106. Sy ED, et al. Prognostic role of tumor-head volume ratio in fetal sacrococcygeal teratoma. *Fetal Diagn Ther* 2009;26(2):75-80. X-5
1107. Tang PH, et al. Magnetic resonance imaging of the fetal central nervous system in Singapore. *Ann Acad Med Singapore* 2009;38(9):774-781. X-5
1108. Tchirikov M. Successful tracheal occlusion using ultrathin fetoscopic equipment combined with real-time three-dimensional ultrasound. *Eur Surg Res* 2009;43(2):204-207. X-4, X-5
1109. Tsukimori K, et al. Ischemic ileal perforation in the donor of monochorionic twins complicated by twin-twin transfusion syndrome. *Fetal Diagn Ther* 2009;26(3):173-176. X-4
1110. Wagner N, et al. Prenatal diagnosis and management of a fetal intra-abdominal teratoma: a case report and review of the literature. *Fetal Diagn Ther* 2009;26(3):170-172. X-4, X-5
1111. Wataganara T, et al. Reverse twin-twin transfusion syndrome after fetoscopic laser photocoagulation of chorionic anastomoses: a case report. *Fetal Diagn Ther* 2009;26(2):111-114. X-4
1112. Wilson RD, et al. Sacrococcygeal teratomas: prenatal surveillance, growth and pregnancy outcome. *Fetal Diagn Ther* 2009;25(1):15-20. X-5
1113. Wilson RD, Johnson A, Ryan G. Current controversies in prenatal diagnosis 2: Should laser ablation of placental anastomoses be used in all cases of twin to twin transfusion? *Prenat Diagn* 2009;29(1):6-10. X-1, X-3, X-4
1114. Xu C, et al. Prenatal tetrandrine treatment can reverse the abnormal conditions in the lung of newborn with congenital diaphragmatic hernia. *Med Hypotheses* 2009;72(5):570-573. X-1, X-4
1115. Zachariah JP, et al. Right ventricle to pulmonary artery conduit augmentation compared with replacement in young children. *Ann Thorac Surg* 2009;88(2):574-580. X-5
1116. Zeidan S, et al. Intralobar sequestration associated with cystic adenomatoid malformation: diagnostic and thoracoscopic pitfalls. *Surg Endosc* 2009;23(8):1750-1753. X-5
1117. Zhang B, et al. Robotic patch-stabilizer using wire driven mechanism for minimally invasive fetal surgery. *Conf Proc IEEE Eng Med Biol Soc* 2009 2009;5076-5079. X-5
1118. Antinolo G, et al. Diagnosis and management of fetal intrapericardial Morgagni diaphragmatic hernia with massive pericardial effusion. *J Pediatr Surg* 2010;45(2):424-426. X-4, X-5

1119. Bawa M, Kannan NL. Even a single third trimester antenatal fetal screening for congenital anomalies can be life saving. *Indian J Pediatr* 2010;77(1):103-104. X-5
1120. Crisan LS, Kontopoulos EV, Quintero RA. Appraisal of the selectivity index in a cohort of patients treated with laser surgery for twin-twin transfusion syndrome. *Am J Obstet Gynecol* 2010;202(2):157 e1-157 e5. X-5
1121. Curran PF, et al. Prenatal steroids for microcystic congenital cystic adenomatoid malformations. *J Pediatr Surg* 2010;45(1):145-150. X-6
1122. Curran S, et al. Reflectance spectrometry for real-time hemoglobin determination of placental vessels during endoscopic laser surgery for twin-to-twin transfusion syndrome. *J Pediatr Surg* 2010;45(1):59-64. X-5
1123. Fagiana AM, et al. Management of a fetal intrapericardial teratoma: a case report and review of the literature. *Congenit Heart Dis* 2010;5(1):51-55. X-4, X-5
1124. Goldberg SP, et al. Surgical management of intrapericardial teratoma in the fetus. *J Pediatr* 2010;156(5):848-849, 849 e1. X-4, X-5
1125. Harrison MR. What if?... Why not? *J Pediatr Surg* 2010;45(1):1-10. X-1, X-3, X-4
1126. Kohl T, et al. Partial amniotic carbon dioxide insufflation (PACI) during minimally invasive fetoscopic surgery: early clinical experience in humans. *Surg Endosc* 2010;24(2):432-444. X-5
1127. Longaker MT. Regenerative medicine: a surgeon's perspective. *J Pediatr Surg* 2010;45(1):11-17; discussion 17-18. X-1, X-4, X-5
1128. Mittal S, et al. Supratentorial neurenteric cysts-A fascinating entity of uncertain embryopathogenesis. *Clin Neurol Neurosurg* 2010;112(2):89-97. X-1, X-4, X-5
1129. Ruano R, et al. Fetal cystoscopy for severe lower urinary tract obstruction—initial experience of a single center. *Prenat Diagn* 2010;30(1):30-39. X-5
1130. Van Mieghem T, et al. Amniotic fluid markers of fetal cardiac dysfunction in twin-to-twin transfusion syndrome. *Am J Obstet Gynecol* 2010;202(1):48 e1-48 e7. X-5
1131. Zhao YY, et al. Application of fetoscopy in the management of monochorionic multiple pregnancies. *Chin Med J (Engl)* 2010;123(1):105-107. X-1, X-4

Appendix D. Ongoing Research

Study Name & Country	Outcomes	Maternal Criteria	Fetal Criteria
<ul style="list-style-type: none"> • RCT of Fetoscopic Endoluminal Tracheal Occlusion with a Balloon vs Expectant Mgmt during Pregnancy in Fetuses with Left-sided CDH and Moderate Pulmonary Hypoplasia • Belgium 	<p>Primary:</p> <p>Occurrence of broncho-pulmonary dysplasia at 28 days of life</p> <p>Secondary:</p> <ul style="list-style-type: none"> • Survival at discharge, • Survival free of bronchopulmonary dysplasia at 28 days of life 	<ul style="list-style-type: none"> • Patients aged 18 years or more, and are able to consent ; • Singleton pregnancy • Accepting of randomization or to comply with return to FETO center <p>Exclusion:</p> <ul style="list-style-type: none"> • Maternal contraindication to fetoscopic surgery or severe medical condition in pregnancy; • Technical limitations precluding fetoscopic surgery, such as severe maternal obesity, uterine fibroids or potentially others, not anticipated at the time of writing this protocol; • Preterm labour, cervix shortened (<15 mm at randomization) or uterine anomaly strongly predisposing to preterm • Diaphragmatic hernia 	<ul style="list-style-type: none"> • Anatomically and chromosomally normal fetus; • Left sided diaphragmatic hernia; • Gestation at 32 wks plus 5 d ; • O/E LHR 25-34.9% ; • O/E LHR 35-44.9% (included) with intrathoracic liver herniation as determined by ultrasound or MRI

<ul style="list-style-type: none"> • Management of Myelomeningocele Study (MOMS) • US 	<p>Primary:</p> <ul style="list-style-type: none"> • Infant death, need for ventricular shunt by 1 year of life, • Bayley Scales of Infant Development MDI and functional-anatomical level of lesion at 30 months of age <p>Secondary:</p> <ul style="list-style-type: none"> • Chiari II malformation, • Neurodevelopmental status at 30 months • Ambulation status 30 months,neuro-muscular defects 30 months • Maternal psychological and reproductive functioning 30 months post-partum 	<p>Inclusion:</p> <ul style="list-style-type: none"> • US resident • able to travel to study site for study • Singleton pregnancy <p>Exclusion:</p> <ul style="list-style-type: none"> • Insulin-dependent pregestational diabetes • Short or incompetent cervix or cervical cerclage, • Placenta previa, • BMI of 35 or more, • previous spontaneous delivery prior to 37 weeks, • HIV+ • Hepatitis B+ • Hepatitis C+ • Uterine anomaly 	<p>Inclusion:</p> <ul style="list-style-type: none"> • Myelomeningocele lesion that starts no higher than T1 and no lower than S1 with hindbrain herniation present • Gestational age at randomization of 19 weeks 0 days to 25 weeks 6 days • Normal karyotype
<ul style="list-style-type: none"> • Effect of Fetal Ovarian Cyst Aspiration to Prevent Torsion • France 	<p>Primary:</p> <ul style="list-style-type: none"> • To avoid neonatal surgery <p>Secondary:</p> <ul style="list-style-type: none"> • U/S pattern of neonatal ovarian cyst • maternal and fetal/neonatal safety of prenatal ovarian cyst aspiration 	<ul style="list-style-type: none"> • Age 18-40 with singleton gestation 	<ul style="list-style-type: none"> • Anechoic ovarian cyst (diameter at least 30mm)

<ul style="list-style-type: none"> • Selective Fetoscopic Laser Photo-coagulation versus Amnioreduction Clinical Trial • US 	<p>Primary:</p> <ul style="list-style-type: none"> • Survival of donor twin at 30 days after birth and no treatment failure • Survival of recipient twin at 30 days after birth and no treatment failure <p>Secondary:</p> <ul style="list-style-type: none"> • Survival times of each twin in utero or after birth • Gestational age at delivery • Placental insufficiency • Cardiac outcome: echocardiographic evidence of cardiac compromise • Neurologic outcome: evidence of brain injury preceding birth by MRI • Postnatal comorbidity 	<p>Inclusion:</p> <ul style="list-style-type: none"> • 16+ years • Diagnosis of TTTS prior to 22wks • Randomized at 24 wks • Both twins are alive • Mono-di twin pregnancy <p>Exclusion:</p> <ul style="list-style-type: none"> • Contraindication to general surgery • General anesthesia • Uterine anomaly • History of preterm labor • Sonographic evidence of fetal CNS injury at time of entry • Associated structural abnormalities 	<ul style="list-style-type: none"> • Same sex with a thin intertwin membrane • Oligo in the donor twin (deepest vertical pocket of ≤ 2 cm) • Decompressed bladder in donor twin not seen to fill during US exam (state II, III, or IV) unless Doppler velocimetry changes and/or echo changes are already present • Polyhydramnios with deepest vertical pocket of >8 cm with or without Doppler or echocardiographic changes in the recipient twin (deepest vertical pocket of >6 if previous AR)
<ul style="list-style-type: none"> • Percutaneous Endoscopic Tracheal Plug/Unplug for CDH • US 	<p>Primary:</p> <ul style="list-style-type: none"> • Neonatal survival at 90 days of life <p>Secondary:</p> <ul style="list-style-type: none"> • Fetal lung growth due to successful fetal tracheal occlusion/unocclusion as determined by serial LHR measurements btw 26 and 34 wks gestation 	<p>Inclusion:</p> <ul style="list-style-type: none"> • 18+ • Meets psychosocial criteria • Pre-authorization from third-party pay or for fetal intervention or ability to self-pay <p>Exclusion:</p> <ul style="list-style-type: none"> • Preterm labor • Pre-eclampsia • Uterine anomaly • Unable/unwilling to stay in Providence, RI or San Francisco until removal of plug at 34 weeks 	<ul style="list-style-type: none"> • Normal fetal echocardiogram • Normal karyotype • Fetal liver herniated into left hemithorax • LHR 1.0 or less as calculated btw 24-26 week's gestation • Fetus is btw 26 and 28 weeks' gestation • Singleton pregnancy

<ul style="list-style-type: none"> • Selective IUGR with absent end-diastolic velocity in the umbilical artery in mono-di twin pregnancies: RCT of expectant mgmt versus laser therapy • US 		<p>Exclusion:</p> <ul style="list-style-type: none"> • Not able to make financial arrangements • Unwilling to be randomized • Unable/unwilling to be followed up 	<p>Inclusion:</p> <ul style="list-style-type: none"> • IUGR defined as sonographic estimated fetal weight at or below the 10th percentile for gestational age • Single placenta • Thin dividing membrane • same gender • Absent twin-peak sign • Gestational age of 16-24 weeks • Absent or reverse-end diastolic flow in the umbilical artery in the IUGR twin • Absent or reverse-end diastolic flow in the umbilical artery in the IUGR twin
			<p>Exclusion:</p> <ul style="list-style-type: none"> • Not able to make financial arrangements • Unwilling to be randomized • Unable/unwilling to be followed up • TTTS • Major congenital anomalies • Unbalanced chromosomal complement • Ruptured or detached membranes • Placental abruption • Chorioamnionitis • Triplets • Active labor • Placenta previa
<ul style="list-style-type: none"> • Effectiveness of Fetal Endotracheal Occlusion (FETO) in the Management of Severe Congenital Diaphragmatic Hernia • US 	<p>Neonatal survival rate after 90 days</p>	<p>Inclusion:</p> <ul style="list-style-type: none"> • Age 16-45 years • Healthy enough to have surgery • Must fully understand and accept the maternal and fetal risks involved • Pre-authorization from third-party payor for fetal intervention, or ability to self-pay. <p>Exclusion:</p> <ul style="list-style-type: none"> • Contraindication to abdominal surgery or general anesthesia • Allergy to latex • Preterm labor, preeclampsia, or uterine anomaly (e.g., large fibroid tumor) • Family unable or refuse to stay in Denver for the duration of the tracheal occlusion period and for the duration of the pregnancy as medically necessary. 	<p>Inclusion:</p> <ul style="list-style-type: none"> • Confirmed diagnosis of CDH • Normal fetal echocardiogram • Normal karyotype • Fetal liver herniated into the left hemithorax • Lung-head ratio (LHR) is 1.0 or less, calculated between 24-26 weeks gestation • Fetus is between 26 and 28 weeks gestation • Singleton pregnancy <p>Exclusion:</p> <ul style="list-style-type: none"> • Failure to meet all inclusion criteria • Other congenital anomalies detected on ultrasound

<ul style="list-style-type: none"> Randomized Clinical Trial in Order to Assess the Effect of Fetoscopic Tracheal Balloon Occlusion on the Postnatal Disease Course in Neonates With Left Congenital Diaphragmatic Hernia Germany 	Primary: <ul style="list-style-type: none"> Need for postnatal ECMO therapy in first 2 days of life 	Inclusion: <ul style="list-style-type: none"> Age 18-50 Resident of European country carrying fetus with left diaphragmatic hernia 	Inclusion: <ul style="list-style-type: none"> Normal karyotype, no further severe anomalies on prenatal ultrasound study Fetal liver herniation into the chest; gestational age-related lung volume between 20-25% of normal as determined by magnetic resonance imaging between 30+0 - 34+0 weeks+days of gestation
	Secondary: <ul style="list-style-type: none"> Survival to discharge Maternal morbidity Fetal / Neonatal morbidity Premature preterm rupture of membranes 	Exclusion: <ul style="list-style-type: none"> Any maternal disease or condition that would result in an increased risk to her health from the experimental procedure 	Exclusion: <ul style="list-style-type: none"> Abnormal fetal karyotype, further severe fetal anomalies on prenatal ultrasound
	<ul style="list-style-type: none"> Unintended preterm delivery Days in intensive care Days in hospital Oxygen dependency on discharge 		

Additional Studies

Study title & location:	Study Description:	Project Start:	Project End:
<ul style="list-style-type: none"> Mechanism of Vasopressin-Mediated Placental Vascular Resistance after Fetal Bypass US 	Investigation of vasopressin and cardiac fetal surgery; selective V1 vasopressin receptor antagonism prevents increased placental vascular resistance and improves fetal gas exchange with fetal cardiac surgery and bypass	1-Apr-2009	31-Mar-2011

Appendix E. Peer Reviewers

N. Scott Adzick, M.D.
Chief of Pediatric Surgery
Children's Hospital of Philadelphia

Frank A. Chervenak, M.D.
Professor and Chairman, Department of Obstetrics and Gynecology
Director of Maternal-Fetal Medicine
Weill Medical College of Cornell University

Robyn Horsager Boehrer, M.D.
Associate Professor
University of Texas Southwestern Medical Center

Anthony Johnson, D.O.
Associate Professor
Baylor College of Medicine

Hanmin Lee, M.D.
Associate Professor of Surgery
Director, Fetal Treatment Center
University of California, San Francisco

Francois I. Luks, M.D., Ph.D.
Professor of Surgery, Pediatrics, Obstetrics and Gynecology
Division of Pediatric Surgery
Brown University

Laurence B. McCullough, Ph.D.
Associate Director for Education
Center for Medical Ethics and Health Policy
Baylor College of Medicine

Rubén Quintero, M.D.
Professor and Director, Division of Maternal-Fetal Medicine
Department of Obstetrics and Gynecology
University of Miami-Jackson Memorial Hospital Fetal Therapy Center

Catherine Y Spong, M.D.
Branch Chief
Pregnancy and Perinatology Branch
National Institute of Child Health and Human Development

Appendix F. Maternal-Fetal Surgical Procedures: Background and Context

Overview

The purpose of the Maternal-Fetal Surgical Procedures report is to describe the current state of research and practice of maternal-fetal surgical procedures; the report does not offer guidance on whether or when such procedures are appropriate. Congenital abnormalities that can be repaired prenatally occur in a small percentage of full-term births, and because of advances in imaging techniques such as ultrasound, many more congenital abnormalities are being diagnosed in utero. As these abnormalities are more frequently recognized prior to delivery, maternal-fetal surgical procedures have emerged as a potential option for treating some of these defects. Substantial questions remain about both the safety and efficacy of fetal surgical corrections. In some cases, the natural history of the conditions is poorly understood, making comparisons to no treatment or postnatal intervention difficult.

In addition, comparisons of fetal versus postnatal surgery must consider the safety of the mother, yet limited comparative data exist. The issue is particularly complicated because while congenital defects are relatively common in aggregate, individual congenital abnormalities occur infrequently, making effective study very difficult. Ongoing trials are evaluating some of the most common fetal surgeries (Appendix D).

Therefore, there is substantial uncertainty about maternal-fetal surgical procedures for patients and their physicians in choosing a course of treatment as well as for stakeholders making coverage decisions. In order to reduce this uncertainty, it is helpful to describe the full scope of comparative outcome evidence for in utero procedures and conventional postnatal (neonatal) interventions. It is of particular importance to weigh benefits against harms of interventions because harms associated with fetal surgery vary with the level of invasiveness and pose risks to the health of the fetus and mother. Risks may include bleeding, infection, preterm labor, complications associated with anesthesia medications, prolonged hospitalization, and threatened maternal reproductive future. The overriding concern in any fetal operation must be maternal and fetal safety. Secondary goals include avoiding preterm labor and accomplishing the goals of the procedure for the fetus.

Maternal-fetal surgical procedures began with transfusions for hemolytic diseases in the 1960s,¹ but the field accelerated in the 1980s with advances in ultrasonography that allowed visualization of the fetus for surgical intervention—as well as earlier diagnosis of abnormalities.² In a 40-year time span, fetal procedures have moved from transfusion-focused work to open surgical repair of conditions such as obstructive uropathy, and is increasingly being done with minimally invasive approaches.³ Although postnatal intervention is best for most fetal abnormalities (particularly in light of risks associated with in utero surgeries), for a few conditions, the fetus's condition can deteriorate so rapidly in the womb as to make early intervention necessary to avoid either death or substantially higher morbidity after birth.

Open surgery on the fetus was first done in 1981 for obstructive uropathy by Dr. Michael Harrison at the University of California, San Francisco (UCSF),^{2,4} and endoscopic approaches have since evolved from largely diagnostic procedures to therapeutic modality over the last 30 years. Soon after the first open procedures, the International Fetal Medicine and Surgery Society (IFMSS) was founded to carefully support growth of the field through the sharing of data, a

registry of cases, and evolving principles for when fetal surgery should be considered. The IFMSS emphasized the need for research transparency through publishing in the peer-reviewed literature. In addition, this group established a set of principles recommended to guide fetal interventions:⁵

- The disorder should be significant
- The natural history (and postrepair development) should be known
- There is inadequate postnatal therapy
- Maternal risks are minor and acceptable
- An animal model exists for defect and procedure
- The defect is an isolated one for which there is a complete and accurate diagnosis
- There is superb parental counseling
- A multidisciplinary team is in agreement regarding the treatment plan
- Patients have access to high-level medical, bioethical, and psychosocial care

The field of maternal-fetal surgery has evolved tremendously. Some approaches are still in the experimental stage, while others have substantially more research or are being increasingly accepted as standard practice. The time is right to assess the status of surgical intervention on the fetus for those conditions most commonly treated in this way. Therefore, the goal of the brief is to describe the current state of literature and practice of maternal-fetal surgical procedures for several congenital abnormalities ranked of high importance by stakeholders:

- Sacrococcygeal teratoma
- Congenital diaphragmatic hernia
- Thoracic lesions: congenital cystic adenomatoid malformation and bronchopulmonary sequestration
- Obstructive uropathy
- Myelomeningocele
- Twin-twin transfusion syndrome
- Cardiac malformations

Key Questions Addressed in This Appendix

The key questions for this brief that are addressed in this appendix were as follows:

Key Question 1.

- a. What fetal diagnoses are currently treatable with a maternal-fetal surgical procedure? For each fetal diagnosis that is potentially treatable with a maternal-fetal surgical procedure, what is the annual number of fetuses that could potentially benefit from the procedure?
- b. What maternal-fetal surgical procedures are done in the United States? What is an estimate of the number of hospitals that perform each procedure and utilization of each procedure?
- c. For each fetal diagnosis, which procedures or techniques are used?
- d. For each maternal-fetal surgical procedure, what anesthesia is used? What are the potential harms to the fetus and mother from the anesthesia?
- e. For each fetal diagnosis, what are the alternatives? For each fetal diagnosis, what are the theoretical advantages and disadvantages (including potential safety issues and harms to

both the mother and fetus) of maternal-fetal surgical procedures relative to the alternatives?

- f. What training programs exist for maternal-fetal surgical procedures? What special requirements are needed in hospitals that perform fetal surgical procedures?

In addition, a systematic scan of the research literature is presented in the full report.

Overview of Methods

Search for Current Practice and Research Data

We searched the Internet extensively to identify locations in the United States offering maternal-fetal surgical procedures and verified identified sites with our key informants. Three primary Web sites contributed the bulk of the information: www.naftnet.org; www.fetalhope.org; and www.tttsfoundation.org. In addition, we searched Lexis Nexis and Proquest for lay articles on maternal-fetal surgical procedures that might point to locations from which we could gather additional practice information (final search 2/6/09). For these searches, we used the terms “fetal surgery” and “in utero surgery” as well as searched individually for each of the conditions being examined in this brief. For information on insurers’ practices, we selected a set of insurers and used the Internet to search for their online coverage policies. Once identified, they were catalogued in a database and printed out for filing with the date of access. To identify current research, we searched Clinicaltrials.gov (clinicaltrials.gov) and the National Institutes of Health Reporter databases (<http://projectreporter.nih.gov>), and we worked with experts to identify any additional research we might have missed.

Expert Discussions

We consulted with experts selected because of their expertise in the following areas: expertise in each of the conditions of interest, those who could offer historical perspective on maternal-fetal surgical procedures, and individuals who had a particular subspecialty expertise, such as ethics. These three expert panels included 17 individuals, with whom we held conversations via phone lasting from 20 to 45 minutes. The conversations were unstructured and intended to elicit context and background related in particular to current practice of maternal-fetal surgery.

Results Regarding Current Practices

Our description of the current practice of maternal-fetal surgical procedures is limited to the United States and is derived from a combination of approaches, including internet sources and key informant discussions.

Geographic distribution and structure of maternal-fetal centers. There is no system of accreditation or certification that would make identifying all practitioners of maternal-fetal surgical procedures straightforward. As with all emerging technologies, there is a tendency for excitement generated around their potential to precipitate their adoption into practice, sometimes in the absence of strong, comparative research, but with the hope of helping infants with poor prognoses. Certain surgical procedures are farther along in their evolution and therefore are

relatively more common than others, in particular, use of shunts for obstructive uropathy (OU) and laser ablation for twin-twin transfusion syndrome (TTTS).

We attempted to identify as many locations currently providing the maternal-fetal surgeries as possible in this brief (Table 1); however, that number and those locations are a rapidly evolving group, and therefore, these data may quickly become out of date. A starting point for identifying centers providing maternal-fetal therapy is the North American Fetal Therapy Network (NAFTnet) (www.naftnet.org). This network is a voluntary association of centers in the United States and Canada that perform advanced in utero techniques (including surgical ones). A similar network exists in Europe and is called Eurofoetus. These centers have agreed to work cooperatively to advance the practice of in utero therapies, including sharing data and providing educational resources for patients. A number of the centers conducting the highest volume of in utero surgical procedures are members of NAFTnet, with some notable exceptions. For example, the USFetus group performs a number of laparoscopic procedures in utero. In addition, we searched the internet and queried experts about who they knew to be using these surgical approaches. Through a combination of methods, we snowballed the list in Table 1. Of note, our goal was to identify centers that provide services to patients beyond experimental attempts and that therefore would be clinically available to U.S. patients. It should be noted that several key informants indicated concern that interventions for TTTS with laser, and for OU with shunting were proliferating perhaps too rapidly without oversight. However, we were unable to identify many sites claiming to offer in utero treatment for OU.

Table 1. Clinical centers offering maternal-fetal surgical procedures by condition and NAFTnet affiliation

Clinical affiliation	Affiliated hospital	NAFTnet Affiliate	Sacroccygeal teratoma	Congenital diaphragmatic hernia (CDH)	Thoracic lesions	Obstructive uropathy	Myelomeningocele (spina bifida)	Twin-twin transfusion syndrome (TTTS)	Cardiac malformations
Baltimore, MD University of MD Center for Advanced Fetal Care	University of Maryland Medical Center/University Hospital	√						√	
Boston, MA Brigham and Women's Hospital/Children's Hospital Advanced Fetal Care	Massachusetts General Hospital/Children's Hospital Boston	√	√	√	√	√		√	√
Chapel Hill, NC UNC Maternal Fetal Medicine	Rex Hospital	√						√	
Cincinnati, OH Fetal Care Center of Cincinnati	Cincinnati Children's Hospital/Good Samaritan Hospital/University Hospital	√	√	√	√	√		√	
Columbus, OH Ohio State University	Ohio State University Medical Center/Nationwide Children's Hospital	√				√		√	
Dallas, TX Southwestern Medical Center	UT Southwestern University Hospital/Parkland Memorial Hospital	√			√	√			
Detroit, MI* Wayne State University	Hutzel Women's Hospital	√							
Houston, TX Baylor: Texas Children's Fetal Center	Texas Children's Hospital/St. Luke's Episcopal Hospital	√	√	√	√	√		√	
Los Angeles, CA Institute for Maternal Fetal Health, University of Southern California	Hollywood Presbyterian Medical Center/Children's Hospital Los Angeles		√	√	√	√		√	√
Milwaukee, WI International Institute for Treatment of TTTS	Wheaton-Franciscan Healthcare/St. Joseph Regional Medical Center							√	
Miami, FL University of Miami	Jackson Memorial Hospital		√	√	√	√		√	√
Minneapolis, MN Minnesota Perinatal Physicians	Abbott Northwestern Hospital							√	

Table 1. Clinical centers offering maternal-fetal surgical procedures by condition and NAFTnet affiliation (continued)

Clinical affiliation	Affiliated hospital	NAFTnet Affiliate	Sacrocoxygeal teratoma	Congenital diaphragmatic hernia (CDH)	Thoracic lesions	Obstructive uropathy	Myelomeningocele (spina bifida)	Twin-twin transfusion syndrome (TTTS)	Cardiac malformations
Nashville, TN Junior League Center for Advanced Maternal-Fetal Care	Monroe Carell Jr. Children's Hospital/Vanderbilt University Medical Center	√			√	√			
New Haven, CT* Yale University Medical Center	Yale-New Haven Hospital	√							
New York, NY Columbia University Medical Center	New York Presbyterian Hospital/Sloane Hospital for Women	√				√			
Philadelphia, PA The Center for Fetal Diagnosis and Treatment	The Children's Hospital of Philadelphia	√	√	√	√	√	√	√	
Phoenix, AZ Phoenix Perinatal Associates	Arrowhead Hospital/Phoenix Children's Hospital	√						√	
Pittsburgh, PA* Magee-Women's Hospital of the University of Pittsburgh Medical Center	University of Pittsburgh Medical Center	√							
Providence, RI The Brown Fetal Treatment Program	Hasbro Children's Hospital/Women and Infants' Hospital of Rhode Island	√		√	√	√		√	
Salt Lake City, UT Maternal-Fetal Services of Utah	St. Mark's Hospital					√		√	
San Diego, CA UCSD Fetal Surgery Program	UCSD Medical Center							√	

Table 1. Clinical centers offering maternal-fetal surgical procedures by condition and NAFTnet affiliation (continued)

Clinical affiliation	Affiliated hospital	NAFTnet Affiliate	Sacroccygeal teratoma	Congenital diaphragmatic hernia (CDH)	Thoracic lesions	Obstructive uropathy	Myelomeningocele (spina bifida)	Twin-twin transfusion syndrome (TTTS)	Cardiac malformations
San Francisco, CA UCSF Fetal Treatment Center	UCSF Children's Hospital	√	√	√	√	√	√	√	
Seattle, WA Evergreen Healthcare	Evergreen Hospital/Eastside Maternal Fetal Medicine at Overlake Hospital Medical Center	√			√	√		√	

*information on procedures offered not publicly available

Models of care. Although a range of modes of care exist, inevitably, maternal-fetal procedures require a team of physicians and staff who are knowledgeable and experienced at working together. Programs may be led primarily either by pediatric surgeons or by obstetricians or may be a collaborative effort between the two specialties in which the obstetrician gains access to the uterus and/or fetus and the pediatric surgeon does the repair. Table 2 presents examples of selected models of care currently in practice; this taxonomy is adapted from Harrison.⁶ These examples are not exclusive or prescriptive; they are simply examples.

Table 2. Selected models of maternal-fetal surgical centers

Model	Description
Academic multidisciplinary	Academic multidisciplinary model with a large team reflecting expertise in perinatology, neonatology, pediatric surgical subspecialties, genetics, prenatal diagnosis, and anesthesia. Developed by pediatric surgeons and includes active participation of a large multidisciplinary conference and strong collaboration with basic sciences and animal research. Provides treatment for a range of conditions and may be led by a pediatric surgeon or maternal fetal medicine (MFM) specialist or both.
Export	Centralized care that travels to the patient; 2 physicians travel with fetoscopic equipment to other network hospitals to perform surgeries; may also train physicians and staff in those centers. In a system as large as Hospital Corporation of America (HCA), the need for availability of services, particularly for the more common conditions such as TTTS, is likely to increase. Rather than having many trained physicians at HCA hospitals, HCA opted to have a surgical team in one location that would go to the hospital where the patient was rather than having the patient come to them. Therefore, they export the program to other sites as needed. In addition, they have offered to participate in the establishment of centers at academic sites in several locations.
Perinatologist-led	MFM specialist alone or with other surgeons as needed (e.g., MFM specialist alone for laser ablation or with a neurosurgeon for myelomeningocele repair). Sometimes uses a “handoff” model where the obstetrician (OB) accesses the uterus, a different surgeon does the repair, and then the OB closes as per usual in cesarean section. In one example, the team includes 1 senior and 1 junior MFM specialist, and 1 senior and 1 junior pediatric surgeon. At least one of the senior physicians must be at each procedure.
Super specialist	An individual or group focuses on developing expertise in treating one condition in particular, or in using one approach. This can serve to centralize expertise.

Fetal surgery centers often also include the role of a “fetal board” or other conference that comprises a multidisciplinary group of individuals who meet regularly to discuss potential cases and review past cases. This approach has been described in the literature⁶⁻⁸ and can be helpful in protecting the surgical team, who may have perceived gain (e.g., opportunity for an exciting procedure, increase in knowledge and scientific discovery, prestige from developing new techniques) from being perceived as the sole decisionmaker or source of information about the procedure’s appropriateness. It is also an important opportunity to share experiences and to put in place mechanisms for tracking outcomes and processes both prospectively and retrospectively. This multidisciplinary approach has been evaluated⁸ and supported as an appropriate model.³

Training to conduct maternal-fetal surgical procedures. No licensing or accreditation group oversees maternal-fetal surgical procedures and credentialing. Indeed, it is difficult to determine what governing group would oversee the training of a subspecialty that includes individuals from diverse medical specialties. Given the learning curve associated with any of these surgical approaches, several experts expressed concern over the practice of traveling to Europe to attend a number of cases over what may be a short period of time (up to several weeks) as the extent of training.⁹ Absent traveling to Europe, there are two primary models of training in the United States: (1) in-house training in which experienced physicians invite other physicians to learn from them and (2) exported training in which experienced groups travel to other centers to train physicians and staff in their own environment and help them to establish the capacity for maternal-fetal surgical procedures.

The first approach (in-house) can either be established as a formal fellowship or as an “apprenticeship” that may serve as a precursor to having an individual physician join a given team. For example, as the site of the earliest open fetal surgeries, University of California San

Francisco (UCSF) has provided training for a number of physicians who have gone on to develop programs at other sites (e.g., Children’s Hospital of Philadelphia, Fetal Care Center of Cincinnati). Physicians at several sites reiterated their openness to having fellow physicians join them to learn surgical procedure.

Three sites currently offer a fellowship: CHOP, Baylor College of Medicine–Texas Children’s Fetal Center, and the Fetal Care Center of Cincinnati. To date, the fellowship at CHOP has produced three “certified fellows.” Cincinnati has had three fellows since 2006, and faculty at Baylor are training their first fellow. Therefore, opportunities to obtain formal fellowship training are exceedingly rare, and the potential need for expanding opportunities has now been raised in the literature.⁹ At both existing fellowships, significant emphasis is placed on the need to observe and understand cases, the selection of appropriate cases for intervention, and the counseling process for families. At CHOP, successful fellows are prepared to do laser ablation for TTTS or place shunts for OU; neither fellowship purports to produce “graduates” immediately prepared to conduct open fetal surgical procedures. CHOP is also home to the only NICHD-funded training grant (T32) in fetal biology and therapy, which provides strong integration of the clinical practice with research.

In the second model, established centers train physicians at other sites and/or help them to establish their program. Training may take place at the original center’s site or at the learning center’s site. For example, Cincinnati Children’s Hospital has agreements in place to offer training in laser coagulation at four sites to selected maternal-fetal specialists with extensive experience in prenatal diagnosis and treatment. These specialists have not yet had the opportunity to learn fetoscopic techniques and invest up to 2 years in training before taking on their own cases. The agreements include an understanding that individuals at the extant sites will come to Cincinnati for training, then faculty from Cincinnati will go to the extant sites to supervise, and finally, that early in their practice, the extant sites will only attempt the procedure on the simpler case in which the placenta is posterior.

A third training model has been proposed in which telemedicine could be used to train and supervise laser coagulation, even internationally,¹⁰⁻¹¹ but issues of insurance liability and other logistics continue to be clarified. Finally, both informants and the literature stress the importance of integrating animal research with practice, both for training and practice purposes. In addition to furthering knowledge and techniques in the field, animal research is a practical way to develop and maintain surgical skills, particularly in the case of low-volume conditions. Some maternal-fetal medicine sites, particularly at academic centers, have ongoing animal research integrated into their programs, and some use these facilities for surgical training. A number of the papers reviewed in the literature review also described development and practice of techniques in the animal lab, with an eye toward describing the numbers of cases necessary to achieve proficiency before moving to human study and practice.¹²⁻¹⁴

Access to clinical care and research. A particular issue garnering discussion is the question of whether maternal-fetal procedures should be regionalized in “centers of excellence.”⁹ Evidence is strong that surgical skill improves with volume; for example, estimates of the number of cases needed to achieve proficiency in laser coagulation in TTTS range from 50¹⁰ to 75,¹⁵ with 20¹⁵ per year suggested to maintain proficiency. Even with the most common conditions that are treatable in utero, the number of cases per year is likely to be low across the United States. Therefore, those cases centralized with surgical teams who would be most practiced, could theoretically

provide the best care.⁹ The two most common of the candidate conditions for in utero repair (TTTS and myelomeningocele) present interesting examples.

In the case of myelomeningocele, prenatal treatment is limited to the Management of Myelomeningocele (MOMS) trial, currently being conducted at three sites (UCSF, CHOP, and Vanderbilt Medical Center). Even with a national agreement not to provide surgical repair outside of the trial, obtaining adequate numbers has been challenging, suggesting that if the treatment were available in more sites, adequate numbers to develop or maintain proficiency would be very difficult to achieve. Enrollment in the trial may have been affected by a drop in the number of U.S. cases, potentially resulting from the introduction of folate supplementation as well as the limited number of centers participating in the study, which may make patients reluctant to participate given that patients randomized to in utero treatment are required to stay at the fetal center for the duration of their pregnancy (potentially 2-3 months).

In the case of TTTS, several experts expressed concern that in utero treatment, specifically laser ablation, was proliferating too rapidly and with little oversight related either to training or practice—a particular concern in light of the learning curve described above. However, empirical evidence to this effect does not exist, so this idea is opinion only. Concerns about the rapidly expanding volume rest on expert opinion and analogies to other surgical fields.

There seems to be some support for regionalization of care, but we did not identify specific suggestions as to how the regional centers might be designated beyond the selection by insurers of centers of excellence where they might require that their insured population seek care. The number of centers necessary depends by condition on the prevalence of cases that are appropriate for intervention and should be determined with consideration of the number of cases needed to develop and maintain surgical proficiency, or other considerations including neonatal intensive care unit (NICU) level and other resource availability. These are metrics that are only beginning to be addressed in the literature, and only for the more common conditions. Conversely, regionalization of care could inhibit access for patients unable to travel, either for medical, financial, or logistical reasons. It should be noted that traveling to obtain in utero therapy most often includes a necessary hotel stay as surgeons prefer that patients remain close by for some period after surgery, even up to delivery. The export model described above is an attempt to mitigate these issues and increase access while keeping services within one system.

The question of distribution of and access to maternal-fetal surgical procedures is integrally connected to payment systems, specifically whether a given technique is in the realm of nonfunded early innovation, funded research, or reimbursed medical care. Early innovation most often takes place in academic medical centers as one time attempts to intervene in a grim clinical prognosis—enthusiasm spreads as surgeons share their experience before a study is necessarily developed. Academic centers may have the means to support innovation; however, for a medical practice to become available to many people, research must be strong enough to demonstrate benefit. An example is that of open surgery to repair myelomeningocele, which was gaining popularity before adequate research was conducted when concerns were raised about high rates of morbidity. The National Institutes of Health is sponsoring a randomized controlled trial (RCT), and all U.S. centers have agreed to a moratorium in the U.S. as part of which the surgery is only offered in the context of the trial.

It is likely that a system of outcomes reporting is necessary in this field, both from the perspective of being able to identify centers providing excellent care, and for transparency about the learning curve in doing this type of procedure. Who might develop such a system or manage it was less clear, but one strong message was that whoever did so would by necessity come from

a multidisciplinary perspective, given the range of disciplines working in this field. In other words, it will not work for a professional organization specifically representing obstetricians or pediatric surgeons to lead development of a reporting structure; conversely, a starting point may be an affiliation such as NAFTnet or the International Fetal Medicine and Surgery Society (IFMSS).

Nonetheless, the most comprehensive way to identify access to care at this point is to understand what care is available clinically and what is available to patients as research protocols. It is impossible to catalog the current level of innovative practice occurring in its pre-research stage. Therefore, currently funded trials are described in Appendix D. Interestingly, in some of the research reviewed, the ability to pay or be covered by insurance was an explicit inclusion criteria. The potential costs associated with a pregnant woman's care following in utero procedures are extremely high and unpredictable. A tension exists between the need to continue to expand research and study of these procedures and the availability of research funding, particularly since research funding would be unlikely to cover unlimited or unanticipated medical costs associated with the procedure or recovery.

Ongoing research studies may also offer an opportunity for patients to access maternal-fetal treatment. Our key informants consistently stressed their concerns that all maternal-fetal surgical approaches should be evaluated in rigorous research, although they had differing opinions on what that might look like. Nonetheless, the field is characterized by a commitment to publishing in order to advance methodology and share new knowledge with colleagues. One concern that was raised both by key informants and in our literature search, however, is the dearth of information on harms reported in studies larger than single cases. In addition to the research listed in the table below, leaders in the field continue to innovate at their respective sites, including new device development and evaluation under FDA jurisdiction. Several key informants who discussed research efforts stressed the importance of clinical innovation taking place with the oversight of a data safety monitoring board, IRB and/or fetal or appropriate review board, even in the earliest stages. The ethical and consent issues associated with development of new surgical approaches and of spread of innovation were of significant interest to many of our key informants, who work hard to straddle a line of enthusiastic innovation and cautious realism about the potential for these interventions.

Ethics and Issues of Consent

Indeed, as soon as physicians began performing maternal-fetal operations in the early 1980s, ethicists started weighing in on the moral, legal, and social implications of prenatal interventions.¹⁶⁻¹⁸ Maternal-fetal approaches raise moral issues at the intersections of abortion debates, disability rights, and self-determination claims. Fetal interventions can be framed as providing an alternative to abortion when prenatal diagnosis reveals that a fetus has congenital abnormalities that would lead to severe morbidity.^{16,19} While in utero surgeries can prevent elective abortions of some fetuses, the ability to correct certain fetal conditions during pregnancy may consequently exacerbate negative views in society of developmental and physical disabilities because they can become viewed as problems that should have been fixed or prevented.²⁰⁻²¹ Moreover, the extent to which pregnant women have the right to refuse treatment that benefits their fetuses but exposes the women to risk has been called into question.²²⁻²⁵

Initially, in the 1980s the ethics literature focused predominantly on the ability of the legal system to force women to undergo fetal surgeries. While there were no reported cases of conflict that emerged from women refusing to consent to treatment, there was significant concern that

fetal approaches were ripe for litigation. Some commentators predicted the inevitability of compulsory surgery being issued from the courts,²⁶ and they proposed preemptive legislation to avoid the courts' involvement.²⁷ The pervasiveness of the ethical debate about the rights of women vis-à-vis the rights of the "not-yet-born child" was a product of the legal atmosphere of the 1980s.²⁸ Specifically, the courts had become involved in legitimizing physicians' control over the behavior of pregnant women as part of a broader movement to promote child welfare by diminishing parental authority.²⁹ Courts issued orders forcing pregnant women to undergo cesarean sections, to consume drugs, or submit to prenatal screening, and they prosecuted women for drug and alcohol use.³⁰⁻³¹

In large measure, the effect of these legal and ethical debates was to frame pregnant women and their fetuses in conflict,³² but there is no evidence that pregnant women understand their self-interest to be at odds with those of their fetuses.³³⁻³⁴ The conflict is more likely to arise between clinicians and pregnant women.³⁵ This can be due to care providers' perceptions that a pregnant woman is not appropriately willing to sacrifice her own interests for those of an "unborn child."³⁶ More likely, however, conflict occurs when physicians advise terminating the pregnancy in cases of fetal disability, but pregnant women desire to continue the pregnancy in spite of a grim prenatal diagnosis.³⁷ Religious beliefs and values often play into these decisions to continue the pregnancy and prompt the decision to undergo in utero procedures.³⁸⁻⁴⁰

Discussions about the conflicting rights of pregnant women and fetuses have subsided to some extent since the mid-1990s. In part, this shift could be attributed to the recognition that maternal-fetal approaches did not have the outstanding benefits to fetuses that ethicists had anticipated.⁴¹⁻⁴² Taking a more measured view of existing interventions, ethicists began discussing the need to more thoroughly evaluate the therapeutic potential of fetal surgical treatment through the development of registries and clinical studies.⁴³⁻⁴⁴ A major thrust to this viewpoint was that defining fetal interventions as "innovation" instead of "research" created a system of insufficient oversight,⁴⁵ particularly because innovation can be harmful and should be designed to minimize adverse outcomes.⁴⁶ In addition to traditional ethicists' involvement in these issues, social scientists began to take an active role in describing and analyzing practices that were actually occurring in fetal surgery centers.^{34,38,47-49} This approach to ethics has focused more attention on the informed consent process, including the social and cultural components to decisionmaking.³⁸

The ethics debates about maternal-fetal surgical procedures draw attention to the differing risks of the procedures to pregnant women and fetuses. In addition to the medical risks to fetuses, pregnant women are exposed to the risks of anesthesia and surgery during the procedure, drugs to prevent premature labor and delivery after the procedure, and the emotional burden of consenting to medical interventions with uncertain outcomes.³⁴ This means that the benefits of these surgeries always have to be considered within the context of the risks to both the pregnant woman and the fetus.

The practical implications of this are that informed consent procedures need to clearly explain all of the risks and benefits of the procedures and that benefits must be optimized through appropriate oversight of fetal interventions. For example, some ethicists have called for interdisciplinary teams to cooperate in the consent process by educating the pregnant woman (and her family) about her options, including but not limited to fetal interventions.⁶ In particular, some ethicists have stated that informed consent should be obtained only by a more neutral member of the care team rather than the surgeon.³⁸ Because not everyone seeking fetal treatment is an appropriate candidate, the informed consent process should educate self-referring

individuals so that their expectations about likely outcomes match current clinical realities. This view of consent underscores recent calls for more oversight of surgical innovations (both prospectively and retrospectively), more precise information about the benefits of fetal approaches in the context of the natural history of the diseases or disabilities being treated, and disclosure of information about the skill sets, experience, and success rates of medical teams performing each procedure. These measures would ensure that pregnant women (and their families) would have more robust information to use in their decisionmaking about fetal intervention.

Background Information on Conditions Included

Cardiac Malformations

Cardiac conditions for which in utero interventions are being performed are those in which there is a severe narrowing in one of the outflow tracts (aortic valve or pulmonary valve), causing progressive damage to the heart muscle in utero. There are three types of cardiac conditions for which in utero intervention is being performed: pulmonary atresia with intact ventricular septum (very narrow pulmonary valve without a connection between the right and left ventricles), critical aortic stenosis with impending hypoplastic left heart syndrome (very small, nonfunctional left ventricle, hypothesized by some investigators to be from underuse secondary to a severely narrow aortic valve), and hypoplastic left heart syndrome with intact atrial septum (no connection between the left and right atrium). All of these conditions, if untreated either in utero or soon after birth, are lethal.

Fetal surgery teams have proposed that in utero intervention can change the progression of the disease, allowing for more normal muscle to grow which can preserve function of both the ventricles in pulmonary atresia with intact ventricular septum and critical aortic stenosis with impending hypoplastic left heart syndrome (HLHS) and could obviate need for emergent atrial septostomy at birth for those patients with HLHS and intact atrial septum.

Critical pulmonary stenosis or atresia with intact ventricular septum. These anomalies portend a poor prognosis. A prospective prevalence study in Canada showed that overall survival was 77 percent at one month and 58 percent at 15 years. Only 33 percent ultimately end up with biventricular repair, 20 percent with Fontan repair, 20 percent with 1.5-ventricle repair, 5 percent with heart transplant, and 38 percent die before reaching definitive repair. Two percent of patients survived without definitive repair.⁵⁰ Fetal intervention to relieve the stenosis and allow for ventricular growth could theoretically increase the number of patients who ultimately end up with a biventricular repair. There is some debate as to whether this is an adequate measure of success since the right ventricle in a two-ventricle repair still has abnormal diastolic dysfunction and may not lead to increased exercise capacity.⁵¹ However, these studies were performed in patients who had not undergone in utero repair. It is possible that if the stenosis is relieved early enough in gestation, there may be adequate time before delivery for growth of the right ventricle. In fetuses with impending hydrops, in utero valvuloplasty could reverse the condition and prevent hydrops and death.

Critical aortic stenosis. Severe aortic stenosis, which is a very narrow aortic valve that develops early during gestation, may result in hypoplastic left heart syndrome. If the stenosis develops in the first trimester, the left ventricle may be tiny by the time a morphological ultrasound is

performed at around 20 weeks. However, if the stenosis develops closer to 20 weeks, the left ventricle may be hypertrophied or hypoplastic, but still visible. In utero aortic balloon valvuloplasty has been suggested as a way to relieve aortic stenosis, thus preserving left ventricular growth and halting progression to hypoplastic left heart syndrome.

The first described attempt at in utero balloon aortic valvuloplasty was reported by Maxwell in London in 1991. The same group reported the first survivor in a case report in 1995.⁵² Since then, there have been scattered attempts at this procedure around the world, but the most abundant work has been performed by the fetal surgery team at Children's Hospital Boston, Massachusetts.

Hypoplastic left heart syndrome and intact atrial septum. A subset of patients with hypoplastic left heart syndrome (HLHS) with an intact or highly restrictive atrial septum will present with severe cyanosis and require immediate postnatal intervention in order to survive. This accounts for approximately 5.7 percent to 11 percent of newborns with HLHS.⁵³⁻⁵⁴ CDC estimates that each year about 975 babies in the United States are born with HLHS.⁵⁵⁻⁵⁶ In other words, each year about 2 out of every 10,000 babies born will be born with HLHS. The approaches that have been used include an emergent stage I palliation, the Norwood procedure, which has a poor survival rate in this scenario (10–28 percent)^{54,57-58} or a neonatal catheter atrial septostomy. In Vlahos's study, patients requiring an urgent neonatal catheter septostomy to decompress the left atrium have a 21 percent mortality before stage I palliation compared to no mortality before a Norwood in patients with an unrestrictive atrial septal defect.⁵⁹

Given the high mortality of infants with HLHS and intact atrial septum, considered to be due to the pulmonary vasculopathy that develops before birth, in utero atrial septostomy has been performed in an attempt to improve postnatal survival. The first report of a balloon atrial septoplasty was in 2004. There is also a single case report using a laser to perform atrial septoplasty.⁶⁰ The balloon atrial septoplasty is performed percutaneously with access usually to the fetal right atrium after traversing the maternal abdominal wall, uterine wall, and fetal chest wall using an 18- or 19-gauge introducer cannula mounted on a metal obturator.⁵⁷ The introducer is advanced into the right atrium and the atrial septum is punctured by the tip of the introducer or with a 22-gauge Chiba needle. A wire is then introduced through the Chiba needle into the left atrium or a pulmonary vein and the needle is exchanged for a balloon angioplasty catheter. The balloon is fully inflated twice. In two cases teams approached the atrial septum from the left atrium. In two cases teams were unable to achieve technical success due to inability to reach the fetal left atrium.⁵⁴

Congenital Diaphragmatic Hernia

Congenital diaphragmatic hernia (CDH) results from abnormal development of the diaphragm, which allows abdominal organs such as the bowel, the stomach, and the liver to protrude into the chest cavity. CDH is an important, relatively common congenital malformation, with incidence in the United States of approximately 1 in every 2,500 births.⁶¹⁻⁶² Fetuses diagnosed in utero as a result of maternal symptoms have mortality risk approaching 75 percent in some older reviews. One of the paradoxes of diaphragmatic hernia care is a trend toward improved outcome of fetuses not diagnosed before birth. This may reflect the fact that less-severe lesions, without the findings of liver in the chest, stomach in the chest, or increased amniotic fluid volume are less likely to be detected by routine ultrasound. Like all fetal diagnoses, the ability to detect less-severe lesions has improved over time, as has our

understanding of fetal lung physiology and advances in ventilator and NICU care, and thus the mortality estimates for defects detected during pregnancy, is continually changing.

After developing techniques for fetal surgical procedures in animal models, the initial attempts to repair CDH in utero were done via open hysterotomy followed by thoracotomy and repair of the defect. This work was hampered by technical challenges, including the inability to prevent preterm birth after a prolonged open uterus surgery and inability of the fetus to tolerate the surgical procedure, which included major manipulation of the liver through which the blood flow from the placenta is delivered. When the procedure was done in fetuses without liver involvement, it was learned that the group who received care at birth had 86 percent survival,⁶³ making the risks of preterm birth from in utero repair less acceptable. Subsequently, new understanding of the pathophysiology of lung fluid and growth suggested that a less invasive approach could be successful. Occluding the trachea of a fetus results in buildup of lung secretions in the pulmonary tree, gradually distending the lungs as well as triggering complex changes in maturation, including DNA synthesis, epithelial and endothelial proliferation, increased phospholipid metabolism and surfactant synthesis. The growing lungs push the bowel and abdominal contents out of the chest cavity to an extent and promote improved lung growth. Less-invasive fetal surgeries have more recently focused on methods to accomplish tracheal occlusion.

Myelomeningocele/Spina Bifida

Myelomeningocele (MMC) is a congenital malformation in which the meninges and spinal cord protrude through a defect in the vertebral arches, muscle, and skin. It is the most commonly observed malformation of the central nervous system, affecting more than 1,000 fetuses in the United States annually.⁶⁴ MMC is the most common form of spina bifida, and although it is rarely fatal, individuals affected with it have a range of disabilities, including paraplegia, hydrocephalus, skeletal deformities, bowel and bladder incontinence and cognitive impairment. It is generally associated with Arnold Chiari malformation (CM), which is often associated with the observed hydrocephalus in these patients. The genesis of CM and its association with the MMC lesion is not entirely understood, but may be due to leaking cerebrospinal fluid.

The etiology of MMC is not entirely understood, although it likely has a genetic component and may be environmentally driven as well.⁶⁵ There is good evidence that folate reduces the incidence of neural tube defects, including this one, but does not inevitably prevent them. The standard treatment has been to close the defect postnatally, and shunting for hydrocephalus is common.

In the early 1990s, animal experiments suggested that the neurologic damage to the spinal cord might be partially due to the exposure of the uncovered neural elements to trauma and amniotic fluid during the pregnancy. This is known as the “two-hit hypothesis” in which the first insult is the defect itself, and the second is the toxic effect of amniotic fluid on the exposed meninges and spinal cord. The hypothesis was supported by the observation that fetal leg movement may be observed up to about 17 weeks’ gestation in fetuses with MMC, but subsequently ceases. Animal research suggested that covering the defect early on could potentially result in better lower extremity and bladder function. Myelomeningocele repair was the first in utero surgery considered for a nonlethal malformation on the basis that its natural history was well known and leads to lifelong disability in the absence of intervention. Furthermore, the defect can be diagnosed prenatally in over 80 percent of cases by maternal

serum alpha-fetoprotein and ultrasound; MRI is used to detect specific anomalies and disease process.

The procedure was initially performed by Bruner and colleagues as a closed laparoscopic covering of the spinal defect, with the first case reported in a letter and in a series of four fetuses published in 1999 (the surgeries were conducted between 1994 and 1997).⁶⁶ Half of the fetuses survived, and both survivors required shunting. In a continuation of this work, four fetuses were operated on using an open approach and compared to four done endoscopically,⁶⁷ and the open surgery showed improved outcomes, while the endoscopic approach had high mortality. The endoscopic approach has been abandoned, and therefore the rest of this overview will focus on literature related to open surgery for MMC repair. Since 1997, more than 200 fetuses with MMC have undergone open surgical repair in the United States.

Obstructive Uropathy

A variety of fetal malformations can lead to distention of the urinary bladder; these include urethral atresia (failure of the bladder stem to properly form so urine cannot exit), posterior urethral valves (which in male fetuses can prevent flow of urine through the full length of the urethra); and megacystis-megaureter-microcolon syndrome (which results from malformation of the organs rather than frank blockage of urine flow), and Prune-belly syndrome (which includes lack of development of abdominal muscles, undescended testicles, and urinary anomalies). Other urinary tract anomalies can result in distension of one or both ureters, such as blockage at the junction with the bladder or at any place along the ureter, which conveys urine from the kidney to the bladder. In this case when there is renal function and a ureteral impass, the distended portion of the urinary tract is the ureter or renal pelvis rather than the bladder.

Goals of fetal therapy have emphasized decompression rather than repair of the specific lesion. The goal of decompression of the distended portion of the urinary tract is to protect remaining renal function and promote lung development. While it is simplistic to attribute these resulting changes to a simple mechanism such as pressure relief on the developing kidney or movement of a column of amniotic fluid up and down the lower respiratory tree, the relief of urinary tract pressure and the presence of amniotic fluid are correlated with improved renal and pulmonary function at birth in some infants. Placement of an indwelling shunt to decompress fetal urinary tract distension was first reported in 1982.⁶⁸ The care team placed a shunt from the bladder to the amniotic cavity by insertion under ultrasound guidance through the maternal skin with a puncture, but not open surgery. This first case by a percutaneous approach was performed at 30 weeks gestation.⁶⁸ In rapid succession, clinical investigators began to intervene earlier in pregnancy with treatment before 18 weeks reported in 1983.⁶⁹ Open procedures to correct the urinary tract anomaly, using techniques similar to those used after birth, have also been reported in the earlier literature. Challenges with increased preterm birth and comparable outcomes with the shunting procedures have resulted in a trend to percutaneous shunting procedures dominating the literature. After a small incision in the maternal skin, generally with local anesthesia only, the shunt is inserted through an introducer sheath into position within the fetal bladder. An internal guide or stylus within the shunt is withdrawn allowing a prefabricated curl or “pigtail” to form at the distal end that helps hold the device within the fetal bladder. As the introducer is completely withdrawn, a second pigtail forms on the opposite end to hold the shunt outside the fetus and to assure drainage of urine into the amniotic cavity. When the shunt type or method was noted by authors to vary from this, we have indicated the difference.

Sacroccygeal Teratoma

Sacroccygeal teratoma (SCT) is a relatively rare condition effecting approximately 1 in 40,000 fetuses or about 100 infants a year in the United States. As a result of ultrasound use, these tumors are increasingly recognized antenatally. The outcomes of prenatally diagnosed, uncomplicated survivors to term are generally good. However, those fetuses with large, vascular tumors have a high incidence of prenatal mortality from high-output cardiac failure or spontaneous hemorrhage into or rupture of the growing tumor. Among fetuses followed in series without hydrops, survival ranges from 32 percent⁷⁰ and 48 percent⁷¹ among infants with high output cardiovascular changes or associated anomalies to 83 percent,⁷² 92 percent,⁷³ and 100 percent in uncomplicated cases.⁷⁴⁻⁷⁵ Fetal surgical procedures for SCT have focused on the small subgroup of fetuses with SCT and hydrops because untreated cases are expected to die in utero or at birth. All series report 100 percent mortality.⁷⁰⁻⁷⁶ In severe cases, SCT with hydrops is associated with maternal risks. Mothers of fetuses with hydrops can develop mirror syndrome, which is a severe form of pre-eclampsia and can be associated with placentomegaly. Mirror syndrome is a maternal contraindication to fetal approaches since the mother is critically ill and delivery has been felt to be indicated for maternal health. Consequently, decisions to intervene need to be made when the fetus is documented to be critically ill while the mother is still in good health.

Thoracic Lesions

Congenital pulmonary airway malformations (CPAM), which include congenital cystic adenomatoid malformation (CCAM) and bronchopulmonary sequestration (BPS), are congenital anomalies of the lung that share the characteristic of a segment of lung being replaced by abnormally developing tissue. CCAMs can have connections to the pulmonary tree and contain air. The tissue is served by blood vessels in the pulmonary circulation.⁷⁷ BPS does not connect to the airway and has blood flow from branches off the aorta as well as the pulmonary circulation. Antenatal diagnosis is most often made by ultrasound.

Only a small subset of patients with congenital pulmonary airway malformations are candidates for in utero treatment. In this subset, the mass is large enough and in such an anatomically critical position that the fetal mediastinum is compressed, leading to impaired venous return with resulting fetal hydrops secondary to cardiac failure. When this occurs early enough in gestational age that delivery and postnatal treatment are not an option, in utero treatment is a possible solution. The majority of CPAMs, however, do not have an indication for prenatal treatment as the outcomes are excellent, with the tumors often regressing throughout pregnancy and causing no neonatal or early childhood symptoms.

Oftentimes one of the more difficult judgments to be made during pregnancy is the frequency with which these tumors should be monitored to detect the small percentage that will cause fetal harm in order to know when to intervene. Distinguishing between these conditions is difficult and some would argue clinically irrelevant until after birth. The final common pathway that leads to consideration of fetal intervention is the same—fetal hydrops—whether the lesion is considered a pure CCAM, BPS, or a hybrid lesion. Evaluation of 40 infants classified as having BPS found 50 percent of infants had elements of CCAM on their lung pathology.⁷⁸

The diagnosis of CCAM is likewise not always certain until after surgery. In separate series 4 of 33 suspected CCAMs had BPS upon pathologic exam;⁷⁹ six of nine had “hybrid lesions”(CCAM and sequestration present in the same lesion), and 16 of 37 were lesions other

than CCAM. In a report from a busy fetal center with 4,551 patients, 38 cases of thoracic lesions were identified, and three of them were BPS.⁸⁰ Based on this considerable overlap, Achiron and colleagues suggested a new classification of lung lesions based on vascular supply which has not yet been adopted.⁸¹

By convention CCAM lesions are grouped into three types: type one is a lesion composed of single or multiple large cysts (more than 2 centimeters in diameter); type two is multicystic composed of multiple small cysts (less than 1 centimeter in diameter); and type three is a solid lesion.⁸² The potential for shunt placement depends upon the type of lesion. Cystic lesions may be drained, but other types are resected.

These lung malformations have a variable course in utero. Natural history reports suggest that the majority of CCAM lesions increase in size in midtrimester and either involute in the third trimester or cause a compressive effect on the fetal thorax resulting in hydrops in the fetus and occasionally a mirror syndrome illness in the mother.⁸³⁻⁸⁴ There are presently no useful predictors of outcome, and serial evaluations are essential to determine course. Hydrops in the fetus results from obstruction of the vena cava and cardiac compression caused by mediastinal shift.⁸⁵ The decision to intervene in utero is often based on the natural history reports that hydrops marks a transition to fetal demise. In 1985, Adzick and colleagues reported on 11 fetuses with CCAM and hydrops with 100 percent mortality.⁸⁶ Hydrops in BPS may result from somewhat different mechanisms with tension hydrothorax increasing the pressure within the thorax and decreasing venous and lymphatic return to the heart. Hydrops in these fetuses has also been reported to usually be fatal if untreated in utero, with only 1 survivor in 33 cases.⁸⁷

At times, large pleural effusions occur without CCAM or BPS, the natural history of these effusions is even less well understood. We did not include interventions for isolated pleural effusions in this review; neither did we include papers that only reported thoracentesis as a treatment.

Twin-Twin Transfusion Syndrome

Background. In twin-to-twin transfusion syndrome (TTTS), twins share a single chorionic membrane and therefore, a single placenta, but have separate amniotic sacs. Approximately 15 percent of monochorionic, diamniotic twin pregnancies are affected by TTTS,⁸⁸ and therefore, estimates based on CDC data are that theoretical incidence of TTTS would be about 1.38 to 1.86 cases per 1,000 live births.⁸⁹ Although incidence studies have found lower numbers, these numbers are probably a reflection of early deaths of affected fetuses in utero that therefore do not get recognized as TTTS pregnancies.

In TTTS, one twin (the donor) transfuses the other twin (the recipient) through intertwin placental vascular anastomoses (or communications). When this occurs, the donor twin becomes hypovolemic, resulting in decreased renal perfusion. Decreased perfusion may result in renal pathology, thus reducing urinary output and amniotic fluid volume in the donor twin's amniotic sac (oligohydramnios). The recipient twin, conversely, is hypervolemic with increased renal perfusion resulting in polyhydramnios. As the overproduction of urine continues, the polyhydramniotic sac can expand and cause uterine distention, leading to premature labor and delivery. Most pregnancies presenting with severe TTTS prior to 26 weeks and not undergoing some sort of therapy will end with dual fetal demise.⁸⁸ When both twins do survive, there is often severe neurologic compromise in survivors as well as other organ failure, including cardiac conditions. Approximately 25 percent of surviving fetuses in a monochorionic twin pair in which one dies will suffer CNS injury. This is thought to be related to either transplacental passage of

cytokines and vasoactive compounds or a result of cerebral ischemia related to hypotension from exsanguinations of the survivor into the vascular bed of the dead twin.

The first reported case of twin-to-twin transfusion was in 1942⁹⁰ and was referenced in 1964, when DeMarco⁹¹ postulated that some aspects of this disorder were explainable by an in utero placental shunt in monozygous twins. The early descriptions often depicted what is likely now known as acute twin-twin transfusion syndrome and were based on live born twins who had sometimes dramatically different hemoglobin levels and birth weights. With the development of ultrasonography, however, we have learned that the cascade of events leading to this outcome begins early, and classic TTTS findings are late manifestations of the condition.⁹²⁻⁹³

With this new information, diagnostic criteria for TTTS evolved to include: same-sex fetuses with a single placenta with lack of lambda sign in early pregnancy; oligohydramnios in the donor sac (<2 cm maximum vertical pocket) and polyhydramnios in the recipient sac (>8 cm maximum vertical pocket at less than 20 weeks or >10 cm after 20 weeks).

After diagnosis, the most common approach to assessing severity in TTTS is the Quintero staging system:⁹⁴

- Stage I: The fetal bladder of the donor twin remains visible sonographically.
- Stage II: The bladder of the donor twin is collapsed and not visible by ultrasound.
- Stage III: Critically abnormal fetal Doppler studies noted. This may include absent or reversed end-diastolic velocity in the umbilical artery, absent or reverse flow in the ductus venosus, or pulsatile flow in the umbilical vein.
- Stage IV: Fetal hydrops present.
- Stage V: Demise of one or both twins.

In 1990, Baldwin and Wittman⁹⁵ presented three prenatally diagnosed twin pairs with in utero twin transfusion syndrome for which they attempted selective reduction. They postulated the importance of a vascular separation. Later that year, De Lia et al. reported the first fetal surgery to treat the underlying pathology.⁹⁶

Four primary approaches exist for intervening in twin-to-twin transfusion syndrome:

- Serial amnioreduction to relieve intra-amniotic pressure and uterine size, and thus prolong the pregnancy. Although the mechanism by which it works is not entirely clear, amnioreduction has been associated with a 50–60 percent survival rate of at least one fetus.⁹⁷
- Termination of the sicker twin, which is likely to rescue the healthier one and is accomplished by cord occlusion, radio frequency ablation, or ligation. This is only used in the presence of significant birth defects.
- Septostomy, in which the intervening membrane is punctured to attempt to increase amniotic fluid in the oligohydramniotic sac, was performed but has largely been abandoned as a therapy.⁹⁸
- Laser ablation of communicating vessels; it is performed either selectively or nonselectively to attempt to protect one twin from hemodynamic disturbances in the other twin. In nonselective ablation, all vessels crossing the dividing membrane are ablated, whereas selective ablation is limited to vessels shown to be communicating between the two fetuses. Selective ablation is most common today, and is the focus of this section of the technical brief. Gaining access to the uterus can be accomplished in three ways: laparotomy to expose the uterus, laparoscopic placement of the fetoscope, and ultrasound-guided placement of the fetoscope.

Gaining access to the uterus can be accomplished in three ways: laparotomy to expose the uterus, laparoscopic placement of the fetoscope, and ultrasound-guided placement of the fetoscope.

References

1. Liley AW. Intrauterine transfusion of foetus in haemolytic disease. *Br Med J* 1963 Nov 2;2(5365):1107–1109.
2. Farrell JA. Fetal treatment center: history, infrastructure, and nursing perspective. *J Perinat Neonatal Nurs* 2007 Jan–Mar;21(1):11–9; quiz 20–21.
3. Chescheir NC, Socol M. The national institutes of health workshop on fetal treatment: needs assessment and future directions. *Obstet Gynecol* 2005 Oct;106(4):828–833.
4. Bruner JP. In their footsteps: a brief history of maternal-fetal surgery. *Clin Perinatol* 2003 Sep;30(3):439–447.
5. International Fetal Medicine and Surgery Society. 2009; Available at: <http://www.ifmss.org>. Accessed July 1, 2010.
6. Harrison MR. Fetal surgery: trials, tribulations, and turf. *J Pediatr Surg* 2003 Mar;38(3):275–282.
7. Wilkinson LG, Powell RW, Cabaniss ML, et al. Surgical problems in the fetus: a multidisciplinary approach. *Am J Surg* 1987 Dec;154(6):685–687.
8. Luks FI, Carr SR, Feit LR, et al. Experience with a multidisciplinary antenatal diagnosis and management model in fetal medicine. *J Matern Fetal Neonatal Med* 2003 Nov;14(5):333–337.
9. Moise Jr KJ, Johnson A, Carpenter RJ, et al. Fetal intervention: providing reasonable access to quality care. *Obstet Gynecol* 2009 Feb;113(2 Pt 1):408–410.
10. Chan FY, Soong B, Taylor A, et al. Fetal endoscopic telesurgery using an Internet Protocol connection: clinical and technical challenges. *J Telemed Telecare* 2003;9 Suppl 2:S12–S14.
11. Quintero RA, Munoz H, Pommer R, et al. Operative fetoscopy via telesurgery. *Ultrasound Obstet Gynecol* 2002 Oct;20(4):390–391.
12. Bannister CM. Fetal neurosurgery—a new challenge on the horizon. *Dev Med Child Neurol* 1984 Dec;26(6):827–830.
13. Harrison MR, Adzick NS. The fetus as a patient. Surgical considerations. *Ann Surg* 1991 Apr;213(4):279–291; discussion 277–278.
14. Han SJ, Hwang EH. The development of fetal surgery. *Yonsei Med J* 2001 Dec;42(6):602–608.
15. Peeters S, Oepkes D, Lopriore E, et al. Fetoscopic laser coagulation in twin-twin transfusion syndrome: the learning curve [abstract]. *Am J Obstet Gynecol* 2007;197:S162.
16. Barclay WR, McCormick RA, Sidbury JB, et al. The ethics of in utero surgery. *JAMA* 1981 Oct 2;246(14):1551–1552, 1554–1555.
17. Ruddick W, Wilcox W. Operating on the fetus. *Hastings Cent Rep* 1982 Oct;12(5):10–14.
18. Robertson JA. The right to procreate and in utero fetal therapy. *J Leg Med* 1982 Sep;3(3):333–366.
19. Robertson JA. Legal issues in prenatal therapy. *Clin Obstet Gynecol* 1986 Sep;29(3):603–611.
20. Engelhardt Jr HT. Current controversies in obstetrics: wrongful life and forced fetal surgical procedures. *Am J Obstet Gynecol* 1985 Feb 1;151(3):313–318.
21. Strauss RP, Davis JU. Prenatal detection and fetal surgery of clefts and craniofacial abnormalities in humans: social and ethical issues. *Cleft Palate J* 1990 Apr;27(2):176–182; discussion 182–183.

22. Fletcher JC. Drawing moral lines in fetal therapy. *Clin Obstet Gynecol* 1986 Sep;29(3):595–602.
23. Goldman EB. Fetal versus maternal rights: who is the patient? *Mich Hosp* 1983 Apr;19(4):23–25.
24. Gilmore A. Is the fetus a patient? *Can Med Assoc J* 1983 Jun 15;128(12):1472, 1475–1476.
25. Pringle KC. Fetal surgery: it has a past, has it a future? *Fetal Ther* 1986;1(1):23–31.
26. Kindregan C. Compulsory fetal surgery: an issue for the future. *Report Hum Reprod Law* 1984 Mar–Apr:Reports, 111–112.
27. Knopoff KA. Can a pregnant woman morally refuse fetal surgery? *Calif Law Rev* 1991 Mar;79(2):499–540.
28. Murray TH. Moral obligations to the not-yet born: the fetus as patient. *Clin Perinatol* 1987 Jun;14(2):329–343.
29. Rauscher K. Fetal surgery: a developing legal dilemma. *St Louis Univ Law J* 1987 Sep;31(3):775–795.
30. Weinberg SR. A maternal duty to protect fetal health? *Indiana Law J* 1983;58(3):531–46.
31. Lenow JL. The fetus as a patient: emerging rights as a person? *Am J Law Med* 1983 Spring;9(1):1–29.
32. Morris C. Technology and the legal discourse of fetal autonomy. *UCLA Womens Law J* 1997 Fall–Winter;8(1):47–97.
33. Blank RH. Emerging notions of women’s rights and responsibilities during gestation. *J Leg Med* 1986 Dec;7(4):441–469.
34. Bliton MJ. Parental hope confronting scientific uncertainty: a test of ethics in maternal-fetal surgery for spina bifida. *Clin Obstet Gynecol* 2005 Sep;48(3):595–607.
35. Brown D, Andersen HF, Elkins TE. An analysis of the ACOG and AAP ethics statements on conflicts in maternal-fetal care. *J Clin Ethics* 1991 Spring;2(1):19–22; discussion 23–24.
36. Howe EG. Unicorns, Carravaggio, and fetal surgery. *J Clin Ethics* 2001 Winter;12(4):333–345.
37. Bliton MJ, Zaner RM. Over the cutting edge: how ethics consultation illuminates the moral complexity of open-uterine fetal repair of spina bifida and patients’ decision making. *J Clin Ethics* 2001 Winter;12(4):346–360.
38. Rothschild BB, Estroff SE, Churchill LR. The cultural calculus of consent. *Clin Obstet Gynecol* 2005 Sep;48(3):574–594.
39. Gonzalez-Abreu MM. Parental voices: You get what you get and you don’t get upset: a child’s answer to life’s biggest challenges. *Clin Obstet Gynecol* 2005 Sep;48(3):527–533.
40. Kennedy D, Kennedy L. Parental voices: our journey of grace. *Clin Obstet Gynecol* 2005 Sep;48(3):534–539.
41. Elias S, Annas GJ. Perspectives on fetal surgery. *Am J Obstet Gynecol* 1983 Apr 1;145(7):807–812.
42. Pendl G. Symposium on ethics and morals related to antenatal treatment of pediatric neurosurgical disorders. Treatment of fetuses in utero—an opinion from central Europe. *Childs Nerv Syst* 1988 Jun;4(3):158–160.
43. Lyerly AD, Mahowald MB. Maternal-fetal surgery for treatment of myelomeningocele. *Clin Perinatol* 2003 Mar;30(1):155–165.
44. Manning FA. Fetal surgery for obstructive uropathy: rational considerations. *Am J Kidney Dis* 1987 Oct;10(4):259–267.
45. Reitsma AM, Moreno JD. Maternal-fetal research and human research protections policy. *Clin Perinatol* 2003 Mar;30(1):141–153.
46. Chervenak FA, McCullough LB. A comprehensive ethical framework for fetal research and its application to fetal surgery for spina bifida. *Am J Obstet Gynecol* 2002 Jul;187(1):10–14.
47. Casper MJ. *Making of the Unborn Patient: A Social Anatomy of Fetal Surgery*. New Brunswick, NJ: Rutgers University Press; 1998.
48. Blizzard D. *Looking Within: A Sociocultural Examination of Fetoscopy*. Cambridge, MA: MIT Press; 2007.

49. Williams C. Dilemmas in fetal medicine: premature application of technology or responding to women's choice? *Sociol Health Illn* 2006 Jan;28(1):1–20.
50. Ashburn DA, Blackstone EH, Wells WJ, et al. Determinants of mortality and type of repair in neonates with pulmonary atresia and intact ventricular septum. *J Thorac Cardiovasc Surg* 2004 Apr;127(4):1000–1007; discussion 1007-1008.
51. Shinebourne EA, Rigby ML, Carvalho JS. Pulmonary atresia with intact ventricular septum: from fetus to adult: congenital heart disease. *Heart* 2008 Oct;94(10):1350–1357.
52. Allan LD, Maxwell DJ, Carminati M, et al. Survival after fetal aortic balloon valvoplasty. *Ultrasound Obstet Gynecol* 1995 Feb;5(2):90–91.
53. Tulzer G, Arzt W, Franklin RC, et al. Fetal pulmonary valvuloplasty for critical pulmonary stenosis or atresia with intact septum. *Lancet* 2002 Nov 16;360(9345):1567–1568.
54. Glatz JA, Tabbutt S, Gaynor JW, et al. Hypoplastic left heart syndrome with atrial level restriction in the era of prenatal diagnosis. *Ann Thorac Surg* 2007 Nov;84(5):1633–1638.
55. Hospital stays, hospital charges, and in-hospital deaths among infants with selected birth defects—United States, 2003. *MMWR Morb Mortal Wkly Rep* 2007 Jan 19;56(2):25–29.
56. National Center on Birth Defects and Developmental Disabilities. Metropolitan Atlanta Congenital Defects Program 2004 Annual Report. Atlanta, GA: Centers for Disease Control and Prevention; 2004.
57. Hehir DA, Dominguez TE, Ballweg JA, et al. Risk factors for interstage death after stage 1 reconstruction of hypoplastic left heart syndrome and variants. *J Thorac Cardiovasc Surg* 2008 Jul;136(1):94–99, 99 e1–3.
58. Rychik J, Rome JJ, Collins MH, et al. The hypoplastic left heart syndrome with intact atrial septum: atrial morphology, pulmonary vascular histopathology and outcome. *J Am Coll Cardiol* 1999 Aug;34(2):554–560.
59. Vlahos AP, Lock JE, McElhinney DB, et al. Hypoplastic left heart syndrome with intact or highly restrictive atrial septum: outcome after neonatal transcatheter atrial septostomy. *Circulation* 2004 May 18;109(19):2326–2330.
60. Quintero RA, Huhta J, Suh E, et al. In utero cardiac fetal surgery: laser atrial septotomy in the treatment of hypoplastic left heart syndrome with intact atrial septum. *Am J Obstet Gynecol* 2005 Oct;193(4):1424–1428.
61. Rudolph CD, Rudolph AM, Hostetter MK, et al., editors. *Rudolph's pediatrics*. New York: McGraw-Hill, Medical Pub. Div; 2003.
62. Butler N, Claireaux AE. Congenital diaphragmatic hernia as a cause of perinatal mortality. *Lancet* 1962 Mar 31;1(7231):659–663.
63. Harrison MR, Adzick NS, Bullard KM, et al. Correction of congenital diaphragmatic hernia in utero VII: a prospective trial. *J Pediatr Surg* 1997 Nov;32(11):1637–1642.
64. Mathews TJ, Honein MA, Erickson JD. Spina bifida and anencephaly prevalence—United States, 1991–2001. *MMWR Recomm Rep*. 2002 Sep 13;51(RR-13):9–11.
65. Fichter MA, Dornseifer U, Henke J, et al. Fetal spina bifida repair—current trends and prospects of intrauterine neurosurgery. *Fetal Diagn Ther* 2008;23(4):271–286.
66. Bruner JP, Richards WO, Tulipan NB, et al. Endoscopic coverage of fetal myelomeningocele in utero. *Am J Obstet Gynecol* 1999 Jan;180(1 Pt 1):153–158.
67. Bruner JP, Tulipan NB, Richards WO, et al. In utero repair of myelomeningocele: a comparison of endoscopy and hysterotomy. *Fetal Diagn Ther* 2000 Mar–Apr;15(2):83–8.
68. Golbus MS, Harrison MR, Filly RA, et al. In utero treatment of urinary tract obstruction. *Am J Obstet Gynecol* 1982 Feb 15;142(4):383–288.
69. Manning FA, Harman CR, Lange IR, et al. Antepartum chronic fetal vesicoamniotic shunts for obstructive uropathy: A report of two cases. *Am J Obstet Gynecol* 1983 Apr 1;145(7):819–822.

70. Flake AW. Fetal sacrococcygeal teratoma. *Semin Pediatr Surg* 1993 May;2(2):113–120.
71. Bond SJ, Harrison MR, Schmidt KG, et al. Death due to high-output cardiac failure in fetal sacrococcygeal teratoma. *J Pediatr Surg* 1990 Dec;25(12):1287–1291.
72. Neubert S, Trautmann K, Tanner B, et al. Sonographic prognostic factors in prenatal diagnosis of SCT. *Fetal Diagn Ther* 2004 Jul–Aug;19(4):319–326.
73. Uchiyama M, Iwafuchi M, Naitoh M, et al. Sacrococcygeal teratoma: a series of 19 cases with long-term follow-up. *Eur J Pediatr Surg* 1999 Jun;9(3):158–162.
74. Chisholm CA, Heider AL, Kuller JA, et al. Prenatal diagnosis and perinatal management of fetal sacrococcygeal teratoma. *Am J Perinatol* 1999;16(1):47–50.
75. Westerburg B, Feldstein VA, Sandberg PL, et al. Sonographic prognostic factors in fetuses with sacrococcygeal teratoma. *J Pediatr Surg* 2000 Feb;35(2):322–325; discussion 325–326.
76. Schmidt KG, Silverman NH, Harison MR, et al. High-output cardiac failure in fetuses with large sacrococcygeal teratoma: diagnosis by echocardiography and Doppler ultrasound. *J Pediatr* 1989 Jun;114(6):1023–1028.
77. Pumberger W, Hormann M, Deutinger J, et al. Longitudinal observation of antenatally detected congenital lung malformations (CLM): natural history, clinical outcome and long-term follow-up. *Eur J Cardiothorac Surg* 2003 Nov;24(5):703–711.
78. Burdis L, Koch DD. The use of cardiopulmonary bypass and extracorporeal membrane oxygenation for support during removal of two teratomas and hydrops fetalis. *J Extra Corpor Technol* 2004 Jun;36(2):182184.
79. Dommergues M, Louis-Sylvestre C, Mandelbrot L, et al. Congenital adenomatoid malformation of the lung: when is active fetal therapy indicated? *Am J Obstet Gynecol* 1997 Oct;177(4):953–958.
80. Crombleholme TM, D’Alton M, Cendron M, et al. Prenatal diagnosis and the pediatric surgeon: the impact of prenatal consultation on perinatal management. *J Pediatr Surg* 1996 Jan;31(1):156–162; discussion 162–163.
81. Achiron R, Zalel Y, Lipitz S, et al. Fetal lung dysplasia: clinical outcome based on a new classification system. *Ultrasound Obstet Gynecol* 2004 Aug;24(2):127–133.
82. Stocker JT, Madewell JE, Drake RM. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. *Hum Pathol* 1977 Mar;8(2):155–171.
83. Gornall AS, Budd JL, Draper ES, et al. Congenital cystic adenomatoid malformation: accuracy of prenatal diagnosis, prevalence and outcome in a general population. *Prenat Diagn* 2003 Dec 15;23(12):997–1002.
84. Adzick NS, Harrison MR, Crombleholme TM, et al. Fetal lung lesions: management and outcome. *Am J Obstet Gynecol* 1998 Oct;179(4):884–889.
85. Harrison MR, Adzick NS, Jennings RW, et al. Antenatal intervention for congenital cystic adenomatoid malformation. *Lancet* 1990 Oct 20;336(8721):965–967.
86. Adzick NS, Harrison MR, Glick PL, et al. Fetal cystic adenomatoid malformation: prenatal diagnosis and natural history. *J Pediatr Surg* 1985 Oct;20(5):483–488.
87. Grethel EJ, Wagner AJ, Clifton MS, et al. Fetal intervention for mass lesions and hydrops improves outcome: a 15-year experience. *J Pediatr Surg* 2007 Jan;42(1):117–123.
88. Johnson A, Moise Jr KJ. Improving survival in twin-twin transfusion syndrome. *Contemporary OB/GYN* 2006;51(12):54–59.
89. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2003. *Natl Vital Stat Rep* 2005 Sep 8;54(2):1–116.
90. Herlitz G. Zur Kenntnis der anämischen Und polyzytämischen Zustände bei Neugeborenen sowie des Icterus gravis neonatorum. *Acta Paediatrica (Upsala)* 1942;29:211.

91. Demarco PG. Feto-fetal transfusions in monozygotic twins: review of the literature and report of two cases. *Clin Pediatr (Phila)* 1964 Dec;3:709–713.
92. Chescheir NC, Seeds JW. Polyhydramnios and oligohydramnios in twin gestations. *Obstet Gynecol* 1988 Jun;71(6 Pt 1):882–884.
93. Brown DL, Benson CB, Driscoll SG, et al. Twin-twin transfusion syndrome: sonographic findings. *Radiology* 1989 Jan;170(1 Pt 1):61–63.
94. Quintero RA, Morales WJ, Allen MH, et al. Staging of twin-twin transfusion syndrome. *J Perinatol* 1999 Dec;19(8 Pt 1):550–555.
95. Baldwin VJ, Wittmann BK. Pathology of intragestational intervention in twin-to-twin transfusion syndrome. *Pediatr Pathol* 1990;10(1-2):79–93.
96. De Lia JE, Cruikshank DP, Keye WR, Jr. Fetoscopic neodymium:YAG laser occlusion of placental vessels in severe twin-twin transfusion syndrome. *Obstet Gynecol* 1990 Jun;75(6):1046–1053.
97. Chescheir NC. Maternal-fetal surgery: where are we and how did we get here? *Obstet Gynecol* 2009;113(3):717–731.
98. Moise Jr KJ, Dorman K, Lamvu G, et al. A randomized trial of amnioreduction versus septostomy in the treatment of twin-twin transfusion syndrome. *Am J Obstet Gynecol* 2005 Sep;193(3 Pt 1):701–707